Archives

Bacterial Infections in Endocrinology

ABSTRACT

 

Bacteria are microscopic organisms that are ubiquitous in the environment and human body. Some bacteria exhibit symbiotic relationship with the human body, while other bacteria are harmful and cause various diseases. Bacteria may infect the endocrine glands either by direct invasion or local or hematogenous spread. Suppurative bacterial infections can involve the pituitary, thyroid, adrenals, and gonads. In the majority of cases, specific risk factors predispose the endocrine glands to such infections. This in turn may lead to temporary or permanent endocrine dysfunction. There may also be states of hormone excess following bacterial infections. This is particularly noted in cases of bacterial thyroiditis. Permanent endocrine dysfunction following bacterial infections will warrant life-long hormone replacement therapy. In acute stages of infection, intravenous or oral antibiotics are the cornerstone of management. The choice of antibiotic is guided by culture and sensitivity report. Sometimes, however, empirical antibiotic therapy may need to be continued as no organism may be isolated on culture. Empirical therapy should provide coverage for gram positive, gram negative, and anaerobic bacteria. If there is abscess formation in any endocrine gland, it may require aspiration and drainage. In this chapter, we have discussed the risk factors, bacteriology, clinical presentation, diagnosis, and management of common bacterial infections involving endocrine glands.

INTRODUCTION

 

The incidence of bacterial infections of endocrine glands is low when compared to that in other organs of the body. The endocrine glands that may be affected by bacterial infections are: pituitary, thyroid, adrenals and gonads. Bacterial infection of parathyroid glands is extremely rare. Certain risk factors may predispose the glands for infection.

 

In general, bacteria may be classified as gram positive, gram negative, and miscellaneous categories. The classification of medically important bacteria is highlighted in another chapter of the Endotext (1). Among all the bacteria, Mycobacterium tuberculosis remains the most common agent involving the endocrine glands (2). Mycobacterium tuberculosis is a weakly gram positive highly aerobic bacterium that can cause tuberculosis in any organ of the body. This organism can affect the adrenal glands and lead to primary adrenal insufficiency. In developing countries, tuberculosis remains the most common cause of primary adrenal insufficiency. Tuberculosis can also affect pituitary, thyroid, and gonads. In this chapter, we are discussing only adrenal tuberculosis, since tuberculosis of the Endocrine system has been covered in great details in another chapter (3). Apart from Mycobacterium tuberculosis, the other common bacteria that may affect the endocrine system are Staphylococcus aureus, Streptococcus pneumoniae, Neisseria meningitides, Escherichia coli, Chlamydia trachomatis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Treponema pallidum, and Yersinia enterocolitica among others. We have tried to present a spectrum of bacterial infections of various endocrine glands including their clinical presentation, investigations, management, long-term prognosis, and follow up.

 

BACTERIAL INFECTIONS OF PITUITARY

 

Infections of the pituitary gland are rare but may cause clinical problems because of the non-specific nature of the presentation (4). Among the various infectious agents, bacterial infections including Mycobacterial infections seem to be the most common. The various bacterial agents causing infection of the pituitary gland are summarized in the table 1. The common bacterial infections of the pituitary gland are described below.

 

Table 1.  Bacterial Agents Causing Infection of Pituitary-Hypothalamus

Bacterial class

Organism

Gram positive bacteria

Staphylococcus aureus, Streptococcus pneumoniae

Gram negative bacteria

E coli, Pseudomonas aeruginosa, Neisseria meningitides

Spirochaete

Treponema pallidum

Mycobacterium

Mycobacterium tuberculosis

 

Pituitary Abscess

 

EPIDEMIOLOGY AND RISK FACTORS

 

Pituitary abscesses are a very rare clinical entity and account for less than 1% of pituitary lesions (4). The first case of pituitary surgery involving an abscess was described in 1848. Since then, there have been around 300 such cases reported in the literature (4, 5). Risk factors include underlying pituitary diseases such as a pituitary adenoma, Rathke’s cyst, craniopharyngioma, lymphocytic hypophysitis, immunocompromised states (uncontrolled diabetes mellitus, tuberculosis, HIV infection, after solid organ transplantation, chemotherapy, radiotherapy), history of surgical exploration in pituitary hypothalamic region, and spread of local infection from meninges and paranasal sinuses (5-7). Rarely, abscess may develop in a normal pituitary gland (6, 8). 

 

BACTERIOLOGY

 

In the majority of cases, culture is negative in pituitary abscess, with only 19.7% cases showing growth of bacteria (9).The most common organisms isolated are Streptococci and Staphylococci. Other bacterial organisms are Escherichia coli, Mycobacteria, Neisseria, and anaerobes (6, 10). As culture is negative in most of the cases, it is important for empirical antibiotic therapy to cover gram positive, gram negative and anaerobic bacteria. Rarely, a fungal etiology is seen.

 

CLINICAL PRESENTATION

 

Clinical presentation can be classified with respect to chronicity as: acute (within days to weeks), subacute (less than a month) and chronic (more than a month). Acute and subacute abscesses have fulminant presentation while chronic abscess has a more indolent course (5). In the initial stages, patients present with headache (67%), fever, meningismus, and malaise. With progression of the disease, neurological symptoms like altered sensorium, seizures, and coma can occur.

 

Extension of infection in nearby areas can lead to visual dysfunction (45%), extra ocular movement defects, and other cranial nerve palsies (4, 8, 9, 11).

 

Both anterior and posterior pituitary hormonal hypofunction can be seen with a pituitary abscess. In the largest series of pituitary abscesses with 60 cases over 23 years, anterior pituitary hormone deficiencies were reported in 81.8% patients whereas diabetes insipidus was reported in 47.9% of the patients. In the same study, 9.3% had isolated hypogonadism, 3.7% had isolated ACTH deficiency, 1.8% had isolated hypothyroidism, and 1.8% hypothyroidism and ACTH deficiency (9).

 

DIAGNOSIS

 

The investigation of choice for the diagnosis of pituitary abscess is MRI (Magnetic Resonance Imaging) with proper sellar cuts. On T1 weighted images, pituitary abscess appears iso-intense to hypo-intense while on T2 weighted images, it is iso-intense to hyper-intense. There is a characteristic rim of enhancement after gadolinium injection around the abscess site (9, 11). Diffusion-weighted imaging (DWI) shows high signal intensity with a decrease in the apparent diffusion coefficient in the region of pus collection (9, 11).

 

MANAGEMENT

 

Trans-nasal trans-sphenoidal surgery and drainage of the abscess is the treatment of choice. The sphenoid sinus may require exploration if extrasellar invasion is suspected. Along with surgical exploration, the patient should be started on intravenous antibiotics empirically with ceftriaxone (alternatives are cefotaxime and cefepime) along with metronidazole for anaerobic coverage. In case of suspicion for Staphylococcus aureus, vancomycin should be added (9, 12). Further intensification or alteration of antibiotics is subjected to clinical improvement and culture and sensitivity reports. Microbiological etiology may not be identified in the majority of cases. Hence, it is imperative to give proper broad-spectrum coverage empirically.

 

PROGNOSIS AND FOLLOW-UP

 

With current standard of care, mortality rate is 10 % and chance of recurrence is <13%. In about 25% of cases hormonal recovery occurs. After recovering from a pituitary abscess, these patients should be followed up by serial MRI at 3, 6 and 12 months (12). Monitoring for anterior and posterior pituitary hormone deficiency should be done in any patient with a pituitary abscess. Replacement with corticosteroid, thyroid, gonadal, and growth hormone therapy may be required if the patient develops deficiency of any of these hormones. Replacement with vasopressin therapy may be required if patient develops central diabetes insipidus following a pituitary abscess.

 

Hypopituitarism Caused by Treponema Pallidum Infection

 

Syphilis caused by Treponema pallidum (a spirochete) may involve the pituitary- hypothalamic region causing syphilitic gumma with non-caseating granulomas (13, 14). It is more common in patients with underlying human immune deficiency virus (HIV) infection. Diagnosis can be made by demonstration of the spirochete in the samples of sellar tissues following trans sphenoidal surgery. Immunological diagnosis can be made by measuring titers of anti-Treponemal antibody in the serum. Treatment consists of intravenous followed by oral antibiotics (13-15). Penicillin is the drug of choice for syphilis. In patients who are allergic to penicillin, doxycycline is a good alternative.

 

BACTERIAL INFECTIONS OF THE THYROID

 

It is rare for bacteria to invade the normal thyroid gland because of the rich vascular supply, good lymphatic drainage, separation of thyroid gland from other structures by fascial planes, high iodine content, and production of hydrogen peroxide inside the gland (16). Both iodine and hydrogen peroxide have bactericidal properties.

 

Acute Suppurative Thyroiditis

 

EPIDEMIOLOGY AND RISK FACTORS      

 

Acute suppurative thyroiditis is rare and is usually due to bacterial infection of the thyroid gland. In severe cases, it can lead to abscess formation and spread to surrounding structures leading to acute obstruction of the respiratory tract. More than 90% of the patients are less than 40 years of age, with females being more commonly affected than males (17, 18). The incidence of acute suppurative thyroiditis lies between 0.1% and 0.7% of all thyroidal illnesses(19). In children acute suppurative thyroiditis is usually due to persistent pyriform sinus and almost always affects the left lobe and is often recurrent (20-22).  Risk factors for acute suppurative thyroiditis are summarized in table 2 (23).

 

Table 2. Risk Factors for Acute Suppurative Thyroiditis

Common risk factors

Pyriform sinus fistula – more common in children and young adults and associated with recurrent disease

Immunocompromised status – AIDS, blood malignancies, uncontrolled diabetes (more common risk factor overall)

Other risk factors

Thyroglossal cyst

Patent foramen cecum

Congenital brachial fistula

Spread of adjacent suppurative infection into thyroid

Anterior esophageal perforation

Underlying thyroid disorders like chronic autoimmune thyroiditis, goiter, and thyroid malignancy

Fine need aspirations/biopsy of thyroid

Dental abscess/ treatment

Systemic autoimmune disorders

 

BACTERIOLOGY

 

Although bacterial agents account for the majority of cases, acute suppurative thyroiditis can also be caused by fungal (immunosuppressive status), parasitic, and tubercular etiology. Common bacterial organisms include Staphylococcus aureus, Streptococcus pyogenes, Staphylococcus epidermidis, and Streptococcus pneumoniae. Rarely other causative bacteria include Klebsiella species, Hemophilus influenzae, Streptococcus viridans, Arcanobacterium haemolyticum, Eikenella corrodensSalmonella species, and Enterobacteriaceae. In the context of immunosuppressed states like HIV-AIDS, acute suppurative thyroiditis can be caused by Mycobacterium tuberculosis, atypical mycobacteria, Salmonella species, Nocardia species and Treponema pallidum (19, 24).

 

CLINICAL PRESENTATION

 

Acute suppurative thyroiditis due to bacterial etiology has a very rapid onset and progression of symptoms if not addressed. The common manifestations are fever, neck pain, and dysphagia. Thyroid gland may be tender on palpation and sometimes there may be swelling with fluctuation suggestive of localized pus collection (25). Very rarely infection can spread to nearby anatomical structures resulting in a more dramatic presentation with stridor due to laryngeal involvement requiring urgent tracheostomy (26). It is important to differentiate this condition from subacute thyroiditis which also presents with systemic symptoms and neck pain (Table 3) (see below).

 

DIAGNOSIS AND MANAGEMENT

 

Laboratory investigations are consistent with acute inflammation characterized by leukocytosis with shift to left, elevated erythrocyte sedimentation rate, raised C- reactive protein (CRP), and other acute inflammatory markers (23). In cases of severe disease, blood cultures may be positive. Ultrasonography of the thyroid may reveal an abscess. The latter requires aspiration and pus should be sent for microbiological diagnosis. Typical findings of acute suppurative thyroiditis on ultrasound are perithyroidal hypoechoic space, effacement of the plane between the thyroid and surrounding tissues, and unilateral presentation [Fig 1] (27). Computed Tomography (CT) offers better spatial resolution and can be used in cases where ultrasound is not showing characteristic findings or when there is involvement of nearby soft tissue structures. Barium swallow studies may be required to diagnose a pyriform sinus, especially in children when there are recurrent episodes of suppurative thyroiditis (28).

Fig 1. A. Ultrasound of the thyroid showing enlargement of the left lobe of the thyroid with heterogenous echotexture, suggestive of thyroiditis B. Ultrasound Doppler showing increased vascularity of the left lobe of the thyroid

Aspiration or surgical drainage of pus with intravenous empirical broad-spectrum antibiotics (especially in sick patients) is the cornerstone of management for acute suppurative thyroiditis. If the patient is immunocompromised, antifungal therapy should be added to initial therapy. In case of extensive involvement of nearby structures, surgical debridement of involved areas may be needed. With respect to culture sensitivity, antibiotic therapy can be modified and once clinical improvement occurs, patients can be switched to oral antibiotics. If there is presence of pyriform fistula, it should be treated either surgically (removal of entire tract with thyroidectomy) or by ablation (21, 29).

 

Subacute Thyroiditis

 

Subacute thyroiditis (also termed as granulomatous, giant cell, or deQuervain’s thyroiditis), is usually due to a viral illness following respiratory illness. Rarely, bacterial infections like Mycobacterium tuberculosis, Treponema pallidum, or Yersinia enterocolitica may cause subacute thyroiditis. Tuberculous thyroiditis is discussed in another chapter (2). Differentiating features of subacute thyroiditis and suppurative thyroiditis are presented in table 3 (19, 30, 31).

 

Table 3. Differentiating Acute Suppurative Thyroiditis and Subacute Thyroiditis

Features

Acute suppurative thyroiditis

Sub-acute thyroiditis

Etiology

Usually bacterial in origin

Usually follows viral upper respiratory tract infection

Presentation

Rapidly evolving, patient can be very toxic with extensive involvement

Presents with systemic symptoms over days to week

Age

Children, 20 to 40 years

20 to 60 years

Sex

Slight female preponderance

More common in females

Fever

 72%

54%

Neck pain

 70%

77%

Neck tenderness

Usually, unilateral (Left sided involvement due to persistent pyriform sinus)

Bilateral and migratory

Redness over skin

Common

Not present

Swelling with fluctuation suggestive of abscess formation

 Common

Not present

History of sore throat

Absent

Present

Clinical features of thyrotoxicosis

Not common

Common in the initial phase

Laboratory

 

 

Leukocytosis

82%

25 to 50 %

Raised ESR

90%

85%

Abnormal thyroid function test

44%

60%

FNAC

Pus

Giant cells, granulomas

Ultrasound Thyroid

Hypoechoic areas with abscess formation, usually unilateral

Ill-defined hypoechoic areas, usually in bilateral lobes

RAIU study

Normal

Decreased in the initial thyrotoxic phase

18 F FDG PET

Increased uptake

Increased uptake

CT scan

Useful when ultrasound is doubtful and when infection extends into peri thyroid tissue

Not useful

Treatment

Antibiotics & drainage of pus

NSAIDS, glucocorticoids in severe cases and sequential follow up of thyroid function tests.

FNAC- fine needle aspiration cytology; RAIU- radioactive iodine uptake; NSAIDS-Non steroidal anti-inflammatory drugs

 

BACTERIAL INFECTIONS OF ADRENALS

 

Tuberculosis of Adrenals

 

Tuberculosis of the adrenal glands is the most common cause of primary adrenal insufficiency in developing countries. An autoimmune etiology remains common in developed countries. Tuberculous infection of the adrenal gland occurs from hematogenous spread from pulmonary or genitourinary sites (32). Adrenals are the most common endocrine gland involved in tuberculosis (2). The symptoms are usually non-specific with generalized weakness, easy fatiguability, loss of weight, loss of appetite, pain in abdomen, and gradually progressive darkening of complexion (Fig 2). These symptoms and signs of adrenal insufficiency do not occur until more than 90% of the glands are destroyed (33). Patient can have low grade fever if the tuberculosis is active and cough and hemoptysis if associated pulmonary involvement is present. In the majority of the cases, the tuberculosis infection may not be active with only a past history of pulmonary tuberculosis (33). Untreated patients may present with adrenal crisis during times of stress. Laboratory investigations reveal low serum cortisol and high plasma adrenocorticotrophic hormone (ACTH). Sometimes, ACTH stimulation test (short synacthen test) may be needed. Adrenal insufficiency is ruled out if serum cortisol level one hour post synacthen (ACTH) stimulation is more than 500-550 nmol/L (14-20 ug/dL depending on the assay). Electrolyte abnormalities noted in adrenal insufficiency are hyponatremia and hyperkalemia. Computed tomography shows bilateral enlarged adrenal masses with areas of necrosis and caseation. In long standing cases, there may be evidence of calcifications (33). Diagnosis is confirmed by adrenal biopsy showing caseating granulomas with acid fast bacilli. Other methods like culture and molecular techniques can be used for diagnosing tuberculosis in biopsy samples. Anti-tubercular treatment (ATT) along with both glucocorticoid and mineralocorticoids remain the treatment of choice. ATT consists of isoniazid - INH (5 mg/kg /d), rifampicin (10 mg/kg /d), pyrazinamide (30 mg/kg /d), and ethambutol (20 mg/kg/d) for 3 to 6 months, subsequently isoniazid and rifampicin for 6 to 12 months (34). In case of multi drug resistant tuberculosis, ATT may be altered with respect to the pattern of resistance. It may require second line medications and longer duration of therapy. Patients usually require lifelong replacement therapy with glucocorticoids and mineralocorticoids.

 

Apart from Mycobacterium tuberculosis, in the context of HIV-AIDS and other immunocompromised states, Mycobacterium avium intracellular and Mycobacterium chelonae may also cause primary adrenal insufficiency.

Fig 2. A. Darkening of the skin in the dorsum aspect of hands in a patient with primary adrenal insufficiency due to adrenal tuberculosis B. Darkening of the palmar aspect including palmar creases of the same patient

Adrenal Abscess

 

An adrenal abscess is a rare clinical condition with very few cases reported in the literature. Organisms that are implicated are Mycobacterium, anaerobes, Salmonella, Nocardia, and E coli. Treatment includes drainage of abscess and antibiotic therapy (35-40). The choice of antibiotic is guided by culture and sensitivity report. In culture negative cases, broad spectrum antibiotics with coverage for gram positive, gram negative, and anaerobic organisms should be considered.

 

Waterhouse-Friderichsen Syndrome

 

Waterhouse-Friderichsen syndrome (WFS) or purpura fulminans is an uncommon clinical entity associated with bilateral adrenal hemorrhage in the setting of severe bacterial sepsis, which was first reported by Rupert Waterhouse and Carl Friderichsen (41). The initial version of this syndrome was classically described with Neisseria meningitidis sepsis. But later it was found that a similar clinical picture was seen with other bacterial infections such as Streptococcus pneumoniaeHemophilus influenzae, Escherichia coli, Staphylococcus aureus, Group A beta-hemolytic Streptococcus, Capnocytophaga canimorsus, Enterobacter cloacae, Pasteurella multocida, Plesiomonas shigelloides,Neisseria gonorrhoeaeMoraxella duplex, Rickettsia rickettsia, Bacillus anthracis, Treponema pallidum,and Legionella pneumophila (42-44).

 

Adrenal glands are predisposed to hemorrhage because around 50-60 small adrenal branches from 3 main adrenal arteries form a subcapsular plexus that drains into the medullary sinusoids through only a few venules (43). Therefore, an increase in adrenal venous pressure due to any cause may lead to hemorrhage. These bacteria may invade the adrenals directly or may produce endotoxins to cause adrenal necrosis and hemorrhage. There is also evidence of microthrombi within the adrenals along with disseminated intravascular coagulation (DIC). Pathologically, organisms are hardly demonstrated in the adrenal specimens (45). The patients are usually sick and present with profound adrenal crisis and shock.  A petechial rash is usually present on the trunk, lower limbs, and mucous membrane and its severity correlates with the degree of thrombocytopenia (44). Treatment involves admission to an intensive care unit and resuscitation with intravenous fluids, intravenous glucocorticoids, and appropriate antibiotics.

 

BACTERIAL INFECTIONS OF GONADS

 

Bacterial Infections of Testes

 

EPIDEMIOLOGY

 

Infection of the epididymis can occur in both children and adults. In severe cases, the inflammation can spread further into testis and present as epididymo-orchitis. If the duration of illness is less than 6 weeks, it is termed as acute epididymo-orchitis, whereas duration more than 6 weeks is termed as chronic. In children, it usually occurs between two and thirteen years of age, whereas in adults, it is common between twenty and thirty years of age (46).

 

BACTERIOLOGY

 

Causative organisms in younger males less than 35 years of age are Neisseria gonorrhoeae and Chlamydia trachomatis. In older men, causative organisms include Escherichia coli, other coliforms, and Pseudomonas. Rare bacterial causes include Ureaplasma species, Mycoplasma genitalium, Mycobacterium tuberculosis, and Brucella species (47-49). Risk factors for epididymitis include urinary tract infections, sexually transmitted diseases, bladder outlet obstruction, prostate enlargement, and urinary tract surgeries or urogenital procedures. In homosexual men, an enteric bacterial etiology is common (46, 50).

 

CLINICAL PRESENTATION

 

Acute epididymitis presents as localized testicular pain. On palpation, there may be swelling in the posterior part of the testis that represents an enlarged testis and inflamed epididymis. More advanced cases present with secondary testicular pain and swelling (epididymo-orchitis). There could be redness of scrotum and hydrocele (reactive fluid collection secondary to infection) (Fig 3). A positive Prehn sign (manual elevation of the scrotum relieves pain) is more often seen with epididymitis than testicular torsion (46).

 

Fig 3. Swelling of bilateral testes with reddening of the skin overlying the scrotum, suggestive of epidymo-orchitis

 

DIAGNOSIS AND MANAGEMENT

 

In all cases of acute epididymo-orchits, it is important to rule out acute surgical conditions like testicular torsion and Fournier’s gangrene. All patients should undergo routine urine microscopy, urine for culture and sensitivity, and a urine nucleic acid amplification test (NAAT) for N. gonorrhoeae and C. trachomatis. NAAT is helpful in diagnosing infections where urine cultures are negative (51). Management depends on the severity of illness, history suggestive of sexually transmitted diseases, and reports of NAAT (summarized in table 4) (46, 52).

 

Table 4. Management of Acute Epididymo-Orchitis

Clinical scenario

Likely organisms

Choice of empirical antibiotic therapy *

Children < 14 years

Various possibilities – secondary to anatomical issues

Treatment based on urine culture results and referral to urologist.

Individuals at risk of sexually transmitted diseases but do not practice anal intercourse

N. gonorrhoeae and C. trachomatis 

 

Single injection of ceftriaxone 500mg intramuscular and oral Doxycycline 100mg twice daily for 10 days. 

 

Alternative for doxycycline – Azithromycin

Alternative for ceftriaxone- Gentamycin

 

Individuals at risk of sexually transmitted diseases but do practice anal intercourse

N. gonorrhoeae, C. trachomatis and enteric pathogens

 

Single injection of ceftriaxone 500mg intramuscular and oral Doxycycline 100mg twice daily for 10 days plus oral levofloxacin 500 mg once daily for 10 days

 

 

Individuals at lower risk of sexually transmitted diseases

Recent urinary tract surgery or instrumentation

 

Enteric pathogens

Oral levofloxacin 500 mg once daily for 10 days

 

*Further treatment should be adjusted based culture and NAAT results; severe cases may require hospitalization and intravenous antibiotics.

 

Bacterial Infections of Ovaries

 

Isolated infection of ovaries is not common. It is usually part of pelvic inflammatory disease. In severe cases, it may present as tubo-ovarian abscess. Tubo-ovarian abscesses are often polymicrobial and typically contain a predominance of anaerobic bacteria. Common organisms include Escherichia coli, Bacteroides fragilis, other Bacteroides species, Pepto-streptococci, and anaerobic streptococci (53). Diagnosis is based on history, physical examination, ultrasound suggesting tubo -ovarian mass or abscess, and microbiological diagnosis. Treatment consists of admission, intravenous antibiotic therapy, and aspiration of abscess if needed. Patients who do not respond, will need surgical intervention (54).

 

 

Yersinia enterocolitica has been implicated in the pathogenesis of autoimmune thyroid disease (55). Immunoglobulins from patients with Yersinia infection inhibit binding of TSH to thyrocytes (56). This could be explained by structural similarity between Yersinia outer membrane proteins (YOP) and epitopes of the TSH receptor (55, 56).

 

Role of gut microbiome has recently implicated in the metabolic syndrome, obesity, and diabetes (57). Many metabolites produced by gut microbes get absorbed into the circulation. They may act on specific receptors to regulate metabolism (58, 59). Also, some bacterial components can act as endocrine factors controlling metabolism(58).

 

CONCLUSION

 

Bacterial infections of the endocrine glands are rare. Pituitary abscesses usually occur in the setting of underlying pathology of the pituitary gland.  It is commonly caused by Streptococci and Staphylococci. MRI of the sella demonstrates a characteristic rim of enhancement after gadolinium injection. Treatment of pituitary abscess is trans-sphenoidal surgery and intravenous antibiotics. Culture is positive in only 19.7% of cases. Acute suppurative thyroiditis is commonly caused by Streptococci and Staphylococci. Important risk factor for acute suppurative thyroiditis in children is pyriform fistula, whereas in adults, it is more common in immunocompromised states. Acute suppurative thyroiditis appear as hypoechoic area on ultrasound. It is treated by ultrasound guided drainage of the abscess and antibiotic therapy. Acute suppurative thyroiditis should be differentiated from subacute thyroiditis. Primary adrenal bacterial infections other than tuberculosis are rare. Waterhouse-Friderichsen syndrome (WFS) is an uncommon clinical entity associated with bilateral adrenal hemorrhage in the setting of severe bacterial sepsis. It is classically described with Neisseria meningitides, but may be associated with other bacteria as well. Toxins produced by bacteria can cause necrosis, hemorrhage, and microthrombi within the adrenal gland leading to WFS. Infection of the epididymis can occur in both children and adults. Sometimes, the inflammation spreads further into testis and presents as epididymo-orchitis. Common bacterial agents causing epididymo-orchitis are N. gonorrhoeae and C.trachomatis. Enteric pathogens should be suspected if there is history of homosexual practice. Management depends on the severity of illness, history of suggestive sexually transmitted diseases, and reports of NAAT (urine nucleic acid amplification test).

 

ACKNOWLEDGEMENTS

 

Dr. Lovekesh Bhatia, Department of Radiodiagnosis, Aadhar Health Institute, Hisar, India

Dr. Vinita Jain, Department of Pediatrics, Aadhar Health Institute, Hisar, India

 

REFERENCES

 

  1. Nagendra L, Boro H, Mannar V. Bacterial Infections in Diabetes. 2022 Apr 5. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
  2. Gupta S, Ansari MAM, Gupta AK, Chaudhary P, Bansal LK. Current Approach for Diagnosis and Treatment of Adrenal Tuberculosis-Our Experience and Review of Literature. Surg J (N Y). 2022 Mar 3;8(1):e92-e97.
  3. Jacob JJ, Paul PAM. Infections in Endocrinology: Tuberculosis. 2021 Mar 14. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
  4. Machado MJ, Ramos R, Pereira H, Barbosa MM, Antunes C, Marques O, Almeida R. Primary pituitary abscess: case report and suggested management algorithm. Br J Neurosurg. 2021 Aug 24:1-4.
  5. Pekic S, Miljic D, Popovic V. Infections of the Hypothalamic-Pituitary Region. 2021 Aug 9. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
  6. Cabuk B, Caklılı M, Anık I, Ceylan S, Celik O, Ustün C. Primary pituitary abscess case series and a review of the literature. Neuro Endocrinol Lett. 2019 Oct;40(2):99-104.
  7. Pekic S, Popovic V. Alternative causes of hypopituitarism: traumatic brain injury, cranial irradiation, and infections. Handb Clin Neurol. 2014;124:271-90.
  8. Adams D, Kern PA. A case of pituitary abscess presenting without a source of infection or prior pituitary pathology. Endocrinol, Diabetes & Metabol Case Reports [Internet]. 2016 Aug 16 [cited 2022 May 10];2016.
  9. Gao L, Guo X, Tian R, Wang Q, Feng M, Bao X, Deng K, Yao Y, Lian W, Wang R, Xing B. Pituitary abscess: clinical manifestations, diagnosis and treatment of 66 cases from a large pituitary center over 23 years. Pituitary. 2017 Apr;20(2):189-194.
  10. Ling X, Zhu T, Luo Z, Zhang Y, Chen Y, Zhao P, et al. A review of pituitary abscess: our experience with surgical resection and nursing care. Transl Cancer Res. 2017 Aug;6(4):852–9.
  11. Vates GE, Berger MS, Wilson CB. Diagnosis and management of pituitary abscess: a review of twenty-four cases. J Neurosurg. 2001 Aug;95(2):233-41.
  12. Bloomer ZW, Knee TS, Rubin ZS, Hoang TD. Case of an atypical pituitary abscess. BMJ Case Rep. 2021 Nov 30;14(11):e246776. 
  13. Bricaire L, Van Haecke C, Laurent-Roussel S, Jrad G, Bertherat J, Bernier M, Gaillard S, Groussin L, Dupin N. The Great Imitator in Endocrinology: A Painful Hypophysitis Mimicking a Pituitary Tumor. J Clin Endocrinol Metab. 2015 Aug;100(8):2837-40.
  14. Benzick AE, Wirthwein DP, Weinberg A, Wendel GD Jr, Alsaadi R, Leos NK, Zeray F, Sánchez PJ. Pituitary gland gumma in congenital syphilis after failed maternal treatment: a case report. Pediatrics. 1999 Jul;104(1):e4. 
  15. Spinner CD, Noe S, Schwerdtfeger C, Todorova A, Gaa J, Schmid RM, Busch DH, Neuenhahn M. Acute hypophysitis and hypopituitarism in early syphilitic meningitis in a HIV-infected patient: a case report. BMC Infect Dis. 2013 Oct 17;13:481.
  16. Har-el G, Sasaki CT, Prager D, Krespi YP. Acute suppurative thyroiditis and the branchial apparatus. Am J Otolaryngol. 1991 Jan-Feb;12(1):6-11. 
  17. Touihmi S, Rkainilham, Mehdaoui A, El boussaadni Y, Oulmaati A. Acute suppurative thyroiditis with abscess. J Pediatr Surg Case Rep. 2021 Feb;65:101757.
  18. Bukvic B, Diklic A, Zivaljevic V. Acute suppurative klebsiella thyroiditis: a case report. Acta Chir Belg. 2009 Mar-Apr;109(2):253-5.
  19. Paes JE, Burman KD, Cohen J, Franklyn J, McHenry CR, Shoham S, Kloos RT. Acute bacterial suppurative thyroiditis: a clinical review and expert opinion. Thyroid. 2010 Mar;20(3):247-55.
  20. Madana J, Yolmo D, Kalaiarasi R, Gopalakrishnan S, Saxena SK, Krishnapriya S. Recurrent neck infection with branchial arch fistula in children. Int J Pediatr Otorhinolaryngol. 2011 Sep;75(9):1181-5. 
  21. Parida PK, Gopalakrishnan S, Saxena SK. Pediatric recurrent acute suppurative thyroiditis of third branchial arch origin--our experience in 17 cases. Int J Pediatr Otorhinolaryngol. 2014 Nov;78(11):1953-7.
  22. Zhang P, Tian X. Recurrent neck lesions secondary to pyriform sinus fistula. Eur Arch Otorhinolaryngol. 2016 Mar;273(3):735-9
  23. Lafontaine N, Learoyd D, Farrel S, Wong R. Suppurative thyroiditis: Systematic review and clinical guidance. Clin Endocrinol (Oxf). 2021 Aug;95(2):253-264
  24. Falhammar H, Wallin G, Calissendorff J. Acute suppurative thyroiditis with thyroid abscess in adults: clinical presentation, treatment and outcomes. BMC Endocr Disord. 2019 Dec 3;19(1):130.
  25. Dunham B, Nicol TL, Ishii M, Basaria S. Suppurative thyroiditis. Lancet. 2006 Nov 11;368(9548):1742.
  26. Minhas SS, Watkinson JC, Franklyn J. Fourth branchial arch fistula and suppurative thyroiditis: a life-threatening infection. J Laryngol Otol. 2001 Dec;115(12):1029-31.
  27. Masuoka H, Miyauchi A, Tomoda C, Inoue H, Takamura Y, Ito Y, Kobayashi K, Miya A. Imaging studies in sixty patients with acute suppurative thyroiditis. Thyroid. 2011 Oct;21(10):1075-80.
  28. Furukawa M, Kano M, Takiguchi T, Umeda R. Piriform sinus fistula as a route of infection in acute suppurative thyroiditis. Auris Nasus Larynx. 1986;13(2):107-12.
  29. Miyauchi A, Inoue H, Tomoda C, Amino N. Evaluation of chemocauterization treatment for obliteration of pyriform sinus fistula as a route of infection causing acute suppurative thyroiditis. Thyroid. 2009 Jul;19(7):789-93. 
  30. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003 Jun 26;348(26):2646-55.
  31. Shrestha RT, Hennessey J. Acute and Subacute, and Riedel’s Thyroiditis. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
  32. Del Borgo C, Urigo C, Marocco R, Belvisi V, Pisani L, Citton R, et al. Diagnostic and therapeutic approach in a rare case of primary bilateral adrenal tuberculosis. J Med Microbiol. 2010 Dec;59 (Pt 12):1527-1529
  33. Kelestimur F. The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function. J Endocrinol Invest. 2004 Apr;27(4):380-6.
  34. Laway BA, Khan I, Shah BA, Choh NA, Bhat MA, Shah ZA. Pattern of adrenal morphology and function in pulmonary tuberculosis: response to treatment with antitubercular therapy. Clin Endocrinol (Oxf). 2013 Sep;79(3):321-5.
  35. Regino CA, Gómez JP, Mosquera-Klinger G. Endoscopic Ultrasound-Guided Transgastric Puncture and Drainage of an Adrenal Abscess in an Immunosuppressed Patient. Clin Endosc. 2022 Mar;55(2):302-304. 
  36. O'NEILL JA Jr, HALL WH. ISOLATED ADRENAL ABSCESS SECONDARY TO SALMONELLA. Arch Surg. 1965 Mar;90:454-6.
  37. Midiri M, Finazzo M, Bartolotta TV, Maria MD. Nocardial adrenal abscess: CT and MR findings. Eur Radiol. 1998;8(3):466-8.
  38. Yokoyama S, Sekioka A, Utsunomiya H, Hara S, Takahashi T, Yoshida A. Adrenal abscess as a complication of Escherichia coli sepsis in neonates: A case report. J Pediatr Surg Case Rep. 2013 Sep;1(9):328–30.
  39. Jin W, Miao Q, Wang M, Zhang Y, Ma Y, Huang Y, et al. A rare case of adrenal gland abscess due to anaerobes detected by metagenomic next-generation sequencing. Ann Transl Med. 2020 Mar;8(5):247. 
  40. Rumińska M, Witkowska-Sędek E, Warchoł S, Dudek-Warchoł T, Brzewski M, Pyrżak B. Adrenal abscess in a 3-week-old neonate - a case report. J Ultrason. 2015 Dec;15(63):429-37.
  41. Varon J, Chen K, Sternbach GL. Rupert Waterhouse and Carl Friderichsen: adrenal apoplexy. J Emerg Med. 1998 Jul-Aug;16(4):643-7. 
  42. Hamilton D, Harris MD, Foweraker J, Gresham GA. Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection. J Clin Pathol. 2004 Feb;57(2):208-9. 
  43. Karki BR, Sedhai YR, Bokhari SRA. Waterhouse-Friderichsen Syndrome. [Updated 2021 Dec 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
  44. Kalinoski T. Waterhouse-Friderichsen Syndrome with Bilateral Adrenal Hemorrhage Associated with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia in an Adult Patient with History of Intravenous Drug Use. Am J Case Rep. 2022 Apr 14;23:e936096.
  45. Guarner J, Paddock CD, Bartlett J, Zaki SR. Adrenal gland hemorrhage in patients with fatal bacterial infections. Mod Pathol. 2008 Sep;21(9):1113-20.
  46. McConaghy JR, Panchal B. Epididymitis: An Overview. Am Fam Physician. 2016 Nov 1;94(9):723-726. 
  47. Tracy CR, Steers WD, Costabile R. Diagnosis and management of epididymitis. Urol Clin North Am. 2008 Feb;35(1):101-8; vii. 
  48. Doble A, Taylor-Robinson D, Thomas BJ, Jalil N, Harris JR, Witherow RO. Acute epididymitis: a microbiological and ultrasonographic study. Br J Urol. 1989 Jan;63(1):90-4. 
  49. Hawkins DA, Taylor-Robinson D, Thomas BJ, Harris JR. Microbiological survey of acute epididymitis. Genitourin Med. 1986 Oct;62(5):342-4.
  50. Kaver I, Matzkin H, Braf ZF. Epididymo-orchitis: a retrospective study of 121 patients. J Fam Pract. 1990 May;30(5):548-52.
  51. Wampler SM, Llanes M. Common scrotal and testicular problems. Prim Care. 2010 Sep;37(3):613-26, x.
  52. Trojian TH, Lishnak TS, Heiman D. Epididymitis and orchitis: an overview. Am Fam Physician. 2009 Apr 1;79(7):583-7.
  53. Kairys N, Roepke C. Tubo-Ovarian Abscess. 2021 Jul 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
  54. Munro K, Gharaibeh A, Nagabushanam S, Martin C. Diagnosis and management of tubo-ovarian abscesses. Obstet Gynecol. 2018 Jan;20(1):11–9.

         Mar;93(3):674-6.

  1. Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014 Jun;170(6):R241-52. 
  2. Li R, Li Y, Li C, Zheng D, Chen P. Gut Microbiota and Endocrine Disorder. Adv Exp Med Biol. 2020;1238:143-164.
  3. Rastelli M, Cani PD, Knauf C. The Gut Microbiome Influences Host Endocrine Functions. Endocr Rev. 2019 Oct 1;40(5):1271-1284
  4. Cani PD, Knauf C. How gut microbes talk to organs: The role of endocrine and nervous routes. Mol Metab. 2016 May 27;5(9):743-52.

Infections in Endocrinology: Tuberculosis

ABSTRACT

 

Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), is responsible for the largest number of deaths worldwide caused by a single organism. Over 25% of the world population is infected with M. tuberculosis, though active infections account only for a small percentage. Though some degree of endocrine dysfunction is invariable in all patients with TB, clinically significant endocrinopathy other than glucose intolerance is rare. This chapter reviews endocrine dysfunction and endocrinopathies associated with TB infection related to the adrenal, thyroid and pituitary glands. Additionally, functional derangement of sodium and calcium homeostasis is also covered. Adrenal involvement can be found in up to 6% of patients with active TB, however isolated adrenal involvement is seen only in a fourth of these. The most common clinical manifestation is Addison’s disease (AD). Clinical manifestations of AD appear only after 90% of the adrenal cortices have been compromised. Thyroid tuberculosis (TTB) is very rare, even in countries with a high prevalence of TB. TB has been seen to involve the thyroid in 0.1 to 1% of patients. Primary pituitary TB (in the absence of systemic involvement and/or constitutional symptoms) is extremely rare, and secondary pituitary TB is more commonly encountered in clinical practice. Pituitary TB should be considered in the differential of a suprasellar mass especially in developing countries, as the condition is potentially curable with treatment. Hyponatremia has been commonly seen in patients admitted to the hospital with TB. The commonest cause of hyponatremia is the syndrome of inappropriate antidiuresis (SIAD). Other causes include untreated primary or secondary adrenal insufficiency, volume depletion, hyponatremia associated with volume excess and hypoalbuminemia and rare cases of cerebral salt wasting seen with tuberculous meningitis. The prevalence of hypercalcemia in patients with TB has ranged from 2-51% in various studies. The primary determinant in the development of hypercalcemia among patients with TB appears to be their Vitamin D status and nutritional calcium intake.

 

INTRODUCTION

 

Mycobacterium tuberculosis the etiological agent of tuberculosis (TB) was directly responsible for 1.3 million deaths in 2019. A majority of these deaths happen in patients without human immunodeficiency virus (HIV) co-infection making M. tuberculosis the pathogen responsible for the largest number of deaths in the world by a single organism. Additionally, TB is among the top ten causes of death worldwide (1).

 

Most cases of primary TB infections are clinically, bacteriologically, and radiologically inapparent. This primary infection in 5-10% patients leads to active disease after a period of latency within 2 years of contracting the infection. In another 5% the disease becomes active much later in life after a decline in general immunity. It is thought that over 25% of the world’s current population is infected with M. tuberculosis though active infections account only for a small percentage. In the year 2019 over 10 million patients were newly diagnosed with clinical TB. South East Asia accounted for over 44% of these along with Africa (25%), Western Pacific (18%), Eastern Mediterranean (8.2%), Americas (2.9%) and Europe (2.5%). The eight countries of India (26%), Indonesia (8.5%), China (8.4%), Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%) account for two thirds of the world’s newly diagnosed cases last year (1).

 

As previously noted most active TB infections are reactivation of latent primary TB though a small but significant percentage of patients have active TB related to new exogenous re-infection. The most common primary site of adult active TB are the highly aerated upper lobes of the lungs. The defining pathology includes the presence of granulomas containing epithelioid cells, Langhan’s giant cells surrounded by lymphocytes with a center of caseous necrosis and varying degrees of fibrosis. This chapter focuses on the endocrinology of tuberculous infection (2, 3).

 

ALTERED IMMUNE-NEUROENDOCRINE COMMUNICATION IN TUBERCULOSIS        

 

The two-way communication between the immune system and the neuroendocrine system is well known and documented. An activated immune cascade can affect all the endocrine systems of the body. Adrenal steroids are the primary hormones that modify immune responses. The up-regulation of the hypothalamic-pituitary adrenal (HPA) axis by inflammation related to infections is primarily mediated by the action of inflammatory cytokines on the hypothalamic releasing factors. Cytokines like Interleukin-6 (IL-6), Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) stimulate the secretion of corticotrophin releasing hormone (CRH) from the hypothalamus leading to corticotrophin (ACTH) secretion from the pituitary. The action of ACTH on the adrenal cortex leads to secretion of both cortisol and dehydroepiandrosterone (DHEA). Cortisol inhibits the T- lymphocyte mediated Th1 response while DHEA antagonizes the cortisol action on Th1 response. This intense immune-endocrine response to acute infection leads to early mobilization of the immune cells and a robust immune response by the host against the offending pathogen (4, 5).

 

However, in TB the chronic persistent activation of the immune-endocrine axis leads to misuse of the immune-endocrine axis and can exacerbate damage to the host. Primarily the prolonged activation of the HPA and resultant increase in glucocorticoid (GC) secretion leads to a change in the T-lymphocyte response from Th1 to Th2 response (6). Beyond this GCs can interfere with gene expression of certain transcription factors like nuclear factor kappa-β(NF-κβ) (7), inhibit the proliferation of effector T cells and cause an increased rate of apoptosis of the regulatory T cells (8). Clinical studies in patients with TB have shown increased circulating levels of cytokines like IL-6, IL-10, interferon-α (IFN-α) and cortisol. However, DHEA levels have been consistently shown to be well below normal levels. In summary, GCs appear to have an adverse effect on the anti-TB immune response while DHEA appears to have a favorable effect. This balance is adversely impacted with the chronic inflammation seen in TB.

 

Some of these changes in immune-endocrinology have also been implicated in the morbidity associated with TB. In vitro studies suggest that negative immune response to mycobacterial antigens was associated with increased IL-6 production which in turn was associated with lower body weights among patients with TB. Higher circulating IL-6 was also associated with loss of appetite (9). The increased circulating GCs additionally mobilize peripheral lipid stores and inhibit protein synthesis and favor loss of lean body mass. Hypothalamic CRH secretion also appear to have direct catabolic effects on the body other than its effect mediated through increased GC secretion (10). Among the adipocyte hormones there is a decrease in leptin and increased secretion of adipocytokines in TB. In an acute infection the above adaptive response appears to be useful by directing limited energy stores to the immune response away from the body’s physiological needs. However, in chronic infections like TB these changes lead to a chronic metabolic deficit leading to cachexia which in turn then affects the further ongoing immune response and disease outcome (11, 12).  

 

Some of these alterations in the immune-endocrine axis in M. tuberculosis infection are summarized in Figure 1.

Figure 1. Immune-Endocrine changes in male patients with tuberculosis (TB). Cytokine release by the T Lymphocytes stimulate the production of releasing factors (RFs) particularly Corticotrophin releasing factor (CRF) by the hypothalamus. Increased corticotrophin release from the pituitary is followed by the increased production of cortisol and dehydroepiandrosterone (DHEA). Transforming growth factor beta (TGF-β) which is increased in TB, in turn, inhibits DHEA production by adrenal cells despite corticotrophin related stimulation to produce increased DHEA. Overall, in patients with TB there is a decrease in the adrenal DHEA production in contrast to patients with acute infections. This unbalanced cortisol/DHEA production ratios from the adrenal cortex along with a reduction in testosterone from the testes favor a Th1→Th2 T Lymphocyte immune shift. The action of cytokines and cortisol on the adipose tissue leads to reduced amounts of leptin production. Leptin is also an immune-stimulant. TB patients also display an increased production of growth hormone (GH) and prolactin probably related to the protracted inflammation, in addition to augmented levels of thyroid hormones via an increase in the pituitary production of thyroid stimulating hormone (TSH). However, despite an increase in TSH there is no change in Free T4 and a decline in Free T3 hormones because of the inhibitory effect of TGF- β This overall pattern is responsible for anorexia, low food intake, lipid mobilization, decrease in protein synthesis which all contribute to the state of cachexia seen in patients with advanced TB (adapted from D’Atillio et al) (12).

ENDOCRINOPATHIES IN PATIENTS WITH TUBERCULOSIS        

 

Though some degree of endocrine dysfunction is invariable in all patients with TB, clinically significant endocrinopathies other than glucose intolerance is rare. In a small study of 50 patients hospitalized with sputum-positive pulmonary TB in South Africa the commonest endocrine dysfunction noted was a low free T3 state as part of sick euthyroid syndrome in over 90% of patients. The other common endocrine dysfunction noted in the study was a 72% prevalence of hypogonadotropic hypogonadism among male patients and a 64% prevalence of hyponatremia of whom almost half of them (17/50) had documented syndrome of inappropriate diuresis (SIAD). No patients in this study had clinically significant adrenal insufficiency and one patient had hypercalcemia (13).

 

In disseminated TB, seeding of the various endocrine glands with mycobacteria and formation of tubercules is common. In an autopsy study performed in over 100 patients who succumbed to disseminated TB done in the eighties, 53% had involvement of the adrenals, 14% had seeding into the thyroid gland, 5% had direct involvement of the testes, and 4% had seeding into the pituitary gland. Among these 100 patients only one had antemortem clinical adrenal insufficiency (14).

 

The full spectrum of possible endocrine abnormalities seen with tuberculosis is summarized in Table 1.

 

Table 1. Endocrine Abnormalities Seen with Mycobacterium Tuberculosis Infection and with Anti-Tubercular Therapy

Hypothalamus

Diabetes Insipidus

Pituitary

1.     Sellar mass lesion

2.     Tuberculous abscess

3.     Sellar Tuberculoma

4.     Thickened stalk with pituitary interruption syndrome

5.     Isolated hyperprolactinemia

6.     Incidental partial or complete hypopituitarism 

7.     Isolated hypogonadotropic hypogonadism

8.     Pituitary dysfunction seen with Tuberculous meningitis

Thyroid

1.     Tubercular thyroiditis

2.     Cold abscess of the thyroid

3.     Chronic fibrosing thyroiditis

4.     Sick euthyroid syndrome

5.     Para-amino-salicylic acid (PAS) related goiter

6.     Ethionamide and rifampicin related thyroid dysfunction

Parathyroid

Inflammation

Pancreas

1.     Stress hyperglycemia

2.     Frank diabetes

3.     Pancreatic abscess 

Testes

1.     Isolated TB orchitis

2.     TB epididymitis

3.     Epididymo-orchitis 

4.     Primary gonadal failure

Ovaries

1.     Tubo-ovarian abscess

2.     Tubal blockage

3.     Unexplained infertility

Water Metabolism

1.     Hyponatremia

2.     Syndrome of inappropriate anti-diuresis (SIAD)

3.     Cerebral salt wasting (CSW)

Vitamin D-Calcium Metabolism

1.     Parathyroid hormone independent hypercalcemia

2.     Vitamin D deficiency/hypocalcemia related to isoniazid and rifampicin

Adrenals

1.     Tubercular adrenalitis

2.     Addison’s disease

3.     Reversible adrenal insufficiency

4.     Isolated DHEA deficiency 

 

In this chapter we will review endocrine dysfunction and endocrinopathies associated with TB infection related to the adrenal, thyroid and pituitary glands. Additionally, functional derangement of sodium, and calcium homeostasis will be covered. Glucose intolerance, diabetes and tuberculosis is a large area of public health and will not covered in this chapter.

 

ADRENALS AND TUBERCULOSIS

 

TB can involve both adrenal glands primarily or the involvement may be part of disseminated TB. Both conditions may present with primary adrenal insufficiency (Addison’s Disease). Anti-tuberculous therapy (ATT)-related enzyme induction abnormalities can also lead to adrenal dysfunction and in some cases unmask subclinical adrenal insufficiency. Chronic steroid therapy used in the treatment of some types of tuberculous infection can lead to suppression of HPA axis and secondary adrenal insufficiency. Finally, it is important to remember that pituitary involvement in central nervous system (CNS) TB can sometimes lead to isolated corticotropin deficiency with adrenal insufficiency or it can be part of generalized hypopituitarism 

 

Tuberculosis and Addison’s Disease

 

Thomas Addison in 1855 first described chronic adrenal failure, or Addison’s disease (AD), due to Mycobacterium tuberculosis infection involving both the adrenal glands. In his paper describing AD, 6/11 patients had tuberculous involvement of the adrenal glands. In 1930, Guttman reported a large series of 566 cases with AD, of which 70% was due to tuberculous adrenalitis (15). In 1956 only 25% of AD was related to TB infection (16). The decreasing incidence of tubercular adrenal failure in Western literature was highlighted in a recent large study of 615 cases of AD from Italy in 2011; in this series only 9% of cases were due to TB (17).

 

This decline in the number of patients with AD related to TB has not been seen in countries endemic for TB like India and South Africa. In India, tuberculous etiology was found in 47% of patients with AD, and of them 85% had enlargement of one or both adrenal glands on imaging (18). The differences between AD due to TB and those with idiopathic AD is summarized in Table 2. In South Africa, 32% of patients with AD had tubercular etiology (19). The most common cause of AD worldwide, however, is autoimmune adrenalitis.

 

Table 2. Differences in Clinical Presentation of Tubercular Addison’s Disease (AD) versus Idiopathic AD (18)

Clinical Features

Tubercular

Idiopathic

p-value

Mean age (in years)

42

35

NS

Durations of symptoms before diagnosis (in months)

14

21

NS

Sex Ratio (M: F)

10:1

14:8

< 0.05

Presentation as crisis (%)

40%

23%

NS

Evidence of other autoimmune disease (%)

10%

27%

< 0.05

Evidence of extra-adrenal TB (%)

55%

9%

< 0.05

Adrenal Cytoplasmic Antibodies (%)

17%

50%

< 0.05

 

PATHOPHYSIOLOGY OF TUBERCULAR ADRENALITIS            

 

Adrenal TB develops from hematogenous or lymphatic spread, hence is often associated with extra-adrenal infection. The rich vascularity of the adrenal gland and high levels of local corticosteroids that suppress cell mediated immunity create an ideal microenvironment for the growth of Mycobacterium tuberculosis (20). Adrenal involvement can be found in up to 6% of patients with active TB, however isolated adrenal involvement is seen only in a fourth of these (1.5-3% of cases with tubercular infection) (21, 22). Clinical manifestations of AD appear only after 90% of the adrenal cortices have been compromised (23).

 

The patterns of adrenal gland involvement in TB are summarized below and in Figure 2 (24):

  1. Chronic infection of the adrenal gland, with clinical manifestations of primary adrenal insufficiency appearing years after initial infection. Pathologically these patients have small atrophic fibrous glands with or without calcification.
  2. Isolated adrenal gland involvement early in the course of disease usually within 2 years of the primary infection. Pathologically these patients most commonly present with bilateral adrenal enlargement because of mass lesions secondary to production of cold abscesses within the adrenal glands. Milder enlargement can be seen in patients with extensive granulomas within the adrenal gland. Lastly, patients with isolated adrenal tuberculosis may also present with normal sized glands with granulomatous inflammation seen microscopically. Calcifications maybe seen in these cases as well.
  3. Secondary adrenal insufficiency due to prolonged steroid therapy in disseminated TB or tubercular involvement of the pituitary or hypothalamus.
  4. Subclinical steroid deficiency unmasked by ATT-related enzyme induction.

Figure 2. Mechanisms of adrenal insufficiency with tuberculosis. Both primary adrenal failure and secondary adrenal insufficiency are possible. The presentation of primary adrenal failure can be both acute and chronic. In patients with acute presentation usually within 2 years of tuberculous infection, the pathological presentations could be one of the three noted. Chronic primary adrenal failure is pathologically defined by atrophic and fibrosed glands. [ATT-Anti-tuberculous therapy

CLINICAL FEATURES

 

Adrenal TB can be found in any age, however is more commonly seen in adults. Rare cases have also been described in the pediatric age group (25, 26). Thomas Addison’s first description of AD showed a constellation of symptoms like “general languor and debility, remarkable feebleness of heart’s action, and a peculiar change in the color of the skin.” Classic manifestations of AD in the form of malaise or fatigue, anorexia, weight loss, nausea, vomiting, muscle and joint pain, orthostatic hypotension, skin hyperpigmentation and salt craving are often present. Mineralocorticoid deficiency leads to postural hypotension, while hyperpigmentation occurs due to activation of the melanocortin 1 receptors (MC1R) in turn because of high ACTH levels (27). In some patients, however, hyperpigmentation can be absent due to reduced stimulation of MC1R from adrenocorticotropin hormone (ACTH), resulting in an alabaster-like appearance (27). A prior history of TB may also be provided in some patients.

 

RADIOLOGIC FINDINGS

 

Computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) are useful non-invasive tools in the diagnosis of adrenal TB. CT has been regarded as the modality of choice for diagnosing adrenal TB, and should include both non-contrast and contrast-enhanced techniques. Adrenal involvement is usually bilateral (28), and findings vary according to course of disease.

 

  • Early stage: In the first two years, CT shows noncalcified enlarged adrenals with areas of lucency reflecting caseous necrosis, and a peripheral rim of contrast-enhanced parenchyma. Contours of the adrenal glands are generally preserved.
  • Late stage: As disease progresses, the adrenals normalize in size, then shrink, and have calcific foci with irregular margins. Calcifications are best visualized on non-contrast CT scans. These may be either diffuse, focal or punctate in nature (22). These findings correlate with long-standing fibrosis and dystrophic calcification seen with tuberculous granulomas.

 

LABORATORY FINDINGS

 

Common findings in patients with adrenal TB include hyponatremia, hyperkalemia and normochromic anemia (27). Hyponatremia can occur due to decreased inhibitory control of vasopressin secretion, resulting in mild SIAD (29). The Mantoux (tuberculin) test usually is strongly positive and erythrocyte sedimentation rate (ESR) is elevated.

 

  • In primary AD, baseline serum ACTH levels are higher than 100 pg/ml, plasma renin levels are elevated and serum aldosterone levels are low. In secondary AD, ACTH levels will be low or inappropriately normal, while mineralocorticoid secretion will be normal (27).
  • Serum DHEAS will also be low in patients with both primary and secondary AD (27).
  • Adrenal insufficiency can be demonstrated by low morning plasma cortisol with a reduced response to synthetic ACTH (27). Impaired ACTH-stimulated cortisol responses have also been observed with lower baseline cortisol levels, and both higher and lower cortisol responses to ACTH stimulation in patients with isolated pulmonary TB without adrenal involvement (24). Injectable tetracosactide hexa-acetate, ACTH 1-24 (Synacthen®) (SST), is not marketed or easily available in many developing countries in the world including India. An alternative ACTH which is injectable long-acting porcine sequence, ACTH 1-39 (Acton Prolongatum®) (APST), is easily available and much cheaper. In a study done recently in India by Nair et al in 20 patients with established adrenal insufficiency and 27 controls, the area under the curve of APST (at 120 min) was 0.986 when compared to the standard SST, thus proving its high accuracy. A serum cortisol cut off value of 19.5 µg/dL at 120-min following APST showed a sensitivity of 100% and specificity of 88% (30).

 

PATHOLOGY OF ADRENAL TUBERCULOSIS

 

Macroscopic involvement of the adrenal gland can be seen in up to 46% of patients with adrenal TB. Bilateral involvement is seen in nearly 70% of patients, however they may not be equally affected. Mean combined weight of adrenal gland ranges from 10-37 gm (mean 17 gm) (31). Caseous necrosis can be seen grossly within a large cavity or within multiple scattered tubercles.

 

Histopathologically, destruction of both the cortex and the medulla is seen with the following patterns of adrenal gland involvement (24):

  1. Presence of granulomas, with or without necrosis. The granulomas show epithelioid cell collections with typical Langhan’s giant cells and an admixture of lymphocytes and plasma cells. Ziehl-Neelsen stain is very useful for detecting acid fast bacilli (AFB) within the necrotic areas, as well as within the granulomas.
  2. Glandular enlargement with destruction of parenchyma by necrotizing granulomas.
  3. Mass lesion secondary to formation of cold abscesses. In these cases, CT-guided fine needle aspiration cytology (FNAC) is helpful for demonstration of AFB, polymerase chain reaction (PCR), and culture for Mycobacterium tuberculosis In most cases, a combination of histopathology, PCR and culture may be required to confirm the diagnosis.
  4. Adrenal atrophy secondary to fibrosis resulting from long-standing tuberculous infection (32).

 

DIFFERENTIAL DIAGNOSIS

 

The differential diagnosis for adrenal enlargement includes primary or metastatic tumors, lymphomas, fungal infections like cryptococcus and histoplasma, amyloidosis, sarcoidosis, hemangiomas and adrenal cortical hyperplasia (24, 28). Tissue sampling for microbiological (PCR and culture) and pathological analysis should adequately distinguish between them.

 

TREATMENT

 

Treatment for active adrenal TB is similar to the regimen followed for extrapulmonary TB with use of multidrug ATT. Rifampicin induces hepatic enzymes that increase the metabolism of glucocorticoids; hence higher doses of replacement glucocorticoids may be required. Rarely, Rifampicin may trigger an adrenal crisis.

 

In cases of chronic disease, adrenal gland function is unlikely to recover due to massive destruction of the gland (20, 28). However, a few authors report improvement in adrenal function when patients are given ATT early in the course of disease (33-35). This may be in part due to the remarkable regenerative capacity of the adrenal cortex to undergo hyperplasia and hypertrophy during active infection (20).

 

Hormone replacement for primary and secondary adrenal insufficiency related to TB follow the same principles as autoimmune or idiopathic primary AD or secondary adrenal insufficiency. In addition to appropriate glucocorticoid replacement mineralocorticoid replacement may be required. Care must be taken to educate patients about stress dosing and the need for parenteral steroids when the patient may not be able to take or absorb oral glucocorticoids. 

 

THYROID AND TUBERCULOSIS

 

The thyroid gland is an uncommon site for infection by M. tuberculosis. Thyroid TB (TTB) is therefore very rare, even in places with a high prevalence of TB. The primary presentation of TTB is as a mass or a goiter. Overt hormonal dysfunction is very uncommon in TTB. However, in patients with tuberculosis affecting any organ clinically insignificant abnormalities in thyroid function tests are very common. ATT also causes both structural and functional thyroid dysfunction. Pre-operative diagnosis of TTB can be made only with a high index of suspicion while evaluating thyroid nodules especially in communities with a high prevalence of TB (36).

 

Epidemiology

 

  1. tuberculosis has been documented to be involved in the thyroid gland of 0.1 to 1% of patients who underwent thyroid tissue sampling for any indication (37-39). In an autopsy series of patients with advanced disseminated TB occurring in the pre- and post-antibiotic era, 14% had evidence of thyroid gland involvement (14). In a large cohort of 2,426 patients from Morocco, only eight had evidence of TB (0.32%). These were in the form of goiter or as a solitary thyroid nodule. In a study from India, thyroid involvement has been seen in 0.43% of specimens obtained from FNAC (40), while among Turkish patients undergoing thyroidectomy, 0.25 - 0.6% showed thyroid involvement by M. tuberculosis (41, 42).

 

Pathogenesis

 

Thyroid involvement in TB is very uncommon. A few postulated intrinsic properties of the thyroid which are proposed not to allow Mycobacterium tuberculosis bacilli to survive include (24, 36):

  • Presence of iodine-containing colloid possessing bacteriostatic activity.
  • High blood flow within the thyroid gland with the presence of intracellular iodine.
  • Increased phagocytosis within the gland, seen in hyperthyroidism.
  • Rich lymphatic supply to the thyroid.
  • Thyroid hormones themselves exercise anti-TB roles.

 

TTB can be primary or secondary

  1. Primary TTB is involvement of the thyroid gland alone, with no evidence of TB elsewhere in the body.
  2. Secondary TTB is usually the result of hematogenous, lymphatic and/or direct spread from an active tubercular focus involving the cervical lymph nodes or larynx. Secondary TTB is much more commonly encountered than primary TTB, and TTB may go undiagnosed in many cases especially where clinical signs are non-specific (24).

 

Clinical Features

 

TTB occurs slightly more commonly in women as compared to men (M: F = 1:1.4) and occurs over a wide age range of 14 to 83 years, median age of 40 ± 16 years for men and 43 ± 17 years for women (36).

 

TTB can manifest as a localized swelling with cold abscess mimicking carcinoma, as multinodular goiter, as a solitary thyroid nodule without cystic component, or very rarely as an acute abscess. The various presentations are summarized in Figure 3. Rarely TTB may present as a goiter or a chronic fibrosing thyroiditis. Presence of cervical lymphadenopathy may raise suspicion of malignancy (36). Clinical presentation is often subacute, but may be acute in cases of abscess (43). Pain associated with swelling, thyroid tenderness, fever and localized extra-thyroidal findings such as dysphagia, dysphonia or recurrent laryngeal nerve palsy are less common in TTB as compared to patients with acute bacterial thyroiditis (24). However, some patients with TTB may present with pyrexia of unknown origin. Table 3 documents with differences in clinical presentation between TTB and bacterial thyroiditis.

Figure 3. Presentations of thyroid tuberculosis (TTB). Relatively common presentations in green and rarer ones in yellow and orange colors.

 

Table 3. Clinical Features that Help Differentiate Between Tuberculous Thyroiditis and Bacterial Thyroiditis

Clinical Features

Tuberculous Thyroiditis

Bacterial Thyroiditis

Pain

-

+++

Pyrexia

+1

+++

Duration of illness (mean duration) (Ref;24)

105 days

18 days

Dysphagia

++

+++

Dysphonia

++

+++

Recurrent Laryngeal Nerve Palsy (Hoarseness)

++

+++

History of previous thyroid illness

-

+

Tenderness over the gland

-

+++

Leukocytosis

-

++

Elevated Erythrocyte Sedimentation Rate (ESR)

+++

+

1Rare reports of presentation as pyrexia of unknown origin

 

Most patients with TTB are euthyroid and do not have pre-existing thyroid disease. Very rarely TTB can be associated with hypothyroidism, with a period of subclinical hyperthyroidism preceding the hypothyroidism (44). Myxedema can occur in cases with extensive destruction of the thyroid gland by disseminated TB, which can also be fatal (45). Past history of TB may be elicited in some cases, and patients may have history of cervical lymphadenopathy (43).

 

Radiological and Laboratory Findings

 

Chest X-ray, ESR, and tuberculin skin test should be performed in all cases of suspected TTB. The diagnosis is made only after FNAC or histopathological examination of the surgical specimen when FNAC is negative (43). Sputum AFB may rarely assist in diagnosis in cases with associated pulmonary TB.

 

Ultrasonography usually shows a heterogenous, hypoechoic mass similar to a neoplastic nodule. Anechoic areas with internal echoes may be seen in abscesses. Contrast-enhanced CT scan can determine the location of the necrotic lesions (46).

 

On MRI the normal thyroid is homogenously hyperintense relative to the neck muscles on both T1 and T2-weighted images. TTB may show intermediate signal intensity due to granulomatous inflammation, however, this appearance is also seen in thyroid carcinoma. Abscesses appear hypointense on T1 and hyperintense on T2-weighted images, and may show peripheral rim of contrast enhancement (47).

 

Thyroid function tests (TFT) are usually normal in patients with TTB. Thyrotoxicosis in the initial stage of rapid release of thyroid hormone, and myxedema in the later stage of thyroid gland destruction have also been noted, and patients may have abnormal TFT accordingly (24). Only 5.2% of patients with TTB have abnormal TFT (36).

 

Pathology of Thyroid TB

 

In most cases, TTB can be diagnosed on FNAC which typically shows epithelioid cell granulomas with Langhan’s giant cells, peripheral lymphocytic infiltration and purulent caseous necrosis. The yield of AFB by the Zeihl Neelsen stain is more with FNAC samples than in biopsies. The aspirates can be sent for TB culture or PCR. TB-PCR is much more sensitive in detecting M. tuberculosis deoxyribonucleic acid (DNA) from FNA samples, and is an alternative to rapid diagnosis of TB in AFB-negative cases (40). The diagnosis is substantiated by histopathology which typically shows granulomas, Langhan’s giant cells and necrosis (Figure 4). Few cases show dense lymphocytic infiltrate with prominent germinal centers, resembling lymphocytic or Hashimoto thyroiditis (Figure 5).

Five pathological varieties of TTB have been described (36):

  1. Multiple miliary lesions throughout the thyroid gland
  2. Goiter with caseation necrosis
  3. Cold abscess
  4. Chronic fibrosing tuberculosis
  5. Acute abscess

Fig 4. Case of TTB showing granulomas within the thyroid parenchyma comprised of epithelioid cells with Langhan’s giant cells (yellow arrows) and foci of necrosis (black arrows). Hematoxylin and eosin, 100x.

Figure 5. Case of TTB showing dense lymphocytic infiltrate with prominent germinal centers in the thyroid parenchyma (arrow). Hematoxylin and eosin, 100x.

 

Differential Diagnosis

 

TTB, although rare, should be considered in the list of differentials for solitary or multinodular thyroid nodules, and abscesses (36). Reidel’s thyroiditis may mimic chronic fibrosing tuberculosis clinically, however histopathology clinches the diagnosis (42).

 

Treatment

 

ATT remains the cornerstone of treatment. Surgery has a limited role with drainage of abscess, avoiding total destruction of gland and subsequent hypothyroidism. However inadvertent total thyroidectomies are performed as the pre-operative diagnosis is commonly a malignancy. In cases were TB was diagnosed prior to surgery, ATT is well tolerated with resolution of symptoms, reduction in thyroid mass symptoms, and with favorable reversal of thyroid hormonal dysfunction. Standard ATT schedules are followed. Thyroid hormone levels should be monitored before, during, and after treatment. Despite strict ATT, recurrence and failure rate is 1% due to resistance to ATT drugs (48).

 

Functional and Structural Alterations of Thyroid Functions with Active Tuberculosis and with Anti-tubercular Therapy

 

Among hospitalized patients with TB without any evidence of involvement of the thyroid gland sick euthyroid syndrome with low free T3 is common. The estimates vary between 63-92% and probably is the commonest endocrinopathy seen in patients with TB (13,49). As with other unwell patients the degree of reduction in Free T3 serves both as a marker for severity of the disease and mortality. In the study by Chow et al, all patients who survived the hospitalization had normal TFT within one month of initiation of ATT. In community dwelling patients with TB, the prevalence of thyroid dysfunction is unclear.

 

Thyroid hormones are metabolized in the liver and the kidneys. In the liver, the enzyme CYP3A4 belonging to the hepatic cytochrome P450 family is responsible for the metabolism. Rifampicin is a potent activator of the P450 system and this leads to an increase in T4 turnover. In most adults with normal a hypothalmo-pituitary-thyroid axis this increase in turnover is compensated by an increase in the production of thyroid hormones and a slight increase in thyroid volume. This may be noted biochemically as a slight increase in free T3 and total T3 levels after rifampicin administration. There are no changes in free T4 and TSH concentrations (50). Among patients with pre-existing thyroid disease with a limited capacity to increase production of thyroid hormones, the rifampicin-mediated increase in free T4 turnover might lead to the need for an increase in thyroid hormone replacement therapy. In a retrospective cohort of patients on levothyroxine replacement therapy, the addition of rifampicin as part of ATT led to a need for a 26% increase in dose in patients on thyroid hormone replacement therapy and a 50% increase in patients on suppressive therapy post thyroidectomy for differentiated thyroid cancer (51).

 

Older anti-tubercular agents have more profound effects on thyroid physiology. Studies by Munkner et al demonstrated an association between the use of p-amino salicylic acid (PAS) and the development of goiter (52). PAS and ethionamide were also associated with significant risk of developing hypothyroidism (53, 54). However, these agents are currently not used as first line agents. It is prudent to monitor TFTs 6-8 weeks after initiation of any of these three agents in patients who have pre-existing thyroid dysfunction.

 

PITUITARY AND TUBERCULOSIS

 

Direct involvement of the pituitary gland by Mycobacterium Tuberculosis is very rare. Some of the earliest published reports of pituitary TB include von Rokitansky who noted tubercles in the hypophysis as early as 1844, Letchworth in 1924 who reported a case of primary pituitary tuberculoma on autopsy examination, and Coleman and Meredith documented a case of pituitary TB in 1940 (55, 56).

 

The spectrum of involvement (Figure 6) of the pituitary gland with TB includes sellar, parasellar, and stalk tuberculomas and sellar tubercular abscesses. Patients with tuberculous meningitis exhibit a range of functional pituitary dysfunction even in the absence of any evidence of direct invasion/extension of the disease into the sella. Among survivors of tubercular meningitis hypopituitarism was noted 10 years after the primary disease. Hypothalamic pituitary dysfunction such as isolated hypogonadotropic hypogonadism may accompany cachexia and weight loss that can complicate more extensive disease. Infiltrative tubercular disease of the stalk can produce pituitary interruption syndrome including isolated diabetes insipidus and hyperprolactinemia.

 

In most cases the diagnosis of tuberculosis of the pituitary is established on histopathology, often in the absence of confirmatory culture studies or positive acid-fast stains (57). Although the diagnosis is difficult on clinical and radiological examination, pituitary TB should be considered in the differential of a suprasellar mass especially in developing countries, as the condition is potentially curable with ATT (58, 59).

 

Figure 6. Spectrum of structural and functional disease of the pituitary seen with tuberculosis

Sellar Tuberculoma/Abscess

 

EPIDEMIOLOGY  

 

The incidence of pituitary TB is very low. In an autopsy series of 3,533 cases, only 2 of 89 intracranial tuberculomas involved the sella turcica, while in another autopsy series of 14,160 cases, only 2 cases of TB were encountered involving the anterior pituitary lobe (50).  In patients with late generalized TB, the incidence of pituitary involvement is 4% (14). Nearly 70% of pituitary TB reported worldwide has been reported from the Indian subcontinent, probably attributable to the higher prevalence of TB in this location (60). In the largest series from India, 18 cases of sellar TB were diagnosed based on histopathology from 1148 pituitary surgeries (60).

 

PATHOGENESIS

 

Pituitary TB can arise either from hematogenous seeding, in the presence or absence of miliary disease, or from direct extension from the brain, meninges or sinuses. TB can either involve the pituitary gland alone, or involve the adjacent and/or distant organs as well (60). Both the adenohypophysis and neurohypophysis may be involved by TB. Supra-sellar extension is common in pituitary TB with only rare cases confined to the sella (57). 

 

CLINICAL FEATURES

 

Pituitary TB occurs at a mean age of 34.1 ± 13.6 years (age range 6 to 68 years), and is more common in women (F:M = 2.7:1). Young children are at high risk of progression of TB including CNS disease. Clinical presentation is often indolent. Duration of symptoms average 4 months (60, 61).

 

Pituitary involvement, either as a sellar abscess or tuberculoma presents primarily with symptoms of a sellar mass. The common presentations clinically are gradual onset of headache (85.2%), visual loss (48.1%) (Figure 7), seizures and cranial nerve palsies. Patients with infiltration of the stalk by tuberculomas may present with central diabetes insipidus with polyuria (8.6%) or menstrual abnormalities related to hyperprolactinemia like amenorrhea in women (37.3%) and galactorrhea (23.7%) (60, 61). Growth retardation and hypogonadism are rare findings in children with pituitary TB (61). Hyperphagia resulting in obesity or weight gain has also rarely been documented which may occur due to the loss of sensitivity of the appetite-regulating network in the hypothalamus to afferent peripheral humoral signals (62). Apoplexy, characterized by acute infarction and/or hemorrhage in the pituitary gland, is an uncommon presentation of pituitary TB (63). Systemic and constitutional symptoms may or may not be present; low grade fever may be seen in 14.8% of patients. Other organs may show evidence of TB in 26.9% (60, 64). Tuberculous meningitis may be associated in a few cases.

Figure 7. Bitemporal hemianopsia demonstrated on perimetry.

RADIOLOGICAL FINDINGS

 

The diagnosis of primary pituitary TB is challenging and often difficult. Radiologically pituitary TB can mimic pituitary adenoma, arachnoid cyst, pyogenic abscess, metastasis, or craniopharyngioma. MRI typically shows a sellar mass which may extend into the suprasellar region, involving the optic nerves and inter-carotid space (Figure 8). T1-weighted MR images appear isointense. T2-weighted images show central hyperintensity corresponding to caseous necrosis, and gadolinium contrast imaging may show thick ring enhancement in the periphery with central hypointense areas. Meningeal enhancement with enhancement of the thickened pituitary stalk may favor non-adenoma etiology. Additional findings like sellar/suprasellar calcification and sellar floor erosion have also been described (57, 63-65).

Figure 8. Magnetic resonance imaging of a patient with pituitary tuberculosis shows a sellar mass lesion measuring 2.1 cm x 1.9 cm x 1.4 cm with suprasellar extension A) heterogenous predominantly increased signal intensity on T2 weighted imaging and B) hypointense on T1 weighted imaging. C and D) Significant homogenous post contrast enhancement of the mass lesion on axial (C) and sagittal (D) views, respectively. Involvement of the pituitary stalk and superior displacement of the optic chiasma is also seen. Bright signal of posterior pituitary is maintained.

MR spectroscopy can detect elevated lipid peaks in a tuberculoma at 0.9, 1.3, 2.0 and 2.8 ppm, and a phosphoserine peak at 3.7 ppm. Lipid resonance at 0.9 and 1.3 ppm occur due to methylene and terminal methyl groups on fatty acids found in caseous necrosis (66)

 

LABORATORY FINDINGS

 

Panhypopituitarism may be encountered on evaluation of anterior pituitary hormones like thyroid stimulating hormone (TSH), early morning cortisol, growth hormone, prolactin, luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

 

Testing for HIV and immunocompromised states should be considered in the appropriate clinical setting. Positive tuberculin test and elevated ESR may be seen in patients with systemic involvement.

 

PATHOLOGY OF PITUITARY TUBERCULOSIS

 

The most common pattern of tuberculous involvement of the pituitary on histopathological examination is granulomas without caseation necrosis (59.6%) as show in Figure 9A. Granulomas may be miliary or may coalesce together to form a conglomerate mass. Reticulin stain helps demonstrate loss of normal reticulin pattern of the pituitary (Figure 9B). The granulomas are composed of epithelioid cells, Langhan’s giant cells, and lymphocytes (Figure 9C-D). Immunohistochemistry (IHC) with CD68 can help confirm the presence of epithelioid histiocytes in cases of unequivocal morphology, while CD3, CD20 and CD138 can highlight a mixture of T-lymphocytes, B-lymphocytes and plasma cells, respectively (Figure 10A-D). Pus and caseation necrosis are seen less commonly, and in these cases the yield of AFB is greater than with cases without necrosis. As with other sites, demonstration of AFB on biopsy material is very low. In such cases growth of M. Tuberculosis organisms on culture and TB PCR aid in diagnosis.

Figure 9. Pituitary tuberculosis. Biopsy of the pituitary showing nests of pituicytes (black arrows) destroyed and separated by confluent granulomas (red arrow). A) low power view, Hematoxylin and Eosin (H&E), 100x; B) corresponding area showing reticulin-free zones (asterisks) occupied by granulomas, Gordon and Sweet’s silver reticulin stain, 100x; C & D) higher power views showing non-caseating granulomas comprised of epithelioid cells with occasional Langhan’s giant cells (top left) and lymphocytes, H&E, 400x.

Figure 10. Immunohistochemistry in pituitary tuberculous granulomas shows mixed inflammatory infiltrate made up of epithelioid histiocytes (CD68), T-lymphocytes (CD3), B-lymphocytes (CD20) and occasional plasma cells (CD138) (A-D, respectively). Diamino benzidine chromogen, 100x.

DIFFERENTIAL DIAGNOSIS

 

Sarcoidosis must be considered in the differential of non-caseating granulomatous hypophysitis, and shows naked granulomas without infiltrating lymphocytes. IgG4-related disease typically shows increase in plasma cells of the IgG4 subtype with storiform fibrosis. Histiocytic lesions like Langerhans cell histiocytosis (LCH) usually involve the infundibulum and typically show presence of Langerhans’s histiocytes with eosinophils. LCH is more common in children and young adults. Other inflammatory lesions involving the pituitary stalk are lymphocytic infundibuloneurohypophysitis (LINH), Wegener’s granulomatosis, and pituitary stalk parasitosis (67). Fungal granulomas involving the hypophyseal region can be ruled out by performing fungal stains on tissue sections (60).

 

TREATMENT

 

Transsphenoidal approach is preferred for surgery and is used for diagnosis and decompression of adjacent structures. Typical intra-operative findings are firm to hard, non-suckable greyish tissue with thickening of the dura. Pituitary TB can be managed conservatively if the diagnosis is confirmed with cerebrospinal fluid TB PCR and other tests.

ATT may be given for up to 18 months and patients should be on periodic follow up with assessment of hormonal profile. Lifelong replacement of hormones may be required in some patients (68). Recurrence of TB in lymph nodes despite completion of 18 months of ATT has been reported to occur due to resistance of M.tuberculosis bacilli to Rifampicin (69).

 

Pituitary Dysfunction in Patients with Tuberculous Meningitis (TBM)

 

In an Indian study of 75 patients with tuberculous meningitis, common pituitary functional abnormalities included hyperprolactinemia (49%), cortisol insufficiency (43%), central hypothyroidism (31%) and multiple hormone deficiencies (29%) (70). Prevalence of functional pituitary abnormalities seen in TBM in multiple studies from India is summarized in Table 4 (71, 72).  In addition, there may be hyponatremia.

 

Table 4. Pituitary Involvement in Patients with Tuberculous Meningitis

 

Delhi (70)

Chandigarh (71)

Lucknow (72)

Number of patients

75

63

115

Any Involvement of Pituitary

 

84.2%

53.9%

Single Axis Involvement

 

39.8%

30.4%

More than one axis (Panhypopituitarism)

29.3%

44.4%

23.5%

Hypogonadotropic Hypogonadism

NR

38.1%

33.9%

Hyperprolactinemia

49.3%

49.2%

22.6%

Secondary Adrenal insufficiency

42.7%

42.9%

13%

Central hypothyroidism

30.7%

9.5%

17.4%

Isolated Growth hormone deficiency

NR

NR

7.8%

Syndrome of Inappropriate anti-diuresis 

NR

NR

9.%

Diabetes Insipidus

Nil

Nil

Nil

NR- Not reported

 

Even among patients who survive tuberculous meningitis, pituitary dysfunction may persist. A study done by Lam in Hong Kong showed growth hormone deficiency to be the most common finding in patients younger than 21 years of age with tuberculous meningitis after 10 years of surviving tuberculous meningitis (73). 

 

WATER IMBALANCE AND TUBERCULOSIS

 

Hyponatremia has been commonly seen in patients admitted to the hospital with TB. Though data about the prevalence of hyponatremia among community treated patients with uncomplicated pulmonary TB is sparse, among inpatients admitted with TB, hyponatremia has been seen in 10-76% of patients (74-78). The commonest cause of hyponatremia is the SIAD. Other causes include untreated primary or secondary adrenal insufficiency, volume depletion, hyponatremia associated with volume excess, and hypoalbuminemia and rare cases of cerebral salt wasting seen with tuberculous meningitis (79) (Figure 11). Hypernatremia is rarely encountered and usually signifies involvement of the hypothalamus or the pituitary stalk leading to diabetes insipidus.

Figure 11. Causes of hyponatremia in patients with Tuberculosis. [SIAD-Syndrome of inappropriate anti-diuresis]. Green boxes are common causes, yellow is less common and the red boxes are rare.

Syndrome of Inappropriate Antidiuresis (SIAD)

 

In the absence of adrenal deficiency, patients with non-CNS TB who are adequately hydrated (euvolemic) the hyponatremia is almost always a consequence of retention of free water despite low serum osmolality (inappropriate antidiuresis). Wiess and Katz first noted the association between active untreated TB and syndrome of inappropriate antidiuresis (SAID). In four patients with active TB and hyponatremia they noted excessive urinary sodium excretion. When these four patients were put on fluid restriction there was an improvement in the serum sodium levels. All patients who survived also had gradual normalization of serum sodium levels and SAID with treatment of TB (80).

 

Three different mechanisms have been proposed for the development of SIAD in patients with tuberculosis without evidence of adrenal involvement.

  1. The first proposed mechanism in common with other pulmonary diseases is the stimulation of baroreceptors by chronic hypoxemia that can accompany extensive pulmonary TB. There is release of anti-diuretic hormone (ADH) in response to baroreceptor stimulation which leads on to SIAD (81).
  2. The second possible mechanism proposed is a shift of the “osmostat” towards the left as seen in patients with decreased effective circulating volume leading to ADH release at lower serum osmolality. Investigators have noted higher circulating ADH levels in the serum despite hyponatremia which subsequently declined when free water was administered. The intact response to hypoosmolality suggested that the osmoregulation set up in the hypothalamus was functioning normally but at a lower osmolar threshold for ADH release (82).
  3. The third mechanism proposed is the ectopic secretion of ADH by the tubercular granuloma. This mechanism was proposed by the authors of a case where a patient with well-established diabetes insipidus developed SIAD and hyponatremia after contracting pulmonary tuberculosis (83).

 

Patients with CNS TB have a higher prevalence of hyponatremia compared to those with pulmonary infections. In adult patients with TBM the prevalence of a low sodium state has varied from 45-65% in different studies (84-86). In children with TBM the prevalence varied from 38-71% in different studies (87-89). In children with TBM and hyponatremia there appears to be an association with mortality and increased intracranial pressures (87, 90). A recent review from India compiled data from over 11 studies comprising a total of 642 patients with TBM and found the prevalence of hyponatremia to be 44%. Unlike non-CNS TB the commonest etiology of hyponatremia among patients with CNS TB is cerebral salt wasting (CSW) rather than SIAD (36% vs 26%) (86). The other less common causes of hyponatremia encountered in TBM include the following

  1. Dehydration and hypovolemic hyponatremia due to anorexia, vomiting, nausea and diarrhea
  2. Drug induced including use of diuretics, osmotic agents like mannitol and anti-seizure medications like carbamazepine and phenytoin.
  3. Secondary adrenal insufficiency and rarely primary adrenal insufficiency

 

CLINICAL PRESENTATION AND TREATMENT OF SIAD ASSOCIATED WITH TUBERCULOSIS        

 

Most patients with SIAD and TB are asymptomatic and do not require any treatment. The hyponatremia accompanying SIAD self corrects itself when ATT is started (82). Fluid restriction is only required in symptomatic patients or in patients with severe hyponatremia. Prior to restricting fluids in patients with non-CNS TB it is important to rule out dehydration either by assessing volume status clinically, assessing volume status with urine spot sodium levels, or measuring central venous pressures in unwell patients. In patients with CNS TB, it is important to rule out CSW prior to initiating fluid restriction. Hypertonic saline infusions are limited to patients with life threatening symptoms like seizures and deep coma attributable to hyponatremia (86). Care should be taken to correct hyponatremia at a rate not faster than 8-10 mEq/L in 24 hours to avoid central pontine myelinolysis.  

 

Cerebral Salt Wasting (CSW)

 

CSW refers to changes in renal salt handling that accompanies CNS disorders which leads to natriuresis and hypovolemia. The accompanying dehydration and decrease in effective circulating volume triggers ADH release via baroreceptors. The action of ADH on collecting tubules then leads to selective water resorption and relative water excess and hyponatremia despite overall hypovolemia. The putative renal natriuretic triggers include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide. In TBM the most likely natriuretic trigger is BNP (91). What induces BNP release in patients with TBM is less well characterized. The putative mechanisms that trigger BNP release include sympathoadrenal activation, increase in intracranial pressure, and vasospasm in cerebral arteries (92). In patients with CNS TB statistically CSW is more likely to be the cause of hyponatremia and should always be ruled out prior to labelling them as SIAD and starting fluid restriction. A simple diagnostic criterion proposed by Kalita et al (86) includes meeting all the 3 essential criteria and meeting at least 3 out of 5 additional supportive criteria to label the patient has having CSW. Table 5 lists the clinical and biochemical differences between SIAD and CSW.

 

Essential Criteria (meets all three)

  1. Polyuria (>3 liters of urine in 24 hours over 2 days)
  2. Documented hyponatremia
  3. Exclusion of other cause of natriuresis like adrenal insufficiency, salt losing nephropathies, use of diuretics, hepatic and cardiac failure.

 

Additional criteria (meet 3 out of 5)

  1. Clinical evidence of hypovolemia and dehydration
  2. Documented negative fluid balance either by careful weight monitoring or by strict intake and output records
  3. Urine spot Sodium > 40 mEq/L
  4. Central Venous Pressure (CVP) < 6 cm of water
  5. Laboratory evidence of dehydration including an increase in hemoglobin and hematocrit, increase in blood urea nitrogen and increase in albumin than previously.

 

Table 5. Differentiation Between Syndrome of Inappropriate Anti-Diuresis (SIAD) and Cerebral Salt Wasting (CSW)

Parameter

SIAD

CSW

Extracellular Volume

Increased

Decreased

Body Weight

Increased

Decreased

Fluid Balance

Positive

Negative

Tachycardia

-

+

Hypotension

-

+

Hematocrit/Albumin/Blood Urea Nitrogen

Normal

Increased

Central Venous Pressure

Normal or slightly high

Decreased

 

TREATMENT OF CSW ASSOCIATED WITH TBM

 

The primary treatment for CSW is fluid replacement with or without oral salt loading for as long as polyuria continues. Isotonic fluids are preferred for replacement. If the patient has a central venous line then the central venous pressure (CVP) measurements would guide the fluid replacements. In the absence of a CVP line fluid balance is needed by either meticulous intake and output charting or use of daily weight measurements.

 

In patient’s refractory to fluid replacement and oral salt loading, oral fludrocortisone (OFC) has been tried as there is an inhibition of the renin-angiotensin-aldosterone system (RAAS) system in CSW. A recent randomized control trial was conducted in 36 patients with CSW associated with TBM. Half of them received OFC (0.4-1mg/day) plus fluid and oral salt and the other half received only fluids and oral salt. The patients who received OFC in addition had quicker normalization of serum sodium levels (4 days vs 15 days; p 0.04) and lesser cerebral infarctions related to vasospasm (6% vs 33%; p 0.04). However, OFC use was associated with severe hypokalemia and significant hypertension in 2 patients each and in one patient there was an episode of pulmonary edema. OFC had to be withdrawn in 2/18 patients because of these serious adverse events. There was no difference in mortality or disability at 3 and 6 months among patients who received OFC vs the patients who did not (93).

 

CALCIUM ABNORMALITIES IN TUBERCULOSIS

 

Hypercalcemia in Patients with Tuberculosis

 

Hypercalcemia has been known to be associated with a number of granulomatous diseases. The three commonest granulomatous diseases causing hypercalcemia include sarcoidosis, TB, and fungal infection (94). The prevalence of hypercalcemia in patients with TB has ranged from 2-51% in studies done from South Africa (2%), Hong Kong (6%), India (10.6%), Sweden (25%), Malaysia (27.5%), Greece (25% & 48%) and Australia (51%) (13, 95-101). In contrast, prospective studies from the United Kingdom, Belgium, and Turkey did not show any hypercalcemia among patients with newly diagnosed tuberculosis (102-104). The primary determinant in the development of hypercalcemia among patients with TB appears to be their Vitamin D status and nutritional calcium intake. In populations with high nutritional calcium intake and adequate sunlight exposure like in Greece and Australia the prevalence of hypercalcemia is highest. Among countries with good sunlight exposure but poor nutritional calcium intake like most Asian countries there is a more modest prevalence of hypercalcemia. The countries with good nutritional calcium intake but poor sunlight exposure and low Vitamin D levels appear to have the lowest prevalence of hypercalcemia. This has been elegantly explained by Chan et al (105). However, some outliers like the higher prevalence in Sweden and moderate prevalence in India are not completely explained by this hypothesis alone.

 

In a recent paper looking at retrospective records of patients admitted with TB at a tertiary care hospital in Vellore almost 20% of patients were found to have albumin-adjusted hypercalcemia. The authors looked at the risk factors for hypercalcemia by comparing them with the patients without hypercalcemia assuming that background nutritional calcium intake and Vitamin D levels were similar. The primary risk factors for the development of hypercalcemia within this group was presence of renal dysfunction or frank renal failure, use of diuretics, disseminated tuberculosis, and presence of co-morbidities like diabetes and hypertension (106).

 

MECHANISM OF HYPERCALCEMIA WITH TUBERCULOSIS

 

The definitive mechanism that causes hypercalcemia among patients with TB is still unclear. Alternative etiologies for hypercalcemia including adrenal insufficiency, primary hyperparathyroidism, primary hyperthyroidism, milk alkali syndrome have been ruled out in many of the case series. Biochemically several investigators have shown an increase in the levels of 1,25-dihydroxy vitamin D along with low or normal levels of 25-hydroxy vitamin D levels. This suggests an increase in the conversion of 25-hydroxy vitamin D to 1,25-dihydroxy vitamin D (107). This conversion is mediated by the enzyme 1-α-hydroxylase found in the kidney. However, hypercalcemia is even reported in patients with chronic renal failure and among those with absent kidneys (108, 109). This suggests a non-renal site of enzymatic activity. 

 

The tubercular granuloma is suggested as the site for the extra renal 1-α-hydroxylase activity (110). Activated macrophages can express 1-α-hydroxylase activity and in patients with active TB activated macrophages retrieved by broncho-alveolar lavage were able to synthesize 1,25 dihydroxy vitamin D in vitro studies (111). The macrophage production of 1-α-hydroxylase is probably important for the immune response to tuberculous infection. The binding of active Vitamin D (1,25-dihydroxy vitamin D) to Vitamin D receptors within the immune cells stimulates autophagy and production of cytokines that contribute to the clearance of the mycobacterium from the body (112, 113). In addition, active Vitamin D contributes to the downregulation of the inflammatory response of the body to reduce damage to bystander host tissues (114). The increased intestinal absorption of calcium and observed hypercalcemia may be an unintended consequence of this immune-protective phenomenon.

 

This also explains why patients with low levels of substrate (25-hydroxy vitamin D) for the enzyme or among those with poor calcium intake there is less likelihood of the development of hypercalcemia.

 

CLINICAL PRESENTATION

 

Most patients with hypercalcemia related to TB infection are asymptomatic. Rarely patients develop symptoms related to hypercalcemia including polyuria, anorexia, nausea, weakness and lethargy, more serious CNS symptoms like delirium.

 

Patients may develop hypercalcemia later in the course of TB after commencement of therapy with improvements in nutritional and albumin status and improvement in nutritional calcium intake. 

 

TREATMENT

 

A Cochrane review of Vitamin D supplementation in patients with TB did not show any benefits in terms of improved outcomes but there was also no increased risk of developing hypercalcemia (115). Most patients have gradual resolution of hypercalcemia on ATT over 1 to 7 months (96).


Hypocalcemia in Patients Treated with Rifampicin and Isoniazid



Hypocalcemia was noted for the first time in United Kingdom during a randomized control trial of anti-tubercular chemotherapy after several months of therapy. Fourteen out of the 325 patients on the trial developed hypocalcemia. In this trial none of the 325 patients was noted to have hypercalcemia. On the whole as a group the mean calcium levels dropped significantly during the course of the treatment trial. The mechanism is proposed to be the action of both Rifampicin and Isoniazid on vitamin D metabolism (102).

 

When isoniazid is given to normal subjects there is a brisk decline in the levels of active Vitamin D (1,25 dihydroxy vitamin D). There is slower decline in the levels of 25-hydroxy vitamin D accompanied by a compensatory increase in the levels of parathyroid hormones. In the same study isoniazid was shown to inhibit cytochrome p450 related hepatic mixed function oxidase and it is assumed that since the renal 1-α Hydroxylase is also related to cytochrome P450 system there would be decreased conversion of 25-hydroxy vitamin D to 1,25 dihydroxy vitamin D (116).

 

On the other hand, rifampicin is an inducer of hepatic hydroxylase which should in theory lead to an increase in active Vitamin D levels. However, when rifampicin was given to normal volunteers there was a fall in 25-hydroxy vitamin D levels with no changes to the levels of 1,25-dihydroxy vitamin D. The possible explanation for this decline is likely to be that the higher metabolic turnover of active Vitamin D induced by rifampicin is not compensated by an increase in dermal production or increased nutritional provision of vitamin D (117). Regardless, in treatment regimens that include both rifampicin and isoniazid there is a very real possibility of the development of not just hypocalcemia but unmasking of rickets and osteomalacia especially when the patient is poorly nourished.


CONCLUSIONS

 

TB can involve almost all endocrine glands as a primary disease-causing destruction and loss of function. In enclosed spaces like the pituitary fossa and neck the granuloma/tuberculoma/cold abscess can replace vital structures and cause symptoms related to a mass. This chapter did not cover direct tubercular involvement of the ovaries, testes, and the pancreas.

 

Additionally, a whole range of functional hormone abnormalities can accompany the effect on chronic inflammation on the immune-endocrine pathways. Metabolic derangement in calcium and water metabolism are covered in detail. Abnormalities in glucose metabolism are not covered because of the vast amount of information now available on the public health aspects of TB and diabetes mellitus.

 

Fortunately, most abnormalities are self-limited and resolve with successful ATT. However, one needs to consider the rare possibility of a hormonal emergency like an adrenal crisis, hypercalcemic emergency, or pituitary apoplexy in the context of TB.

 

REFERENCES

 

  1. World Health Organization. Global Tuberculosis Report 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf (Accessed 28 Nov 2020)
  2. Lyon SM, Rossman MD. Pulmonary tuberculosis. Microbiol Spectr (2017) 5:TNMI7–0032. doi: 10.1128/microbiolspec.TNMI7-0032-2016
  3. Ndlovu H, Marakalala MJ. Granulomas and inflammation: host-directed therapies for tuberculosis. Front Immunol (2016) 7:434.
  4. Besedovsky H, del Rey A. Immune-neuro-endocrine interactions: facts and hypothesis. Endocr Rev (1996) 17:64–95. doi:10.1210/edrv-17-1-64
  5. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev (1999) 79:1–71
  6. Straub RH, Schuld A, Mullington J, Haack M, Schölmerich J, Pollmächer T. The endotoxin-induced increase of cytokines is followed by an increase of cortisol relative to dehydroepiandrosterone (DHEA) in healthy male subjects. J Endocrinol (2002) 175:467–74.
  7. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NFκB activity through induction of IκB synthesis. Science (1995) 270:286–90.
  8. Pandolfi J, Baz P, Fernández P, Discianni Lupi A, Payaslián F, Billordo LA, et al. Regulatory and effector T-cells are differentially modulated by dexamethasone. Clin Immunol (2013) 149:400–10.
  9. van Lettow M, van der Meer JWM, West CE, van Crevel R, Semba RD. Interleukin-6 and human immunodeficiency virus load, nut not plasma leptin concentration, predict anorexia and wasting in adults with pulmonary tuberculosis in Malawi. J Clin Endocrinol Metab (2005) 90:4771–6.
  10. Kellendonk C, Eiden S, Kretz O, Schütz G, Schmidt I, Tronche F, et al. Inactivation of the GR in the nervous system affects energy accumulation. Endocrinology (2002) 143:2333–40.
  11. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition (2000) 16:1009–12.
  12. D’Attilio L, Santucci N, Bongiovanni B, Bay ML and Bottasso O (2018) Tuberculosis, the Disrupted Immune-Endocrine Response and the Potential Thymic Repercussion as a Contributing Factor to Disease Physiopathology. Front. Endocrinol. 9:214.
  13. Post FA, Soule SG, Willcox PA, Levitt NS. The spectrum of endocrine dysfunction in active pulmonary tuberculosis. Clin Endocrinol (Oxf). 1994 Mar;40(3):367-71.
  14. Slavin RE, Walsh TJ, Pollack AD. Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. Medicine (Baltimore). 1980 Sep;59(5):352-66.
  15. Guttman P. Addison’s disease: A statistical analysis of 566 cases and a study of pathology. Arch Pathol 1930; 10:742-5.
  16. Sanford JP, Favour CB. The interrelationships between Addison's disease and active tuberculosis: a review of 125 cases of Addison's disease. Ann Intern Med. 1956 Jul;45(1):56-72.
  17. Betterle C, Morlin L. Autoimmune Addison’s Disease. Endocr Dev 2011; 20:171-72.
  18. Agarwal G, Bhatia E, Pandey R, Jain SK. Clinical profile and prognosis of Addison's disease in India. Natl Med J India. 2001 Jan-Feb;14(1):23-5.
  19. Soule S. Addison's disease in Africa--a teaching hospital experience. Clin Endocrinol (Oxf). 1999 Jan;50(1):115-20.
  20. Roy A, Bhattacharjee R, Goswami S, Thukral A, Chitra S, Chakraborty PP, et al. Evolving adrenal insufficiency. Indian J Endocr Metab 2012;16:S367-70.
  21. Alvarez S, McCabe WR. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Med 1984;63:25-55.
  22. Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW. Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status. World J Radiol 2015;28:336-42.
  23. Maitra A. The endocrine system. In: Kumar V, Abbas AK, Aster AC, editors. Robbins and Cotran Pathologic Basis of Disease. Philadelphia; Elsevier. 9th edition. 2015. P. 1073-139.
  24. Vinnard C, Blumberg EA. Endocrine and metabolic aspects of tuberculosis. Microbiol Spectr 2017;5:1-19.
  25. Chhangani NP, Sharma P. Addison’s disease. Indian Ped 2003; 40:904-5.
  26. Sharma S, Joshi R, Kalelkar R, Agrawal P. Tuberculous adrenal abscess presenting as adrenal insufficiency in a 4-year-old boy. J Tropical Ped 2018;0:1-4.
  27. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol 2015:3;216-26.
  28. Herndon J, Nadeau AM, Davidge-Pitts CJ, Young WF, Bancos I. Primary adrenal insufficiency due to bilateral infiltrative disease. Endocrine 2018;62:721-8.
  29. Erichsen MM, Lovas K, Skinningsrud B, Wolff AB, Undlien DE, Svatberg J, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009;94:4882-4890.
  30. Nair A, Jayakumari C, George GS, Jabbar PK, Das DV, Jessy SJ, Aneesh TS. Long acting porcine sequence ACTH in the diagnosis of adrenal insufficiency. Eur J Endocrinol. 2019 Dec;181(6):639-645.
  31. Lam KY, Lo CY. A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis. Clin Endocrinol 2001;54:633-9.
  32. Friedman F. The pathology of the adrenal gland in Addison’s disease with special reference to adrenocortical contraction. J name to be found 1948;42:181-200.
  33. Annear TD, Baker GP. Tuberculous Addison’s disease. A case apparently cured by chemotherapy. Lancet 1961;2:577-8.
  34. Penrice J, Nussey SS. Recovery of adrenocortical function following treatment of tuberculous Addison’s disease. Postgrad Med J 1992;68:204-5.
  35. Kelestimur F. Recovery of adrenocortical function following treatment of tuberculous Addison’s disease. Postgrad Med J 1993;69:832-4.
  36. Bulbuloglu E, Ciralik H, Okur E, Ozdemir G, Ezberci F, Cetinkaya A. Tuberculosis of the thyroid gland: review of the literature. World J Surg 2006;30:149-55.
  37. Rankin FW, Graham AS. Tuberculosis of the thyroid gland. Ann Surg 1932;94:625-48.
  38. Das DK, Pant CS, Chachra KL, Gupta AK. Fine needle aspiration cytology diagnosis of tuberculous thyroiditis. A report of eight cases. Acta Cytol 1992;36:517-22.
  39. Mondal A, Patra DK. Efficacy of fine needle aspiration cytology in the diagnosis of tuberculosis of the thyroid gland: a study of 18 cases. J Laryngol Otol 1995;109:36-8.
  40. Gupta N, Sharma K, Barwad A, Sharma M, Rajwanshi A, Dutta P, et al. Thyroid tuberculosis – role of PCR in diagnosis of a rare entity. Cytopathol 2011;22:392-6.
  41. Ozekinci S, Mizrak B, Saruhan G, Senturk S. Histopathologic diagnosis of thyroid tuberculosis. Thyroid 2009;19:983-6.
  42. Akbulut S, Sogutcu N, Arikanoglu Z, Bakir S, Ulku A, Yagmur Y. Thyroid tuberculosis in Southeastern Turkey: is this the resurgence of a stubborn disease? World J Surg 2011;35:1847-52.
  43. Majid U, Islam N. Thyroid tuberculosis: a case series and a review of the literature. J Thyroid Res 2011;vol?:1-4. doi:10.4061/2011/359864
  44. Luiz HV, Pereira BD, Silva TN, Veloza A, Matos A, Matos C, et al. Thyroid tuberculosis with abnormal thyroid function – case report and review of the literature. Endocr Pract 2013;19:e44-e49.
  45. Barnes P, Weatherstone R. Tuberculosis of the thyroid: two case reports. Br J Dis Chest 1979;73:187-91.
  46. Kang BC, Lee SW, Shim SS, Choi HY, Baek SY, Cheon YJ. US and CT findings of tuberculosis of the thyroid: three case reports. Clin Imaging 2000;24:283-6.
  47. Madhusudhan KS, Seith A, Khadgawat R, Das P, Mathur S. Tuberculosis of the thyroid gland: magnetic resonance imaging appearances. Singapore Med J 2009;50:e235-e238.
  48. El Malki HO, El Absi M, Mohsine R…. Tuberculosis of the thyroid. Diagnosis and treatment. Ann Chir 2002;127:385-7.
  49. Chow CC, Mak TW, Chan CH, Cockram CS. 1995. Euthyroid sick syndrome in pulmonary tuberculosis before and after treatment. Ann Clin Biochem 32:385–391.
  50. Christensen HR, Simonsen K, Hegedus L, Hansen BM, Dossing M, Kampmamn JP, et al. Influence of rifampicin on thyroid gland volume, thyroid hormones, and antipyrine metabolism. Acta Endocrinol (Copenh). 1989; 121: 406–410.
  51. Kim HI, Kim TH, Kim H, Kim YN, Jang HW, Chung JH, et al. (2017) Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication. PLoS ONE 12(1): e0169775
  52. Munkner T. Studies on goiter due to para-aminosalicylic acid. Scand J Respir Dis. 1969;50(3):212-26.
  53. Chhabra N, Gupta N, Aseri M L, Mathur SK, Dixit R. Analysis of thyroid function tests in patients of multidrug resistance tuberculosis undergoing treatment. J Pharmacol Pharmacother 2011;2:282-5
  54. Munivenkatappa S, Anil S, Naik B, et al. Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field. Journal of Tuberculosis Research. 2016 Sep;4(3):105-110.
  55. Letchworth TW. Tuberculoma of the pituitary body. Br Med J 1924;1127.
  56. Kirshbaum JD, Levy HA. Tuberculoma of hypophysis with insufficiency of anterior lobe: a clinical and pathological study of two cases. Arch Intern Med 1941;68:1095-104.
  57. Ben Abid F, Abukhattab M, Karim H, Agab M, Al-Bozom I, Ibrahim WH. Primary pituitary tuberculosis revisited. Am J Case Rep 2017;18:391-4.
  58. Sunil K, Menon R, Goel N, Sanghvi D, Bandgar T, Joshi SR, et al. Pituitary tuberculosis. J Assoc Physicians India 2007;55:453-6.
  59. Dutta P, Bhansali A, Singh P, Bhat MH. Suprasellar tubercular abscess presenting as panhypopituitarism: a common lesion in an uncommon site with a brief review of literature. Pituitary 2006;6:73-7.
  60. Sharma MC, Arora R, Mahapatra AK, Sarat-Chandra P, Gaikwad SB, Sarkar C. Intrasellar tuberculoma – an enigmatic pituitary infection: a series of 18 cases. Clin Neurol Neurosurg 2000;102:72-7.
  61. Cellen S, Whittaker E, Eisenhut M, Grandjean L. Cerebral tuberculomas in a 6-year-old girl causing central diabetes insipidus. BMJ Case Rep 2018. DOI: 10.1136/bcr-2018-226590.
  62. Dayal D, Muthuvel B, Sodhi KS. Obesity as the presenting feature of sellar-suprasellar tuberculoma. Indian J Endocr Metab 2018;22:176-7.
  63. Srisukh S, Tanpaibule T, Kiertiburanakul S, Boongird A, Wattanatranon D, Panyaping T, et al. Pituitary tuberculoma: a consideration in the differential diagnosis in a patient manifesting with pituitary apoplexy-like syndrome. ID Cases 2016;5:63-6.
  64. Roka YB, Roka N, Pandey SR. Primary pituitary tubercular abscess: a case report. J Nepal Med Assoc 2019;57:206-8.
  65. Mittal P, Dua S, Saggar K, Gupta K. Magnetic resonance findings in sellar and suprasellar tuberculoma with hemorrhage. Surg Neurol Int 2010;1:73.
  66. Saini KS, Patel AL, Shaikh WA, Magar LN, Pungaonkar SA. Magnetic resonance spectroscopy in pituitary tuberculoma. Singap Med J 2007;48:783-6.
  67. Doknic M, Miljic D, Pekic S, Stojanovic M, Savic D, Manojlovic-Gacic E, et al. Single center study of 53 consecutive patients with pituitary stalk lesions. Pituitary 2018. DOI: 10.1007/s11102-018-0914-2.
  68. Agrawal VM, Giri PJ. Tuberculosis: a common infection with rare presentation, isolated sellar tuberculoma with panhypopituitarism. J Neurosci Rural Pract 2019;10:327-30.
  69. Antony G, Dasgupta R, Chacko G, Thomas N. Pituitary tuberculoma with subsequent drug-resistant tuberculous lymphadenopathy: an uncommon presentation of a common disease. BMJ Case Rep 2017.
  70. Dhanwal DK, Vyas A, Sharma A, Saxena A. Hypothalamic pituitary abnormalities in tubercular meningitis at the time of diagnosis. Pituitary 2010;13:304-10.
  71. Mohammed H, Goyal MK, Dutta P, Sharma K, Modi M, et al. Hypothalamic and pituitary dysfunction is common in tubercular meningitis: A prospective study from a tertiary care center in Northern India. J Neurol Sci. 2018 Dec 15;395:153-158.
  72. More A, Verma R, Garg RK et al. A study of neuroendocrine dysfunction in patients of tuberculous meningitis. J Neurol Sci. 2017 Aug 15;379:198-206.
  73. Lam KS, Shamm MM, Tam SC, Ng MM, Ma HT. Hypopituitarism after tuberculous meningitis in childhood. Ann Intern Med1993; 118:701-6.
  74. Chung DK, Hubbard WW. 1969. Hyponatremia in untreated active pulmonary tuberculosis. Am Rev Respir Dis 99:595–597.
  75. Morris CD, Bird AR, Nell H. 1989. The haematological and biochemical changes in severe pulmonary tuberculosis. Q J Med 73:1151–1159
  76. Jonaidi Jafari N, Izadi M, Sarrafzadeh F, Heidari A, Ranjbar R, Saburi A. 2013. Hyponatremia due to pulmonary tuberculosis: review of 200 cases. Nephrourol Mon 5:687–691
  77. Dash M, Sen RK, Behera BP, Sahu SS. Prevalence of hyponatremia in pulmonary tuberculosis. Int J Adv Med 2020;7:63-6.
  78. Khan K, Rasool N, Mustafa F, Tariq R. Hyponatremia Due to Pulmonary Tuberculosis in Indian Population. Int J Sci Stud 2017;5(5):98-101.
  79. Chaya BE, Rajesh KN, Mohan K, Mahesh DM. Hyponatremia in tuberculosis: Focus on brain instead of adrenals. Neurol India 2018;66:1515-6.
  80. Weiss H, Katz S. Hyponatremia resulting from apparently inappropriate secretion of antidiuretic hormone in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1965 Oct;92(4):609-16.
  81. Anderson RJ, Pluss RG, Berns AS, Jackson JT, Arnold PE, Schrier RW, McDonald KE. 1978. Mechanism of effect of hypoxia on renal water excretion. J Clin Invest 62:769–777.
  82. Hill AR, Uribarri J, Mann J, Berl T. 1990. Altered water metabolism in tuberculosis: role of vasopressin. Am J Med 88:357–364.
  83. Lee P, Ho KK. 2010. Hyponatremia in pulmonary TB: evidence of ectopic antidiuretic hormone production. Chest 137:207–208.
  84. Roca B, Tornador N, Tornador E. 2008. Presentation and outcome of tuberculous meningitis in adults in the province of Castellon, Spain: a retrospective study. Epidemiol Infect 136:1455–1462.
  85. Misra UK, Kalita J, Bhoi SK, Singh RK. A study of hyponatremia in tuberculous meningitis. J Neurol Sci. 2016 Aug 15; 367:152-7.
  86. Misra UK, Kalita J and Tuberculous Meningitis International Research Consortium. Mechanism, spectrum, consequences and management of hyponatremia in tuberculous meningitis [version 1; peer review: 2 approved] Wellcome Open Research 2019, 4:189 https://doi.org/10.12688/wellcomeopenres.15502.1 (accessed November 2020)
  87. Cotton MF, Donald PR, Schoeman JF, Aalbers C, Van Zyl LE, Lombard C. 1991. Plasma arginine vasopressin and the syndrome of inappropriate antidiuretic hormone secretion in tuberculous meningitis. Pediatr Infect Dis J 10:837–842.
  88. Inamdar P, Masavkar S, Shanbag P. Hyponatremia in children with tuberculous meningitis: A hospital-based cohort study. J Pediatr Neurosci. 2016;11(3):182-187.
  89. Singh BS, Patwari AK, Deb M: Serum sodium and osmolal changes in tuberculous meningitis. Indian Pediatr. 1994; 31(11): 1345–50.
  90. Cotton MF, Donald PR, Schoeman JF, Van Zyl LE, Aalbers C, Lombard CJ. 1993. Raised intracranial pressure, the syndrome of inappropriate antidiuretic hormone secretion, and arginine vasopressin in tuberculous meningitis. Childs Nerv Syst 9:10–15.
  91. Berendes E, Walter M, Cullen P, et al.: Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet. 1997; 349(9047): 245–59.
  92. Lenhard T, Külkens S, Schwab S: Cerebral salt-wasting syndrome in a patient with neuroleptic malignant syndrome. Arch Neurol. 2007; 64(1): 122–25
  93. Misra UK, Kalita J, Kumar M: Safety and Efficacy of Fludrocortisone in theTreatment of Cerebral Salt Wasting in Patients with Tuberculous Meningitis: A Randomized Clinical Trial. JAMA Neurol. 2018; 75(11): 1383–91.
  94. Jacobs TP, Bilezikian JP. Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab. 2005 Nov;90(11):6316-22.
  95. Shek CC, Natkunam A, Tsang V, Cockram CS, Swaminathan R. Incidence, causes and mechanism of hypercalcaemia in a hospital population in Hong Kong. Q J Med. 1990 Dec;77(284):1277-85.
  96. Sharma SC. Serum calcium in pulmonary tuberculosis. Postgrad Med J. 1981 Nov;57(673):694-6.
  97. Lind L, Ljunghall S. Hypercalcemia in pulmonary tuberculosis. Ups J Med Sci. 1990;95(2):157-60
  98. Liam CK, Lim KH, Srinivas P, Poi PJ. Hypercalcaemia in patients with newly diagnosed tuberculosis in Malaysia. Int J Tuberc Lung Dis. 1998 Oct;2(10):818-23.
  99. Kitrou MP, Phytou-Pallikari A, Tzannes SE, Virvidakis K, Mountokalakis TD. Hypercalcemia in active pulmonary tuberculosis. Ann Intern Med. 1982 Feb;96(2):255.
  100. Roussos A, Lagogianni I, Gonis A, Ilias I, Kazi D, Patsopoulos D, Philippou N. Hypercalcaemia in Greek patients with tuberculosis before the initiation of anti-tuberculosis treatment. Respir Med. 2001 Mar;95(3):187-90.
  101. Need AG, Phillips PJ, Chiu F, Prisk H. Hypercalcaemia associated with tuberculosis. Br Med J. 1980 Mar 22;280(6217):831.
  102. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association. Br J Dis Chest. 1981 Apr;75(2):141-53.
  103. Keleştimur F, Güven M, Ozesmi M, Paşaoğlu H. Does tuberculosis really cause hypercalcemia? J Endocrinol Invest. 1996 Nov;19(10):678-81.
  104. Fuss M, Karmali R, Pepersack T, Bergans A, Dierckx P, Prigogine T, Bergmann P, Corvilain J. Are tuberculous patients at a great risk from hypercalcemia? Q J Med. 1988 Nov;69(259):869-78.
  105. Chan TY. Differences in vitamin D status and calcium intake: possible explanations for the regional variations in the prevalence of hypercalcemia in tuberculosis. Calcif Tissue Int. 1997 Jan;60(1):91-3.
  106. John SM, Sagar S, Aparna JK, Joy S, Mishra AK. Risk factors for hypercalcemia in patients with tuberculosis. Int J Mycobacteriol 2020;9:7-11
  107. Abbasi AA, Chemplavil JK, Farah S, Muller BF, Arnstein AR. Hypercalcemia in active pulmonary tuberculosis. Ann Intern Med. 1979 Mar;90(3):324-8.
  108. Felsenfeld AJ, Drezner MK, Llach F. Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis. Arch Intern Med. 1986 Oct;146(10):1941-5.
  109. Gkonos PJ, London R, Hendler ED. Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. N Engl J Med. 1984 Dec 27;311(26):1683-5.
  110. Isaacs RD, Nicholson GI, Holdaway IM. Miliary tuberculosis with hypercalcaemia and raised vitamin D concentrations. Thorax. 1987 Jul;42(7):555-6.
  111. Cadranel J, Garabedian M, Milleron B, Guillozo H, Akoun G, Hance AJ. 1,25(OH)2D2 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J Clin Invest. 1990 May;85(5):1588-93.
  112. Facchini L, Venturini E, Galli L, de Martino M, Chiappini E. 2015. Vitamin D and tuberculosis: a review on a hot topic. J Chemother 27:128–138.
  113. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV,Kwiatkowski D. 1998. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage like cell line. Infect Immun 66:5314–5321.
  114. Coussens AK, Wilkinson RJ, Hanifa Y, et al. 2012. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 109: 15449–15454.
  115. Sinclair D, Abba K, Grobler L, Sudarsanam TD. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD006086.
  116. Brodie MJ, Boobis AR, Hillyard CJ, et al: Effect of Isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther 1981; 30:363-370.

Brodie MJ, Boobis AR, Dollery CT, et al: Rifampicin and vitamin D metabolism. Clin Pharmacol Ther 1980; 27:810-814.

Protozoa and Endocrine Dysfunction

ABSTRACT

 

Protozoa are parasitic organisms that are among the most important pathogens worldwide. They are classified into four groups and in infected persons, the disease process may be asymptomatic. Of the four groups, Flagellates and Sporozoa are implicated in the causation of endocrine dysfunction and metabolic abnormalities. The disease condition caused by the flagellates include Giardiasis, Leishmaniasis, and Trypanosomiasis and all cause endocrine abnormalities that range from growth retardation, hypogonadism, adrenal insufficiency, thyroid dysfunction which is largely a resultant effect of the sick euthyroid syndrome, and the syndrome of inappropriate ADH secretion. The Sporozoan disease that notably give rise to metabolic abnormalities is malaria especially severe malaria which is commonly caused by P Falciparum infection. Hypoglycemia is one of the defining criteria for severe malaria and in Africa where malaria is endemic the reported prevalence rate of hypoglycemia in children is as high as 60%. Other abnormalities which are infrequently reported requiring treatment albeit temporarily are hyperglycemia, hypocalcemia, and diabetes insipidus. Adrenal insufficiency when is present is a poor prognostic factor in severe malaria. Toxoplasmosis is acquired or vertically transmitted and may present with neuroendocrine manifestations and adrenal insufficiency resulting from infiltration of the affected endocrine organs with the parasites.

 

PROTOZOA

 

A parasite is an organism that lives on or in a host organism and gets its food from or at the expense of its host. The three main classes of parasites that can cause disease in humans include helminths, protozoa, and ectoparasites.

 

Protozoa are microscopic, one-celled organisms that can be free-living or parasitic in nature. Their ability to multiply in humans contributes to their survival and also permits serious infections to develop from just a single organism. Transmission of protozoa that live in a human’s intestine to another human typically occurs through a fecal-oral route and for those that live in the blood or tissue of human’s transmission to other humans is via an arthropod vector (1). Protozoa that are infectious to humans are classified into four groups based on their mode of movement;

 

Mastigophora – the flagellates, e.g., GiardiaLeishmania, Trypanosoma

Sporozoa – organisms whose adult stage is not motile e.g., PlasmodiumCryptosporidium, Toxoplasma gondii,

Ciliophora – the ciliates, e.g., Balantidium

Sarcodina – the ameba, e.g., Entamoeba

 

MASTIGOPHORA  

 

Mastigophora is a phylum of protozoans of the Kingdom Protista, consisting mainly of free-living flagellated unicellular organisms that reproduce by binary fission and whose habitat includes fresh and marine waters. Leishmania and Trypanosoma live in the blood, lymph, and tissue spaces and are typically transmitted from one host to another by blood feeding arthropods.

 

Giardiasis 

 

This is a diarrheal illness that is caused by Giardia (also known as Giardia intestinalis, Giardia lamblia, or Giardia duodenalis). It is a microscopic parasite and is the most common cause of protozoa associated diarrhea worldwide. The prevalence rate of Giardiasis is higher in developing countries than in the developed countries of the world with Giardia species being endemic in areas of the world that have poor sanitation and high-risk groups including immunocompromised individuals (2-3).

 

MODE OF TRANSMISSION

 

The parasite is found on surfaces or in soil, food, or water that has been contaminated with feces from infected humans or animals. Infection is transmitted commonly through ingestion of infectious G lamblia cysts. In the intestine, excystation occurs and trophozoites are released into the feces. A summary of the transmission of the parasite is shown in Figure 1.

Giardia infrequently is transmitted sexually specifically through oral-anal practices. The incubation period is 3-35 days but 7-10 days on the average.

Figure 1. Life Cycle of Giardia. Source- Centers for Disease Control and Prevention

CLINICAL PRESENTATION

 

The clinical manifestations include acute or chronic diarrheal disease, but the infection may be asymptomatic even in children. In a Nigeria Study (3) that evaluated stool samples of children aged between 0-5 years, about half-(41%) were positive for G. lamblia. The extraintestinal manifestations of Giardiasis include allergic presentations resulting from immune system activation, and long-term consequences such as ocular pathologies, arthritis, allergies, growth failure, muscular, and metabolic complications (4-5).

 

ENDOCRINE AND METABOLIC ABNORMALITIES

 

The complications relating to endocrine and metabolic dysfunction include growth failure and hypothyroidism. The Nigerian Report described above showed a positive association between asymptomatic giardiasis and malnutrition. The relation between Giardiasis and growth failure is explained mainly by malabsorption leading to protein energy malnutrition and micronutrient deficiencies. Other than nutritional status, other contributory factors to growth stunting in children include sanitary and socio-economic conditions, loss of intestinal surface area, and maldigestion (4-5).

 

Giardia infection has no direct effect or impact on thyroid function but has been reported to indirectly affect thyroid status. Worsening of hypothyroidism related to malabsorption of levothyroxine tablets occasioned by the presence of Giardia infection has been documented in the literature (6-7).

 

DIAGNOSIS AND MANAGEMENT

 

The diagnosis is made by demonstration of cysts or trophozoites in stool samples. Other means of diagnosis include small bowel biopsy and stool ELISA. The mainstay of treatment is metronidazole. Patients with stunted growth often experience catch- up growth following treatment of giardiasis.

 

Leishmaniasis  

 

Leishmaniasis is a poverty related protozoal disease caused by the Leishmania donovani complex. There are 3 main forms of leishmaniases – visceral (also known as kala-azar, the most serious form of the disease), cutaneous (the most common), and mucocutaneous. The clinical spectrum of leishmaniasis ranges from a self-resolving cutaneous ulcer to a mutilating mucocutaneous disease and even to a lethal systemic illness. In Nigeria cutaneous leishmaniasis is the commonly occurring type and has been noted to occur in Northern Nigeria especially in areas bordering the Niger Republic.

 

Types of Leishmaniasis

 

MODE OF TRANSMISSION

 

Leishmania spp. is a parasite with a dimorphic life cycle that is controlled by the passage from vector to host .All three forms of Leishmaniasis are transmitted by the bite of infected female sand fly. The vector phase of the life cycle begins when the vector ingests blood containing the parasites with the parasites undergoing differentiation and ultimately becoming promastigotes and pass into the proboscis where where they can inoculate the host during feeding of the vector (8). These human and vector stages of Leishmania are shown in Figure 2. Infiltration of the reticuloendothelial system by amastigotes leads to the biochemical and clinical features of the disease.

 

Vertical transmission of visceral leishmaniasis may occur during pregnancy while cutaneous leishmaniasis may be transmitted through physical contact. Transmission via contaminated needles, blood transfusion, sexual intercourse and vertical transmission are modes of transmission that are documented albeit infrequently (8).

Figure 2. Life cycle of Leishmania. Source -CDC

CLINICAL PRESENTATION

 

Visceral Leishmaniasis (VL) may present with fever, malnutrition, weight loss , hepatosplenomegaly and death if treatment is delayed or sub-optimal. Cutaneous Leishmaniasis presents with skin ulceration and nodules and the Mucocutaneous form of Leishmaniasis with skin and mucous involvement.

 

ENDOCRINE AND METABOLIC ABNORMALITIES

 

Evidence of involvement of several endocrine organs- pituitary, adrenal, thyroid, and sex glands- via histopathologic studies have been documented in VL (9). However abnormal endocrine function tests in some instances without clinical manifestations have been documented.

 

Reports from Africa and Europe show that thyroid function may be affected in VL but the abnormalities detected are most likely a result of euthyroid sick syndrome (ESS) or non-thyroidal illness (NTI) with no clinical presentation of thyroid disease (10-12). VL has been reported to present with primary adrenal insufficiency in with clinically overt features and in some cases biochemical evidence without clinical features may occur. Primary adrenal insufficiency (AI) was reported in VL in a patient without HIV infection and a patient with concomitant HIV infection and was attributable to parasitic infiltration of the organ (13-14). A Brazilian Series reported a prevalence rate of AI to be about 50% in persons with VL (12). In the Brazilian Report (12) that compared hormonal parameters between persons with chronic leishmaniasis and control subjects, the following were noted in some of the subjects with leishmaniasis; a) features of pituitary dysfunction characterized by low TSH, low T4, and low T3 levels (ESS/NTI), b) elevated ACTH with normal cortisol levels, c) high FSH, LH, and low testosterone levels. Other endocrine abnormalities include low parathyroid hormone (PTH) and decreased total and ionized calcium levels.

 

An unusual presentation of VL is adrenal cysts which has been reported to come to clinical attention because of the mass effect (15-16). The Syndrome of inappropriate ADH secretion (SIADH) is often reported in VL with hyponatremia documented as a significant contributory factor to mortality of the disease (17). The endocrine and metabolic abnormalities of Leishmaniasis and potential mechanisms underlying their occurrence are shown in Table 1. 

 

Table 1. Endocrine and Metabolic Dysfunction in Visceral Leishmaniasis

Endocrine Gland

 Hormonal Status

The Level of Abnormality

Underlying Mechanism

Presentations

Thyroid Gland

Low TSH, Low T3, Low T4

 

High TSH, Low T4, Low T3

Hypothalamic/Pituitary Axis

 

ESS/NTI

Malnutrition in VL may lead to suppressed TSH and subsequent low TH production.

Parasitism of the pituitary gland.

 

No clinical features of thyroid disease

 

Low T4, High TSH

Primary hypothyroidism /Thyroid gland

 

Primary thyroid insufficiency due to the infiltration of the thyroid gland causing thyroiditis

 

Adrenal Gland

Low Cortisol, High ACTH

Primary adrenal insufficiency

Parasitic Infiltration of the adrenal cortex

 Mucosal pigmentation, chronic diarrhea, weight loss

 

High ACTH, Normal Cortisol

Primary adrenal insufficiency

Parasitic Infiltration of the adrenal cortex

These patients have normal cortisol levels but were unable to mount an adequate response to stress

 

High ACTH, high cortisol

Hypothalamus, Pituitary

Stress Response

 

Parathyroid gland

Low PTH, Hypocalcemia

Renal (interstitial nephritis) and GIT

Hypomagnesaemia resulting from increased renal loss.

GIT loss from possible malabsorption and frequent diarrhea.

 

Posterior pituitary gland

Syndrome of inappropriate ADH secretion (SIADH)

Hypothalamo-Pituitary Axis

Volume depletion from vomiting leading to increased serum osmolality and resultant Vasopressin release from the PPG.

Intense inflammatory response from multiple organ involvement leads to activation of HPA axis and Vasopressin release.

 

Hyponatremia, elevated urinary osmolality and reduced serum osmolality

Gonads

High FSH, High LH and low testosterone

Primary hypogonadism

Parasitism of the testes, reduced testicular size with fewer Sertoli and Leydig cells. Malnutrition may be contributory to the low testosterone level

Delayed Puberty

Erectile dysfunction

 

DIAGNOSIS AND TREATMENT

 

A combination of clinical symptoms and laboratory parameters clinches the diagnosis. The laboratory tests involve the detection of the parasites in samples taken from the base of the ulcer and dermal scrapings- Wright ‘s stain detects round or ovoid parasite in the cytoplasm of macrophages.

 

Polymerase chain reaction for detection of the parasite in peripheral blood and bone marrow samples IS diagnostic. Other tests to support the diagnosis is the Leishman test, which essentially refers to observation of a delayed tuberculin type of reaction following an Intradermal injection of leishmanial antigen.

 

The mainstay of treatment is the pentavalent antimony compounds. Other pharmacotherapies include amphotericin B, oral miltefosine, pentamidine, and antibiotics. Treatment is individualized, thus persons with associated endocrine/metabolic dysfunction are treated on a case-by-case basis.

 

Trypanosomiasis  

 

This is an anthropozoonosis caused by a protozoan hemoflagellate. Trypanosoma cruzi in American trypanosomiasis, also known as Chagas disease, is transmitted to human host by a tick. Human African trypanosomiasis (HAT) also known as sleeping sickness is caused by Trypanosoma brucei gambiense in West and Central Africa andTrypanosoma brucei rhodosiense in East Africa is transmitted to human hosts by bites of infected tsetse flies.

Figure 3. The pathogen in human African trypanosomiasis

MODE OF TRANSMISSION

 

In HAT the tsesefly (glossina specie) injects metacyclic trypomastogotes into the skin and these pass into the blood stream and are subsequently carried to other parts of the body and body fluids. The tsetsefly becomes infected when it bites an infected person. Trypanosoma brucei gambiense may also be acquired congenitally from an infected mother.

 

Chagas disease is transmitted by a group of blood-feeding insects known as kissing bugs or triatomid bugs. The pathogen normally circulates between bugs and wild animals in sylvatic habitats; infected bugs in domestic habitats can transmit Chagas to humans and domestic animals (dogs, guinea pigs). Details of the life cycle and transmission of the pathogen is shown in Figure 4.

Figure 4. Transmission of Chagas Disease

CLINICAL PRESENTATION

 

Trypanosomiasis may cause acute illness but on the other hand the infection may be asymptomatic. Chagas disease (CD) presents in three phases: acute, indeterminate, and chronic. The acute phase occurs immediately following infection and is usually asymptomatic in most people but when symptomatic, presentation is essentially those of malaise and skin lesions. The indeterminate phase is usually asymptomatic but may progress to a chronic phase where organ systems mainly the heart and sometimes the gastrointestinal tract are affected.

 

HAT is characterized by an early hyper-hemolytic phase in which the trypanosomes are restricted to the blood and the lymphatic system and also characterized by organomegaly and lymphadenopathy. This is followed by a late phase or the meningo-encephalitic stage characterized by neuro-psychiatric and endocrinal disorders.

 

ENDOCRINE AND METABOLIC ABNORMALITIES   

 

These occur infrequently and includes systemic neuroendocrine manifestations in the sympathetic and parasympathetic ganglia. In HAT, documented endocrine abnormalities include adrenal insufficiency, hypothyroidism, and hypogonadism in the absence of autoantibodies (18). Some authors have reported thyroid dysfunction specifically hypothyroidism in untreated HAT (19).

 

Adrenal insufficiency in trypanosomiasis may be primary or secondary and this is seen especially in untreated cases (20). The adrenal may serve as a reservoir for the T. cruzi infection and some investigators have noted a correlation between Chagasic myocarditis and infection within the central vein of the adrenal gland (21).

 

Secondary hypogonadism in both sexes had also been demonstrated in some reports which clearly showed that in the majority of the cases, the pathology was not at the level of the pituitary gland but rather an extra pituitary origin (22). Clearly, primary hypogonadism was not demonstrated to be a contributory factor to cases of hypogonadism in persons with trypanosomiasis.

 

Metabolic abnormalities are infrequently reported however a case of spurious hypoglycemia (23) has been documented in which hypoglycemia was attributable to invitro utilization of glucose by the parasite. The metabolic and endocrine abnormalities are shown in Table 2.

 

Table 2. Endocrine and Metabolic Dysfunction in Trypanosomiasis

Endocrine Gland

 Hormone /Hormonal status

The level of abnormality

Possible reason

Clinical Presentation

Thyroid Gland

Low TSH, Low T3 Low T4

 

High TSH, Low T4, Low T3

Secondary hypothyroidism

 

Primary hypothyroidism 

Elevated plasma cytokines related to untreated HAT

Parasitic thyroiditis

 

HPA Axis

Subnormal Cortisol response to ACTH

 

 

 

 

 

Subnormal cortisol response to ACTH

 

Subnormal ACTH and cortisol response to (CRT) test

 

Primary Adrenal Insufficiency

 

 

 

 

 

 

 

Secondary adrenal insufficiency

Parasitic invasion of the adrenal gland.

Iatrogenic: Suramin in doses exceeding the quantity employed in the treatment of trypanosomiasis inhibits adrenocortical hormone synthesis.

Adaptation of the HPA state to the cytokines released due to inflammatory status of the underlying disease

 

Glucose metabolism

Low glucose levels

Spurious Hypoglycemia

 

 

Clinical hypoglycemia

Invitro utilization of glucose by trypanosome

 

Iatrogenic: Pentamidine

 

HPG Axis

In Men: Low Testosterone, Low LH and FSH

 

Positive response of testosterone to GnRH/LHRH stimulation

 

 

In women: Low Estradiol, low basal LH and FSH levels and positive response to GnRH/ LHRH

Secondary hypogonadism

 

 

 

 

 

Tertiary hypogonadism

 

 

 

 

 

Tertiary hypogonadism

Most likely due to inflammatory status of the underlying disease

 

 

 

Mechanism not known but may be due to cytokine release

 

 

 

 

 

Mechanism not known but may be due to cytokine release

Loss of libido, Impotence

 

 

 

 

Impotence

 

 

 

 

 

 

 

Amenorrhea

 

 

 

 

DIAGNOSIS  

 

Diagnosis of HAT involves a three-tiered approach for infections due to T.b. Gambiense and a two-tiered approach for that due to T.b. rhodosiense. The three steps for gambiense HAT include a screening test, diagnostic confirmation, and stage determination while that for rhodesiense HAT are diagnostic confirmation and stage determination. Screening is for gambiense HAT involves serology - CATT (Card Agglutination Test for Trypanosomiasis), which detects the presence of specific antibodies in the patient’s blood or serum. Diagnostic confirmation is done to detect the presence of trypanosomes in lymph node aspirates, chancre smear, or in blood. Stage determination is via the detection of trypanosomes (after centrifugation) and white cell count in the cerebrospinal fluid (lumbar puncture):Hemolymphatic stage is characterized by the absence of trypanosomes AND ≤ 5 white cells/mm3 and the Meningoencephalitic stage is defined by evidence of trypanosomes OR > 5 white cells/mm3.

 

Diagnosis of Chagas disease is via identification of Trypanosoma cruzi by direct microscopy of fresh blood or blood concentrated by the microhematocrit method. Serological tests for anti-Trypanosoma cruzi antibodies are performed for cases of suspected disease but no definitive diagnosis by microscopy.

 

PHARMACOTHERAPY FOR TRYPANOSMIASIS

 

Acute or chronic Chagas disease can be treated with either benznidazole or nifurtimox for those without cardiac or GIT complications. Drugs employed in the management of HAT include Nifurtimox, Eflornithine, Melarsoprol, Pentamidine, and Prednisolone (24).

 

SPOROZOANS

 

Sporozoans are a group of non-flagellated, non-ciliated and non-amoeboid protists that are responsible for diseases such as malaria and toxoplasmosis.

 

Malaria

 

Malaria is an infection caused by single-celled parasites that enter the blood through the bite of an Anopheles mosquito. These parasites, called plasmodia, belong to at least five species; P falciparum, P vivax, P ovale, P malariae and P knowlesi. Plasmodium parasites spend several parts of their life cycle inside humans and another part inside mosquitoes. During the human part of their life cycle, Plasmodium parasites infect and multiply inside liver cells and red blood cells.

 

Malaria infection begins when an infected female Anopheles mosquito bites a person, injecting Plasmodium parasites, in the form of sporozoites, into the bloodstream and then to the liver. In the liver, asexual multiplication of the sporozoites take place and these are released from the liver as merozoites which invade the red blood cells and multiply within the red cells until the cells burst and the released merozoites invade more red cells with the cycle repeating itself and causing fever. Some of the merozoites leave the cycle of asexual multiplication and instead of replicating within the cells develop into sexual forms of the parasites known as gametocytes. Following the bite of an infected person, gametocytes are ingested by the mosquito and develop into gametes which ultimately become sporozoites which travel to the mosquito’s salivary glands (25).

CLINICAL PRESENTATION

 

Uncomplicated malaria presents with fever, headache, and generalized malaise. Severe malaria refers to the demonstration of asexual forms of the malaria parasites (commonly P falciparum) in a patient with a potentially fatal manifestations or complications of malaria. Severe malaria is characterized by altered mentation, severe hemolysis, some metabolic abnormalities, and organ complications.

 

ENDOCRINE AND METABOLIC ABNORMALITIES

 

Hypoglycemia is commonly documented in severe malaria and hyperglycemia although infrequently reported is seen in severe malaria as well as uncomplicated malaria. Hypocalcemia is also reported in severe malaria as well as in cases of uncomplicated malaria.

 

Hypoglycemia may be iatrogenic due to quinine administration or due to increased glucose turnover secondary to increased glucose uptake resulting from anaerobic glycolysis and alterations in glucose production in severe malaria (26). Nigeria Reports have hypoglycemia (blood glucose <2.2mmol/L) documented in 60% of children diagnosed with severe malaria (27). Hyperglycemia on the other hand infrequently occurs in persons with malaria and it may present in uncomplicated malaria or severe malaria due to P falciparum infection. The causes of hyperglycemia sometimes necessitate the temporary use of insulin and is multifactorial. These include release of counter-regulatory hormones in response to the stress of the underlying malaria disease condition and pro inflammatory cytokines which increase blood glucose (28). Other proposed reasons for hyperglycemia are reduced sensitivity to insulin and increased gastric and small intestine permeability for sucrose in malaria patients (29-30).

 

Hypocalcemia is reported in severe malaria as well as in cases of uncomplicated malaria. It has been shown that there is an inverse relationship between parasite load and calcium levels with calcium levels returning to normal following treatment and parasite clearance (31). Altered magnesium metabolism and disturbed parathyroid gland function have been documented as possible reasons for hypocalcemia in malaria (32).

 

The pituitary-thyroid axis may be depressed in severe malaria and this is most likely attributable to adaptations of the pituitary-thyroid axis to the underlying illness. A Report has noted suppressed T4 and TSH levels with a poorly responsive pituitary gland to TRH stimulation as evidenced by low TSH levels following stimulation (33-34).  Another possible mechanism underlying the secondary hypothyroidism is parasitic sequestration within the hypothalamo-pituitary portal system (35).

 

Clinical and biochemical parameters of central diabetes insipidus which in some cases warranted treatment has been reported in severe malaria. The suggested mechanism is obstruction of the neurohypophyseal microvasculature (36-37).

 

Primary and secondary adrenal insufficiency which may present with subnormal cortisol levels and in some cases overt features of hypocortisolemia may be seen in severe malaria. Primary adrenal insufficiency may be due to necrosis or impaired circulation due to sequestration of parasites. Some reports have results suggestive of cytokines playing a role in modulating the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Other potential mechanisms for secondary adrenal insufficiency are erythrocyte sequestration within the hypothalamic -pituitary portal system, altered setpoint for cortisol inhibition of ACTH, and production of a peptide like mammalian somatostatin which has been found to inhibit ACTH secretion in vitro (38-39).

 

DIAGNOSIS AND TREATMENT

 

Direct microscopy employed on thin and thick blood films enable parasite detection, species identification, quantification, and monitoring of parasitemia. Serology via the rapid diagnostic tests which detects the parasite antigen can be employed.

Figure 5: Giemsa-stained peripheral blood smear. Arrow A showing a classic, ring-shaped trophozoite of Plasmodium falciparum. Arrow B showing a classic, headphone-shaped trophozoite of P. falciparum. Arrow C showing two trophozoites of P. falciparum within the same red blood cell. (Reproduced from BMJ Case Reports (Surce-Parikh et al. Classic image: peripheral blood smear in a case of Plasmodium falciparum cerebral malaria http://dx.doi.org/10.1136/bcr-2014-205820

Severe malaria regardless of the infecting specie is treated with intravenous Artesunate and interim oral treatment, artemether -lumefantrine. Other oral antimalarial drugs are Atovaquone-proguanil, Quinine. and Mefloquine.

 

Toxoplasmosis

 

Toxoplasmosis is an infection with Toxoplasma gondii, an obligate intracellular protozoon, which is ingested in the form oocysts in material contaminated by feces from infected cats. Oocysts may also be transported to food by flies and cockroaches.

 

TRANSMISSION  

 

It is primarily an intestinal parasite in cats and has a wide host of intermediate hosts including sheep and mice and exists in three forms: oocysts, tachyzoites, and bradyzoites. Oocysts are only produced in the definitive host – the cat. When passed in the feces and then ingested, the oocysts can infect humans and other intermediate hosts where they develop into tachyzoites- rapidly multiplying trophozoite form of T. gondii. They divide rapidly in cells, causing tissue destruction and spreading the infection. The transmission of toxoplasmosis is shown in Figure 5. Tachyzoites in pregnant women are capable of infecting the fetus. Eventually tachyzoites localize to muscle tissues and the CNS where they convert to tissue cysts, or bradyzoites which is the dormant stage. This is thought to be a response to the host immune reaction. Ingestion of cysts in contaminated meat is also a source of

infection, as bradyzoites transform back into tachyzoites upon entering a new host.

Figure 5. Mode of transmission of toxoplasmosis

CLINICAL PRESENTATION

 

Toxoplasmosis is often asymptomatic or associated with mild self-limiting symptoms except in immunocompromised persons and sometimes in cases that are congenitally transmitted via the transplacental route (congenital toxoplasmosis).

 

CNS toxoplasmosis is one of the most common and important opportunistic infections in patients who are immunocompromised -the clinical manifestations are often nonspecific, with the most common presenting symptoms being headache, lethargy, fever, and focal neurologic signs. In congenital toxoplasmosis (CT), chorioretinitis is the most common manifestation and may cause seizure, hydrocephalus, and psychomotor delay.

 

ENDOCRINE AND METABOLIC ABNORMALITIES

 

Endocrine defects in toxoplasmosis are usually neuroendocrine in nature and may occur in congenital toxoplasmosis as well as acquired toxoplasmosis. Endocrine manifestations of   Toxoplasmosis include hypogonadotropic hypogonadism, precocious puberty, short stature, and diabetes insipidus. Documented hormonal abnormalities in persons with congenital toxoplasmosis result from hypothalamo-pituitary dysfunction and include growth hormone, gonadotropin, and ADH deficiency (40-41) (Figure 6).

Figure 6. Computerized tomography of brain showing dilated ventricles with multiple subependymal and parenchymal calcifications (arrow). (Source: Mohammed S et al; Congenital toxoplasmosis presenting as central diabetes insipidus in an infant: a case report BMC Res Notes. 2014; 7: 184.

Hypogonadotropic hypogonadism may occur transiently as a result of the modulation of the hypothalamus-pituitary axis by cytokines. Trypanosomiasis which is seen as a ring enhancing lesions in the brain during MRI imaging is an organic cause of the neuroendocrine abnormalities noted in some series (42-44).

 

Toxoplasmosis has been suggested as a possible risk factor for type 2 diabetes mellitus. Some Researchers have suggested that Toxoplasma gondii directly effects pancreatic cells through beta cell destruction (45-46).

 

DIAGNOSIS AND TREATMENT  

 

Diagnosis is made via direct detection of the parasites in body fluid and tissue samples.

Serology and molecular techniques are also employed in the diagnosis. Imaging preferable MRI is of use in suspected CNS involvement. Pyrimethamine, Sulfadiazine and Trimethorprin, and sulfamethoxazole are pharmacotherapies for managing toxoplasmosis.

 

BALANTIDIASIS

 

Balantidiasis is a disease caused by Balantidium coli, a ciliated protozoan and the only ciliate known to be capable of infecting humans. It is transmitted via contaminated water or food through cysts often associated with swine, the primary reservoir host. Endocrine and metabolic dysfunction or abnormalities are not documented in Balantidiasis.

 

SARCODINA

 

Amoebiasis is a diarrhea illness caused by infection with Entamoeba histolytica and is acquired by fecal-oral transmission. In some instances, extraintestinal diseases may occur but endocrine and metabolic dysfunction are not known to occur.

 

CONCLUSION

 

Protozoal infections are rare but significant causes of metabolic and endocrine abnormalities. The possibility of protozoal infections as possible causes of these abnormalities should be sought out in regions where these infections are prevalent especially after exclusion of other commonly occurring causes.

 

REFERENCES

 

  1. Mousa HA. The Hidden Scene behind the High prevalence of Giardiasis and other infectious diseases in developing countries. J Infect Dis Ther 2014; 2:e106. doi:10.4172/2332-0877.
  2. Werner Espelage , Matthias an der Heiden, Klaus Stark, Katharina Alpers. Characteristics and risk factors for symptomatic Giardia lamblia infections in Germany. BMC Public Health. 2010;10:41. doi: 10.1186/1471-2458-10-41.
  3. Inabo HI, Yau B, Yakubu SE Asymptomatic Giardiasis and Nutritional Status of Children in Two Local Government Areas in Kaduna State, Nigeria. Sierra Leone Journal of Medical Research; 2011;3:157-162.

4       Jeffrey R. Donowitz, Masud Alam, Mamun Kabir, Jennie Z. Ma, Forida Nazib, James A. Platts-Mills, Luther A. Bartelt, Rashidul Haque, William A. Petri, Jr, A Prospective Longitudinal Cohort to Investigate the Effects of Early Life Giardiasis on Growth and All Cause Diarrhea, Clinical Infectious Diseases, 2016;63(6) 792–797.

  1. Simsek Z, Zeyrek FY, Kurcer MA Effect of Giardia infection on growth and psychomotor development of children aged 0-5 years. Journal of Tropical Pediatrics 2004;50(2):90-3.
  2. Radaeli Rde F, Diehl LA. Increased levothyroxine requirement in a woman with previously well-controlled hypothyroidism and intestinal giardiasis. Arq Bras Endocrinol Metabol 2011;55:81-4.
  3. Seppel T, Rose F, Schlaghecke R. Chronic intestinal giardiasis with isolated levothyroxine malabsorption as reason for severe hypothyroidism - implications for localization of thyroid hormone absorption in the gut. Exp Clin Endocrinol Diabetes. 1996;104:180-2.
  4. Miroslava Avila-García, Javier Mancilla, Enrique Segura-Cervantes and Norma Galindo-Sevilla (March 19th 2014). Transmission to Humans, Leishmaniasis - Trends in Epidemiology, Diagnosis and Treatment, David M. Claborn, IntechOpen, DOI: 10.5772/57271.https://www.intechopen.com/books/leishmaniasis-trends-in-epidemiology-diagnosis-and-treatment/transmission-to-humans
  5. Meleney HE. The histopathology of kala-azar in the hamster, monkey and man. Am J Pathol. 1925;1:147–168.
  6. Nahid R. Yousif, Rimaz E. Gurashi, Mohamed A. El Tahir, Safa Wadidi. Abd El Karim A. Abdrabo. Evaluation of Thyroid Function among Visceral Leishmaniasis Sudanese Patients. African Journal of Medical Sciences, 2018; 3 (8) .
  7. Al-Ezzy AI, Abood WN. Correlation of Rk39-Specific Antibodies and Thyroid Function in Patients with Visceral Leishmaniasis. Eurasian J Med. 2016;48(3):181-185.
  8. Frederico Araujo Lima Verde, Francisco Agenor Araujo Lima Verde, Augusto Saboia Neto, Paulo César Almeida, Emir Mendonça Lima Verde. Hormonal Disturbances in Visceral Leishmaniasis (Kala-Azar) Am J Trop Med Hyg. 2011; 84(5): 668–673.
  9. Mondain-Miton V, Toussaint-Gari M, Hofman P, Marty P, Carles M, De Salvador F, et al. Atypical leishmaniasis in a patient infected with human immunodeficiency virus, Clin Infect Dis 1995;21:663-665.
  10. Kaneria MV, Jagtap S, Modi C, Kamath S. Atypical presentation of Visceral Leishmaniasis. JAPI 2005;53
  11. Brandonisio O, Fumarola L, Spinelli R, Gradoni L. Unusual presentation of leishmaniasis as an adrenal cystic mass. Eur J Clin Microbiol Infect Dis. 2002 ;21(9):682-3.
  12. Brenner DS, Jacobs SC, Drachenberg CB, Papadimitriou JC. Isolated visceral leishmaniasis presenting as an adrenal cystic mass. Arch Pathol Lab Med. 2000 ;124(10):1553-6.
  13. Daher EF, Soares DS, Filho SL, et al. Hyponatremia and risk factors for death in human visceral leishmaniasis: new insights from a cross-sectional study in Brazil. BMC Infect Dis. 2017;17(1):168.
  14. Reincke M, Arlt W, Heppner C, Petzke F, Chrousos GP, Allolio B. Neuroendocrine dysfunction in African trypanosomiasis. The role of cytokines. Ann N Y Acad Sci. 1998 ;840:809-21.
  15. Reincke M, Allolio B, Petzke F, Heppner C, Mbulamber D, Vollmer D et al. Thyroid dysfunction in African trypanosomiasis: a possible role for inflammatory cytokines. Clin Endocrinol (Oxf) 1993;39(4): 455-461
  16. Reincke M, Allolio B, Petzke F, Heppner C, Mbulamber D, Vollmer D et al. Impairment of Adrenocortical Function Associated with Increased Plasma Tumor Necrosis Factor-Alpha and Interleukin-6 Concentrations in African Trypanosomiasis. Neuroimmunomodulation 1994;1:14–22.
  17. Paolo WF, Nosanchuk JD. Adrenal Infections International journal of infectious diseases. 2006; 10(5): 343-353)
  18. Boersma A, Noireau F, Hublart M. Gonadotropic axis and Trypanosoma brucei gambiense infection, Annales de la Société belge de médecine tropicale 1989;69(2):127-35.
  19. Nieman, Roger E., et al. “Severe African Trypanosomiasis with Spurious Hypoglycemia.” The Journal of Infectious Diseases, 1989; 159:360-362.
  20. Pan American Health Organization. Guidelines for diagnosis and treatment of Chagas disease. Washington, D.C. 2019.
  21. Baer K, Klotz C, Kappe SH, et al. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathogens. 2007;(11):e171.
  22. Planche T, Dzeing A, Ngou-Milama E, Kombila M, Stacpoole PW. Metabolic complications of malaria. Curr Top Microbiol Immunol 2005;295:105-36.
  23. Osonuga OA, Osonuga Ifabunmi, Derkyi-Kwarteng L. Prevalence of hypoglycemia among severe malaria children in rural Africa population, Asian Pacific Journal of Tropical Disease 2011; 1(3):192–194.
  24. Kiely A, McClenaghan NH, Flatt PR, Newsholme P. Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic beta-cell line. J Endocrinol. 2007 ;195(1):113-23.
  25. Singh Y, Joshi SC, Satyawali V, Gupta A. A case of severe falciparum malaria presenting with hyperglycemia. J Med Trop 2014;16:39-41
  26. Singh Yatendra, Joshi Subhash C., Satyawali Vivekanand, Gupta Abhisek .A case of severe falciparum malaria presenting with hyperglycemia. Journal of Medicine in the Tropics 2014:16:39-41.
  27. Prabha MR, Pereira P, Chowta N, Hegde BM. Clinical implications of hypocalcemia in malaria. Indian J Med Res. 1998;108:62-5..
  28. Singh PS, Singh N. Tetany with Plasmodium falciparum infection. J Assoc Physicians India. 2012;60:57-8. .
  29. Feinsod FM, Heinrich G Malaria infection presenting with symptoms of thyroid insufficiency and amenorrhoea. Trans R Soc Trop Med Hyg 1981;75(1):117-8.
  30. Davis,TM, Supanaranond W, Pukrittayakamee S,Krishna S,  Hart GR,  Burrin JR, et al. The pituitary-thyroid axis in severe falciparum malaria: evidence for depressed thyrotroph and thyroid gland function.  Trans R Soc Trop Med Hyg 1990;84(3):330-5.
  31. Selvaraj V. Hypopituitarism: A rare sequel of cerebral malaria – Presenting as delayed awakening from general anesthesia. Anesth Essays Res. 2015; 9(2): 287–289.
  32. Premji R, Roopnarinesingh N, Cohen J, Sen S. Cerebral Malaria: An Unusual Cause of Central Diabetes Insipidus 2016 |Article ID 2047410 | https://doi.org/10.1155/2016/2047410.
  33. Grimwade K, French N, Mthembu D, Gilks C. Polyuria in association with Plasmodium falciparum malaria in a region of unstable transmission. Trans R Soc Trop Med Hyg. 2004 ;98(4):255-60.
  34. Timothy M. E. Davis, Li Thi Anh Thu, Tran Quang Binh, Ken Robertson, John R. Dyer, Phan Thi Danh, Desiree Meyer, Miles H. Beaman, Trinh Kim Anh. The hypothalamic-pituitary-adrenocortical Axis in Severe Falciparum Malaria: Effects of Cytokines, The Journal of Clinical Endocrinology & Metabolism, 1997; 82, (9):3029–3033.
  35. Mohapatra MK, Barihar PK, Mohapatra A.Adrenal insufficiency in severe falciparum malaria: its outcome and prediction by discriminant score. IJCMR 2019;6(9):148-155.
  36. Mohamed, S., Osman, A., Al Jurayyan, N.A. et al. Congenital toxoplasmosis presenting as central diabetes insipidus in an infant: a case report. BMC Res Notes 2014;( 7): 184 https://doi.org/10.1186/1756-0500-7-184
  37. Suresh Babu, P.S., Nagendra, K., Sarfaraz Navaz, R. et al. Congenital toxoplasmosis presenting as hypogonadotropic hypogonadism. Indian J Pediatr 2007; 74: 577–579.
  38. Massa G, Vanderschueren-Lodeweyckx M, Van Vliet G, Craen M, de Zegher F, Eggermont E. Hypothalamo-pituitary dysfunction in congenital toxoplasmosis. Eur J Pediatr. 1989 ;148(8):742-4.
  39. Oktenli C, Doganci L, Ozgurtas T, Araz RE, Tanyuksel M, Musabak U. Transient hypogonadotrophic hypogonadism in males with acute toxoplasmosis: suppressive effect of interleukin-1b on the secretion of GnRH.Human Reproduction 2004;19(4):859-866
  40. Setian N, Andrade RSF, Kuperman H, Della Manna T, Dichtchekenian V, and Damiani D. Precocious Puberty: An Endocrine Manifestation in Congenital Toxoplasmosis. Journal of Pediatric Endocrinology and Metabolism. 2002;15:9, https://doi.org/10.1515/JPEM.2002.15.9.1487
  41. Hamidreza Majidiani, Sahar Dalvand, Ahmad Daryani, Ma de la Luz Galvan-Ramirez, Masoud Foroutan-Rad. Is chronic toxoplasmosis a risk factor for diabetes mellitus? A systematic review and meta-analysis of case–control studies. The Brazilian Journal of Infectious Diseases, 2016;20(6):605-609.
  42. Shahnaz Shirbazou, Ali Delpisheh, Rahim Mokhetari, and Ghafor Tavakoli. Serologic Detection of Anti Toxoplasma gondii Infection in Diabetic Patients. Iran Red Crescent Med J. 2013 15(8): 701–703.

Helminths And Endocrinology

ABSTRACT

Helminths are parasitic worms that can infect humans. They are broadly classified as flatworms (including Cestodes and Trematodes) and roundworms (nematodes). These worms infect organs such as intestines, liver, skin, as well as other tissues. These infections are more common in underdeveloped parts of the world affecting almost one-sixth of the world population. These infections can lead to a variety of endocrine manifestations. A decreased risk of developing type 2 diabetes mellitus has been observed in affected populations. Helminths modulate the host immunity towards a type 2 immune response which is anti-inflammatory in nature. An increase in T regulatory cells has also been seen which reduces T cell response to infections.  By virtue of these changes, chronic inflammation is suppressed in adipose tissues - this phenomenon may explain the protective effect in type 2 diabetes mellitus. A reduction in insulin resistance independent of BMI has been observed in animal as well as human studies. Hepatic lipid production can be reduced by the soluble egg antigen from certain schistosomes. The immunomodulatory effects of helminth infections can also protect against autoimmune endocrine conditions such as type 1 diabetes mellitus and Graves' disease. These observations may reflect the well-known "hygiene hypothesis". Thyroid nodules and hypothyroidism can occur in helminth infections. Insights into thyroid physiology, including thyroid hormone receptors and de-iodination pathways, have been obtained from studies in helminths. Certain helminth infections can impair osteoclast maturation suggesting potential implications for osteoporosis. Similarities between human and helminth bone morphogenetic protein pathways have been observed. Adrenal masses as well as adrenal insufficiency, have been observed in helminth infections. Infertility has frequently been reported with Schistosomiasis due to inflammation in the genital tracts. An estrogen like compound may be produced by schistosomes which can lead to hypogonadism in males. The helminth, Caenorhabditis elegans can serve as a model for studies on Kallman syndrome as the KAL-1 gene appears to be functionally conserved in this helminth.  A reduction in IGF-1 levels may be seen in adults infected with helminths. Apart from these manifestations, novel insights regarding endocrine disease mechanisms as well endocrine physiology can be derived from studies on helminths.

INTRODUCTION

The term helminth refers to parasitic worms which are broadly classified as flatworms (including Cestodes and Trematodes) and roundworms (nematodes) (1). These infections may be soil-transmitted and present as intestinal infections while others may invade different tissues such as blood vessels or other organs. These parasitic worms are endemic in several parts of the world, specifically in underdeveloped and parts of developing countries (1). It is estimated that approximately one-sixth of the world’s population is affected by helminth infections  (2). Helminths employ complex mechanisms to evade host immunity. They induce malnutrition in the host while simultaneously ensuring an adequate supply of nutrients for their own growth and reproduction.

Table 1. Classification of Helminths

PHYLUM

 

Affected Organ

Examples

Platyhelminths

Intestine

Cestodes -Taenia, Echinococcus

Liver

 Trematodes- Schistosoma, Fasciola

 

 Nematodes

Intestine

Ascaris, Enterobius, Necator, Ancylostoma, Trichuris, Strongyloides

Cutaneous

Strongyloides

Tissues

Onchocerca, Loa, Wuchereria

 

These immunological and metabolic interactions between helminth and the host may modulate the pathophysiology of several endocrine disorders including diabetes, thyroid disorders, and gonadal disorders apart from others. A discussion of each of these groups of disorders is presented below.

DIABETES MELLITUS

Diabetes mellitus is among the most common endocrine disorders with its rapidly growing prevalence earning it the designation of a pandemic. While type 1 diabetes mellitus is an autoimmune disease, type 2 diabetes is mediated by insulin resistance which is of multifactorial origin with genetics, environmental factors, and inflammation all playing their part. Among these factors, it has been noticed that areas with a high prevalence of soil-transmitted helminth infections have a relatively lower prevalence of diabetes (3). Although several other factors may also be operational in such areas, there are several proposed mechanisms by which helminth infections may influence diabetes and its pathogenesis.

Type 2 Diabetes Mellitus

Type 2 diabetes mellitus has been described as a chronic inflammatory disorder. Chronic inflammation in adipose tissues has been shown to be among the factors underlying this disease. The inflammatory process in adipose tissue involves infiltration by inflammatory cells such as lymphocytes, macrophages, and neutrophils.  Eosinophils on the other hand appear to have an anti-inflammatory effect. Apart from infiltration, several phenotypic changes occur in these cells which tip the balance towards inflammation. These include the predominance of T helper type 1 (Th1) and T helper type 17 (Th17) instead of the T helper type 2 (Th2) and the regulatory T cells (Tregs). The Th1 and Th17 cells promote the macrophage activation into classically activated macrophages (CAM) which in turn secrete inflammatory markers such as tumor necrosis factor-alpha (TNF-α), interleukin 6 and 12(IL6, IL12). TNF-α has been shown to interfere with insulin signaling. On the other hand, Th2 and T reg cells secrete IL-3 and IL 4 which stimulate the formation of alternatively activated macrophages (AAM) which are anti-inflammatory and express IL-10. Adipokines such as leptin, lipocalin 2, retinol-binding protein (RBP4), resistin, angiopoietin-like protein 2 (ANGPTL2), IL-6, IL-1, CC-chemokine ligand 2 (CCL2), CXC-chemokine ligand 5 (CXCL5) are also pro-inflammatory while adiponectin may have anti-inflammatory actions.

Helminth infections are associated with induction of type 2 immune response which involves increased activation of Th2 cells, eosinophilia, and production of IgE. The Th2 response in turn manifests as increased secretion of IL-4, IL-5, IL-9, IL-10, IL-13 which are anti-inflammatory. This also promotes the induction of anti-inflammatory AAMs.  Similarly, helminth infections are associated with an increase in T reg cells which mediate a state of T cell hypo-responsiveness. These changes on one hand limit the damage to host tissues by uncontrolled inflammation in response to helminth antigens and on the other hand prevent the clearance of the helminth from the host. The T cell hypo-responsiveness to parasite antigens can spill over to other antigens as well and this phenomenon has been invoked to explain the reduced prevalence of certain allergic and autoimmune disorders in helminth infected populations. Therefore, it has been hypothesized that since the immunological changes associated with helminth infections are anti-inflammatory in nature, they can reduce chronic inflammation in adipose and other tissues, thereby mitigating insulin resistance and the resultant type 2 diabetes.

The above hypothesis is supported by epidemiological data. In a study from China, previous schistosome infection was associated with a lower prevalence of obesity and metabolic syndrome as compared to those without such infection (4). Another study, which used ultrasonography to document chronic liver disease caused by schistosomiasis, found that metabolic syndrome prevalence was reduced to half of that seen in those without evidence of schistosomiasis (5). Serological evidence of chronic Strongyloides stercoralis infection was associated with a 61% lower risk of developing type 2 diabetes as compared to those who did not have this infection, despite adjustment for parameters such as age, BMI, and hypertension (6). In Indonesia, higher insulin sensitivity was demonstrated in patients who had infections with soil-transmitted helminths as evidenced by lower BMI and HOMA-IR levels (7). A randomized controlled trial to demonstrate the effect of ongoing helminth infection on insulin sensitivity has been conducted (8). This trial randomized households in an area endemic for helminth infection to receive albendazole or placebo over a period of time. In this trial, treatment of helminth infected subjects with albendazole lead to an increase in insulin resistance along with a reduction in IgE and eosinophil counts. However, at the community level, insulin resistance remained unchanged (9).

While the mechanisms of the reduction in type 2 diabetes have not been concretely studied in humans, animal studies provide support for the role of immunomodulation. Infections with Schistosoma mansoni, Nippostrongylus brasiliensis, and Litomosoides sigmodontis have been shown to increase eosinophils and AAMs in mice with diet-induced obesity (10–12). These animals had improved insulin sensitivity and glucose tolerance - this effect was lost in eosinophil deficient mice. S. mansoni soluble egg antigen and egg-derived ὠ-1 antigens stimulate innate lymphoid type 2 cells which produce IL-5 and IL-13 cytokines necessary for sustaining eosinophils and AAMs (13). L. sigmodontis Ag-treated obese mice had greater numbers of CD4+Foxp3+ Tregs in white adipose tissues as compared to controls indicating the upregulation of these cells as a mechanism of reducing insulin resistance (12).

Apart from these immunomodulatory mechanisms, the effect on body weight and gut microbiota are also potential mechanisms. The soluble egg antigen of S. japonicum, has been shown to reduce hepatic expression of microRNA 802 (miR802) which suppresses hepatic lipid production by upregulating the AMPK pathway. This has been proposed to be a future therapeutic target in obesity (14). However, the effect of helminth infection on insulin sensitivity has been shown to be independent of BMI in mice (10). This echoes the study on Australian aboriginals where the findings persisted despite adjusting for BMI (6).

Similarly, data on gut microbiota changes is scanty and conflicting. A few studies show an increase in gut bacterial diversity after helminth infection (15,16). Other authors have not found any significant changes in gut microbiota (17). While the mechanisms require further elucidation in both animal as well as human studies, there seems to be sufficient evidence to support the role of helminth infections in modulating the pathophysiology of type 2 diabetes.

Type 1 Diabetes Mellitus

Regarding type 1 diabetes, the type 2 immune response and suppressive regulatory environment induced by helminths may induce a protective effect. The incidence of type 1 diabetes has been increasing rapidly in developed countries and these regions are relatively less affected by helminth infections (18). The hygiene hypothesis has been invoked to explain this phenomenon (19). There are very few human studies which directly look at helminth infection and amelioration of type 1 diabetes risk. Enterobiasis did not reduce risk of type 1 diabetes in a population based study (19). Several animal studies do support the protective role of helminth infection. Axenic Caenorhabditis elegans antigen can protect against type 1 diabetes in the non-obese diabetes (NOD) mouse model (20). Trehalose produced by some helminths can alter intestinal microbiota leading to induction of CD8+ T cells which protect against type 1 diabetes in mice models (21). The severity of type 1 diabetes in mice models is ameliorated by recombinant Schistosoma japonicum cystatin and fructose-1,6-bisphosphate aldolase (22). Interestingly, children with schistosomiasis appear to have islet cell antibodies and defects in insulin secretion when compared to non infected siblings of children with insulin-dependent diabetes mellitus (23). Future studies may further shed light on this interesting topic.

THYROID DISORDERS

There appears to be a bidirectional relationship between the thyroid gland and helminth infections. On one hand, helminths appear to possess several proteins which are analogous to those involved in human thyroid physiology while on the other hand helminths can play a role in several thyroid diseases.

Thyroid hormone receptors which were earlier thought to be found only in chordates have been found to be present in S. mansoni (24). Two homologues of mammalian thyroid receptor (TR) has been isolated and characterized in S. mansoni (25), The thyroid hormone receptor beta from S. japonicum has also been characterized and evaluated as a vaccine candidate for this infection (26). Similarly, a nuclear hormone receptor has been identified in S. stercoralis which has some resemblance with steroid/thyroid hormone receptor found in humans (27). A transthyretin like protein has also been identified in Schistosoma dublin and Caenorhabditis elegans, although its function is unclear (28). Thyroid hormones may be essential for helminth growth and multiplication. In mice infected with Schistosoma mansoni, thyroid hormone therapy led to parasite multiplication and an increase in size whereas iodine deficient or thyroid hormone receptor knockout mice had lesser parasite numbers and smaller sized worms (29).

Some novel insights into thyroid physiology have also come from studies in helminths. Studies on the nematode Caenorhabditis have helped elucidate the mechanisms behind toxic effects of excess iodine - the dual oxidase maturation factor (DOXA-1) being among the implicated factors (30). Similarly, helminth studies have shown that iodotyrosine deiodinase may also have a role in regulating potassium channels in muscles (31).

Hypothyroidism and Thyroid Nodules

With respect to thyroid disorders, hypothyroidism and thyroid nodules appear to have some associations with helminth infections. S. stercoralis has been associated with hypothyroidism in one case report (32). Fasciola gigantica infection in buffaloes has been shown to lead to lymphocytic thyroiditis and hypothyroidism (33).

Hydatid cyst disease can mimic thyroid nodules and is often diagnosed by fine needle aspiration cytology (34). Cysticerosis may also present as a thyroid nodule (35). Similarly, microfilaria have also been found in fine needle aspirations from the thyroid (36). Schistosomiasis may interfere with technetium pertechnetate uptake in various tissues including the thyroid as demonstrated in mice- this may have implications for thyroid scan performed in infected humans (37).

Hyperthyroidism

Graves' disease, which is the most common cause of hyperthyroidism, may be affected by helminth infections. Considering that helminths affect host immune response and Graves' disease is an autoimmune process, such an association is not unexpected. Graves' disease is characterized by autoantibodies to the TSH receptor which leads to gland enlargement, hyperthyroidism, as well as extrathyroidal manifestations such as orbitopathy and dermopathy.  Animal models of Graves' disease have been developed which involve introduction of TSH receptor complementary DNA. It has been shown in such a mouse model that prior infection with S. mansoni may lead to a sustained Th2 type immune response towards the parasite egg antigens. This Th2 type immune response prevented the development of Graves' disease when mice were immunized with non-replicative recombinant adenovirus expressing the human TSHR. However, if given after disease onset, the Schistosoma infection could not cure the disease. Graves’ disease was once thought to be a Th2-type immune response, but recent studies have described a Th1-type as well as a Th2-type response suggesting that reversal of an activated immune response to the TSH receptor is not possible (38).  Based on similar findings with other infections, a hygiene hypothesis for Graves disease has also been proposed (39). 

BONES AND CALCIUM METABOLISM

There is limited information regarding calcium metabolism and bone health in helminth infections. Hydatid cyst disease involving the vertebrae has been described recently  and pathological hip fracture has also been reported (40,41). However, this is likely to represent direct involvement of the bone rather than alterations in bone metabolism.

Inflammatory arthritis is associated with secondary osteoporosis. The Th2 type immune response seen with helminth infections may attenuate inflammatory arthritis. N. brasiliensis was able to inhibit arthritis and bone loss in two experimental models of inflammatory arthritis (42). In vitro osteoclast differentiation has been shown to be inhibited by excretory/ secretory products from Heligmosomoides polygyrus bakeri, a murine helminth (43).  C-terminal sequence of Fasciola helminth defense molecule-1 (C-FhHDM-1) has been shown to reduce RANKL secretion as well as prevents both the formation of osteoclasts and acidification of lysosomes in animal models [6]. These features may be beneficial in osteoporotic states. However, in a study on pregnant mice, Heligmosomoides bakeri infection in late pregnancy and lactation led to a decrease in maternal bone mineral density and was associated with an increase in levels of inflammatory cytokines (IL-1 beta and IL-6) (44).

There may be several similarities between human and helminth physiology with respect to certain metabolic pathways. Homologues of  osteonectin, also called SPARC [Secreted Protein Acidic and Rich in Cysteine]), have been found in C. elegans while S. mansoni has homologues of TGF-beta receptor (45,46). More recently, it has been found that bone morphogenetic protein signaling may be conserved between humans and helminths, especially C. elegans. Secreted Modular Calcium-binding protein-1 (SMOC-1) gene identified in Caenorhabditis elegans may promote BMP signaling leading to the growth of the helminth (47,48). While BMP pathway plays several roles in human physiology including bone growth, the implications of these discoveries in helminths are still unclear.

 ADRENALS

Helminth infections in the adrenal with presentation as an adrenal mass have been reported in the literature.  Paragonimus westermani has been reported in a patient who had a lung cavity and an adrenal mass (49). Echinococcus multilocularis can infrequently present as a right adrenal mass detected incidentally (50). Adrenal schistosomiasis has also been reported (51). F. gigantica can cause adrenal insufficiency in animals (33). Acute adrenal insufficiency accompanied by adrenal hemorrhage has also been reported with S. stercoralis (52).

Activation of the hypothalamic-pituitary-adrenal axis leading to immunosuppression has been shown in mouse studies with Angiostrongylus cantonensis (53). While chronic immunosuppressive  therapy can lead to hyperinfection with helminths like S. stercoralis (54,55), adrenalectomized mice appeared to have higher worm burden and worm fecundity rates when infected with S mansoni (56). Previous mouse studies have shown adrenal hypertrophy and higher cortisol levels in S. mansoni infection (57). In vitro treatment of S. mansoni with adrenal hormones suggests that DHEA has a toxic effect with cercariae being more susceptible than schistosomula and adults (58).

GONADS

The manifestations of helminth infections with respect to gonads include hypogonadism and infertility. 

Hypogonadism

  1. mansoni infection has been associated with low normal testosterone and elevated estrogen levels in males although hepatic dysfunction may also play a role in these abnormalities (59). Patients infected with Loa loa and Mansonella perstans filariasis are more likely to have low testosterone and elevated gonadotropins as compared to control subjects (60). Further research in this area revealed that an estradiol-related compound was present in schistosome worm extracts (61). Later, the same authors confirmed the presence of this estradiol-related compound by mass spectrometry and also demonstrated that this compound has an antagonistic activity on the estrogen receptor and leads to a reduced expression of the estrogen receptor (62). Schistosome eggs can also convert estrogens to catechol-estrogens which in turn can be metabolized to active quinones. These quinones can cause DNA modifications and are implicated in the pathogenesis of malignancies related to schistosomiasis (63). These hormonal changes explain the pathogenesis of hypogonadism in schistosomiasis.

 Infertility

Schistosomiasis has been well recognized as a cause of infertility especially in females. Apart from hypogonadism caused by alterations in the estrogen axis, schistosomiasis can affect the genital tract leading to infertility. Genital involvement occurs in the form of granulomatous inflammation, fibrosis, and adhesion formation. The manifestations of this infection in females include tubal blockage, tubal pregnancy, tubal abortions, hemoperitoneum, preterm births, and miscarriages (64). Males can also have direct testicular inflammation along with, blockage of the genital ductal system and venous drainage leading to infarction. However, the involvement of male genital tract has been reported infrequently (65). Female infertility has also been reported with enterobiasis (66). Filarial involvement of male genitalia leading to hydrocele is well recognized (67). Male sterility can occur in such cases (68).

Some insights into genetic hypogonadism may come from helminth studies. The gene responsible for Kallman syndrome, KAL-1, appears to have a functionally conserved homologue in C. elegans. This gene plays a role in morphogenesis by influencing migration of epidermal cells in C. elegans. This discovery has established C. elegans as a model for study of Kallman syndrome for which a mouse model has proved to be elusive [33].

GROWTH

Children with helminth infections may have impaired growth- a phenomenon that can easily be attributed to malnutrition. However, helminth infections in adults are associated with significantly lower free IGF-1 which showed improvement after anti-helminth treatment(69). IGF-BP3 levels remain unchanged. Thus, direct effects on the GH-IGF-1 axis may occur in these infections.

CONCLUSION 

Table 2. Endocrine Manifestations of Helminth Infections

May protect against development of type 2 and type 1 diabetes mellitus

Hypothyroidism and thyroid nodules

May protect against Graves' disease

May protect against osteoporosis

Adrenal masses and acute adrenal insufficiency

Hypogonadism and infertility

Growth failure via reduction in IGF-1levels

 

In conclusion, helminths appear to play an important role in several endocrine disorders in endemic areas. Apart from contributing to the pathogenesis of disease, they may have a protective effect in some metabolic disorders. Novel insights regarding endocrine disease mechanisms as well endocrine physiology can be derived from studies using helminths. This is an interesting area for research which should encourage both helminthologists as well as endocrinologists.

REFERENCES

  1. Bethony J, Brooker S, Albonico M, Geiger S, Loukas A, D D, Pj H. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006;367(9521):1521–32.
  2. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasit. Vectors 2014;7(1):37.
  3. de Ruiter K, Tahapary DL, Sartono E, Soewondo P, Supali T, Smit JWA, Yazdanbakhsh M. Helminths, hygiene hypothesis and type 2 diabetes. Parasite Immunol. 2017;39(5):e12404.
  4. Chen Y, Lu J, Huang Y, Wang T, Xu Y, Xu M, Li M, Wang W, Li D, Bi Y, Ning G. Association of Previous Schistosome Infection With Diabetes and Metabolic Syndrome: A Cross-Sectional Study in Rural China. J. Clin. Endocrinol. Metab. 2013;98(2):E283-7.
  5. Shen S-W, Lu Y, Li F, Shen Z-H, Xu M, Yao W-F, Feng Y-B, Yun J-T, Wang Y-P, Ling W, Qi H-J, Tong D-X. The potential long-term effect of previous schistosome infection reduces the risk of metabolic syndrome among Chinese men. Parasite Immunol. 2015;37(7):333–339.
  6. Hays R, Esterman A, Giacomin P, Loukas A, McDermott R. Does Strongyloides stercoralis infection protect against type 2 diabetes in humans? Evidence from Australian Aboriginal adults. Diabetes Res. Clin. Pract. 2015;107(3):355–361.
  7. Wiria AE, Hamid F, Wammes LJ, Prasetyani MA, Dekkers OM, May L, Kaisar MMM, Verweij JJ, Guigas B, Partono F, Sartono E, Supali T, Yazdanbakhsh M, Smit JWA. Infection with Soil-Transmitted Helminths Is Associated with Increased Insulin Sensitivity. PloS One 2015;10(6):e0127746.
  8. Tahapary DL, de Ruiter K, Martin I, van Lieshout L, Guigas B, Soewondo P, Djuardi Y, Wiria AE, Mayboroda OA, Houwing-Duistermaat JJ, Tasman H, Sartono E, Yazdanbakhsh M, Smit JWA, Supali T. Helminth infections and type 2 diabetes: a cluster-randomized placebo controlled SUGARSPIN trial in Nangapanda, Flores, Indonesia. BMC Infect. Dis. 2015;15(1):133.
  9. Tahapary DL, de Ruiter K, Martin I, Brienen EAT, van Lieshout L, Cobbaert CM, Soewondo P, Djuardi Y, Wiria AE, Houwing-Duistermaat JJ, Sartono E, Smit JWA, Yazdanbakhsh M, Supali T. Effect of Anthelmintic Treatment on Insulin Resistance: A Cluster-Randomized, Placebo-Controlled Trial in Indonesia. Clin. Infect. Dis. 2017;65(5):764–771.
  10. Hussaarts L, García-Tardón N, van Beek L, Heemskerk MM, Haeberlein S, van der Zon GC, Ozir-Fazalalikhan A, Berbée JFP, Willems van Dijk K, van Harmelen V, Yazdanbakhsh M, Guigas B. Chronic helminth infection and helminth-derived egg antigens promote adipose tissue M2 macrophages and improve insulin sensitivity in obese mice. FASEB J. 2015;29(7):3027–3039.
  11. Yang Z, Grinchuk V, Smith A, Qin B, Bohl JA, Sun R, Notari L, Zhang Z, Sesaki H, Urban JF, Shea-Donohue T, Zhao A. Parasitic nematode-induced modulation of body weight and associated metabolic dysfunction in mouse models of obesity. Infect. Immun. 2013;81(6):1905–1914.
  12. Berbudi A, Surendar J, Ajendra J, Gondorf F, Schmidt D, Neumann A-L, Wardani APF, Layland LE, Hoffmann LS, Pfeifer A, Hoerauf A, Hübner MP. Filarial Infection or Antigen Administration Improves Glucose Tolerance in Diet-Induced Obese Mice. J. Innate Immun. 2016;8(6):601–616.
  13. Hams E, Bermingham R, Wurlod FA, Hogan AE, O’Shea D, Preston RJ, Rodewald H-R, McKenzie ANJ, Fallon PG. The helminth T2 RNase ω1 promotes metabolic homeostasis in an IL-33- and group 2 innate lymphoid cell-dependent mechanism. FASEB J. 2016;30(2):824–835.
  14. Ni Y, Xu Z, Li C, Zhu Y, Liu R, Zhang F, Chang H, Li M, Sheng L, Li Z, Hou M, Chen L, You H, McManus DP, Hu W, Duan Y, Liu Y, Ji M. Therapeutic inhibition of miR-802 protects against obesity through AMPK-mediated regulation of hepatic lipid metabolism. Theranostics 2021;11(3):1079–1099.
  15. Lee SC, Tang MS, Lim YAL, Choy SH, Kurtz ZD, Cox LM, Gundra UM, Cho I, Bonneau R, Blaser MJ, Chua KH, Loke P. Helminth Colonization Is Associated with Increased Diversity of the Gut Microbiota. PLoS Negl. Trop. Dis. 2014;8(5):e2880.
  16. Kay G, Millard A, Sergeant M, Midzi N, R G, T M, A I, N N, F M, M P. Differences in the Faecal Microbiome in Schistosoma haematobium Infected Children vs. Uninfected Children. PLoS Negl. Trop. Dis. 2015;9(6):e0003861.
  17. Cooper P, Walker AW, Reyes J, Chico M, Salter SJ, Vaca M, Parkhill J. Patent Human Infections with the Whipworm, Trichuris trichiura, Are Not Associated with Alterations in the Faecal Microbiota. PLOS ONE 2013;8(10):e76573.
  18. Zaccone P, Hall SW. Helminth infection and type 1 diabetes. Rev. Diabet. Stud. RDS 2012;9(4):272–286.
  19. Bager P, Vinkel Hansen A, Wohlfahrt J, Melbye M. Helminth infection does not reduce risk for chronic inflammatory disease in a population-based cohort study. Gastroenterology 2012;142(1):55–62.
  20. Jackson-Thompson B, Torrero M, Mitre B, Long J, Packiam M, Mitre E. Axenic Caenorhabditis elegans antigen protects against development of type-1 diabetes in NOD mice. J. Transl. Autoimmun. 2020;3:100065.
  21. Shimokawa C, Kato T, Takeuchi T, Ohshima N, Furuki T, Ohtsu Y, Suzue K, Imai T, Obi S, Olia A, Izumi T, Sakurai M, Arakawa H, Ohno H, Hisaeda H. CD8+ regulatory T cells are critical in prevention of autoimmune-mediated diabetes. Nat. Commun. 2020;11(1):1922.
  22. Yan K, Wang B, Zhou H, Luo Q, Shen J, Xu Y, Zhong Z. Amelioration of type 1 diabetes by recombinant fructose-1,6-bisphosphate aldolase and cystatin derived from Schistosoma japonicum in a murine model. Parasitol. Res. 2020;119(1):203–14.
  23. Soliman AT, El-Nawawy AA, El-Azzouni OF, Amer EA, Demian SR, El-Sayed MH. High prevalence of islet cell antibody and defective insulin release in children with schistosomiasis. J. Trop. Pediatr. 1996;42(1):46–49.
  24. Wu W, Niles EG, LoVerde PT. Thyroid hormone receptor orthologues from invertebrate species with emphasis on Schistosoma mansoni. BMC Evol. Biol. 2007;7:150.
  25. Wu W, LoVerde PT. Nuclear hormone receptors in parasitic Platyhelminths. Mol. Biochem. Parasitol. 2019;233:111218.
  26. Qiu C, Liu S, Hong Y, Fu Z, Wei M, Ai D, Lin J. Molecular characterization of thyroid hormone receptor beta from Schistosoma japonicum and assessment of its potential as a vaccine candidate antigen against schistosomiasis in BALB/c mice. Parasit. Vectors 2012;5:172.
  27. Siddiqui AA, Stanley CS, Skelly PJ, Berk SL. A cDNA encoding a nuclear hormone receptor of the steroid/thyroid hormone-receptor superfamily from the human parasitic nematode Strongyloides stercoralis. Parasitol. Res. 2000;86(1):24–29.
  28. Richardson SJ, Hennebry SC, Smith BJ, Wright HM. Evolution of the thyroid hormone distributor protein transthyretin in microbes, C. elegans, and vertebrates. Ann. N. Y. Acad. Sci. 2005;1040:448–451.
  29. Saule P, Adriaenssens E, Delacre M, Chassande O, Bossu M, Auriault C, Wolowczuk I. Early variations of host thyroxine and interleukin-7 favor Schistosoma mansoni development. J. Parasitol. 2002;88(5):849–855.
  30. Zhaofa X, Jintao L, Yu L, Long M. The BLI-3/TSP-15/DOXA-1 dual oxidase complex is required for iodide toxicity in Caenorhabditis elegans. G3 Bethesda 2014;5(2):195–203.
  31. de la Cruz IP, Ma L, Horvitz HR. The Caenorhabditis elegans Iodotyrosine Deiodinase Ortholog SUP-18 Functions through a Conserved Channel SC-Box to Regulate the Muscle Two-Pore Domain Potassium Channel SUP-9. PLoS Genet. 2014;10(2):e1004175.
  32. Yue S, Min L. [Strongyloides stercoralis infection with hypothyroidism: one case report]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2017;29(3):393–394.
  33. Ganga G, Varshney JP, Sharma RL, Varshney VP, Kalicharan null. Effect of Fasciola gigantica infection on adrenal and thyroid glands of riverine buffaloes. Res. Vet. Sci. 2007;82(1):61–67.
  34. Dissanayake PI, Chennuri R, Tarjan G. Fine-needle aspiration diagnosis of primary hydatid disease of the thyroid; first reported case in the USA. Diagn. Cytopathol. 2016;44(4):334–337.
  35. Gupta S, Sodhani P. Clinically unsuspected thyroid involvement in cysticercosis: a case report. Acta Cytol. 2010;54(5 Suppl):853–856.
  36. Yenkeshwar PN, Kumbhalkar DT, Bobhate SK. Microfilariae in fine needle aspirates: a report of 22 cases. Indian J. Pathol. Microbiol. 2006;49(3):365–369.
  37. Góes VC, Neves RH, Arnóbio A, Bernardo-Filho M, Machado-Silva JR. Streptozotocin (STZ) and schistosomiasis mansoni change the biodistribution of radiopharmaceutical sodium (99m)Tc-pertechnetate in mice. Nucl. Med. Biol. 2016;43(9):581–586.
  38. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B. Schistosoma mansoni and alpha-galactosylceramide: prophylactic effect of Th1 Immune suppression in a mouse model of Graves’ hyperthyroidism. J. Immunol. 2004;173(3):2167–2173.
  39. Nagayama Y, McLachlan SM, Rapoport B, Oishi K. Graves’ hyperthyroidism and the hygiene hypothesis in a mouse model. Endocrinology 2004;145(11):5075–5079.
  40. Meinel TR, Gottstein B, Geib V, Keel MJ, Biral R, Mohaupt M, Brügger J. Vertebral alveolar echinococcosis-a case report, systematic analysis, and review of the literature. Lancet Infect. Dis. 2018;18(3):e87–e98.
  41. Salman F, Khan MI, Hussain I, Abdullah HMA. Pathological fracture of femoral neck in a middle-aged woman: a rare presentation of primary hydatid cyst disease in humans. BMJ Case Rep. 2018;2018:bcr-2017-222980.
  42. Chen Z, Andreev D, Oeser K, Krljanac B, Hueber A, Kleyer A, Voehringer D, Schett G, Bozec A. Th2 and eosinophil responses suppress inflammatory arthritis. Nat. Commun. 2016;7:11596.
  43. Sarter K, Kulagin M, Schett G, Harris NL, Zaiss MM. Inflammatory arthritis and systemic bone loss are attenuated by gastrointestinal helminth parasites. Autoimmunity 2017;50(3):151–157.
  44. Odiere MR, Scott ME, Weiler HA, Koski KG. Protein deficiency and nematode infection during pregnancy and lactation reduce maternal bone mineralization and neonatal linear growth in mice. J. Nutr. 2010;140(9):1638–1645.
  45. Schwarzbauer JE, Spencer CS. The Caenorhabditis elegans homologue of the extracellular calcium binding protein SPARC/osteonectin affects nematode body morphology and mobility. Mol. Biol. Cell 1993;4(9):941–952.
  46. Beall MJ, Pearce EJ. Human transforming growth factor-beta activates a receptor serine/threonine kinase from the intravascular parasite Schistosoma mansoni. J. Biol. Chem. 2001;276(34):31613–31619.
  47. DeGroot MS, Shi H, Eastman A, McKillop AN, Liu J. The Caenorhabditis elegans SMOC-1 Protein Acts Cell Nonautonomously To Promote Bone Morphogenetic Protein Signaling. Genetics 2019;211(2):683–702.
  48. Schultz RD, Bennett EE, Ellis EA, Gumienny TL. Regulation of extracellular matrix organization by BMP signaling in Caenorhabditis elegans. PloS One 2014;9(7):e101929.
  49. Kwon YS, Lee HW, Kim HJ. Paragonimus westermani infection manifesting as a pulmonary cavity and adrenal gland mass: A case report. J. Infect. Chemother. Off. J. Jpn. Soc. Chemother. 2019;25(3):200–203.
  50. Spahn S, Helmchen B, Zingg U. Alveolar echinococcosis of the right adrenal gland: a case report and review of the literature. J. Med. Case Reports 2016;10(1):325.
  51. Poderoso WLS, Santana WB de, Costa EF da, Cipolotti R, Fakhouri R. Ectopic schistosomiasis: description of five cases involving skin, one ovarian case and one adrenal case. Rev. Soc. Bras. Med. Trop. 2008;41(6):668–671.
  52. Mutreja D, Sivasami K, Tewari V, Nandi B, Nair GL, Patil SD. A 36-year-old man with vomiting, pain abdomen, significant weight loss, hyponatremia, and hypoglycemia. Indian J. Pathol. Microbiol. 2015;58(4):500–505.
  53. Chen A-L, Sun X, Wang W, Liu J-F, Zeng X, Qiu J-F, Liu X-J, Wang Y. Activation of the hypothalamic-pituitary-adrenal (HPA) axis contributes to the immunosuppression of mice infected with Angiostrongylus cantonensis. J. Neuroinflammation 2016;13(1):266.
  54. Jones N, Cocchiarella A, Faris K, Heard SO. Pancreatitis associated with Strongyloides stercoralis infection in a patient chronically treated with corticosteroids. J. Intensive Care Med. 2010;25(3):172–174.
  55. Darlong J. Strongyloides hyper infection in a steroid dependent leprosy patient. Lepr. Rev. 2016;87(4):536–542.
  56. Morales-Montor J, Mohamed F, Damian RT. Schistosoma mansoni: the effect of adrenalectomy on the murine model. Microbes Infect. 2004;6(5):475–480.
  57. Antonios SN, Ismail HI, el-Nouby KA, Khalifa EA. Morphometric and histochemical study of the adrenal cortex in experimental schistosomiasis mansoni. J. Egypt. Soc. Parasitol. 2001;31(1):13–20.
  58. Morales-Montor J, Mohamed F, Ghaleb AM, Baig S, Hallal-Calleros C, Damian RT. In vitro effects of hypothalamic-pituitary-adrenal axis (HPA) hormones on Schistosoma mansoni. J. Parasitol. 2001;87(5):1132–1139.
  59. Saad AH, Abdelbaky A, Osman AM, Abdallah KF, Salem D. Possible role of Schistosoma mansoni infection in male hypogonadism. J. Egypt. Soc. Parasitol. 1999;29(2):307–323.
  60. Lansoud-Soukate J, Dupont A, De Reggi ML, Roelants GE, Capron A. Hypogonadism and ecdysteroid production in Loa loa and Mansonella perstans filariasis. Acta Trop. 1989;46(4):249–256.
  61. Botelho MC, Crespo M, Almeida A, Vieira P, Delgado ML, Araujo L, Machado JC, Correia da Costa JM. Schistosoma haematobium and Schistosomiasis mansoni: production of an estradiol-related compound detected by ELISA. Exp. Parasitol. 2009;122(3):250–253.
  62. Botelho MC, Soares R, Vale N, Ribeiro R, Camilo V, Almeida R, Medeiros R, Gomes P, Machado JC, Correia da Costa JM. Schistosoma haematobium: Identification of new estrogenic molecules with estradiol antagonistic activity and ability to inactivate estrogen receptor in mammalian cells. Exp. Parasitol. 2010;126(4):526–535.
  63. Cardoso R, Lacerda PC, Costa PP, Machado A, Carvalho A, Bordalo A, Fernandes R, Soares R, Richter J, Alves H, Botelho MC. Estrogen Metabolism-Associated CYP2D6 and IL6-174G/C Polymorphisms in Schistosoma haematobium Infection. Int. J. Mol. Sci. 2017;18(12):2560.
  64. Ribeiro AR, Luis C, Fernandes R, Botelho MC. Schistosomiasis and Infertility: What Do We Know? Trends Parasitol. 2019;35(12):964–971.
  65. Kini S, Dayoub N, Raja A, Pickering S, Thong J. Schistosomiasis-induced male infertility. Case Rep. 2009;2009:bcr0120091481.
  66. Dezsényi B, Sárközi L, Kaiser L, Tárkányi K, Nikolova R, Belics Z. Gynecological and obstetrical aspects of Enterobius vermicularis infection. Acta Microbiol. Immunol. Hung. 2018;65(4):459–465.
  67. Mand S, Debrah AY, Klarmann U, Mante S, Kwarteng A, Batsa L, Marfo-Debrekyei Y, Adjei O, Hoerauf A. The role of ultrasonography in the differentiation of the various types of filaricele due to bancroftian filariasis. Acta Trop. 2011;120 Suppl 1:S23-32.
  68. Panda DK, Mohapatra DP. Bancroftian filariasis associated with male sterility. BMJ Case Rep. 2018;2018:bcr-2017-223236.
  69. Kurniawan F, Tahapary DL, de Ruiter K, Yunir E, Biermasz NR, Smit JWA, Supali T, Sartono E, Yazdanbakhsh M, Soewondo P. Effect of anthelmintic treatment on serum free IGF-1 and IGFBP-3: a cluster-randomized-controlled trial in Indonesia. Sci. Rep. 2020;10(1):19023.

 

 

Bacterial Infections In Diabetes

ABSTRACT

Bacteria are microscopic single-celled organisms that exist in millions inside and outside the human body. Some bacteria are harmful and can cause a multitude of diseases in human beings. Diabetes mellitus, being a global pandemic, serves as an important cause of susceptibility to bacterial infections. Uncontrolled hyperglycemia is associated with impaired innate and adaptive immune responses that predispose to bacterial infections. In addition, chronic complications of diabetes like neuropathy (sensorimotor and autonomic) and peripheral vascular disease can lead to skin ulcerations with secondary bacterial infections. Diabetes also increases the incidence of infection related mortality. The relationship of diabetes and bacterial infections can be reciprocal, with certain infections like periodontitis exacerbating insulin resistance. Abnormalities in the bacterial flora of the gastrointestinal tract can play a role in the development of diabetes. Bacteria can infect any organ in the human body, the most common sites of infection in diabetes being the urinary tract, respiratory tract, skin, and soft tissues. Certain bacterial infections are very specific for diabetes like emphysematous pyelonephritis, emphysematous cholecystitis, and malignant otitis externa. Different antibiotic regimens (empirical and culture-specific) have been recommended for different bacterial infections, depending upon the site and severity. Our chapter gives an overview of the various bacteria, important from the standpoint of diabetes. We have also discussed the epidemiology and pathogenesis of bacterial infections in diabetes. In addition, we have highlighted the spectrum of bacterial infections and their management in diabetes. Stringent glycemic control, vaccination, adequate foot care practices, source control are some of the preventive measures to avoid bacterial infections in diabetes. Adequate knowledge about the spectrum and management of bacterial infections is important to prevent morbidity and mortality in diabetes.

INTRODUCTION

Diabetes is on the rise worldwide, with a global prevalence in adults in 2019 being 9.3% of the world population. In total numbers, this reflects a population of 463 million people with diabetes worldwide in 2019, with a projection of an increase to 700 million adults by 2045. A further 1.1 million children and adolescents under the age of 20, live with type 1 diabetes (1). The association between diabetes and bacterial infections is well recognized clinically and further adds to the morbidity associated with diabetes and its complications (2).

 

Patients with diabetes have a two-fold higher risk of community-acquired bacterial infections such as pneumococcal, streptococcal, and enterobacterial infections as compared with patients without diabetes (3-5). Urinary tract infections are more frequent in patients with diabetes. Janifer et al reported a high prevalence of 42.8% in 1157 South Indian subjects with type 2 diabetes (6). In a large retrospective cohort study in England comparing 102,493 patients with diabetes mellitus vs. n = 203,518 matched control subjects, incidence rate ratios (IRR) for infection-related hospitalizations were 3.71 (95% CI, 3.27 to 4.21) in those with type 1 diabetes mellitus and 1.88 (95% CI, 1.83 to 1.92) in those with type 2 diabetes mellitus (7). Diabetes is also associated with an average twofold higher risk of infection related mortality compared with individuals without diabetes (8).

 

Increased incidence and severity of bacterial infections in diabetes has been linked to an impaired innate and adaptive immune responses within the hyperglycemic environment (9).

Apart from hyperglycemia, other chronic complications of diabetes may also predispose patients to infections. For example, neuropathy in combination with peripheral vascular disease in diabetes can lead to ulcerations in the skin and secondary infections (10).

There is a bidirectional relationship between diabetes and bacterial infections. While diabetes increases the susceptibility to bacterial infections and its complications, chronic infections such as periodontitis is associated with increased pro inflammatory cytokines which can exacerbate insulin resistance and worsen glycemic control (11). There is a recent growing evidence that abnormalities in the microbiota composition can have a major role in the development of diabetes (12).

 

Awareness regarding the complex inter relationships between diabetes and associated bacterial infections is important for prevention and prompt treatment. A wide spectrum of bacterial infections such as malignant otitis externa, emphysematous pyelonephritis, emphysematous cholecystitis tend to be more common in diabetics than in others, and other infections may be more severe in diabetics than in nondiabetics (13). Infections may also be the first manifestation of long-standing unrecognized diabetes (14). The following figure illustrates the classification of medically important bacteria (15).

Fig 1. Classification of medically important bacteria

 

EPIDEMIOLOGY OF COMMON BACTERIAL INFECTIONS IN DIABETES

Epidemiology of common bacterial infections in diabetes with associated pathogens is shown in Table 1.

Table 1. Epidemiology of Common Bacterial Infections in Diabetes with Associated Pathogens

 

Epidemiology

Pathogens

Ref

Bacterial meningitis

Relative Risk = 2.2 (95% CI, 1.9–2.6) in diabetes compared to patients without diabetes

S pneumonia

Listeria monocytogenes

16

Malignant otitis externa

Odds ratio of prior diabetes in Malignant otitis externa is 10.07 (95% CI, 8.15-12.44)

 

Pseudomonas aeruginosa

17,18

Periodontitis

Odds Ratio = 1.34 (95% CI, 1.07–1.74) for periodontitis in diabetes  compared to patients without diabetes

 

Staphylococcus species

Streptococcus species

Bacillus species

E. Coli

19,20

Community Acquired pneumonia

(CAP)

Relative risk = 1.64 (95% CI 1.55–1.73) for CAP in patients with diabetes

 

Streptococcus pneumoniae

Legionella

Haemophilus influenza

21,22

Hospital Acquired pneumonia

Incidence Rate Ratio = 1.21, (95% CI,1.03–1.42) for postoperative pneumonia in diabetes

 

Pseudomonas species

Staphylococcus aureus

 

23, 24

Infective endocarditis

Odds ratio =1.9 (95% confidence interval 1.8-2.1)

 

Streptococcus viridans

Staphylococus aureus

Enterococcus species

25,26

Emphysematous Cholecystitis (EC)

60% of patients with EC had diabetes

Clostridium perfringens

Escherichia coli

27,28

Pyogenic liver abscess

Relative Risk = 3.6 (95% CI 2.9-4.5) in diabetes

 

 

 

Klebsiella pneumoniae

29,30

Urinary tract Infections

In patients with type 1 DM, adjusted odds ratio = 1.96 (95 % CI, 1.49–2.58)

In patients  with type 2 diabetes, adjusted Odds ratio = 1.24 (95 % CI, 1.10–1.39)

 

Escherichia coli

 

Other Enterobacteriaceae such as Klebsiella spp., Proteus spp., Enterobacter spp., and Enterococci

 

31,32

Bacterial skin and mucous membrane infections

In patients with type 1 DM, adjusted odds ratio = 1.59 (95 % CI, 1.12–2.24)

In patients  with type 2 diabetes, adjusted Odds ratio = 1.33 (95 % CI, 1.15–1.54)

 

Folliculitis        Group A streptococcus

                         Staphylococcus Aureus

 

 

Furunculosis     Streptococcus pneumoniae

Cellulitis

 

 

31, 33

Osteomyelitis of foot

20% of diabetic foot infections were associated with osteomyelitis.

 

More often poly-microbial

 

Gram positive : Staphylococcus aureus, Staphylococcus epidermidis, Streptococci, Enterobacteriaceae

 

Gram Negative : Escherichia coliKlebsiella pneumonia,  ProteusPseudomonas aeruginosa

 

34,35

GLYCEMIC CONTROL AND RISK OF INFECTIONS

Poor glycemic control increases the risk of infections in diabetes. A recent study examined the association between glycemic control in 85,312 patients with diabetes mellitus aged 40–89 years and the incidence of infection (36).  Infection rates rose steadily with HbA1c, which was particularly evident among those with HbA1c >11% (36).

 INCREASED INCIDENCE OF INFECTIONS IN DIABETES: PATHOPHYSIOLOGY

Infections are an important concern in individuals with diabetes due to the immune system’s failure to fight off invading pathogens (37). Diabetes progression itself is associated with immune dysfunction; autoimmunity in T1DM and low-grade chronic inflammation in T2DM (38).

 

Numerous studies have investigated the diabetes-related mechanisms that impair the host’s defence against pathogens. These mechanisms include a complex interplay between the host’s innate immunity and adaptive immunity (39, 40, 41). As noted earlier, chronic complications of diabetes can also predispose to infections (10).

The proposed mechanisms for increased susceptibility to infections in diabetes are depicted in figure 2.

Fig 2. Complex interactions between immune dysregulation (both innate and adaptive) from glycemic status, organism specific factors and diabetic complications plays major role in development of diabetes related infections.

Innate immunity

Cellular innate immunity is affected in uncontrolled diabetes. The steps involved in pathogen elimination by polymorphonuclear (PMN) leucocytes are:

(a) PMN adhesion to vascular endothelium, initially via the cell surface adhesion molecule L-selectin and then integrins

(b) transmigration through the vessel wall down a chemotactic gradient

(c) phagocytosis and microbial killing (2).

Hyperglycemia induces an increase in intracellular calcium concentration thereby reducing adenosine triphosphate (ATP) levels, which in turn leads to reduced phagocytic ability of polymorphonuclear cells. Correction of hyperglycemia leads to a significant reduction in intracellular calcium levels, an increase in ATP content, and improved phagocytosis (42). The hyperglycemic environment also inhibits glucose-6-phosphate dehydrogenase (G6PD) with resultant increase in apoptosis of polymorphonuclear leukocytes, and reduced polymorphonuclear leukocyte transmigration through the endothelium. Superoxide production is reduced in parallel with increasing glycemic exposure and consequently results in decreased microbial killing (2). Hyperglycemia is associated with increased formation of advanced glycation end products (AGE). AGE albumin has been shown to bind to the receptor for AGE (RAGE) present on neutrophils. This binding inhibits transendothelial migration and Staphylococcus aureus induced production of reactive oxygen species (ROS), resulting in impaired bacterial killing (43). Hyperglycemia also adversely affects the humoral component of innate immunity. Deficiency of C4 complement as well as decreased complement activation has been demonstrated in diabetes. This results in decreased opsonisation and phagocytosis of microbes. (44,45). Increased duration of cytokine response, increased pro-inflammatory cytokine gene expression and impaired local cytokine production leads to a dysregulated cytokine response in uncontrolled diabetes further increasing susceptibility to severe infections (46, 47, 48). 

Adaptive Immunity

There are two broad classes of adaptive immunity responses—antibody responses and cell-mediated immune responses, which are carried out by B cells and T cells respectively. In antibody responses, B cells are activated to secrete immunoglobulins which bind to the invading microbial antigens and block their binding to receptors on host cells. Antibody binding also marks invading pathogens for destruction by the phagocytes (49). Decreased levels of circulating immunoglobulins (IgG antibodies) as well as increased non enzymatic glycation of IgG antibodies leading to quantitative and qualitative defects in the humoral responses have been demonstrated in uncontrolled diabetes (50,51).

 

In cell-mediated immune responses, the second class of adaptive immune response, T cells which are activated by certain cytokines and antigen presenting cells, react directly against a foreign antigen that is presented to them on the surface of a host cell or themselves secrete cytokines that activate macrophages to destroy the invading microbes after phagocytosis (47). Dysregulation between anti-inflammatory and proinflammatory cytokines and defects at the level of antigen presenting cells in uncontrolled diabetes leads to dysfunction of T cells (52, 53). The role of immune systems and pathogenesis of bacterial infections is depicted in figure 3.

Fig 3. Pathogenesis of bacterial infections in diabetes. Describes role of various components of innate and adaptive immunity in pathogenesis of bacterial infection in diabetes; G6PD-Glucose 6 phosphate dehydrogenase; PMN-Polymorphonuclear cells; NADPH – Nicotinamide adenine dinucleotide phosphate; ROS- Reactive oxygen species; ATP -Adenosine triphosphate; AGEs- Advanced glycation end products; RAGE-Receptor for advanced glycation end products. 

Chronic Complications of Diabetes Predisposing to Infections

Over 50% of men and women with diabetes have bladder dysfunction which may impair voiding and increase the risk for urinary tract infections (54). The presence of renal disease and urinary incontinence in women are also predisposing factors for urinary tract infections. Diabetic cystopathy secondary to autonomic nervous dysfunction in long standing diabetes is characterized by a loss of sensation of bladder distension leading to decreased frequency of voiding and increased post-void residual urine volume. The possibility that voiding disorders may contribute to UTI should be considered in all diabetic patients (55).  

 

Peripheral diabetic neuropathy contributes to motor, autonomic, and sensory components of neuropathic foot ulcers. Damage to motor neurons of the foot musculature may lead to an imbalance of flexors and extensors, anatomic deformities, and eventual skin ulcerations. Damage to autonomic nerves impairs sweat gland function in the foot leading to a decreased ability to moisturize skin, resulting in epidermal cracks and skin breakdown. Lastly, the affected sensory component results in a loss of sensation of foot and reduced awareness of minor injuries (56). With ischemia, often as a result of related peripheral arterial disease, neuropathy can result in impaired barrier defences, skin ulcers with poor healing, and an increased risk of secondary infections and gangrene (57).

 

Pulmonary autonomic neuropathy in diabetes reduces mucociliary clearance and predisposes the lung to infections. Furthermore, hyperglycemia and insulin resistance impair collective surfactant D-mediated host defences of the lung in diabetes. Loose junctions between airway epithelial cells, which increase the transepithelial glucose gradient along with an increase in the glucose concentration of the airway surface liquid due to hyperglycemia, may dampen the airway defence against infection, resulting in lung bacterial overgrowth in diabetes (58).

SPECTRUM OF BACTERIAL INFECTIONS

Head and Neck Infections

BACTERIAL MENINGITIS

The majority of bacterial meningitis cases in adults is caused by Streptococcus pneumoniae. Listeria monocytogenes meningitis is more often found in elderly patients (>60 years) and those with acquired immune-deficiencies, such as diabetes. Immunodeficiency associated with diabetes is also a predisposing factor for pneumococcal and Haemophilus influenzae meningitis. Patients with bacterial meningitis and diabetes mellitus are older, have more comorbidities, frequently present with altered mental status and have higher mortality. In patients with diabetes, empirical antibiotics should include Cefotaxime/ ceftriaxone plus amoxicillin/ampicillin/ penicillin G (16, 59, 60).

MALIGNANT OTITIS EXTERNA

 Malignant otitis externa (MOE) is an invasive, potentially life-threatening infection of the external ear and skull base. MOE affects immunocompromised individuals and its presentation in an otherwise healthy individual should prompt an investigation for diabetes mellitus or other immune-deficiencies. In most cases, the causative agent of MOE is Pseudomonas aeruginosa. Typical patients with MOE are elderly individuals who have diabetes and severe, unremitting otalgia, aural fullness, otorrhea, and conductive hearing loss. Headache, temporomandibular joint pain, and decreased oral intake secondary to trismus may also be present. Findings of pain disproportionate to the examination, otorrhea, and granulation tissue along the floor of the ear canal at the bony–cartilaginous junction are usually the first nonspecific signs and symptoms of MOE. Important principles of treatment include aggressive control of diabetes and culture directed antibiotic therapy for at least 6-8 weeks. Although surgical intervention is no longer standard of care for MOE, it does require biopsy and culture, and may require local debridement of granulation tissue and bony sequestration or drainage of associated abscess. Long-term monotherapy with oral ciprofloxacin (750 mg twice daily) has been proposed as the preferred initial antibiotic regimen. However, microbial resistance to ciprofloxacin has been described and numerous studies have proposed carbapenem or third- generation cephalosporins as the initial empirical treatment. Recurrence rates of 15% to 20% have been reported for MOE (18, 61, 62). The risk factors for malignant otitis externa and its pathogenesis in diabetes are depicted in figure 4.

Fig 4. Risk factors for Malignant Otitis Externa and its pathogenesis in diabetes

PERIODONTITIS

Periodontitis is a complex chronic inflammatory condition in which inflammation in the periodontal tissues is stimulated by the long-term presence of the subgingival biofilm (figure 5). Periodontitis is a slowly progressing disease but the tissue destruction that occurs is largely irreversible. In the early stages, the condition is typically asymptomatic, is not usually painful, and many patients are unaware until the condition has progressed enough to result in tooth mobility. Advanced periodontitis is characterized by gingival erythema and edema, gingival bleeding, gingival recession, tooth mobility, suppuration from periodontal pockets, and tooth loss. In a randomized clinical trial, intensive periodontal treatment was associated with better glycemic control (A1C 8.3% vs 7.8% in control subjects and intensive treatment group respectively). Oral and periodontal health should be promoted as integral components of diabetes management (63, 64).

Fig 5. Chronic periodontitis with gingival inflammation in a patient with poorly controlled diabetes

DEEP NECK SPACE INFECTIONS/ABSCESS

Patients with diabetes are susceptible to spreading deep neck infections with a high frequency of complications, including tracheostomy and prolonged hospital stay. Odontogenic infections and upper airway infections are the leading reported causes of deep neck infections and the most common organism isolated is Klebsiella pneumoniae.  Early open surgical drainage remains the most appropriate method of treating deep neck abscesses. The choice of empirical antimicrobial agents in diabetic patients should take into account the agents effective against Klebsiella pneumoniae (65).

Respiratory Infections

COMMUNITY ACQUIRED PNEUMONIA

Patients with diabetes are at high risk of hospitalization due to community acquired pneumonia (CAP) (figure 6). Atypical clinical features like impaired consciousness and more severe pneumonia at admission are reported in patients with diabetes. Acute onset of disease, cough, purulent sputum, and pleuritic chest pain are less frequent among patients with diabetes. S. pneumonia, Legionella, and H influenza are frequent causative organisms of pneumonia in diabetes (22). Studies have also reported increased incidence of Klebsiella and pneumococcal pneumonia (3, 66). Independent risk factors for mortality in patients with diabetes and CAP are advanced age, bacteremia, septic shock at admission, and gram-negative pneumonia (22). The American Thoracic Society guidelines recommend combination therapy with amoxicillin/ clavulanic acid/ cephalosporin and macrolide/ doxycycline or monotherapy with respiratory fluoroquinolone for initial outpatient treatment in patients with diabetes. Beta lactam + macrolide or beta-lactam + fluoroquinolone is recommended in cases of severe in-patient pneumonia. Coverage for Pseudomonas aeruginosa is recommended in case of prior respiratory isolation, recent hospitalization with parenteral antibiotics treatment, and locally validated risk factors for Pseudomonas aeruginosa (67). The American Diabetes Association recommends vaccination against pneumococcal strains with one dose of PPSV23 (pneumococcal polysaccharide vaccine) between the ages of 19–64 years and another dose after 65 years of age. The PCV13 (pneumococcal conjugate vaccine) is no longer routinely recommended for patients over 65 years of age because of the declining rates of pneumonia due to these strains. All children are recommended to receive a four-dose series of PCV13 by 15 months of age. For children with diabetes who have incomplete series by ages 2–5 years, a catch-up schedule is recommended to ensure that these children have four doses. Children with diabetes between 6–18 years of age are also advised to receive one dose of PPSV23, preferably after receipt of PCV13 (68).

Fig 6. Radiographs of lower respiratory tract infection. A- Postero-anterior view radiograph of chest showing right middle lobe and left lower lobe consolidation in a patient with diabetes. B- Postero-anterior view radiograph of chest showing right lower lobe consolidation in a patient with diabetes

Cardiovascular Infections  

INFECTIVE ENDOCARDITIS

Infective endocarditis (IE) in diabetes is associated with poorer outcomes (figures 7 and 8). Diabetes mellitus was associated with increased mortality, acute heart failure, stroke, atrioventricular block, septic shock, and cardiogenic shock. The clinical profile of native valve infective endocarditis (NVIE) patients with diabetes is reported to be different compared to those without diabetes. Patients with diabetes had higher rates of comorbidities, and IE risk factors such as older age, and hemodialysis. They were less likely to have structural heart disease (valvular heart disease and congenital heart disease) and intravenous drug abuse. Patients with diabetes had higher rates of staphylococcus species, enterococci, and gram-negative microorganisms reflecting the increased health care utilization in DM patients, exposing them to nosocomial infections (26). Ampicillin with flucloxacillin or oxacillin with gentamicin is recommended as initial empirical therapy in community acquired native valves or late prosthetic valves (≥ 12 months post-surgery) endocarditis. Vancomycin with gentamicin and rifampicin is recommended in early PVE (<12 months post-surgery) or nosocomial and non-nosocomial healthcare associated endocarditis (69).

Fig 7. Two-dimensional Echocardiography of a patient with diabetes showing aortic root abscess (red arrowhead) and vegetations attached to aorto-mitral continuity (blue arrowhead), suggestive of infective endocarditis

 

Fig 8. Two-dimensional echocardiography in a patient with diabetes, showing large vegetation (blue arrowhead) attached to the posterior mitral leaflet, suggestive of infective endocarditis

Gastrointestinal Infections  

EMPHYSEMATOUS CHOLECYSTITIS

Emphysematous cholecystitis (EC) is an uncommon but serious biliary tract infection that occurs in increased frequency with male preponderance among diabetics. The common causative organisms are Clostridium perfringens and E. coli (28). Clinical findings of EC may be indistinguishable from those of uncomplicated cholecystitis although occasional crepitus may be present in some patients. The emphysematous infection is diagnosed by radiographic demonstration of gas on plain films or by CT. The treatment of choice is rapid surgical removal of the gallbladder and broad-spectrum antimicrobial therapy. Mortality caused by this infection is substantially higher than that of uncomplicated cholecystitis, ranging 15% to 25% compared with less than 4 percent (13).

LIVER ABSCESS

Diabetes is a strong, potentially modifiable risk factor for pyogenic liver abscess (figure 9). Pyogenic liver abscess patients with diabetes are older, with isolate of Klebsiella. pneumoniae being the predominant pathogen and require an increased use of combined antibiotic therapy with carbapenems. However, these patients have fewer abdominal surgeries and fewer E. coli infections as compared to patients without diabetes. In addition, poorly controlled glycemia in pyogenic liver abscess patients is associated with high incidence of fever and abscesses in both the lobes of the liver (29, 30).

Fig 9. Contrast enhanced axial (A) and sagittal (B) CT images showing multifocal well defined hypodense lesions involving both lobes of liver suggestive of liver abscesses in a patient with diabetes 

Urinary Tract Infections

The urinary tract is the most frequent site of infection in patients with diabetes (8, 70, 71). The spectrum of urinary tract infections in these patients ranges from asymptomatic bacteriuria (ASB) to lower UTI (cystitis), pyelonephritis, and severe urosepsis. Serious complications of UTI, such as emphysematous cystitis and pyelonephritis (figure 10), renal abscesses and renal papillary necrosis, are all encountered more frequently in type 2 diabetes than in the general population (72, 73).

Figure 10. Emphysematous pyelonephritis. Non contrast CT abdomen of a 45-year-old female with emphysematous pyelonephritis showing bilateral enlarged kidney with evidence of abscess formation on either side (black arrowheads) and air pockets in left kidney

 

The most common pathogens isolated from diabetic patients with UTI are E. coli, other Enterobacteriaceae such as Klebsiella spp., Proteus spp., Enterobacter spp., and Enterococci. Patients with diabetes are more prone to have resistant pathogens as the cause of their UTI, including extended-spectrum β-lactamase-positive Enterobacteriaceae, fluoroquinolone-resistant uropathogens, carbapenem-resistant Enterobacteriaceae, and vancomycin-resistant Enterococci. (32, 74).

 

As a general rule, treatment of UTI in diabetic patients is similar to that of UTI in non-diabetic patients. Antibiotic choice should be guided by local susceptibility patterns of uropathogens. First-line treatment recommendations for various types of UTI are detailed in Table 2 (74).

 

Table 2. First Line Antibiotics for Various Types of UTI in Diabetes

Type of urinary tract infection (UTI)

Gender

Antibiotic treatment

Route

Dosage

Duration of treatment

Asymptomatic bacteriuria

Male and female

None

 

 

 

Acute cystitis

Female

Nitrofurantoin

Per oral

100 mg BD/TDS

5 days

Complicated lower UTI  (catheter associated UTI)

Male and female

Ciprofloxacin

Per oral

200-500 mg BD

7-14 days

Ofloxacin

Per oral

200 mg BD

7-14 days

Trimethoprim-Sulfamethoxazole

Per oral

960 mg BD

7-14 days

Cefuroxime

Per oral

500 mg BD

7-14 days

Uncomplicated pyelonephritis

Female

Ciprofloxacin

Intravenous

400 mg BD

7 days

Ciprofloxacin

Per oral

500 mg BD

7 days

Ofloxacin

Intravenous

400 mg BD

7 days

Gentamicin

Intravenous

5 mg/kg OD

7 days

Cefuroxime

Intravenous

750 mg TDS

7-14 days

Cefuroxime

Per oral

500 mg BD

7-14 days

Complicated pyelonephritis/urosepsis

Male and female

Ciprofloxacin

Intravenous

400 mg BD

10-14 days

Ofloxacin

Intravenous

400 mg BD

10-14 days

Gentamicin

Intravenous

5 mg/kg OD

10-14 days

Amikacin

Intravenous

15 mg/kg OD

10-14 days

Piperacillin-Tazobactum

Intravenous

4.5 g TDS

10-14 days

Ertapenem

Intravenous

1 g OD

10-14 days

OD-once daily, BD-twice daily, TDS-thrice daily

Skin and Soft Tissue Infections 

Skin and soft tissue infections (SSTI) cause a substantial morbidity in patients with diabetes (75). SSTIs commonly seen in diabetes include cellulitis, abscess, decubitus ulcer, folliculitis, impetigo, carbuncle and furuncle, and surgical site infections. SSTI-associated complications such as gangrene, osteomyelitis, bacteremia, sepsis, and SSTI-associated hospitalizations are higher in patients with diabetes compared to those without diabetes (76).

FOOT INFECTIONS IN DIABETES

Foot infections in diabetes remain the most frequent complication requiring hospitalization and the most common precipitating event leading to lower extremity amputation (figure 11) (77-79).

Fig 11.  A-Trophic changes in the bilateral feet of a patient with diabetes with clawing of toes, thickened toe nails, loss of hair and shiny skin texture. B-Infected foot ulcer with slough in the plantar aspect of heel of a patient with diabetes. C-Another infected foot ulcer involving the entire sole in a patient with diabetes, the ulcer shows presence of granulation tissue along with oozing of pus and slough

 

Outcomes in patients presenting with an infected foot ulcer are poor. In one large prospective study at the end of one year, the ulcer had healed in only 46% (and it later recurred in 10% of these), while 15% had died and 17% required a lower extremity amputation (80). There are various validated classification systems to assess the severity and prognosis of foot ulcers and infection. One such scoring system is the SINBAD system which grades area, depth, sepsis, arteriopathy, and denervation plus site as either 0 or 1 point creating an easy to use scoring system that can achieve a maximum of 6 points (81). The IWGDF (International Working Group on the Diabetic Foot) infection classification is recommended to characterize and guide infection management in diabetic foot infections. The IWGDF/IDSA (Infectious Diseases Society of America) classification consists of four grades of severity for diabetic foot infection (Table 3) (82, 83).

 

Table 3. IWGDF/IDSA Classification for Foot Infections

Clinical classification of infection, with definitions

IWGDF classification

Uninfected

No systemic or local symptoms or signs of infection

 

1 (Uninfected)

Infected

·       At least, 2 of these items are present

·       Local swelling or induration

·       Erythema >0.5 cm around the wound

·       Local tenderness or pain

·       Local increased warmth

·       Purulent discharge

And no other cause(s) of an inflammatory response of the skin (eg. trauma, gout, acute Charcot neuro-osteoarthropathy, fracture, thrombosis or venous stasis)

 

Infection with no systemic manifestation involving:

·       only the skin or subcutaneous tissue (not any deeper tissues) and

·       any erythema present does not extend >2 cm around the wound

2 (mild infection)

Infection with no systemic manifestation involving:

·       erythema extending ≥ 2 cm from the wound margin, and/or

·       tissue deeper than skin and subcutaneous tissue (e.g., tendon, muscle, joint, bone)

3 (moderate infection)

Any foot infection with associated systemic manifestations (of the systemic inflammatory response syndrome [SIRS]), as mentioned by ≥2 of the following:

·       Temperature >38 degree celsius or <36 degree Celsius

·       Heart rate >90 beats/ minute

·       Respiratory rate >20 breaths/minute or PaCO2 <4.3 kPa (32 mm Hg)

·       White blood cell count >12,000/mm3 or <4000/mm3 or >10% immature (band) forms

 

4 (Severe infection)

Infection involving bone (osteomyelitis)

Add ‘O’ after 3 or 4

 

The empirical antibiotic choice is guided by the history, clinical examination, severity of infection, likely etiological agent, and previous antimicrobial sensitivity pattern. Studies from temperate climates in North America and Europe have consistently demonstrated that the most common pathogens in diabetic foot infections are aerobic gram-positive cocci, especially Staphylococus aureus, and to a lesser extent, streptococci and coagulase-negative staphylococci. More recent studies of diabetic foot infections from patients in tropical/subtropical climates (mainly Asia and northern Africa) have shown that aerobic gram-negative bacilli are often isolated, either alone or in combination with gram-positive cocci. Empirical treatment aimed at Pseudomonas aeruginosa, which usually requires either an additional or broad-spectrum agent should be considered in tropical/subtropical climates or if Pseudomonas aeruginosa has been isolated from previous cultures of the affected patient. Obligate anaerobes can play a role in diabetic foot infections, especially in ischemic limbs and in case of abscesses. Empirical treatment of these pathogens, e.g., with an imidazole (metronidazole), or beta-lactam with beta lactamase inhibitor, should be considered for diabetic foot infection associated with ischemia or a foul-smelling discharge. THE IWGDF guidelines on empirical antibiotic therapy for diabetic foot infections are outlined in table 4 (83).

 

Table 4. Empirical Antibiotic Therapy Recommended by IWGDF Guidelines for Diabetic Foot Infections

Severity of infection

Additional factors

Usual pathogen(s)

Potential empirical regimens

Mild

No complicating features

Gram positive cocci

Semi synthetic penicillin; 1st generation cephalosporins

Beta lactam allergy or intolerance

Gram positive cocci

Clindamycin;Fluroquinolone;Trimethoprim-sulfamethoxazole;Macrolide;Doxycycline

 

Recent antibiotic exposure

Gram positive cocci + Gram negative rods

β-lactamase inhibitor-amoxicillin/clavulanate; Trimethorpim-sulfamethoxazole; Fluoroquinolone

High risk for MRSA

MRSA

Linezolid; Trimethoprim-sulfamethoxazole; doxycycline; macrolide

Moderate or severe

No complicating features

Gram positive cocci ± Gram negative rods

β-lactamase inhibitor-amoxicillin/clavulanate; second or third generation cephalosoporins

 

Recent antibiotic exposure

Gram positive cocci ± Gram negative rods

β-lactamase 2-ticarcillin/clavulanate, piperacillin/tazobactum; 3rd generation cephalosporins; group I carbapenems (depends on prior therapy)

 

Macerated ulcer or warm climate

Gram negative rods including pseudomonas

β-lactamase 2-ticarcillin/clavulanate, piperacillin/tazobactum; semi synthetic penicillins + ceftazidime; semi synthetic penicillins + ciprofloxacin; group 2 carbapenems

 

Ischemic limb/necrosis/gas forming

Gram positive cocci ± Gram negative rods ± Anaerobes

β-lactamase inhibitor or 2; group 1 or 2 carbapenems; 2nd or 3rd generation cephalosporins + clindamycin or metronidazole

 

MRSA risk factors

MRSA

Consider adding or substituting with glycopeptides; linezolid; daptomycin; fusidic acid; trimethoprim-sulfamethoxazole ± rifampicin; doxycycline

 

Risk factors for resistant gram negative rods

ESBL

(Extended spectrum beta lactamase producing bacteria)

Carbapenem; Aminoglycoside and Colistin; Fluoroquinolone

MRSA-Methicillin resistant Staph aureus ; 1st generation cephalosporins-Cefadroxil, cefazolin, cephalexin; 2nd generation cephalosporins-Cefotetan, cefoxitin, cefuroxime, cefprozil; 3rd generation cephalosporins-Cefixime, cefotaxime, cefpodoxime; β-lactamase 2-ticarcillin/clavulanate, piperacillin/tazobactum; group 1 carbapenem: ertapenem; group 2 carbapenem: imipenem, meropenem, doripenem

FOURNIER’S GANGRENE

Fournier's gangrene (FG) is a fulminant form of infective necrotising fasciitis of the perineal, genital, or perianal regions, which commonly affects men with diabetes (figure 12) (84). Diabetes mellitus is reported to be present in 20%–70% of patients with Fournier’s gangrene (85). FG shows vast heterogeneity in clinical presentation, from insidious onset and slow progression to rapid onset and fulminant course, the latter being the more common presentation. The local signs and symptoms are usually dramatic with significant pain and swelling. The patient also has pronounced systemic signs; usually out of proportion to the local extent of the disease. Crepitus of the inflamed tissues is a common feature because of the presence of gas forming organisms. As the subcutaneous inflammation worsens, necrotic patches start appearing over the overlying skin and progress to extensive necrosis (86).

 

There has been an associated increased incidence of FG with the use of SGLT2 inhibitors in diabetes. The US Food and Drug Administration (FDA) has identified 55 cases of FG in patients receiving SGLT2 inhibitors between 2013 and 2019, out of which 39 were men and 16 were women (87). Time to onset of FG after initiation of SGLT2-inhibitors varied considerably, ranging from 5 days to 49 months (87). All patients were sick and had surgical debridement. Three patients died (87).  SGLT2-inhibitors cause glycosuria that can enhance the growth of bacterial flora in the urogenital milieu. This in turn increases the risk of urogenital infections, including FG. All types of SGLT2-inhibitors have been associated with FG. The FDA has issued a warning about the risk of FG to be added to the prescribing information of all SGLT2-inhibitors and to the patient medication guide.

 

Cultures from the wounds commonly show poly microbial infections by aerobes and anaerobes, which include coliforms, klebsiella, streptococci, staphylococci, clostridia, bacteroides, and corynebacteria (88). FG has a high mortality rate of 40% (85) and warrants an aggressive multimodal approach, which includes haemodynamic stabilisation, broad spectrum antibiotics and surgical debridement (86).

Fig 12. Fournier’s gangrene. Redness, swelling of the scrotum, penis and perineal tissues with necrosis and sloughing of the overlying skin

NECROTIZING FASCIITIS

Necrotizing fasciitis (NF) has been defined as a severe soft-tissue infection that causes extensive necrosis of subcutaneous tissue and fascia, relatively sparing the muscle and skin tissue (figure 13) (89). Based on bacterial culture results, NF is classified into the following categories: type I, which consists of synergistic polymicrobial infection; type II, representing infections caused by group A Streptococcus alone or combined with Staphylococcus; and type III, which comprises infections caused by Vibrio species (90).  Diabetic NF patients are reported to be more susceptible to polymicrobial and monomicrobial Klebsiella pneumoniae infections, which should be considered when choosing empirical antibiotics for these patients (91).

Fig 13. A and B Necrotizing fasciitis; black necrotic tissue and slough seen invading the subcutaneous tissues and fascia

INFECTION MIMICS IN DIABETES

Charcot Neuroarthropathy   

Charcot neuroarthropathy is a limb-threatening, destructive process that occurs in patients with neuropathy associated with medical diseases such as diabetes mellitus. Clinicians treating diabetic patients should be aware that the early signs of acute Charcot neuroarthropathy, such as pain, warmth, edema mimic foot infection. Early detection and prompt treatment can prevent joint and bone destruction, which, if untreated, can lead to morbidity and high-level amputation. The differentiation between acute presentations of Charcot’s joint and osteomyelitis is often difficult because the two conditions have many features in common. However, the lack of systemic sepsis or fever, significant hyperglycemia and leukocytosis may direct the diagnosis towards neuropathic joint (92, 93).

INFECTIONS AS A RISK FACTOR FOR DIABETES

Infections have been documented as a predisposing factor for Type 2 Diabetes Mellitus. Recent studies have revealed H. pylori infections to be significantly higher among diabetic patients than in non-diabetic patients (94, 95). Evidence suggests that advanced periodontitis also compromises glycemic control. Furthermore, periodontal treatment has been associated with improvement in glycemic control (63, 64). Abnormalities in the microbiota composition can have a major role in the development of obesity and diabetes. A reduced microbial diversity is associated with inflammation, insulin-resistance, and adiposity.  A rise in the Firmicutes/Bacteroidetes ratio is found to be related to a low-grade inflammation and to an increased capability of harvesting energy from food. Changes in some metabolites, such as short-chain fatty acids (SCFAs), produced by gut microbiota, and decreased amounts of the Akkermansia muciniphila are associated with the presence of type 2 diabetes (12). Increased pro inflammatory cytokine response in infections leads to insulin resistance. Even pathogen products, such as lipopolysaccharide and peptidoglycans, can cause insulin resistance leading to development of diabetes (96).

CONCLUSION

Awareness regarding the spectrum and severity of infections, in diabetes, is essential for prevention and prompt treatment. Strict glycemic control, proper choice of antibiotics and source control form the cornerstones of management. Preventive measures like vaccination and foot care practises go a long way in reducing infection related morbidity and mortality in diabetes.

REFERENCES

  1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. 2017. 
  2. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007; 23:3–13.
  3. Thomsen RW, Hundborg HH, Lervang HH, et al. Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study. Diabetes Care 2004; 27:1143–7.
  4. Thomsen RW, Riis AH, Kjeldsen S, et al. Impact of diabetes and poor glycaemic control on risk of bacteremia with haemolytic streptococci groups A, B, and G. J Infect 2011;63:8–16.
  5. Thomsen RW, Hundborg HH, Lervang HH, et al. Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteremia: a 10-year population based study among adults. Clin Infect Dis 2005; 40:628–31
  6. Janifer J, Geethalakshmi S, Satyavani K, Viswanathan V. Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol. 2009 Jul; 19(3):107.
  7. Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care. 2018 Mar 1;41(3):513-21.
  8. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003 Feb 1;26(2):510-3.
  9. Frydrych LM, Fattahi F, He K, Ward PA, Delano MJ. Diabetes and sepsis: risk, recurrence, and ruination. Front Endocrinol (Lausanne).2017 Oct 30;8:271.
  10. Shaw JE, Boulton AJ. The pathogenesis of diabetic foot problems: an overview. Diabetes. 1997 Sep 1;46(Supplement 2):S58-61.
  11. Mirza BA, Syed A, Izhar F, Ali Khan A. Bidirectional relationship between diabetes and periodontal disease: review of evidence. J Pak Med Assoc. 2010 Sep 1;60(9):766-8.
  12. Pascale A, Marchesi N, Govoni S, Coppola A, Gazzaruso C. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Curr Opin Pharmacol. 2019 Dec 1;49:1-5.
  13. Calvet HM, Yoshikawa TT. Infect Dis Clin North Am. 2001 Jun 1;15(2):407-21.
  14. Clive S, Cockram C, Wong BCK. Diabetes and Infections. Textbook of Diabetes. Holt RI, Cockram C, Flyvbjerg A, Goldstein BJ (editors). John Wiley & Sons; 2017 Mar 6. 799-820.
  15. Harvey RA, Champe PC, Fisher BD, Strohl WA. Microbiology. Philadelphia: Lippincott Williams & Wilkins. 2007
  16. Van Veen KE, Brouwer MC, Van Der Ende A, Van De Beek D. Bacterial meningitis in diabetes patients: a population-based prospective study. Sci Rep. 2016 Nov 15;6(1):1-7.
  17. Yang TH, Xirasagar S, Cheng YF, Wu CS, Kao YW, Shia BC, Lin HC. Malignant Otitis Externa is Associated with Diabetes: A Population-Based Case-Control Study. Ann Otol Rhinol Laryngol. 2020 Jun;129(6):585-90.
  18. Carlton DA, Perez EE, Smouha EE. Malignant external otitis: the shifting treatment paradigm. Am J Otolaryngol. 2018;39(1):41-45.
  19. Wang TT, Chen TH, Wang PE, Lai H, Lo MT, Chen PY, Chiu SY. A population- based study on the association between type 2 diabetes and periodontal disease in 12,123 middle-aged Taiwanese (KCIS no. 21). J Clin Periodontol. 2009;36(5):372–9.
  20. Ali T, Rumnaz A, Urmi UL, Nahar S, Rana M, Sultana F, Iqbal S, Rahman MM, Rahman NA, Islam S, Haque M. Type-2 Diabetes Mellitus Individuals Carry Different Periodontal Bacteria. Pesqui. Bras. Odontopediatria Clín. Integr. 2021 Apr 2;21.
  21. Brunetti VC, Ayele HT, Yu OH, Ernst P, Filion KB. Type 2 diabetes mellitus and risk of community-acquired pneumonia: a systematic review and meta-analysis of observational studies. CMAJ Open. 2021 Jan;9(1):E62.
  22. Di Yacovo S, Garcia-Vidal C, Viasus D, Adamuz J, Oriol I, Gili F, Vilarrasa N, García-Somoza MD, Dorca J, Carratala J. Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus. Medicine (Baltimore). 2013 Jan;92(1):42-50.
  23. Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. Acta Diabetol. 2001 Jun 1;38(2):77-82.
  24. López-de-Andrés A, Perez-Farinos N, de Miguel-Díez J, Hernández-Barrera V, Jiménez-Trujillo I, Méndez-Bailón M, de Miguel-Yanes JM, Jiménez-García R. Type 2 diabetes and postoperative pneumonia: an observational, population-based study using the Spanish hospital discharge database, 2001-2015. PLoS One. 2019 Feb 6;14(2):e0211230.
  25. Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of infectious endocarditis in patients with type II diabetes mellitus. J Diabetes Complications. 2007 Nov 1;21(6):403-6.
  26. Abe T, Eyituoyo HO, De Allie G, Olanipekun T, Effoe VS, Olaosebikan K, Mather P. Clinical outcomes in patients with native valve infective endocarditis and diabetes mellitus. World J Cardiol. 2021 Jan 26;13(1):11.
  27. Abengowe CU, McManamon PJ. Acute emphysematous cholecystitis. Can Med Assoc J. 1974 Nov 16;111(10):1112.
  28. Safwan M, Penny SM. Emphysematous cholecystitis: a deadly twist to a common disease. J Diagn Med Sonogr. 2016 May;32(3):131-7.
  29. Thomsen RW, Jepsen P, Sørensen HT. Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis. 2007 May 1;44(9):1194-201.
  30. Li W, Chen H, Wu S, Peng J. A comparison of pyogenic liver abscess in patients with or without diabetes: a retrospective study of 246 cases. BMC Gastroenterol. 2018 Dec;18(1):1-9.
  31. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.
  32. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AI. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects.Diabetes Care. 2002 Aug; 25(8):1405-9
  33. Atreja A, Kalra S. Infections in diabetes. J Pak Med Assoc. 2015 Sep 1;65(9):1028-30.
  34. Lavery LA, Armstrong DG, Peters EJ, Lipsky BA. Probe- to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic? Diabetes Care. 2007 Feb;30(2):270-4
  35. Giurato L, Meloni M, Izzo V, Uccioli L. Osteomyelitis in diabetic foot: a comprehensive overview. World J Diabetes. 2017 Apr 15;8(4):135.
  36. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018 Oct 1;41(10):2127-35.
  37. American Diabetes Association. AD Standards of medical care in diabetes--2013.Diabetes Care. 2013;36 (Suppl. 1):S11–S66.
  38. Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016;4:148–158
  39. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012 Mar;16(Suppl1):S27.
  40. Schuetz P, Castro P, Shapiro NI. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care. 2011 Mar 1;34(3):771-8.
  41. Gan YH. Host susceptibility factors to bacterial infections in type 2 diabetes. PLoS Pathog. 2013 Dec 26;9(12):e1003794.
  42. Alexiewicz JM, Kumar D, Smogorzewski M, Klin M, Massry SG. Polymorpho- nuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med. 1995;123:919–924.
  43. Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, et al. (2002) RAGE- mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol. 71: 433–444.
  44. Stoeckle M, Kaech C, Trampuz A, Zimmerli W. The role of diabetes mellitus in patients with bloodstream infections. Swiss Med Wkly. 2008;138:512-9. 

  45. Ilyas R, Wallis R, Soilleux EJ, Townsend P, Zehnder D, et al. (2010) High glucose disrupts oligosaccharide recognition function via competitive inhibition: A potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology 216: 126–131.
  46. Geerlings SE, Brouwer EC, VanKessel KC, Gaastra W, Stolk RP, Hoepelman AI. Cy- tokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 2000;30:995–1001
  47. Graves DT, Naguib G, Lu H, Leone C, Hsue H, Krall E. Inflammation is more persistent in type 1 diabetic mice. J Dent Res. 2005;84:324–328
  48. Stegenga ME, van der Crabben SN, Dessing MC, et al. Effect of acute hyper- glycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cyto- kine production and neutrophil function in humans. Diabet Med. 2008;25:157–164.
  49. Alberts A, Johnson A, Lewis J, Raff M, Roberts K, Walter P. The Adaptive Immune System. Molecular Biology of the Cell. New York: Garland Science; 2002.
  50. Liberatore RR Jr, Barbosa SF, Alkimin MG, et al. Is immunity in diabetic patients influencing the susceptibility to infections? Immunoglobulins, complement and phagocytic function in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2005;6:206–212
  51. Lapolla A, Tonani R, Fedele D, et al. Non- enzymatic glycation of IgG: an in vivo study. Horm Metab Res. 2002;34:260– 264
  52. Spatz M, Eibl N, Hink S, et al. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol. 2003; 221:15–26
  53. Rubinstein R, Genaro AM, Motta A, Cremaschi G, Wald MR. Impaired immune responses in streptozotocin-induced type I diabetes in mice. Involvement of high glucose. Clin Exp Immunol. 2008;154: 235–246.
  54. Frimodt-moller C. Diabetic cystopathy : epidemiology and related disorders. Ann Intern Med. 1980; 92: 318-321.
  55. Fünfstück R, Nicolle LE, Hanefeld M, Naber KG. Urinary tract infection in patients with diabetes mellitus. Clin Nephrol. 2012 Jan 1;77(1):40.
  56. Aumiller WD, Dollahite HA. Pathogenesis and management of diabetic foot ulcers. JAAPA. 2015 May 1;28(5):28-34.
  57. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003 Dec 1;26(12):3333-41.
  58. Kolahian S, Leiss V, Nürnberg B. Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord. 2019 Sep;20(3):303-19.
  59. van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, Leib SL, Mourvillier B, Ostergaard C, Pagliano P, Pfister HW. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016 May 1;22:S37-62.
  60. Pomar V, de Benito N, Mauri A, Coll P, Gurguí M, Domingo P. Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus. BMC Infect Dis. 2020 Dec;20:1-9.
  61. Carfrae MJ, Kesser BW. Malignant otitis externa. Otolaryngol Clin North Am. 2008 Jun 1;41(3):537-49.
  62. Ciorba A, Cultrera R, Di Laora A, Grilli A, Bianchini C, Aimoni C. Malignant otitis externa in the antibiotic resistance era: key to successful treatment. B-ENT. 2018. 14:119-123
  63. Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R. Periodontitis and diabetes: a two-way relationship. Diabetologia. 2012 Jan;55(1):21-31.
  64. D'Aiuto F, Gkranias N, Bhowruth D, Khan T, Orlandi M, Suvan J, Masi S, Tsakos G, Hurel S, Hingorani AD, Donos N. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. 2018 Dec 1;6(12):954-65.
  65. Huang TT, Tseng FY, Liu TC, Hsu CJ, Chen YS. Deep neck infection in diabetic patients: comparison of clinical picture and outcomes with nondiabetic patients. Otolaryngol Head Neck Surg. 2005 Jun;132(6):943-7.
  66. Saibal MA, Rahman SH, Nishat L, Sikder NH, Begum SA, Islam MJ, Uddin KN. Community acquired pneumonia in diabetic and non-diabetic hospitalized patients: presentation, causative pathogens and outcome. Bangladesh Med Res Counc Bull. 2012;38(3):98-103.
  67. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-67.
  68. American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021 Jan;44(Supplement 1):S40-52.
  69. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC) endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075-128.
  70. Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1997;11(3):735–750.
  71. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus.N Engl J Med. 1999;341(25):1906–1912
  72. Mnif MF, Kamoun M, Kacem FH, et al. Complicated urinary tract infections associated with diabetes mellitus: pathogenesis, diagnosis and management.Indian J Endocrinol Metab. 2013;17(3):442–445.
  73. Kofteridis DP, Papadimitraki E, Mantadakis E, et al. Effect of diabetes mellitus on the clinical and microbiological features of hospitalized elderly patients with acute pyelonephritis. J Am Geriatr Soc. 2009;57(11):2125–2128.
  74. Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Synd Obes. 2015;8:129.
  75. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia. 2010 May;53(5):914-23.
  76. Suaya JA, Eisenberg DF, Fang C, Miller LG. Skin and soft tissue infections and associated complications among commercially insured patients aged 0–64 years with and without diabetes in the US. PLoS One. 2013 Apr 10;8(4):e60057.
  77. Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med 2018;35:78-88.
  78. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis 2007;44:562-5.
  79. Tan TW, Shih CD, Concha-Moore KC, et al. Disparities in outcomes of patients admitted with diabetic foot infections. PLoS One 2019;14:e0211481.
  80. Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med 2018;35:78-88.
  81. Ince P, Abbas ZG, Lutale JK, Basit A, Ali SM, Chohan F, et al. Use of the SINBAD classification system and score in comparing outcome of foot ulcer management on three continents. Diabetes Care. 2008;31(5):964-7.
  82. Monteiro‐Soares M, Russell D, Boyko EJ, Jeffcoate W, Mills JL, Morbach S, Game F, International Working Group on the Diabetic Foot (IWGDF). Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). Diabetes Metab Res Rev. 2020 Mar;36:e3273.
  83. Lipsky BA, Senneville É, Abbas ZG, Aragón‐Sánchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, van Asten SA, Urbančič‐Rovan V. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update).Diabetes Metab Res Rev. 2020 Mar;36:e3280.
  84. Smith G L, Bunker C B, Dineeen M D. Fournier's gangrene.Br J Urol 1998 Mar;81(3):347-55.
  85. Morpurgo E, Galandiuk S. Fournier's gangrene. Surg Clin North Am. 2002 Dec 1;82(6):1213-24.
  86. Thwaini A, Khan A, Malik A, Cherian J, Barua J, Shergill I, Mammen K. Fournier’s gangrene and its emergency management. Postgrad Med J. 2006 Aug 1;82(970):516-9.
  87. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019 Jun 4;170(11):764-769.
  88. Yaghan RJ, Al-Jaberi TM, Bani-Hani I. Fournier's gangrene. Dis Colon Rectum. 2000 Sep 1;43(9):1300-8.
  89. Lin C, Yeh FL, Lin JT, Ma H, Hwang CH, Shen BH, et al. Necrotizing fasciitis of the head and neck: an analysis of 47 cases.Plast Reconstr Surg. 2001;107(7):1684–93.
  90. Giuliano A, Lewis F, Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis.Am J Surg. 1977;134(1):52–7.
  91. Cheng NC, Tai HC, Chang SC, Chang CH, Lai HS. Necrotizing fasciitis in patients with diabetes mellitus: clinical characteristics and risk factors for mortality. BMC Infect Dis. 2015 Dec;15(1):1-9.
  92. Jain R, Brown M, Boynton EL. Not another Diabetic Foot Infection: A Case Report of Charcot's Joint. Can J Plastic Surg. 1996 Dec;4(4):1-6.
  93. Varma AK. Charcot neuroarthropathy of the foot and ankle: a review. J Foot Ankle Surg. 2013 Nov 1;52(6):740-9.
  94. Mabeku LB, Ngamga ML, Leundji H. Helicobacter pylori infection, a risk factor for Type 2 diabetes mellitus: a hospital-based cross-sectional study among dyspeptic patients in Douala-Cameroon. Sci Rep. 2020 Jul 22;10(1):1-1.
  95. Bener A, Ağan AF, Al-Hamaq AO, Barisik CC, Öztürk M, Ömer A. Prevalence of Helicobacter pylori infection among type 2 diabetes mellitus. Adv Biomed Res. 2020;9:27.
  96. Chakraborty S, Bhattacharyya R, Banerjee D. Infections: a possible risk factor for type 2 diabetes. Adv Clin Chem. 2017 Jan 1;80:227-51.

 

 

 

Diabetes Mellitus and Tuberculosis

ABSTRACT

 

The converging epidemics of non-communicable disease like DM (DM) and an infectious disease like tuberculosis (TB) is a double burden. DM is increasing in the same population that is at high risk for developing TB. There is a two-to-four-fold higher risk of active TB in individuals with DM and up to 30% of individuals with TB are likely to have DM. Immune deficiency either in absolute or relative quantities are sufficient for re-activation of latent TB. From a 10% risk of reactivation over the whole lifetime of an immunocompetent individual, the risk of reactivation increases to 10% every year in immune-deficient individuals. DM impairs cell mediated immunity and poor glycemic control affects cytokine response and alters the defenses in the alveolar macrophages. Fever, hemoptysis, extensive parenchymal lesions, and lung cavities are more common in those with DM particularly heavier and older males. DM increases the risk of treatment failure, death, and relapse. Evidence collected from meta-analysis conclude that DM can increase the odds of developing Multi Drug resistant TB (MDR-TB). The synergism between DM and TB necessitates bi-directional screening. Sputum examination for Ziehl-Neelsen staining is both a sensitive and specific screening test. Rapid molecular diagnostic tests like cartridge based nucleic acid amplification tests (CB-NAAT) are useful in cases where there is a high-index of suspicion and difficulty in arriving at a definitive diagnosis exists. Random plasma glucose and HbA1c (glycosylated Hemoglobin) measurements are convenient tests for DM screening that can be done in non-fasting individuals. Screening for DM more than once during the course of illness is sensible so that transient DM and new-onset DM can be identified. Anti-TB drugs affect glycemic control as they interact with anti-diabetic drugs by either stimulating or inhibiting the metabolizing enzymes. They may also aggravate metabolic, ocular, and neuropathic complications of DM. Insulin is the preferred drug in most instances. The presence of renal and hepatic dysfunction affects TB and hyperglycemic management.

 

INTRODUCTION

 

Tuberculosis (TB) and diabetes mellitus (DM) are two diverse conditions of immense public health importance existing for centuries. TB was traditionally identified with poverty while DM was considered as an entity associated with prosperity. TB is today one of the commonest and widespread communicable infectious diseases largely but not necessarily confined to low-economic groups. DM on the other hand spearheads the group of chronic non-communicable diseases affecting people across all socio-economic strata. Contrary to previous beliefs, a larger number of people with DM are living in middle- and low-income countries. Unfortunately, these are the countries where DM is expected to increase in the near future (1). Both DM and TB have been associated with significant morbidity and mortality from time immemorial. Advancements in modern medical science over the years has definitely improved the outcome in both these conditions. But the magnitude of these two diseases has not waned and both are collaborative in worsening each other. In fact, the increase in the population affected with DM is sustaining the TB epidemic.

 

TB is associated with the endocrine system in different ways. The effects of TB on the endocrine system are discussed in detail in another Endotext chapter (2).  The interaction of TB and DM is discussed in this chapter.

 

TUBERCULOSIS

 

TB is a global health threat, particularly to the poor and the susceptible. It is estimated that on average approximately 9 to 10 million people are affected by TB and around 1 to 2 million succumb to it annually (3). In 2019, 1.3 million people died due to TB. In developed countries, TB has slipped down in ranking among the global list of top 10 diseases causing mortality. However, in the underdeveloped regions it still remains among the top 10 diseases with high mortality (up to 30%). When in concurrence with retroviral infections, the risk of active TB is 12 to 20 times higher and the mortality is higher even in developed countries (4). Multi drug resistant TB is another rising problem which requires expensive second line drugs and a longer duration of treatment. A large proportion of the global population is at risk and the true prevalence and the annual incidence also depends on access to health care facilities and the laboratory-based testing capacity of the regions. Individuals who are in close contact with affected individuals, people living in crowded places, immigration to a country or area with a high prevalence of TB, and children less than 5 years of age are considered vulnerable to getting infected by the TB bacilli (Table 1). Bacillary load in the sputum of the infectious individual and close proximity to the infectious persons are two important external determinants for infection in any individual after exposure.

 

Table 1. Risk Factors for TB Infection, Disease, and Outcome

Stage of TB

Intrinsic Factors

Extrinsic factors

 

Exposure to infection

Closeness of contact

Duration of contact

Load of Bacilli

 

 

Overcrowding and lack of ventilation

Indoor pollution

Community prevalence of TB

Tobacco Use, Drug abuse

Alcohol

Migration

 

 

Infection to disease progression

Altered Immune status (disease or drug induced)

Lack of BCG vaccination

Nourishment

DM

Malignancy

Respiratory diseases like Silicosis

Age

Male

Disease Outcome  

Female sex, Social Stigma, Immune status, Malnourishment, DM, Malignancy, Age, MDR-TB,

Barriers to health care access:   Cultural, Geographical, Economical, Weak social support, Weak health care support

 

Latent Tuberculosis

 

In most of the exposed individuals the infection is quelled by the immune system and the bacilli are fenced inside a granuloma or tubercle, immunologically aborting an active disease. This is a subclinical disease (LTBI – Latent TB infection) which doesn’t have symptoms and can last for weeks or decades. This latent infection is seen in nearly one third of the world population. Even though non-infectious, they carry the risk (about 10%) of re-activation into active TB later (primary progressive TB) (5). Such re-activation occurs in immunocompromised as in HIV infection, those on immunosuppressive agents (such as post organ transplant, autoimmune diseases, and allergic diseases), conditions like DM, alcoholism, substance abuse, silicosis, malnutrition, steroid therapy, renal failure, malignancies, indoor air pollution, and smoking. The World Health Organization (WHO) has guidelines on the approach to latent TB especially in countries where the burden of TB is low (an incidence of < 100 / 1, 00,000 per year). It strongly recommends screening and treatment of latent TB in high-risk individuals in these countries (6).

 

TB is an airborne infectious disease which spreads by droplets. TB affects the lungs primarily (Pulmonary TB) and when it affects the pleura, bones/joints, abdominal organs, lymph nodes, and meninges it is called extra-pulmonary TB. Mycobacterium tuberculosis, the causative agent has a thick mycolic acid cell wall that enables its survival in the environment and in its host. External to its cell membrane it has a peptidoglycan polymer which makes it impermeable. Its cell wall also contains lipoarabinomannan which enables its phagocytosis by macrophages and facilitates its survival inside macrophages in airways especially alveoli (7). The ability of the host’s defense system then determines whether the outcome is a progressive primary pulmonary disease or a latent state.

 

DIABETES MELLITUS

 

The prevalence of DM is rapidly increasing to justify it to be termed as an epidemic disease. According to WHO, the global prevalence of DM has doubled from 4.7 % in 1980 to 8.5% in 2014 (8). From an estimated prevalence of 463 million in 2019, it is estimated to increase to 578 million in 2030, and 700 million in 2045. For every diagnosed individual with DM there is another undiagnosed person with DM (9). The differences in the prevalence of DM between high and middle-income countries and similarly between rural and urban population are decreasing.

 

According to WHO, non-communicable diseases constitute 7 out of the top 10 leading causes of death and DM is prominent among them. In 2019 the estimated number of deaths to have occurred due to DM globally is approximately 4 million (10). DM is associated with significant morbidity due to its microvascular and macrovascular complications and high cardiovascular mortality. DM is a major cause of cardiac ischemia, stroke, renal failure, blindness, and amputations.

 

 

The high prevalence of DM and TB being in epidemic proportions has rightly earned them the names ‘the converging epidemics’ and ‘double burden’ (11,12). Due to rapid changes in lifestyle, urbanization, and epidemiological changes, DM is increasingly seen in low- and medium-income groups, and in younger individuals more frequently than before. The prevalence of DM is increasing faster where TB is endemic already. Unfortunately, these are the regions in the world where health care facilities are less common. According to International Diabetes Federation, the 50-55% increase in the prevalence of DM over the next 2 decades will occur predominantly in the continent of Africa (10). A longitudinal, multi-national study involving low-income countries concluded that an odds ratio of 4.7 for prevalence and 8.1 for incidence of TB is highly likely in those counties where DM has increased over the last decade (13). The WHO states that younger age group individuals are three times more likely to get infected with TB (14). There is a two-to four-fold higher risk of active TB in individuals with DM compared to non-diabetic individuals (15). According to a meta-analysis by Wilkinson et al, around 4 % of people with type 2 DM develop TB (16). Since the number of individuals with undiagnosed DM in the world is expected to be more than 50%, the proportion of TB in DM also should be much higher. Analytical models that try to project the future burden of TB in DM predict that the increase in DM counteracts the decreasing incidence of TB by at least 3% over the next 15 years (17).

 

Increased chances of finding undetected and uncontrolled hyperglycemia in close household contacts of subjects with TB have been mentioned in studies from Asian counties. In fact, a systemic analysis of a group of heterogenous studies on bi-directional screening i.e., screening for TB in DM affected individuals and vice versa has shown some evidence to support active screening for both DM and TB in the affected individuals and family members (18). Up to 35% of TB patients may have DM and the quoted figures are variable in literature (19). Jean Jacques Noubiap et al in their systematic review and meta-analysis of data from 2.3 million people with TB world-wide estimated that the prevalence of DM in patients with TB is around 15 % and was twice that of the general population (20). These data clearly give epidemiological evidence for the co-existence of DM and TB as a syndemic. A potentially lethal combination of a communicable disease and a non-communicable disease having a synergistic effect is a challenge on the public health system.

 

Epidemiology of Diabetes Among Patients with Active Tuberculosis

 

The WHO collaborative framework recommends for a joint plan for DM and TB related activities which have to be reflected in the national plans on non-communicable diseases and TB respectively (21). As per the WHO approximately15% of TB cases in the world are associated with DM. Of these 15%, India accounts for more than 40% of the cases (19). Estimates of the burden of DM and TB co-existence has primarily come from studies looking at prevalence of DM and glucose intolerance among newly diagnosed patients with TB diagnosed in TB clinics. The community prevalence of these two disorders co-existing are not clear. Many of these studies have been done in hospitals where sicker patients with TB are treated which would probably account for a higher percentage of patients having glucose intolerance and DM. In a study from five randomly selected TB care clinics in the southern state of Tamil Nadu, around 25% of patients with TB had coexisting DM. Around 10% of these patients had newly diagnosed DM. Risk factors for having DM in this group of patients included older age, higher basal metabolic index (BMI), family history of DM among first degree relatives, and following a sedentary lifestyle (22). Close to Tamil Nadu in the southern state of Kerala, the prevalence of DM in patients with TB was nearly double that observed in the previous study. Among the patients with TB in Kerala, 44% had DM. Among them about half (21%) had newly diagnosed DM (23). The risk of DM was higher among those with sputum positive TB in both of these studies. In a study from Odisha on the Eastern part of India, 13.9% of tribal patients with TB had DM suggestive of a significant burden of disease even among poorer regions of the country (24). In a retrospective study, among 1000 patients with TB from the northern state of Punjab, 11.6% had DM and TB coexistence (25). In the same state the authors found 30% of patients with TB diagnosed in a tertiary referral hospital had DM (26).

 

To better understand the prevalence of DM among newly diagnosed patients with TB a large multicentric study involving five centers is in progress (GIANT Study - Glucose Intolerance Among New patients with TB - Clinical Trial Registry India - CTRI/2019/05/019396). This study incorporates simultaneous OGTT and HbA1c determinations at three different time points to ascertain if HbA1c can replace the standard oral glucose tolerance test (OGTT) in this population and avoid the inconvenience of performing an OGTT.

 

A recent systemic review and meta-analysis ascertained the worldwide prevalence of DM among active cases of TB. This meta-analysis involved over 200 studies that included a little under 2.3 million patients with active TB. The overall pooled prevalence was similar to the WHO estimate of 15% prevalence of DM in patients with active TB. However, this varied from 0.1% in Latvia to 45% in the Marshall Islands. The high prevalence areas as per the International Diabetes Federation included North America, Western Pacific (which includes Australia and China), South East Asia, North Africa, and Middle East Asia (27). Figure 1 summarizes the information on the prevalence of DM and active TB in 7 regions of the world.

Figure 1. Prevalence of DM among patients with active TB in the seven International Diabetes Federation (IDF) regions of the world. The areas in red have the high burden of DM co-existing with active TB. The low burden areas are marked in blue. (adapted from ref 27)

DIABETES PREDISPOSING TO TUBERCULOSIS

 

Absolute or relative immune deficiency is sufficient for re-activation of latent TB. The association of increased prevalence of TB in immune deficient diseases like HIV is well established. The wider prevalence of DM makes DM a more important risk factor for developing TB than retroviral diseases. The higher incidence of multi-drug resistant TB reported to be significant in some studies (Odds Ratio of 2.1) reiterates the role of immune dysregulation in DM (28). The immune response in DM to TB is supposed to be hyper-reactive but ineffective and even deleterious as it may produce pulmonary tissue damage.

 

Chronic hyperglycemia impairs immunity (both innate and adaptive). DM impairs cell mediated immunity and poor glycemic control affects cytokine response and alters the defenses in the alveolar macrophages. Hyperglycemia disrupts the recruitment of neutrophils, chemotactic movement of monocytes, and phagocytic action of alveolar macrophages. Also, the antigen-specific interferon-gamma release is affected as the T-helper cell activation is ineffective. In addition, altered pulmonary microvasculature and micronutrient deficiency facilitate the invasion and establishment of TB as surveillance and nutrition is compromised. The chronic immunosuppression or ineffective immune response predisposes the individual for TB infection and with a higher bacilli load. This is summarized in Figure 2.

Figure 2. DM is associated with increase in active TB and relapse in TB which both may be a result of the direct effect of diabetes. There is increased death in DM and TB which may be secondary to TB or due to the inherent excess mortality of DM due to cardiovascular disease

CLINICAL PRESENTATION

 

The manifestations of tuberculous infection in patients with DM have been documented to be different from those without diabetes. Fever and hemoptysis in diabetic population is more common compared to the general population. Radiographic differences include higher than usual parenchymal lesions and lung cavities (30). There are reports of a higher incidence of lower lobe involvement in individuals with DM in contrast to the classical upper lobe involvement in the general population. Also, a higher rate of other atypical presentations like a reduced rate of sputum conversion (low quality evidence), higher probability of treatment failure and death (moderate quality evidences) is known to occur when DM occurs with TB. A higher rate of recurrence and reactivation of latent TB infection (OR=1.83) has been documented (31). Subjects affected with TB and DM are found to be heavier and older males compared to those without diabetes. More pulmonary than extra-pulmonary involvement is seen in TB with DM (32).

 

Outcome

 

Negative smear or culture on two separate occasions while on treatment and on completion of treatment defines a cured TB (Table 2). Apart from being a risk factor for increased incidence of active TB, co-existence of DM worsens the outcome even in treated patients. In the pre-insulin era, the commonest cause of death in DM apart from diabetic coma was the co-affection with TB (33). DM increases the risk of treatment failure, death and relapse. The risks are likely to be an underestimation as loss of follow-up or unreported death has been a major problem in data collection on outcome in TB management. In a systematic review and meta-analysis by Baker et al, the risk ratio for combined treatment failure and death was 1.69. The risk ratio for death was 1.89 when unadjusted and went up to 4.95 when adjusted for age and other confounding factors.

 

Table 2. Terminology and Definitions

Terminology

Definitions

Treatment completed

Bacteriologically confirmed TB patient who has completed treatment without evidence of failure, but not yet completed sputum test to prove negative result in the last month of treatment and on at least one previous occasion

Cured

Bacteriologically confirmed TB in whom smear- or culture-was negative in the last month of treatment and on at least one previous occasion

Treatment Success

The sum of cured and treatment completed

Treatment Failed

Sputum smear or culture positive at or beyond 5th month of treatment

Died

A proven patient who dies for any reason before or during the course of treatment

Lost to follow-up

A proven patient who did not start treatment or who has interrupted treatment for 2 or more consecutive months

Not Evaluated

A proven patient for whom no treatment outcome is assigned. Includes cases “transferred out” to another treatment unit as well as cases for which the treatment outcome is unknown to the reporting unit

Terminology and Definitions adopted from RNTCP, Revised National TB Control Programme, Training Course for Programme Manager (Modules 1-4), 2011.Training modules. Central TB Division. https://tbcindia.gov.in.

 

The risk ratio for relapse was 3.89 but no additional risk of TB relapse in those with multidrug resistant TB was demonstrated. In their analysis, Baker et al found that the effect of co-existing DM on sputum conversion 2 to 3 months after treatment was variable (0.79 to 3.25) and wide (34). Persistence of sputum positivity i.e., delay in sputum conversion has been shown in a few studies. The authors conclude that advancing age and underlying co-morbidity contribute to death and is not due to drug resistant TB or severity of hyperglycemia (35).

 

BI-DIRECTIONAL SCREENING FOR DIABETES AND TUBERCULOSIS

 

The synergism between DM and TB in terms of epidemiology and outcome necessitates bi-directional screening for the presence of either TB or DM in the presence of the other disorder. The Collaborative Framework for Care and Control of TB and DM proposed by the World Health Organization (WHO) along with the International Union against TB and Lung is an effort towards bi-directional screening and management of both these conditions (36). Studies implementing bi-directional screening point towards its feasibility and effectiveness (18).

 

Screening for Active TB Among Patients with Diabetes

 

The diagnosis and treatment of TB is affected by substantial delay which occurs at multiple levels a) between the onset of symptoms and clinical presentation b) clinical presentation and suspicion of TB c) Clinical suspicion of TB and its confirmation. This is due to variability in symptoms, host immunity, lack of knowledge, paucity of access to medical care, and lack of rapid and reliable diagnostic tools. The average delay even in resource- rich countries after presentation to heath care system is 3 weeks (37). According to WHO, patients with suspected TB should be promptly sent to TB diagnostic and treatment centers and evaluated accordingly.

 

The higher risk of TB in diabetic population compels intensive screening for detection of TB at the earliest time so as to reduce transmission, morbidity, and mortality. WHO recommends for TB surveillance among patients with DM in settings with medium to high TB burdens. The practical difficulties are the non-availability of TB screening tools in all DM clinics. Also, in areas of low TB burden, the cost-effectiveness is low. The number needed to screen to detect one case of active TB depends on the prevalence in that area. Screening of all patients with clinical history during their visit to diabetic clinic and additional testing in symptomatic and high-risk patients should be undertaken. Also screening for TB whenever there is unexplained worsening of metabolic control would help detect occult cases. Different modalities (clinical, radiological, sputum microbiology) alone or in combination are used for screening individuals with DM for the presence of active TB.

 

Clinical Assessment

 

It is inexpensive and requires minimum time. Fever, cough of more than 2 weeks duration, hemoptysis, weight loss, night sweats, and exposure to a case of active TB are the clinical clues to suspect pulmonary TB. Lymphadenopathy, fever with altered sensorium, neck stiffness, abdominal symptoms like ascites, intestinal obstruction etc. all favor the possibilities of extra-pulmonary TB. But clinical symptoms lack both sensitivity and specificity as it excludes asymptomatic patients and relies on the presence of symptoms.

 

Radiography of the Chest

 

It has good sensitivity to pick up asymptomatic pulmonary cases, but there can be false positive results. Inconsistent evidence exists on the presence of atypical findings of TB in the chest x-rays of individuals with diabetes. The presence of clinical symptoms of fever, cough, hemoptysis, and weight loss with an abnormal chest-x-ray helps in the presumptive diagnosis of TB. Figure 3, 4, and 5 show different radiological presentations of pulmonary TB.

Figure 3. Chest Radiographs suggesting fibrocavitatory lesions. Post primary infections and reactivation of pulmonary TB are more likely to cavitate. They are most common in the posterior segments of the upper lobes (85%) as seen in Picture A. Red arrow pointing to the cavity. The other common site is the superior segment of the lower lobe (Picture B) Yellow arrow pointing to the cavity (Picture courtesy- Prof Mary John, Christian Medical College and Hospital, Ludhiana)

Figure 4. Chest Radiographs suggesting lobar consolidation. (Picture courtesy- Prof Mary John& Dr Neeru Mittal, Christian Medical College and Hospital, Ludhiana)

Figure 5. Chest Radiographs suggesting miliary TB. It represents hematogenous dissemination of an uncontrolled tuberculous infection. Although implants are seen throughout the body, the lungs are usually the easiest location to image. Miliary deposits appear as 1-3 mm diameter nodules uniformly distributed in the lung parenchyma. (Picture courtesy- Prof Mary John & Dr Neeru Mittal, Christian Medical College and Hospital, Ludhiana)

Microscopic Examination 

 

Sputum collected for Ziehl-Neelsen staining and examination for acid -fast bacilli is both sensitive and specific. Even-though they are the commonly used confirmatory tests, most diabetes-oriented clinics are unlikely to have standard laboratory facilities for sputum tests even though having a radiography unit for screening TB appears feasible (32). Sputum tests have limitations in cases of scanty sputum or salivary contamination especially in children. If sputum availability is scanty then sputum is induced by saline nebulization, which if not helpful, can be followed by bronchoscopy assisted lavage or trans-bronchial pulmonary biopsy.

 

Sputum Culture

 

The gold standard test is sputum culture for TB bacilli but is both time consuming (turnaround time 8 weeks) and expensive. It cannot be used for all individuals attending the DM clinic and is reserved for those patients where the index of suspicion is high and in difficult cases when other available tests are not contributory for diagnosis. Sputum culture is also useful for assessing response in multi-drug resistant TB.

 

Rapid Molecular Diagnostic Tests

 

Tests like cartridge based nucleic acid amplification test (CB-NAAT) (Figure 6) or rapid automated molecular test Expert MTB/ RIF assay using polymerase chain reaction have a quick turnaround time of two hours and additional advantage of using a single sputum sample. They also detect the presence of rifampicin resistance. Being expensive it cannot be used for screening all patients with DM even though it has high sensitivity and specificity. But they are useful in cases with high-index of suspicion and difficulty in arriving at a definitive diagnosis.

Figure 6. All district hospitals in India have been provided with Cartridge Based-Nucleic Acid Amplification Testing equipment under the RNTPC program. Picture of the equipment at Civil Hospital, Ludhiana (Picture courtesy- Dr Ashish Chawla, Civil Hospital, Ludhiana)

Screening for Latent TB Among Patients with Diabetes

 

As mentioned earlier, Identification and treatment of latent TB infection to prevent its progression to active disease is necessary to prevent morbidity, mortality, and spread of TB. The WHO AND USPSTF (US preventive services task force) have issued strong guidelines for the screening and treatment of latent TB infection in high risk adults aged more than 18 years in countries with low incidence of TB (38,39).The high risk groups include persons hailing from countries with high TB prevalence, persons residing in homeless shelters and correctional facilities, immunocompromised individuals (HIV, those on immunosuppressants including post-organ transplant), silicosis, those receiving dialysis, those receiving anti-TNF-alfa inhibitor treatment, previously treated TB, and persons who come in contact with those active TB (household contacts and health care workers). The Mantoux tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are the two screening tests used and they are moderately sensitive and highly specific (40,41). In the tuberculin test, purified protein derivative (PPD) is injected intradermally and assessed within 48 to 72 hours for the presence of induration which is a palpable hard swelling (a diameter of more than 10 mm is considered positive) over the injected area (42,43). In the IGRA a single venous blood sample is taken for the assay and the reports are available within a day. They are particularly useful in those who are unlikely to return for TST test reading and BCG vaccinees.

 

There is no consensus on the issue of screening for latent TB infection in DM as a high-risk group. The results of studies done previously have been inconsistent. Studies have shown a variable prevalence of latent TB infection and there are no randomized controlled trials demonstrating the benefits of screening. Similarly, there are no recommendations for chemoprophylaxis of latent TB infection in individuals with DM due to the lack of randomized controlled trials that show benefit. The small added risk of hepatotoxicity with chemoprophylactic drugs given for TB in latent TB infection has been the only concern arguing against such measures.

 

Screening for Diabetes in Tuberculosis

 

In geographical regions with a high prevalence of diabetes, screening for hyperglycemia in TB affected individuals is highly recommended (14). Detection and monitoring of hyperglycemia is an essential part of infection management in any patient with an infectious disease. Chronic infectious diseases like TB thrive in hyperglycemic individuals and the outcome is unfavorable in a hyperglycemic milieu. Recognition of hyperglycemia during the entire course of the illness in TB affected individuals implies either monitoring of pre-existing hyperglycemia or new onset of transient or permanent hyperglycemia. Transient hyperglycemia is a manifestation secondary to the insulin resistance induced by the inflammation of TB infection. There is evidence that hyperglycemic status improves during the course of anti-TB treatment. The optimal time to screen for DM in TB patients on anti-TB treatment is thus unresolved particularly when it is well known that transient hyperglycemia exists during the course of TB. Many groups have advocated for screening more than once during the course of illness i.e., once at the initiation of treatment and at least once again either during and at the time of completion of TB treatment.

 

In regions with high prevalence of diabetes, younger age of onset of DM is on the rise and this is an emerging problem. There is a three times higher risk for younger individuals to get TB and a two-to four-fold higher risk in diabetic individuals compared to non-diabetic individuals. Hence screening for DM in all individuals 18 years of age or older appears logical.

 

The type of tests for screening patients with TB for DM depends on the availability of the local health care facilities, cost of the tests, and the ability of patients to come back for additional or repeat tests. Symptom based screening for DM has a low sensitivity. Risk score-based screening also is marred by low sensitivity and specificity. Random plasma glucose test and HbA1c (glycosylated Hb) are convenient tests that can be done in non-fasting individuals as screening tests. Glycosylated Hb test which doesn’t require a fasting blood sample helps to differentiate stress induced hyperglycemia from spontaneous onset pre-existing diabetes. Oral glucose tolerance test (OGTT) with 75 gm helps in identifying impaired glucose tolerance (IGT) and frank DM. A FBG ≥126 mg/dL or random plasma glucose ≥200 mg/dl on two tests is diagnostic of diabetes; FBG 110to 125 mg/dL is considered as impaired fasting glucose and post glucose values between 141- to 199 mg/dl is taken as impaired glucose tolerance (43,44). In one study, the number of TB patients needed to screen (NNS) for detecting DM was on average 40. But in the same population it was lower among smear positive subjects (NNS = 23), in age less than 40 years (< 40 years vs. > 40 years NNS = 35 Vs 47), in males (male vs. female NNS = 31 vs. 116), smokers (smoker vs. non-smoker NNS = 27 vs. 68) and HIV positive (Positive vs. Negative 22 Vs 43) indicating that there are high risk individuals (46).

 

Currently, screening for DM in individuals with TB and screening for TB in patients with DM where the prevalence is > 100/1,00,000 population appears feasible. Once diagnosed as having diabetes, diet and drug therapy is initiated and the patients are followed up closely for assessing the glycemic response. Transient hyperglycemic situations improve either spontaneously or with minimal medical intervention. After completion of TB medications, regular follow-up with glycemic monitoring is recommended for all patients who had diabetes.

 

MANAGEMENT OF DIABETES AND TUBERCULOSIS 

 

Anti-Tuberculosis Therapy in Diabetes

 

Management of DM should be according to the existing global guidelines with adaptations according to the regional needs. The treatment of TB in DM is not different from the general population. DOTs (Directly Observed Treatment, short-course) is a patient-centered WHO strategy adopted to treat individuals with active TB. A trained health worker provides drugs and observes in-person the patient taking the drug. It guarantees compliance, completion of the treatment course and prevents transmission, treatment failure and development of drug resistance. For newly detected TB, 2 months of intensive phase with 4 drugs (INH, Rifampicin, Pyrazinamide and Ethambutol) and 4 months of continuation phase with 3 drugs (except pyrazinamide) is the standard regimen. For those with a relapse 3 months of intensive therapy with 5 drugs (streptomycin in addition) followed by 4 months of continuation phase with 3 drugs (except pyrazinamide and streptomycin) is administrated.

 

In Chronic Kidney Disease

 

All four first line drugs (RIF, INH, PZA and EMB) can be used in patients with CKD. Up to 50% dose reduction for EMB and PZA may be needed in patients with creatinine clearance <10 ml/min. Regular monitoring is advised to ensure optimal therapy.

 

Adverse Effects of Anti-TB Drugs

 

INH induced peripheral neuropathy may worsen the underlying diabetic neuropathy. Pyridoxine is supplemented to prevent this. INH is also associated with hepatitis. Ethambutol is known to produce optic nerve toxicity which may confound diabetic retinopathy. Also, ethambutol and rifampicin are known to affect the kidneys. Rifampicin can induce immune-allergic reactions. Pyrazinamide is rarely associated with liver injury but its more common side effect is hyperuricemia induced joint pain. Streptomycin is potentially associated with renal and cochleo-vestibular toxicity

 

Multi-Drug Resistant TB (MDR-TB)

 

Multi-drug resistant TB (MDR-TB) is an added medical and economical burden as it is much more difficult to treat, involves therapy with atypical anti-TB drugs for a longer duration of time, and requires referral to specialty centers. Infections caused by mycobacterial strains which are resistant to INH and rifampicin are called multi-drug resistant TB infections. If there is additional resistance to one fluroquinolone and one of the additional inject able drugs (Kanamycin, Capreomycin or Amikacin) then it is called extensive drug resistant TB (XDR-TB). It is associated with poor outcomes and risk of continued transmission (47). Treatment outcome always has been poor due to the complex drug regimen, non-availability of all the drugs, and the possible occurrence of XDR-TB. The reason for resistance is multi-factorial including patient’s non-compliance to therapy, incomplete or inadequate treatment of susceptible TB, decision error by the treating community, etc. Resistance to drugs arises from mutations which are spontaneous and restricted to specific gene loci making it detectable without much difficulty.

 

There is inconsistent data on the incidence of TB-drug resistance in diabetes. Tegegne et al in their meta-analysis concluded that DM can increase the odds of developing MDR-TB.  (47,48). Observational studies have shown delayed clearance of mycobacterium, failure of treatment, relapse and death in the presence of DM (49). The possible theoretical explanations pertaining to the influence of DM in developing resistance include lower drug concentrations, hyperglycemia induced acute and chronic effects of immune regulation, and the presence of more extensive disease in DM affected individuals (50).

 

Altered plasma concentrations of the anti-TB drug rifampicin has been demonstrated in the continuation phase (but not in the induction phase) of TB treatment in individuals with DM (51). The heavier body weight of insulin resistant individuals with DM is supposed to be one of the reasons because of the use of fixed-dose combination drugs. Giving an exact weight-based dose for a longer duration of time is suggested to overcome this hurdle (52). In addition, DM can influence the plasma concentrations of anti-TB drugs. The absorption, distribution, and metabolism of anti-TB drugs may be altered either due to local gastrointestinal causes (gastropathy, polypharmacy mediated interactions) or dysautonomia of DM predisposing to treatment failure.

 

After initiation of treatment all patients should be closely followed for evidence of resistance. Persistent sputum positivity at the end of 2-3 months of ATT therapy should prompt a look for evidence of drug resistance. CT chest features have been demonstrated to be different from non-DM subjects. Pulmonary segment consolidation and lobe consolidation seen as moth-eaten cavities without a wall and filled with fluid are the features mentioned in published data. They are accompanied by bronchial damage (53). Multiple moth-eaten cavities in chest CT while on ATT should prompt the suspicion of MDR-TB. Rapid molecular techniques like CB-NAAT or sputum culture for sensitivity should be used to look for drug resistance. All MDR-TB should be referred to specialized centers dealing with MDR-TB.

 

Drug Therapy in Multi-Drug Resistant Tuberculosis

 

The second line drugs are generally less efficacious and more toxic. In the presence of drug resistance second line agents are used in multiple combinations to address different pharmacological targets in the mycobacterium. In addition to one of the first line drugs to which there is retained susceptibility, an injectable agent, a fluroquinolone and class 4 and class 5 drugs are used in combination to combat MDR-TB (53). Bedaquiline and Delamanidare are new anti-TB drugs used in MDR-TB

 

Bedaquiline belongs to the diarylquinoline group. It inhibits mycobacterial ATP-synthase activity. A shorter time to sputum conversion compared to placebo has been demonstrated. The adverse effects include enzyme induction,electrolyte imbalance, QTc prolongation, and gastrointestinal toxicity (54).

 

Delamanid a dihydro-imidazooxazole that inhibits mycolic acid synthesis also has shown a shorter time period taken for sputum conversion while used in the regimen for MDR-TB. A dose dependent association with QT prolongation occurs (55).

 

Linezolid an oxazolidinone has demonstrated 87% sputum conversion but more than 80% of patients had adverse effects. Peripheral neuropathy, myelosuppression, optic neuropathy, and rhabdomyolysis have been documented in study subjects.

 

ANTI-DIABETES THERAPY IN TUBERCULOSIS    

 

The outcome of TB in DM is also dependent on good glycemic control. The management of hyperglycemia in TB depends on many factors like age, duration of diabetes, presence of complications of DM and co-morbidities, existing drugs, patient support and preferences, economic background and access to medical facilities.

 

Changes in the lifestyle pattern is once again reiterated when starting ATT. Adequate nutrition with high quality protein without affecting glycemic control is the corner stone of managing nutrition associated glycemic status in TB. In the presence of nephropathy or liver disease, the protein intake has to be modified appropriately and spurious use of protein is avoided. Vitamins particularly pyridoxine (B6), methylcobalamine (B12), vitamin A and Vitamin D should be adequately replaced. Tobacco use and alcohol consumptions have to be stopped. Moderate intensity exercise can help weight lose and improve glycemic control in overweight individuals.

 

Drug regimen, monitoring and follow-up should be individualized to maximize benefit with minimal discomfort and side effects like hypoglycemia, arrhythmias etc. Monitoring of capillary blood glucose at home, dose adjustment, monitoring of renal and liver functions are required during follow-up.

 

Anti-TB drugs can influence the metabolism of anti-diabetic medications (Table 3). Rifampicin, by cytochrome p450 enzyme induction, increases the metabolism of most oral anti-diabetic drugs, which may worsen the hyperglycemia. INH on the other hand inhibits cytochrome P450 enzymes and prolongs the effect of anti-diabetic drugs.

 

Table 3. Anti TB Drugs and Drug Metabolism (Ref 57-59)

Anti TB drug

Effect on Cytochrome P 450

Effect on anti- diabetic drugs

Rifampicin

Induces the cytochrome enzymes thereby accelerating the elimination of drugs like sulphonylureas, thiazolidinediones, and meglitinides

Reduced effect of sulphonylureas by one-third due to CYP2C-mediated accelerated metabolism leading to hyperglycemia

 

Reduced effect of thiazolidinedione by half due to CYP2C8-mediated accelerated metabolism leading to hyperglycemia

INH

Inhibits

Reduced elimination through action on CYP2C9; persistent effect and risk of hypoglycemia

Bedaquiline

Enzyme inducer

Can reduce the effect of anti- diabetic drugs

 

 

Aggressive therapy of DM is necessary for optimal response to TB therapy (Table 4). Insulin is the drug of choice in most illnesses including TB; insulin has the advantage of producing an anabolic effect, positive influence on appetite, and faster relief of hyperglycemic symptoms. It is the most suitable anti-hyperglycemic agent in cachexic and low BMI individuals. It is a mandatory therapeutic agent in Type 1 diabetes, pancreatic diabetes, severe DM and TB, coexisting renal or hepatic diseases, situations complicated by drug interactions and oral drug intolerance. Insulin is neutral in drug-to-drug interactions and achieves glycemic control faster than oral drugs. In the presence of fasting hyperglycemia of > 200 with ketonuria, Insulin is used to treat the hyperglycemia. It is also the preferred drug in renal impairment. The main disadvantage with insulin is that it has to be injected and more than twice a day in presence of infection/ stress. The indications for insulin use in patients with active TB and DM is summarized in Figure 7.

Figure 7. Indications of Insulin Use in patients with Type 2 DM and Active TB

Metformin has the advantage of not producing hypoglycemia when used alone. It can however reduce appetite and needs caution while being used in renal or hepatic dysfunction. It doesn’t interact much with ATT and doesn’t influence cytochrome enzyme induced metabolism. It can help to shorten the course of TB therapy. It modifies the immune response and inflammation. It acts on the mitochondrial respiratory chain and can reduce the intracellular growth by acting through AMPK pathway which has a negative impact on the inflammatory process.

 

Table 4. Anti-Diabetic Drug Use in Patients with Tuberculosis

Drug

Advantages

Disadvantages

Comment

 

Insulin

Increases appetite,

weight; anabolic effect; No drug interactions with ATT

Injectable

 

Needs supervision for change in requirement

Preferred in lean diabetes, secondary diabetes, severe DM with ketosis or hyperosmolar state

Metformin

Oral;

Cost-effective and easily available

Not influenced by ATT; positive anti-TB adjuvant action

Gastrointestinal disturbances;

Needs renal and hepatic function monitoring; Change in eGFR (< 35 ml/ min/l) or > 3 times raised liver enzymes necessitates stopping metformin;

Not suitable in hypoperfusion states (risk of lactic acidosis)

Not potent in severe hyperglycemic situations. Can be used in mild forms of hyperglycemia.

Sulphonylureas

Quick restoration of euglycemia

Long-acting drugs can induce hypoglycemia in anorexic people

Shorter acting sulphonylureas such as gliclazide and glipizide

DPP4- inhibitors

Less hypoglycemic potential

? Risk of immune dysregulation – respiratory

Infection

Selective use

Alpha glucosidase inhibitors

No hypoglycemia

GI intolerance

In mild post meal elevation

Thiazolidinediones

Against insulin resistance

Hepatic

Selective use

SGLT2

inhibitors

No hypoglycemia

 

Dehydration, DKA

Selective use

 

 

Metformin increases the host cell production of reactive oxygen species and acidification of mycobacterial phagosome (60). It has been found to downregulate oxidative phosphorylation, mammalian target of rapamycin (mTOR) signaling, and type I interferon response pathways (61).  Sulphonylureas can be used for quick glycemic control. The long acting sulphonylureas like glibenclamide and glimepride have a risk of prolonged hypoglycemia particularly seen in anorexic individuals. Their plasma concentration and their duration of action are modified by drugs acting on cytochrome P450 system and hence monitoring of glycemic status is essential while on these drugs. Thiazolidinediones (pioglitazone) do not produce GI symptoms and are non-hypoglycemic when used as monotherapy. Monitoring of hepatic enzymes is required particularly when TB drugs are co-administered. Alpha-glucosidase inhibitors may be helpful in mild postprandial hyperglycemias. SGLT-2 inhibitors have the risk of further weight loss, euglycemic ketoacidosis, worsening of dehydration in sick patients, and urinary tract infections. They should not be used for glycemic control in patients who are sick and cachexic. In individuals who have no contra-indications they can be continued selectively under close follow-up (62, 63).

 

CO-MORBIDITIES OF DIABETES

 

Cardiovascular Disease in Diabetes and Tuberculosis

 

The commonest cause of mortality in DM is cardiovascular disease due to atherosclerosis manifesting as coronary heart disease (myocardial infarction /cardiac failure), stroke and peripheral vascular disease. TB also has a possible role in chronic vascular inflammation, autoimmunity and inhabitation of TB bacilli atheromatous plaque (64). It also affects the myocardium (65). After successful initiation of TB treatment which is done on a priority basis, DM and cardiovascular status should be assessed. In addition to hyperglycemia management, lifestyle modification, antihypertensive treatment, lipid-lowering therapy, and anti-platelet therapy are the corner stones of management of cardiovascular disease in DM irrespective of the presence or absence of TB. In the presence of hemoptysis anti-platelet drugs are withdrawn or held back. Cessation of smoking and moderation of alcohol has to be counselled about. Anti-hypertensive therapy is initiated during review visits and titrated. Anti-lipid therapy using statins are added gradually and the liver enzymes should be monitored during the course of therapy while on ATT.

 

Renal Dysfunction in Diabetes and Tuberculosis

 

More than a third of individuals with DM develop renal complications due to diabetes. This complicates TB in many ways including increased susceptibility to TB and difficulty in the management of TB (66). In patients with chronic renal failure and on dialysis there is a 6.9‐ to 52.5‐fold risk of developing TB (67). Peritoneal TB is another risk for CKD patients on peritoneal dialysis. The altered immune function in chronic renal impairment increases susceptibility to TB (68). CKD adversely affects TB and its treatment. The anti-TB drugs (ethambutol and pyrazinamide) require dose reduction by up to 50%. Insulin is preferred in most instances for glycemic control. Short acting sulphonylureas or repaglinide can be used as an alternative.

 

Hepatic Dysfunction in Diabetes and Tuberculosis

 

DM liver pathology includes fatty liver disease, NASH, and cirrhosis. In TB, drug induced hepatitis is a concern. In such cases the drugs are withdrawn until resolution of hepatotoxicity. Pyrazinamide is withdrawn completely. Quinolones, ethambutol, and ofloxacin can be used instead of the first line agents. Anti-TB drugs are restarted when the liver enzymes are normalized. Insulin is the drug of choice in severe chronic liver disease with diabetes. Metformin is preferred in fatty liver but withdrawn in cirrhosis.

 

Tuberculosis and Diabetes in HIV – The Triangular Overlap

 

DM and HIV are two independent risk factors for developing TB. The wider prevalence of DM makes DM a more important risk factor for developing TB than retroviral diseases. A significantly higher preponderance of DM over HIV has been reported in cases of pulmonary TB while extra-pulmonary TB was predominant in HIV-TB patients (69). DM is increasing in areas where TB and HIV are rampant. Literature reports on the influence of HIV-co infection on DM with TB have been contradictory. Studies have reported reduced odds of developing DM in HIV infected TB patients (70).  A paradoxical protective effect of HIV on the development of TB was reported (71). However, they were cross-sectional single center studies of limited sample size and had used single random blood glucose tests for screening. But in a case-control study the association between DM and TB in HIV was found to be strong except when HbA1c was used for screening. This may be because of anemia of HIV compromising the true HbA1c value (72). HIV testing is mandatory in all presumptive TB and confirmatory assessment using Gene Xpert MTB/RIF assay for drug resistance.

 

PREVENTIVE METHODS

 

Aggressive DM screening among the population with TB and effective management of both TB and DM can improve outcome on an individual basis. The more effective approach to have an impact at the community level is to have a preventive strategy like vaccination against TB and aggressive prevention and management of DM (29).

 

SUMMARY

 

Epidemiological evidence for an uncharacteristic alliance between non-communicable disease like DM and a communicable disease like TB as a syndemic are overwhelming. A two-to four-fold higher risk of active TB in individuals with DM and twice the prevalence of DM in patients with TB explains the double burden. Ranked among the top ten mortal diseases, the geographical spread of both these diseases is unfortunately overlapping and the co-existence is progressive. They are increasing alarmingly in those regions where health care facilities are limited. DM impacts TB both from infection to disease stage and disease stage to progression stage. Chronic hyperglycemia compromises the alveolar defenses.

 

Latent TB infection is a dormant subclinical disease which lasts for weeks or decades. Immune deficiency either in absolute or relative quantities are sufficient for its re-activation. The clinical and radiological presentations of active TB have been reported to be pulmonary predominantly and atypical when DM co-exists with TB. DM increases the risk of treatment failure, death and relapse. The risk ratio for combined treatment failure and death was 1.69, unadjusted and adjusted risk ratios for death were 1.89 and 4.95 respectively and risk ratio for relapse was 3.89.

 

Bidirectional screening is recommended to improve the outcome in both diseases. Sputum microscopic examination, rapid molecular tests, random plasma glucose and glycosylated hemoglobin are the available among the screening tests with their own merits and limitations.

 

Anti-TB treatment has adverse impact on glycemic control and the complications of diabetes. The metabolism of some DM drugs is modified by ATT which affects glycemic control. Modifications of medications are required in co-morbid illnesses of DM like cardio-vascular diseases, renal, and hepatic dysfunction. Insulin is the drug of choice in lean diabetes, severe hyperglycemia, ketotic states, anorexic patients, and in drug intolerance. Metformin if tolerated has an advantage as a non-hypoglycemic agent with some favorable anti-TB activity.

 

Lifestyle modification, antihypertensive treatment, lipid-lowering therapy, and anti-platelet therapy are the cornerstones in the management of cardiovascular disease in DM and TB. Anti-platelet drugs are withdrawn in patients with hemoptysis. Chronic kidney diseases can predispose to TB and its management is complicated by drug toxicity and dose adjustment of ATT is required along with careful monitoring of response and renal functions. In case of ATT induced hepatotoxicity, ATT is withdrawn and second line agents are substituted. Once liver enzymes normalize the first line drugs are restarted cautiously.

 

Effective preventive strategies like vaccination against TB and aggressive prevention and management of DM will be the approach to be adopted till time throws new light on the means to fight these dual epidemics more effectively.

 

REFERENCES

 

  1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94(3):311-321.
  2. Jacob JJ, Paul PAM. Infections in Endocrinology: Tuberculosis. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; March 14, 2021.
  3. Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010; 375(9728):1814-1829. doi:10.1016/S0140-6736(10)60483-7
  4. World Health Organization. Global Tuberculosis Report 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf (Accessed 28 Nov 2020)
  5. Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. Pulm Med. 2013; 2013:828939. doi:10.1155/2013/828939
  6. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015; 46(6):1563-1576. doi:10.1183/13993003.01245-2015
  7. Lee RE, Li W, Chatterjee D, Lee RE. Rapid structural characterization of the arabinogalactan and lipoarabinomannan in live mycobacterial cells using 2D and 3D HR-MAS NMR: structural changes in the arabinan due to ethambutol treatment and gene mutation are observed. Glycobiology. 2005; 15(2):139-151. doi:10.1093/glycob/cwh150
  8. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet. 2010 Sep 18;376(9745):958. Hillage, H L [corrected to Hillege, H L]]. Lancet. 2010; 375(9733):2215-2222. Doi: 10.1016/S0140-6736(10)60484-9.
  9. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium:International Diabetes Federation, 2019. https://diabetesatlas.org/en/resources/(Accessed 8 March 2021)
  10. World Health Organization. Global tuberculosis report 2019: World Health Organization; 2019. https://www.who.int/tb/publications/global_report/en/ (Accessed 8 March 2021)
  11. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009 Dec; 9(12):737-46. Doi: 10.1016/S1473-3099(09)70282-8. PMID: 19926034; PMCID: PMC2945809.
  12. Viswanathan, V., Bajaj, S., Kalra, S. et al. RSSDI clinical practice recommendations for diagnosis, prevention, and control of the diabetes mellitus-tuberculosis double burden. Int J Diabetes Dev Ctries 2017; 37, 379–399
  13. Goldhaber-Fiebert JD, Jeon CY, Cohen T, Murray MB. Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. Int J Epidemiology. 2011 Apr; 40(2):417-28. Doi: 10.1093/ije/dyq238. Epub 2011 Jan 20. PMID: 21252210; PMCID: PMC3621385.
  14. World Health Organization/International Union Against Tuberculosis and Lung Disease. Provisional collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15. Geneva, Switzerland: WHO, 2011.
  15. Hayashi, S., &Chandramohan, D. (2018). Risk of active tuberculosis among people with diabetes mellitus: systematic review and meta-analysis. Tropical medicine & international health: TM & IH, 23(10), 1058–1070. https://doi.org/10.1111/tmi.13133
  16. Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus co morbidity: A systematic review. PLoS One. 2017; 12(4):e0175925. Published 2017 Apr 21. doi:10.1371/journal.pone.0175925.
  17. Odone A, Houben RM, White RG, Lönnroth K. The effect of diabetes and under nutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol. 2014; 2(9):754-764. doi:10.1016/S2213-8587(14)70164-0
  18. Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health. 2010; 15(11):1300-1314. doi:10.1111/j.1365-3156.2010.02632.
  19. Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol. 2014; 2(9):730-739. doi:10.1016/S2213-8587(14)70109-3
  20. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. Lancet Glob Health. 2019; 7(4):e448-e460. doi:10.1016/S2214-109X(18)30487
  21. Collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15
  22. Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS One. 2012;7(7):e41367.
  23. Balakrishnan S, Vijayan S, Nair S, et al. High diabetes prevalence among tuberculosis cases in Kerala, India. PLoS One. 2012;7(10):e46502.
  24. Manjareeka M, Palo SK, Swain S, Pati S, Pati S. Diabetes Mellitus among Newly Diagnosed Tuberculosis Patients in Tribal Odisha: An Exploratory Study. J Clin Diagn Res. 2016;10(10):LC06-LC08.
  25. Singh SP, Singh SP, Kishan J, Kaur S, Ramana S. Association of tuberculosis and diabetes Mellitus: an analysis of 1000 consecutively admitted cases in a tertiary care hospital of North India. Pan Afr Med J. 2016;24:4
  26. Kodiatte A, John M, Jacob JJ. Diabetes mellitus and prediabetes among patients with tuberculosis in a single north Indian tertiary care centre. J R Coll Physicians Edinb. 2020;50(3):242-246.
  27. Noubiap JJ, Nansseu JR, Nyaga UF, Nkeck JR, Endomba FT, Kaze AD, Agbor VN, Bigna JJ. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. Lancet Glob Health. 2019 Apr;7(4): e448-e460.
  28. Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis. 2007; 45(4):428-435. doi:10.1086/519841
  29. Crevel RV, Critchley JA. The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice. Trop Med Infect Dis. 2021; 6(1):8. Published 2021 Jan 8. doi:10.3390/tropicalmed6010008
  30. Chiang CY, Lee JJ, Chien ST, et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. PLoS One. 2014; 9(4):e93397. Published 2014 Apr 3. doi:10.1371/journal.pone.0093397
  31. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013; 68(3):214-220. Doi: 10.1136/thoraxjnl-2012-201756.
  32. Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014; 2(9):740-753. doi:10.1016/S2213-8587(14)70110
  33. Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract. 2014; 106(2):191-199. doi:10.1016/j.diabres.2014.06.011.
  34. Baker MA Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011; 9:81. Published 2011 Jul 1. doi:10.1186/1741-7015-9-81
  35. Chang JT, Dou HY, Yen CL, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc. 2011; 110(6):372-381. doi:10.1016/S0929-6646(11)60055-7
  36. Collaborative framework for care and control of tuberculosis and diabetes. WHO/HTM/TB/2011.15
  37. Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis. 2009; 9:91. Published 2009 Jun 11. doi:10.1186/1471-2334-9-91
  38. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015; 46(6):1563-1576. doi:10.1183/13993003.01245-2015]
  39. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016; 316(9):962-969. doi:10.1001/jama.2016.11046
  40. Mansilla Bermejo MJ, Sanz Gil MJ, Moraleda Velasco P, Alvárez Prado A, Carbayo García JJ, Mata Guijarro F. Lectura de la prueba de la tuberculinaenpacientesdiabéticos de un centro de salud [Tuberculin test in diabetic patients in a health centre]. Aten Primaria. 1995; 16(3):154-157.
  41. Vega Torres RA, Conde JG, Díaz M. Prevalence of tuberculin reactivity and risk factors for the development of active tuberculosis upon admission to a nursing home. P R Health Sci J. 1996; 15(4):275-277
  42. Nwabudike LC, Ionescu-Tîrgovişte C. Intradermal reactions to purified protein derivative in patients with diabetes mellitus. Rom J Intern Med. 2005; 43(1-2):127-132.
  43. Dabhi PA, Thangakunam B, Gupta R, et al. Screening for prevalence of current TB disease and latent TB infection in type 2 diabetes mellitus patients attending a diabetic clinic in an Indian tertiary care hospital. PLoS One. 2020; 15(6):e0233385. Published 2020 Jun 5. doi:10.1371/journal.pone.0233385
  44. Kumpatla S, Aravindalochanan V, Rajan R, Viswanathan V, Kapur A. Evaluation of performance of A1C and FPG tests for screening newly diagnosed diabetes defined by an OGTT among tuberculosis patients-a study from India. Diabetes Res Clin Pract. 2013; 102(1):60-64. doi:10.1016/j.diabres.2013.08.007]
  45. Sariko ML, Mpagama SG, Gratz J, Kisonga R, Saidi Q, Kibiki GS, Heysell SK. Glycated haemoglobin screening identifies patients admitted for retreatment of tuberculosis at risk for diabetes in Tanzania. J Infect Dev Ctries. 2016 Apr 28; 10(4):423-6. Doi: 10.3855/jidc.7324. PMID: 27131008; PMCID: PMC4869164.
  46. Naik B, Kumar AM, Satyanarayana S, et al. Is screening for diabetes among tuberculosis patients feasible at the field level? Public Health Action. 2013; 3(Suppl 1):S34-S37. doi:10.5588/pha.13.0022
  47. Tegegne BS, Habtewold TD, Mengesha MM, Burgerhof JG. Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis. Syst Rev. 2017; 6(1):6. Published 2017 Jan 14. Doi: 10.1186/s13643-017-0407-9.
  48. Pérez-Navarro LM, Fuentes-Domínguez F, Morales-Romero J, Zenteno-Cuevas R. Factoresasociados a tuberculosis pulmonarenpacientes con diabetes mellitus de Veracruz, México [Factors associated to pulmonary tuberculosis in patients with diabetes mellitus from Veracruz, México]. Gac Med Mex. 2011; 147(3):219-225.
  49. Kang YA, Kim SY, Jo KW, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration. 2013; 86(6):472-478. doi:10.1159/000348374
  50. Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health. 2010; 15(11):1289-1299. doi:10.1111/j.1365-3156.2010.02625.
  51. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006; 43(7):848-854. doi:10.1086/507543
  52. Van Ingen J, Aarnoutse RE, Donald PR, et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis. 2011; 52(9):e194-e199. doi:10.1093/cid/cir184.
  53. Song Q, Zhang G, Jiang H, Ren Y, Lu X. Imaging Features of Pulmonary CT in Type 2 Diabetic Patients with Multidrug-Resistant Tuberculosis. PLoS One. 2016; 11(3):e0152507. Published 2016 Mar 29. doi:10.1371/journal.pone.0152507
  54. Kurz SG, Furin JJ, Bark CM. Drug-Resistant Tuberculosis: Challenges and Progress. Infect Dis Clin North Am. 2016; 30(2):509-522. doi:10.1016/j.idc.2016.02.010
  55. U.S. Food and Drug Administration. SIRTURO Prescribing Information.http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.
  56. Shimokawa Y, Sasahara K, Yoda N, Mizuno K, Umehara K. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull. 2014; 37(11):1727-1735. doi:10.1248/bpb.b14-00311 ]
  57. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther. 2001;69(6):400-406. doi:10.1067/mcp.2001.115822
  58. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther. 2004;76(3):239-249. doi:10.1016/j.clpt.2004.05.001
  59. Boglou P, Steiropoulos P, Papanas N, Bouros D. Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus. BMJ Case Rep. 2013;2013:bcr2012008528. Published 2013 Apr 16. doi:10.1136/bcr-2012-008528
  60. Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014; 6(263):263ra159.doi:10.1126/scitranslmed.3009885.
  61. Yu X, Li L, Xia L, et al. Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review. BMC Infect Dis. 2019; 19(1):859. Published 2019 Oct 17. doi:10.1186/s12879-019-4548-4
  62. Niazi AK, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. J Diabetes MetabDisord. 2012; 11(1):28. Published 2012 Dec 20. doi:10.1186/2251-6581-11-28
  63. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. CurrOpin Endocrinol Diabetes Obes. 2017; 24(1):73-79. doi:10.1097/MED.0000000000000311
  64. Huaman MA, Henson D, Ticona E, Sterling TR, Garvy BA. Tuberculosis and Cardiovascular Disease: Linking the Epidemics. Trop Dis Travel Med Vaccines. 2015; 1:10. doi:10.1186/s40794-015-0014-5
  65. Liu A, Hu Y, Coates A. Sudden cardiac death and tuberculosis - how much do we know? Tuberculosis (Edinb). 2012; 92(4):307-313. doi:10.1016/j.tube.2012.02.002
  66. CKD TB : Ates G, Yildiz T, Danis R, et al. Incidence of tuberculosis disease and latent tuberculosis infection in patients with end stage renal disease in an endemic region. Ren Fail. 2010; 32(1):91-95. doi:10.3109/08860220903367528
  67. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial. 2003; 16(1):38-44. doi:10.1046/j.1525-139x.2003.03010.x
  68. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007; 72(3):247-259. doi:10.1038/sj.ki.5002343
  69. Gupta S, Shenoy VP, Bairy I, Srinivasa H, Mukhopadhyay C. Diabetes mellitus and HIV as co-morbidities in tuberculosis patients of rural south India. J Infect Public Health. 2011;4(3):140-144. doi:10.1016/j.jiph.2011.03.005
  70. Faurholt-Jepsen D, Range N, Praygod G, et al. Diabetes is a risk factor for pulmonary tuberculosis: a case-control study from Mwanza, Tanzania. PLoS One. 2011;6(8):e24215. doi:10.1371/journal.pone.0024215
  71. Kibirige D, Ssekitoleko R, Mutebi E, Worodria W. Overt diabetes mellitus among newly diagnosed Ugandan tuberculosis patients: a cross sectional study. BMC Infect Dis. 2013; 13:122. Published 2013 Mar 5. doi:10.1186/1471-2334-13-122
  72. Boillat-Blanco N, Ramaiya KL, Mganga M, et al. Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms. J Infect Dis. 2016;213(7):1163-1172. doi:10.1093/infdis/jiv568

 

Diabetes Management During Ramadan

ABSTRACT

Muslims contribute to 25% of the world population and majority of them reside in the diabetes and obesity endemic Asia-Pacific region. Fasting during Ramadan is one of the five pillars of Islam and an obligatory duty for all healthy adolescents and adult Muslims. However, Islam exempts the ill and pregnant women from fasting. Despite this, many individuals with diabetes who are at high risk from fasting, fast during Ramadan. Individuals fasting during Ramadan are less likely to see their physicians before starting the fast and more likely to fast against medical advice. Hence, these individuals are at increased risk of hyperglycemia, hypoglycemia, and cardiovascular and renal complications. Management of diabetes during Ramadan needs a comprehensive and integrated planning and dissemination of knowledge through the healthcare providers and Muslim religious leaders. Diabetes care should start in the pre-Ramadan period, continue through Ramadan, and follow-up in the post-Ramadan period.

 

INTRODUCTION

 

Muslims contribute to approximately 25% of world population and are distributed across >200 countries across the globe (1,2). Of this, 61.7% of Muslims live in Asia-Pacific region, which is also a region experiencing the diabetes epidemic (3,4).

 

Ramadan is the 9th holy month of the Islamic lunar calendar. Fasting during Ramadan is one of the five pillars of Islam (5). Fasting during Ramadan is an obligatory duty for all healthy adolescents and adult Muslims aimed at spiritual and holistic wellbeing of the individual (1,5). The Holy Quran exempts the sick, medically unfit, or those traveling from fasting during the holy month (1,5).

 

 

Fasting during Ramadan involves complete abstinence from food, medication, drink (including water), or any other form of nutrition (including via a percutaneous endoscopic gastrostomy tube) from dawn to sunset (1, 2, 6).  The fasting during Ramadan is a type of intermittent fasting as it is observed for 10–21 hours depending on the geographical location and solar season and is observed daily for 29–30 consecutive days (1, 2). Individuals fasting during Ramadan take two main meals, Suhoor (pre-dawn meal) and Iftar (post sunset meal) and eat nothing from sunrise to sunset (1, 2, 6).

 

It is estimated that about 79% of Muslims with type 2 diabetes (T2D) and about 43% of them with type 1 diabetes (T1D) fast during Ramadan (7). Of those who fast during Ramadan, 64% fasted every day, and 94.2% fasted for at least 15 days (8). The medication timings of these individuals with diabetes need to be adjusted to pre-dawn and post-sunset timings (1,2). Also, many of these individuals fast against medical advice (9, 10).

 

Since a huge proportion of individuals with diabetes fast during Ramadan, and many are at risk due to fasting, management of diabetes during Ramadan and proper fasting guidance is critical (1,2). 

 

EFFECTS OF FASTING DURING RAMADAM

 

Physiological Changes

 

Fasting during Ramadan is associated with a number of physiological changes.

 

CHANGES IN FEEDING PATTERNS AND ENERGY INTAKE

 

Ramadan fasting differs from other forms of fasting as there is no consumption of any food or drink between dawn and sunset. Hence, the timing between the meals is very long, and this disrupts the normal physiology with disruption in the normal rhythm and fluctuations seen in various homeostasis and endocrine processes (Figure 1). Major changes occur in glucose homeostasis in individuals with diabetes that results in post Iftar hyperglycemia and risk of hypoglycemia during the day (Figures 2 and 3)

Figure 1. Changes in feeding patterns and energy intake during various fasting periods (11, 12). (I) normal feeding, (II) Ramadan fasting and (III) prolonged fasting and starvation.

 Figure 2. Mean continuous glucose monitoring (CGM) profiles from healthy individuals (12, 13).

Figure 3. Mean continuous glucose monitoring (CGM) profiles from individuals with diabetes fasting during Ramadan (12, 13).

DECREASE IN TOTAL SLEEP TIME

Total sleep time decreases by approximately 1 hour, with a decrease in sleep period time, rapid eye movement (REM) sleep proportion and duration. Additionally, delayed sleep and an increase in non-REM sleep proportion, sleep latency, and daytime sleepiness by1-point on the Epworth sleepiness scale is also observed (ESS) (12).

ALTERATION OF CIRCADIAN RHYTHM AND HORMONE LEVELS

Sudden alteration of circadian rhythm and hormone levels occurs due to sudden changes in sleep and wake cycles and feeding patterns. Fasting can induce epigenetic changes in genes that control the circadian rhythm (12). The change in circadian rhythm triggers many catametabolic changes, alteration in temperature, and changes in the normal rhythm of hormones like insulin, glucagon, leptin, ghrelin, cortisol, melatonin, growth hormone, and testosterone (12,14). The various changes seen are:

 

  • Insulin resistance and increased glucagon levels: excessive glycogen breakdown and increased gluconeogenesis
  • Cortisol circadian rhythm shows a shift with a blunting of the morning to evening ratio. However, serum cortisol levels do not change by end of Ramadan month.
  • Morning adiponectin levels are reduced
  • Morning and evening growth hormone levels are reduced
  • Large increases in morning leptin levels
  • No major shifts in diurnal ghrelin level

 

By the end of Ramadan significant decrease in serum levels of ghrelin, leptin, and melatonin are observed along with modest reductions in testosterone in men.

SHIFT IN FLUID BALANCE

A sudden shift in fluid balance is seen because of an absolute restriction of fluid intake between dawn and sunset. This may precipitate dehydration in a hot climate which may in turn cause hypotension and falls (6). Uncontrolled hyperglycemia can exacerbate the dehydration due to an osmotic diuresis (6). Dehydration in individuals with T2D can present as low blood pressure, lethargy, or syncope. Dehydration can also increase the risk of thrombosis and stroke due to hemoconcentration and hypercoagulability (6). Other fluid related changes are not considered a major cause of concern and include higher fluid and total water intake between sunset and dawn; urine osmolality increases significantly in the afternoon to conserve water and reduce urine output (12).

ALTERED ENERGY BALANCE

Altered energy balance is seen due to a sudden increase in food intake at Iftar. During Ramadan there is a reduction in activity and energy expenditure which is offset by the reduced time spent during sleep (12).

GUT MICROBIOTA

Intermittent fasting during Ramadan can have direct impact on the gut microbiota which could lead to positive changes in health (12).

 LIPID CHANGES

Fasting during Ramadan has been shown to be associated with a significant increase in high-density lipoprotein-cholesterol (HDL-C) and a significant decrease in total triglycerides, total cholesterol, and low-density lipoprotein-cholesterol (LDL-C) (6, 15).

Physical and Mental Wellbeing

Fasting during Ramadan can have both positive and negative effects on the physical and mental wellbeing of the individuals (Table 1) (16).

Table 1. Positive and Negative Effects on Physical and Mental Wellbeing of Individuals Fasting During Ramadan (16)

Positive benefits

Negative effects

Sense of fulfilment

Sleep deprivation and disruption of circadian rhythm leading to an increase in fatigue and reduction in cognition

More lethargy 

Improvements in:

Weight and BMI

Self-control and ability to resist temptations

Glucose excursions causing feelings of being unwell

Greater sense of:

Empathy for less fortunate

Community

Fostering relationships

Heightened feelings of fear for diabetes related complications

Participation in Sunnah practices for greater spiritual benefits

Temporary changes in weight

Reducing potentially harmful vices, such as smoking, for greater physical and mental wellbeing

Short term feelings of stress anxiety, irritability, and agitation

BMI- body mass index

 

The month long fasting during Ramadan has been associated with significant reduction in weight, waist circumference, and fat mass, especially in those who are overweight or obese (15, 17).

 RISKS OF FASTING DURING RAMADAN IN INDIVIDUALS WITH DIABETES

The various risks of fasting in individuals with diabetes who fast during Ramadan are:

  • Hyperglycemia
  • Hypoglycemia
  • Macrovascular: Cardiovascular disease (CVD) including stroke
  • Microvascular: Chronic kidney disease (CKD)
  • Dehydration

Dual Risk of Hyperglycemia and Hypoglycemia

In people with diabetes fasting during Ramadan there can be an increase in glucose variability and therefore there is increased risk of both hyperglycemia and hypoglycemia (12).

HYPERGLYCEMIA

The meals at Iftar are calorie dense and can cause a significant and rapid rise in blood glucose (BG) levels in people with diabetes (12). The EPIDIAR study showed that the hospitalization rate for severe hyperglycemia during Ramadan increased significantly in individuals with T2D (P<0.001). The hospitalization rate for severe hyperglycemia (with or without ketoacidosis) during Ramadan increased insignificantly for individuals with T1D (P = 0.1635) (6,7).

HYPOGLYCEMIA

The CREED study showed that hypoglycemia incidence before Ramadan was associated with significantly increased risk of hypoglycemia during Ramadan (18). This association between hypoglycemia incidence before and during Ramadan has been seen through multiple studies across continents (1,18,19). Similarly, the EPIDAR study7 showed that T1D and T2D patients had a 4.7-fold and a 7.5-fold increase, respectively, in severe hypoglycemia requiring hospitalization during Ramadan. Hypoglycemia during Ramadan was significantly associated with the use of sulfonylureas and insulin (18,19). Severe and non-severe hypoglycemia rates are fewer with second-generation sulfonylureas, Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), insulin analogues, and sodium-glucose transporter-2 (SGLT-2) inhibitors (20-25). During the early Ramadan period, patients on sulfonylureas and those on ≥2 antidiabetic medications have significant increase in mean amplitude of glycemic excursions (26).

 

Other factors influencing the incidence of hypoglycemia during Ramadan include season, geographical location, fasting duration, time since diagnosis, gender, anthropometric measures, dietary behaviors, and pre-fasting education (1). 

Macrovascular (Cardiovascular and Cerebrovascular) and Microvascular Risk (Renal Complications)

Diabetes increases the risk of CVD and stroke, and individuals with diabetes who have pre-existing CVD or stroke are at greater risk of complications when fasting (27). Individuals with unstable CVD or stroke are also at very high risk from fasting. Individuals with diabetes and CKD stage 3 are at high-risk from fasting while those with stage 4-5 are at very high risk from fasting during Ramadan (27). Patients on dialysis or those who had a kidney transplant are also considered high risk from fasting (27).

 

Factors associated with increased risk of fasting during Ramadan are high carbohydrate intake, inadequate hydration, high activity levels, poor sleeping patterns, and missing doses of essential medicines (27).

 

All these high to very high-risk individuals should be discouraged from fasting. If they still decide to fast, then pre-Ramadan assessment and education and monitoring during Ramadan and post-Ramadan should be carried out under the expert guidance of a multidisciplinary team (diabetologist, cardiologist, neurologist, nephrologist, nutritionist etc.) (27). Weekly monitoring during Ramadan by a health care provider should be encouraged.

 

Pre-Ramadan assessment and education should begin three months prior to Ramadan and all efforts should be made to stabilize the doses of the various drugs, adjust them to morning and evening dose, and those on insulin should be taught self-titration of dose based on SMBG (27).

Patients with CKD, on dialysis or those who had a kidney transplant should be encouraged to routinely monitor electrolytes and creatinine at various time-points during Ramadan (27). A diet rich in potassium and phosphorus should be avoided (27).

 MANAGEMENT OF DIABETES DURING RAMADAN

5 R's of Ramadan Care

 

The management of diabetes during Ramadan and in general can be summarized under the mnemonic termed as the 5 R's of Ramadan care (Table 2).

 

Table 2. The 5 R's of Ramadan Care (28)

The 5 R

Significance

Respect

Respect the patient's attitudes, wishes, and needs, and consider these while planning therapy

Speak with the patient with empathy for his religious beliefs

Risk stratification

This is an essential backbone for pre-Ramadan counseling

Revision of Therapy

Diabetes therapy will need to be revised based on risk of hyperglycemia and hypoglycemia, and other risk factors

Regular Follow Up

Regular follow-up with HCP before, during and after Ramadan is necessary to ensure a safe and healthy fasting experience

Reappraisal of Strategy

Diabetes is a dynamic condition, and constant reappraisal is required during the current and next fasting period

HCP- health care provider

Pre-Ramadan Management of Diabetes

DM management in people planning to fast during Ramadan should ideally start six to eight or maximum 12 weeks before the first day of fasting (6, 29). Diabetes assessment and plan of care pre-Ramadan should ideally follow the flow chart shown in Figure 4 (6, 29).

Figure 4. Diabetes assessment and plan of care pre-, during and post Ramadan (6, 29)

 

Patient education during this time-period is necessary because many patients follow a self-management approach of diabetes during Ramadan and do not appreciate the risks and implications of fasting on DM and its medications, and fast against medical advice (6, 19). Physicians need to be sensitized about this time-period for their Muslim patients as many may not realize the religious sensitivities associated with DM management during Ramadan (6).

PRE-RAMADAN EDUCATION

The pre-Ramadan diabetes education should cover:

Risk quantification, exemptions, and removing misconceptions

  • Blood glucose monitoring
  • Fluids and dietary advice
  • Physical activity and exercise advice
  • Medication adjustment
  • When to break the fast
  • Recognition of hypoglycemia and hyperglycemia symptoms

RISK STRATIFICATION OF PEOPLE WITH DIABETES

The pre-Ramadan time period should be used to understand the individual’s risks associated with fasting, and develop an individualized treatment plan for the individual who falls in the lower risk category and can fast. The risk stratification is done based on several factors (6, 9, 10):

  • Type and duration of diabetes
  • DM treatment regime and polypharmacy with multiple glucose lowering drugs
  • Level of glycemic control
  • Risk or occurrence of hypoglycemia
  • DM self-management capability including hypoglycemia awareness, motivation for self-monitoring blood glucose (SMBG), frailty, and cognition
  • DM complications and comorbidities
  • Ongoing/recent severe illness
  • Renal impairment
  • Social determinants affecting assess and adherence to treatment including economic and education level
  • For those with T1D: access to continuous glucose monitoring (CGM) and advanced insulin technologies

 

The IDF-DAR Practical Guidelines 2021 stratify the individuals with DM who are going to fast during Ramadan into three risk categories, low, moderate and high (Figure 5) (29).

Figure 5. IDF-DAR 2021 Ramadan risk score and risk categories for fasting (2, 30)

 

DM patients who had a history of severe hypoglycemia ≤3 months before Ramadan, recurrent hypoglycemia, or of hypoglycemia unawareness are considered high risk (31). Young individuals and adolescents start fasting during Ramadan with the onset of puberty, and those with T1D are considered to be high risk for fasting and generally discouraged from fasting (9).

 

Many DM patients may need to be upgraded to high-risk category during the current coronavirus-2019 (COVID-19) pandemic and thus likely to fall under the ‘advised not to fast’ risk category (6).

 

Patients with high-risk scores are advised not to fast as fasting is not considered safe for these individuals (29). However, since fasting during Ramadan is a personal choice, the individuals deciding to fast despite being cautioned against it, should be monitored very closely during and after Ramadan (6, 19).

 

Individuals with low and moderate risk scores are educated about the risks and advised to fast with strict BG monitoring, and adjustments to diet/nutrition and medications (29). The individuals are closely monitored during Ramadan by their health care providers (HCPs) and advised to come for a post Ramadan follow-up. At this follow-up visit, the HCPs asses the glycemic control, and discuss the challenges faced to make the next Ramadan fasting more risk free. Pre-Ramadan risk assessment, education and advise is known to improve the fasting experience of individuals with DM (6).

Blood Glucose Monitoring

 

Self-monitoring blood glucose (SMBG) should be stressed upon and encouraged. Moderate to low-risk individuals with diabetes can monitor their BG once or twice daily but those at high risk of fasting should be encouraged to follow a 7-time-point guide for SMBG during Ramadan (Figure 6) (29). Additional BG check should be done if the individual experiences symptoms of hypoglycemia, hyperglycemia, or feel unwell (29).

 

Figure 6. A seven time-point blood glucose monitoring guide for people with diabetes fasting during Ramadan (29)

Fluids and Dietary Advice

Detailed diet plan for Ramadan is provided through Ramadan specific medical nutrition therapy (MNT) and Ramadan Nutrition Plan (RNP) (29,32). Adequate fluid intake should be encouraged between sunset and dawn.

Physical Activity and Exercise Advice

Individuals with diabetes who are fasting should be encouraged to carry out their normal physical activity (29). Taraweeh prayers, which involve activities such as bowing, kneeling, and rising, can be considered as part of daily exercise activities (29). Rigorous exercise/activity during the fasting period should be avoided as this can increase the risk of hypoglycemia and dehydration, especially during the last few hours of fasting (29).

Medication Adjustment

All medications (diabetes and non-diabetes) should be reviewed in the pre-Ramadan period to see which medications need a dose and time adjustment. The change should be made well before Ramadan and monitored through appropriate clinical and laboratory evaluation (29). Patients on insulin should be taught self-titration of units based on SMBG values (10).

When to Break the Fast

This is an essential component of Pre-Ramadan education. All individuals with diabetes who are fasting during Ramadan should be advised to break their fast if:

  • Blood glucose <70 mg/dL (3.9 mmol/L)
  • Advise to re-check within 1 hour if BG is between 70–90 mg/dL (3.9–5.0 mmol/L)
  • Blood glucose >300 mg/dL (16.6mmol/L)
  • Symptoms of hypoglycemia, hyperglycemia, dehydration or acute illness occur

Recognizing Symptoms of Hypoglycemia and Hyperglycemia

All individuals with diabetes who are fasting during Ramadan and their caregivers should be taught to recognize symptoms of hypoglycemia and hyperglycemia (Figure 7) (29). If they recognize these symptoms, they should be advised to break their fast.

Figure 7. Symptoms of hypoglycemia and hyperglycemia (29)

 The Medico-Religious Interplay in Ramadan

Muslims believe that Ramadan is a blessed month, and see fasting during the holy month of Ramadan as a deeply meaningful and spiritual experience (1, 30). A significant number of individuals with diabetes fast during Ramadan, even against medical advice and despite the religious exemptions available to the sick (1, 30, 33). This population also includes adolescents with T1D, who fast against medical advice (9). Individuals with diabetes who fast during Ramadan are more likely to avoid consulting their doctors (12).

 

International Diabetes Federation (IDF) and Diabetes and Ramadan (DAR) International Alliance collaborated to form the IDF-DAR Practical Guidelines 2021 to help healthcare providers (HCPs) better manage diabetes in patients fasting during the month-long holy period of Ramadan (2).

 

It is important to make these individuals with diabetes who cannot fast due to their medical condition understand that they are equally blessed even if they do not fast (30). Many individuals with diabetes who fast prefer to take fasting related advice from their holy leader (Imam). Hence, the right message and education should be disseminated by both the HCPs and the religious leaders (Table 3) (30). HCPs should avoid medical jargons, and counsel patients from a religious standpoint; and religious leaders should integrate into their counseling the value and significance of exemptions in context with the medical advice.

 

Table 3. Medical and Religious Risk Score Recommendations (30)

Risk score

Medical recommendations

Religious recommendations

LOW RISK

0-3 points

Fasting is probably safe. Ensure

1. Medical Evaluation

2. Medication adjustment

3. Strict monitoring

1. Fasting is obligatory

2. Advice not to fast is not allowed except if patient

is unable to fast due to:

3.     -  Physical burden of fasting

4.     -  Has to take medication or food or drink during the fasting hours on medical advice

MODERATE RISK

3.5-6 points

Fasting safety is uncertain

Ensure:

1. Medical Evaluation

2. Medication adjustment

3. Strict monitoring

1. Fasting is preferred but patients may choose

not to fast if they are concerned about their

health after consulting the doctor and taking

into account the full medical circumstances

and patient’s own previous experiences

2. If the patient does fast, they must follow

medical recommendations including regular blood glucose monitoring

HIGH RISK

>6 points

Fasting is probably unsafe

Advise against fasting

 

Medical Nutrition Therapy (MNT) and Ramadan Nutrition Plan (RNP) for People with Diabetes

MNT is an essential component of diabetes management and includes both meal plans and diabetes education, aimed at improving lifestyle and diabetes related behavior (4). MNT helps achieve the desired glycemic control and helps the overweight and obese individuals with T2D improve their lifestyle and lose weight (4). MNT should be appropriate and accurate for the patient’s age, comorbidities, lifestyle requirements, and other medical needs. MNT should be easily absorbed; affordable, easily accessible, acceptable (through right aroma and consider taste preferences), and attractive (visually appealing) (4). This improves adherence to the MNT (4).

 

An MNT plan for individuals with diabetes is essential for safe fasting during Ramadan (32). Structured Ramadan-specific MNT (34) has shown to improve fasting BG and triglyceride levels and pre-dawn and pre-bed SMBG values compared to patients with T2D receiving standard care (34).

 

Structured Ramadan-specific MNT includes (32, 34):

  1. Pre-Ramadan nutrition education
  2. Individualized energy and balanced macronutrient prescriptions for non-fasting period (sunset to sunrise) to prevent hypoglycemia during fasting state
  3. Well distributed carbohydrate intake to prevent post meal hyperglycemia
  4. At least one serving/day of diabetes-specific formula to be taken during Suhoor and/or pre-bed snack.
  5. Diet plan should consider other comorbidities.
  6. Ramadan toolkits:
  • Ramadan flip chart
  • 14-day menu plan
  • Ramadan Nutrition Plate (RNP)
  • Festive season nutrition plan (Syawal nutrition plan)

 

RNP “is a mobile and web-based application designed to help healthcare professionals (HCPs) individualize medical nutrition therapy (MNT) for people with diabetes” who are fasting during Ramadan (32). A well designed and customized RNP is a prerequisite to safe and confident fasting during Ramadan (32). Apart from nutrition, the platform also provides education regarding safe fasting during Ramadan. It helps individuals to safely fast who have no access to HCPs during Ramadan. Several RNPs have been developed for different countries to suit their regional customs, beliefs, and preferences. HCPs can use their country specific RNP, Ramadan Nutrition plate, and well-balanced meal (Table 4) (4, 32) as a guide to individualize the MNT during Ramadan (32).

 

Table 4. Macronutrient Meal Composition for Ramadan (4, 32)

Macronutrient

Recommended amount

Recommended sources

Sources not recommended

Carbohydrate

•                ≤130 g/day

•                Accounts for 40-45% of total caloric intake

•                Adjust as per cultural setting and individual preferences

Low glycemic index and glycemic load carbohydrates: whole grains, legumes, pulses, temperate fruits, green salad, and most vegetables

Foods rich in sugar, refined carbohydrate, processed grains, or starchy foods: sugary beverages, traditional desserts, white rice, white bread, low fiber cereal, and white potatoes

Meal

Calorie%

Carbohydrate exchange*

Suhoor

30-40

3-5

Iftar snack

10-20

1-2

Iftar meal

40-50

3-6

Healthy snack (if required)

10-20

1-2

Fiber

20-35g/day (or 14g /1000 kcal)

High fiber foods: unprocessed food, vegetables, fruits, seeds, pulses, and legumes

 

Fiber helps to provide satiety during Iftar and to delay hunger after Suhoor

-

Protein

•                ≥1.2g/kg of adjusted body weight

•                Accounts for 20-30% of the total caloric intake.

•                Protein enhances satiety and gives sensation of fullness. Also helps to maintain lean body mass

•                Fish, skinless poultry, milk and dairy products, nuts, seeds, and legumes (beans),

•                low fat milk and milk products

•                Protein with a high saturated fat content such as red meat (beef, lamb) and processed meats (increase CVD risk)

Lipids

•                Between 30–35% of the total calorie intake.

•                The type of fat is more important than the total amount of fat in reducing CVD risk.

•                Limit saturated fat to < 7%. PUFA and MUFA should comprise the rest of the fat intake.

• Limit dietary cholesterol to < 300 mg/day or < 200 mg /day if LDL cholesterol > 2.6 mmol/L

•                Consume fat from PUFA and MUFA (e.g., olive oil, vegetable oil, or blended oil (PUFA and Palm oil)). Oily fish (e.g., such as tuna, sardines, salmon, and mackerel) as a source of omega 3-fatty acids

•                Minimize saturated fat, including red meat (beef and lamb), ghee, and foods high in trans-fats (e.g., fast foods, cookies, some margarines).

* 1 Carbohydrate exchange = 15 g Carbohydrates; CVD, cardiovascular disease; MUFA, Monounsaturated fatty acids; PUFA, Polyunsaturated fatty acids

 Medical Management of Diabetes During Ramadan

Diabetes assessment and plan of care during and post Ramadan should ideally follow the flow chart shown in Figure 4 (6,29).

MEDICAL MANAGEMENT OF T1D DURING RAMADAN IN ADOLESCENTS AND YOUNG INDIVIDUALS

TID is treated with insulin replacement therapy. After the Pre-Ramadan risk stratification, adjustments are made to the patient’s dosing, timing, and type of insulin regime based on the patient’s risk level.

Insulin Regimens

There is no conclusive evidence supporting efficacy and safety of a particular insulin regime over another in adolescents with T1D who are fasting during Ramadan. The insulin regime is therefore based on affordability, access to treatment (medication, specialist and advanced technology), and cultural preferences (9).

 

Changing the insulin regime just before Ramdan is likely to result in dose errors and increase the risk of hypoglycemia. Hence, every effort should be made to continue the same regime, but with proper dose modifications and comprehensive counseling covering diet, lifestyle, physical activity, SMBG, and self-titration of insulin dose (10).

 

The most commonly used insulin regimens in adolescents are (9):

  1. Basal-bolus regimens –multiple dose injections (MDI) adjusted according to meal (preferred option)
  2. Conventional twice daily neutral protamine Hagedorn (NPH)/regular short acting (human) insulin
  3. Continuous subcutaneous insulin infusion (CSII) with or without sensors
  4. Premixed insulins (generally not recommended for T1DM)

 

Of these, MDI and CSII are closer to providing the physiological insulin secretion pattern.

Table 5 gives guidance on dose modifications of different insulin regimes.9 SMBG should be encouraged and the patients or their caregivers taught to self-titrate the insulin dose based on the BG levels (Table 6) (10).

 

Table 5. Insulin Dose Adjustments During Ramadan (10,35)

Insulin

Dose modification

Timing

Glucose monitoring

MDI (basal bolus) with analogue insulins

Basal insulin

30-40% dose reduction

Take at Iftar

5–7-point glucose monitoring*

MDI (basal bolus) with analogue insulins

RAI

Suhoor dose reduced 30-50%

Skip pre-lunch dose Iftar dose to be adjusted according to the 2hr post Iftar BG levels

Take at Iftar and Suhoor

5–7-point glucose monitoring*

MDI (basal bolus) with conventional insulins

NPH insulin

No dose modification at Iftar

50% dose reduction at Suhoor

Take at Iftar and Suhoor

5–7-point glucose monitoring or 2-3 staggered readings throughout the day*

MDI (basal bolus) with conventional insulins

Regular insulin

Suhoor dose reduced by 50%

Skip pre-lunch dose

Iftar dose unchanged unless needs to be adjusted according to the 2hr post Iftar BG levels

Take at Iftar and Suhoor

7-point glucose monitoring or 2-3 staggered readings throughout the day*

Premixed (analogue or conventional) once daily

No dose modification

Take at Iftar

At least 2-3 daily

Readings*

Premixed (analogue or conventional) twice daily

No dose modification at Iftar

50% dose reduction at Suhoor

Take at Iftar and Suhoor

At least 2-3 daily

Readings*

CSII / Insulin Pump

Basal rate adjustment

10-30% increase for the initial few hours of Iftar

20-40% decrease for the final 3-4 hours of fast

Bolus doses

Same ICR and ISF principles as followed prior to Ramadan

Reduce the dose post-Suhoor by 20%

CGM

* And whenever any symptoms of hypoglycemia/hyperglycemia develop or feeling unwell

ICR- Insulin Carbohydrate Ratio; ISF- Insulin Sensitivity Factor; RAI- rapid analogue insulin

 

Table 6. SMBG Guided Dose Titrations for Different Types of Insulin During Ramadan (10)

Fasting/pre-Iftar/pre-Suhoor blood glucose

Basal insulin

Short-acting insulin

Premixed insulin

pre-Iftar

pre-Iftar*/post-Suhoor**

pre-Iftar insulin modification

<70 mg/dL (3.9 mmol/L) or symptoms

Reduce by 4 units

Reduce by 4 units

Reduce by 4 units

<90 mg/dL (5.0 mmol/L)

Reduce by 2 units

Reduce by 2 units

Reduce by 2 units

90-126 mg/dL (5.0-7.0 mmol/L)

No change

No change

No change

>126 mg/dL (7.0 mmol/L)

Increase by 2 units

Increase by 2 units

Increase by 2 units

>200 mg/dL (16.7 mmol/L)

Increase by 4 units

Increase by 4 units

Increase by 4 units

*Reduce the insulin dose taken before Suhoor; **Reduce the insulin dose taken before Iftar

Recommendations for Insulin Regimes
  1. T1D management during Ramadan should be individualized according to patient’s need, preference, affordability, acceptability, and access to treatment (9).
  2. The basal-bolus regime is the preferred regime and consists of a long-acting insulin analogue (basal insulin) and a premeal rapid acting insulin analogue (bolus insulin) (9).
  3. Associated with a lower risk of hypoglycemia when compared to conventional, twice-daily, insulin regimens
  4. The bolus insulin dose should be dependent on the carbohydrate count of the meal. It should ideally be given 20 minutes before the meal for better post-prandial BG control.
  5. Boluses covering Suhoor and Iftar should be based on Insulin Carbohydrate Ratio (ICRs) and Insulin Sensitivity Factor (ISFs)

 

Approximately 70% of hypoglycemia occur during the last six hours of fasting. Hence, the type of basal insulin used, reduction in basal insulin dose and modification of insulin timing are the tools used to avoid hypoglycemia:

  • Ramadan fasting should be started with a reduction of basal insulin-starting with 20% and individualizing up to 40% as required
  • Basal insulin can be administered earlier in the day to minimize insulin exposure during the last few hours of fasting when BG levels are low.
  • Basal insulin can also be taken at Iftar or earlier in the evening
  • First-generation basal insulin analogues (such as glargine U-100) are more likely to cause hypoglycemia than the second generation, long-acting insulin analogues (glargine U-300 and degludec). However, the choice of insulin should be individualized based on risk of hypoglycemia.
  • Long-acting insulin analogues are preferred over intermediate acting (NPH/human insulin) as they provide a steady fall of BG towards normal levels by sunset time (9).
  • Twice daily regimens are more likely to be associated with hyperglycemia (9).
  • Twice daily regimens are usually not preferred during Ramadan, but if they are the only choice available to the patient, their timing and dose needs to be more closely monitored depending on the timing, portion size and carbohydrate content of meal (9).
  • Premixed twice daily insulin regimes are not recommended during Ramadan period as they require fixed carbohydrate intake at fixed timing, and this may be difficult for adolescents to follow (9).
  • There is emerging evidence that T1D patients can fast during Ramadan with fewer complications with the help of newer technologies such as insulin pump therapy, CGM and hybrid closed-loop systems (6).
  • CSII with insulin pumps in adolescents help achieve the targeted glycemic control with reduction in hyperglycemia and severe hypoglycemia, and provides more flexibility, improved quality of life and decreased risk of complications like diabetic ketoacidosis (9).
  • CSII allows for easier management of DM and reduces risk of complications than MDI (9)
  • The basal and bolus doses are adjusted through algorithms on the pump or through sensors and mobile applications (in more advanced versions)
  • Basal insulin is reduced by 20-35% in the last 4-5 hours before Iftar and increased by 10-30% after Iftar up to midnight
  • Prandial insulin bolus calculation is based on usual ICR and ISR
  • Bolus doses can be delivered in three different ways:
  • Standard dosing: Immediately before meals
  • Extended or square dosing: gradual dosing over a certain time period
  • Combo or dual wave bolus: combination of standard and extended
  • High fat content diet as seen during Iftar is likely to benefit from extended or combo bolus dosing (9).
  • Insulin pumps augmented with CGM provide better glycemic control and reduce complications considerably in adolescents with T1D. These sensor-augmented pumps are of two types (9):
  • Low Glucose Suspend (LGS) function pumps: The high-risk BG threshold for HE is pre-set in these pumps. The insulin administration can be automatically suspended for ≤2 hours when sensors detect BG levels below the pre-set threshold
  • Predictive Low Glucose Suspend (PLGS) pumps: Insulin administration is automatically suspended before BG reaches hypoglycemic levels (70 mg/dL [3.9 mmol/L]).
  • Automated insulin delivery (closed loop): These can suspend or increase insulin delivery based on sensor-based BG values. Thus, closed loops help increase time in range (TIR) and minimize hypoglycemia and hyperglycemia.
  • Types: Hybrid closed-loop automated insulin delivery systems; Do-It-Yourself Artificial Pancreas Systems (DIY APS)
  • However, CSII is a costly technology, has limited access in many countries, and therefore is not widely available due to cost and accessibility constraints (9).

MEDICAL MANAGEMENT OF ADULTS WITH T1D DURING RAMADAN  

Patients advised to self-monitor BG at 7-time-point points: when fasting; post-breakfast; pre-lunch; post-lunch; pre-dinner; post dinner; and midnight (9).

 

Dose adjustments for the different insulin regimes should start during the pre-Ramadan period and every attempt should be made to attain the desired glycemic goal but at low risk for hypoglycemia.

 

Short acting insulin analogues (glulisine, lispro, or aspart) are associated with less hypoglycemia and better improvement in postprandial glycemia than regular insulin. Premixed insulins are generally not preferred during Ramadan (9).

 

Table 5 provides guidance on dose modifications of different insulin regimes (9). SMBG should be encouraged and the patients taught to self-titrate the insulin dose based on the BG levels (Table 6) (10).

MEDICAL MANAGEMENT OF T2D DURING RAMADAN

Medical management of Ramadan in patients with T2D varies with wide variety of oral and injectable glucose lowering drugs (GLDs) used during Ramadan as shown in Table 9. Patients may be on one or more oral GLDs or a combination of oral and injectable GLDs.

 

Table 9. Different Types of Glucose Lowering Drugs Used by Patients with T2D During Ramadan (1,10)

Oral glucose lowering drugs

Injectable glucose lowering drugs

Sulfonylurea (gliclazide, glipizide, glimepiride, glibenclamide, or glyburide)

Long/intermediate basal insulins (insulin glargine, insulin detemir, insulin degludec or NPH)

 

Insulin: insulin pump, multiple daily injections, insulin lispro, insulin glargine, soluble human insulin, insulin detemir, and biphasic insulin

Biguanides (Metformin)

Bolus prandial rapid or short-acting insulins (lispro, glulisine, aspart or regular human insulin)

Thiazolidinediones (pioglitazone)

Premixed insulins (fixed ratio combinations of short and intermediate acting insulins)-usually not recommended during Ramadan

DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin)

GLP-1 RA (lixisenatide, exenatide, liraglutide, dulaglutide, semaglutide)

SGLT2-I (dapagliflozin, canagliflozin, empagliflozin, and ertugliflozin)

Alpha-glucosidase inhibitor (acarbose, voglibose)

Short-acting insulin secretagogues (repaglinide and nateglinide)

Oral GLP-1 RA (semaglutide)

 

  DPP-4, dipeptidyl peptidase 4; GLP-1 RA, Glucagon-like peptide-1 receptor agonists (GLP-1 RAs); NPH, neutral protamine Hagedorn; SGLT2-I, Sodium/glucose cotransporter-2 inhibitors

 

After the Pre-Ramadan risk stratification, adjustments are made to the patient’s GLDs. Some patients may need a change of medications too depending on their risk level. Preference is given to GLDs with better glycemic control and lower risk of hypoglycemia.

Oral Glucose Lowering Drug Adjustments During Ramadan
  • In general, non-sulfonylureas GLDs are superior in lowering hypoglycemia incidence than sulfonylureas (1).
  • Metformin is the most commonly used first line oral GLD, and has minimal risk of hypoglycemia (10).
  • Sulfonylureas are the most commonly used second line oral GLDs after metformin, especially in resource limited settings (10).
  • Short-acting insulin secretagogues can be useful GLDs during Ramadan because of their short duration of action and low risk of hypoglycemia (10).
  • DPP4 inhibitors are well tolerated during fasting and have a low hypoglycemia risk (10).
  • SGLT2 inhibitors are the newest class of oral GLDs used in T2D. They have demonstrated effective glycemic control during Ramadan even in patients with cardiovascular diseases/chronic kidney disease, and have low risk of hypoglycemia (10, 36).
  • An individual should be started on a SGLT2 inhibitor at least 2-4 weeks before Ramadan for the BG levels to stabilize during the fasting time.
  • Of the thiazolidinediones, only pioglitazone is widely approved for T2DM, has low hypoglycemia risk, but clinical data on its use during Ramadan is limited (10).

 

Table 10. Oral Glucose Lowering Drugs Used During Ramadan: Dose Modifications and Timing Adjustments in Individuals with Type 2 Diabetes (10)

Oral GLD

Dose modification

Timing

Metformin once daily

No dose modification

Take at Iftar

Metformin twice daily

No dose modification

Take at Iftar and Suhoor

Metformin thrice daily

No modification to morning dose. Afternoon dose to be combined with evening dose

Take morning dose before Suhoor and evening dose at Iftar

Prolonged release metformin

No dose modification

Take at Iftar

Sulfonylureas once daily

Reduce dose in patients with well controlled BG levels

Take at Iftar

Sulfonylureas twice daily

In patients with well controlled BG levels Iftar dose remains the same. Suhoor dose is reduced

Take at Iftar

Older sulfonylureas (e.g., glibenclamide)

Avoid and replace with 2nd generation SUs such as glicazide, glicazide MR, and glimepiride

Short-acting insulin secretagogues thrice daily dosing

Reduce or re-distribute to two doses

Take before Iftar and Suhoor

DPP4 inhibitor once daily

No dose modification

Take at Iftar

DPP4 inhibitor twice daily (vildagliptin)

No dose modification

Take at Iftar and Suhoor

SGLT2 inhibitors

No dose modification

Take at Iftar

Thiazolidinedione

No dose modification

Take at Iftar

  BG, blood glucose; DPP-4, dipeptidyl peptidase 4; MR, modified release; SGLT2-I, Sodium/glucose cotransporter-2 inhibitors; SU, sulfonylurea

Injectable Glucose Lowering Drug Adjustments During Ramadan
  • Most patients with long-standing T2D eventually need insulin to manage their BG levels. Various insulin regimes are used in T2D (table 9) (1, 10) and in general, the use of insulin increases the risk of hypoglycemia during Ramadan.
  • Insulin can be given as single daily injection, MDI or as CSII through insulin pumps. The insulin regime is therefore based on affordability, access to treatment (medication, specialist and advanced technology), and cultural preferences (9).
  • Changing the insulin regime just before Ramdan is likely to result in dose errors and increase risk of hypoglycemia. Hence, every effort should be made to continue the same regime, but with proper dose modifications and comprehensive counseling covering diet, lifestyle, physical activity, SMBG, and self-titration of insulin dose (10).
  • Table 5 shows the various insulins and how their doses and timing are adjusted during Ramadan.
  • SMBG guided dose titrations for different insulin types are shown in Table 6.
  • GLP-1 RAs can be safely used with other GLDs including metformin and insulin. They have low hypoglycemia risk, but the risk could be higher if given with insulin or sulfonylureas. However, dose needs to be titrated at least 2-4 weeks prior to Ramadan (10).
Individuals on Multiple Antidiabetic Therapy

Individuals on multiple GLDs are at higher risk of hypoglycemia during Ramadan (18). The risk of hypoglycemia is highest if they are on ≥4 GLDs or on a combination of metformin, DPP4I and basal insulin (37).

 

In individuals on multiple GLDs, the risk of hypoglycemia is dependent on several factors such as type and number of GLDs, duration of diabetes, pre-Ramadan glycemic control, renal function, and presence of other comorbidities (10).

 

Individuals on ≥3 GLDs who are fasting during Ramadan should receive comprehensive counseling and advice before the start of Ramadan, and it should cover diet, lifestyle, physical activity, SMBG, and dose and time modifications of GLDs (10).

 

Individuals on a combination of insulin and SUs are at highest risk of hypoglycemia and require a dose reduction GLDs (approximately 25-50% reduction in insulin dose) during Ramadan.

 

Flash glucose monitoring, CGM, activity monitoring, risk stratification, dose adjustments, and use of artificial intelligence-based algorithms that cover one or more of these aspects are the various tools that are likely to help high-risk patients with T2D fast with fewer hypoglycemia and hyperglycemia related complications (6, 10).

MANAGEMENT OF DIABETES IN SPECIAL POPUATIONS DURING RAMADAN

As discussed, individuals who are considered high risk for fasting during Ramadan need special pre-Ramadan risk stratification, counseling, dose modification, and need to follow strict SMBG during Ramadan, and those on insulin should be capable of self-titrating their insulin dose based on their BG values.

 

This is especially true for special population considered high risk due to a high probability of harm caused by fasting during Ramadan (5). This special population of high-risk individuals with diabetes includes pregnant women, elderly, and people with CVD or CKD. All these individuals are usually advised not to fast, but many do decide to fast against medical advice (5).

Management of Diabetes/Gestational Diabetes During Ramadan

Even in healthy pregnant women, fasting during Ramadan results in biochemical changes that almost mimic the effects of prolonged fasting (35). Ramadan fasting results in an increase in triglycerides (TG), free fatty acids (FFA), and ketones in healthy pregnant women along with a decrease in glucose and insulin (35). However, data on physiological and biochemical changes caused by fasting during Ramadan in pregnant women with diabetes is largely lacking.

 

Pregnancy is an exemption from fasting. However, many pregnant women choose to fast during Ramadan. A detailed discussion regarding the potential risks of fasting must be held with them.

While healthy pregnant women can generally fast safely with no maternal or fetal risk, those with hyperglycemia need to strictly monitor their BG levels to prevent hyperglycemia, hypoglycemia, and adverse maternal and fetal outcomes (35).

 

  • Pre-Ramadan assessment should begin months before Ramadan, and apart from risk stratification, should focus on breaking general myths like ‘finger-prick testing for BG levels breaks their fast’, encourage SMBG, and educate about the maternal and fetal risks of both hypoglycemia and hyperglycemia (35).
  • Pregnant women with diabetes should maintain normal physical activity while fasting. The Taraweeh prayer they offer should be considered as exercise for which insulin doses should be adjusted as required (35).
  • Fiber rich food and drinking 2-3 liters of water a day should be encouraged. Suhoor should be taken as late as possible (35).
  • Insulin and/or metformin are the treatment of choice in pregnancy with diabetes. Though glibenclamide is also used in some patients, its use should be discouraged during Ramadan. Some women with gestational diabetes may be managed on diet and/or metformin too.
  • The metformin dose may not need any change during pregnancy but the dose of insulin should be modified as discussed in Table 5 (10, 35). Insulin dose titration should be guided by SMBG as shown in Table 6.
  • SMBG should be carried out as guided in Figure 6. Pregnant women with diabetes should strictly monitor and maintain their BG levels as follows (35):
  • Fasting between 70-95 mg/dL (3.9 – 5.3 mmol/L).
  • Post-prandial < 120 mg/dL (6.7 mmol/L).
  • Pregnant women with diabetes should break their fast if (35):
  • BG levels < 70 mg/dL (3.9 mmol/L) during fasting hours.
  • Feel unwell.
  • Feel reduced fetal movement.
  • Pregnant women with diabetes should carry out regular SMBG at the following time points (35):
  • Before the sunset meal.
  • 1-2 hours after meals
  • Once during the day while fasting, particularly in the afternoon.
  • Anytime they feel unwell.
Management of Diabetes in Elderly with Diabetes Fasting During Ramadan

Older age (≥ 65 years) by itself can be considered a high risk for fasting during Ramadan in individuals with diabetes, even though many elderly fast successfully during Ramadan (38). Older individuals with diabetes are less likely to fast than younger ones (DAR 2020 survey: 71.2% of ≥ 65 years intended to fast compared to 87.3% of those < 65 years) (39). However, fasting during Ramadan being a personal choice, many older adults with diabetes do choose to fast during Ramadan. The DAR Global Survey (2020) also showed that the elderly were more motivated to fast with 69% of those aged ≥ 65 years fasting for 30 days compared to 60% of those < 65 years (39).

 

Elderly (≥ 65 years) with diabetes were significantly more likely to break their fast than younger (<65 years) individuals with diabetes (17% vs. 11.5%; P<0.001) (39). Similarly, they were significantly more likely to break their fast due to hypoglycemia than their younger counterparts (67.7% vs.55.4%; P=0.02).

 

Fasting during Ramadan in elderly with diabetes needs special consideration and attention because:

  • Diabetes related complications are higher in elderly and they need careful BG monitoring and GLD dose adjustments, which should be started well before Ramadan (38).
  • Fasting related complications likely to be seen in elderly with diabetes can be due to both hyperglycemia and hypoglycemia, and also include impaired renal function, impaired postural balance, poor attention, and volume depletion. The risk increases with the number of days fasted (38).
  • The DAR 2020 survey showed that hypoglycemia was significantly higher in elderly as compared to younger population (17.4% vs.15.2%; P<0.001) (39).
  • 9% of those aged ≥ 65 visited the emergency department compared to 4.3% of individuals aged < 65
  • Elderly were also more likely to get hospitalized due to hypoglycemia
  • While 31.5% reduced their GLD dosing, 17% made no change to their medication dose
  • The use of SUs and insulin increases risk of hypoglycemia. 32.7% of elderly need insulin, probably due to long standing diabetes.
  • The DAR 2020 survey also showed that significantly greater number of elderly with diabetes who are fasting had hyperglycemia (BG levels > 16.6 mmol/L or 300 mg/dL) during Ramadan (19.3% vs. 15.6%; P=0.006) (39). 8.4% of the elderly had to attend the emergency department due to hyperglycemia related complications.
  • The DAR 2020 survey showed that the majority (80%) do not break their fast even if they have hyperglycemia, and 20% do not change their behavior (food intake, medication change), 25% reduced their food intake, and 21% increased their medication dose (39).
  • In the DAR 2020 Global Survey, 21% of participants with T2DM aged ≥ 65 years checked their BG levels once or less than once a week. Only around 10% checked their BG levels 3–4 times a day. There was no change in SMBG behavior during Ramadan (39).
  • Research on elderly fasting during Ramadan is largely lacking.38 Landmark trials in Ramadan like the EPIDIAR study which was used to formulate many recommendations for individuals with diabetes fasting during Ramadan, did not include the elderly.7
  • The elderly population is growing fast, and therefore there will be more individuals with diabetes who are ≥ 65 years and intend to fast (40)
  • The risk of fasting is much higher in elderly than in younger population with diabetes (38). This is because the elderly have more comorbidities (hypertension, hyperlipidemia, CVDs, CKD etc.) than the younger population (38, 39).
  • Elderly with diabetes and impaired renal functions, CVD, dementia, frailty, and/or those with risk of falls are at higher risk for complications during fasting than elderly without comorbidities (38). Therefore, risk stratification of elderly with diabetes who decide to fast during Ramadan should be based not only on age, but also on their comorbidities, functional capacity, and ability to manage medications and carry out SMBG, cognition, and social circumstances (38).

 

Hence, the elderly with diabetes are a high-risk category for fasting during Ramadan. They need proper Pre-Ramadan risk stratification, education, and support to ensure that they can fast safely with proper SMBG and medication monitoring.

 

Table 11 covers the basic recommendations for elderly who intend to fast during Ramadan.

 

Table 11. Basic Recommendations for Elderly who Intend to Fast During Ramadan

MEDICATIONS AND REGIMENS

•                Choose medications that have a lower hypoglycemia risk

•                 Make dose adjustments to lower the risk of hypoglycemia

•                 For individuals on SUs, gliclazide and glimepiride should be used instead of glibenclamide

•       SGLT2 inhibitors doses should be reviewed for benefit vs risks of adverse events especially in elderly with impaired renal function or those on diuretics

•       Insulin: dose titration based on SMBG should be taught and dose modifications carried out based on the insulin type

SMBG

•                 Increase frequency to a 5-point time scale

•                 Use CGM if available and feasible

DIET AND PHYSICAL ACTIVITY

•                 Individualized diet and activity plan

•                 Started before Ramadan and adhere during fasting days

•                 Medication doses and timings adjusted according to diet and physical activity level

•                 Adequate nutrition should be stressed and education provided

•                 Hydration ensured through proper planning

SOCIAL SUPPORT

Given that elderly may have cognition, memory, and physical deficits, adequate support should be ensured pre-Ramadan to ensure SMBG, adherence to diet and physical activity plan, insulin dose titration, and oral GLD dose modification

AWARENESS OF RISK OF COMPLICATIONS

•                 Discuss and document symptoms and events to increase awareness and recognition of complications

•                 Both patient and caregiver should be educated to recognize the symptoms of complications

  CGM, continuous glucose monitoring; GLD, glucose lowering drugs; SMBG, self-monitoring of blood glucose

Other Concerns Regarding Management of Diabetes During Ramadan

MANAGEMENT OF COMORBID HYPOTHYROIDISM

Hypothyroidism is commonly seen in patients with diabetes. Usually, thyroxine is taken half an hour before breakfast. However, during Ramadan, the breakfast time is shifted to pre-dawn. This is a time of rush and individuals may find it difficult to time the thyroxine dose half an hour before Suhoor. Similarly, if thyroxine is pushed to evening, then taking it half an hour before Iftar is usually difficult as usually this meal is taken with rest of the family and by Iftar time hunger score is high. Hence, thyroxine may be taken late (after a 4-hour gap) at night as long as no heavy meal is taken between Iftar and late night (12).

BARIATRIC SURGERY

Diabesity (co-existing diabetes and obesity) is of pandemic proportions across the world (4). Bariatric surgery is commonly performed in individuals with diabesity. Bariatric surgery poses certain concerns regarding fasting during Ramadan as these individuals cannot consume large meals and therefore absorb certain macronutrients (12).

GAPS AND WAY FORWARD

The last few decades have contributed immensely to the growing knowledge and clinical experience of health care providers regarding the clinical and metabolic complications of fasting, pre-fasting assessment, risk stratification and initiation of changes in medication dose and timing and dietary/lifestyle modifications during Ramadan (1). However, greater efforts are required to improve communication between the medical experts and religious scholars in order to ensure that medical guidance regarding safe fasting during Ramadan is best received by the public (30). Further well-designed clinical trials are required to assess the best treatment options for adolescents and adults with diabetes who fast during Ramadan. Artificial intelligence, use of RNP and other such tools need to be integrated to ensure safe fasting during Ramadan.

 ACKNOWLEDGEMENTS

All named authors for this manuscript meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship. All authors take full responsibility for the integrity of the work and have given final approval for the published version. The authors acknowledge Dr. Kokil Mathur and Dr. Punit Srivastava from Mediception Science Pvt. Ltd, Gurgaon, India for providing writing and editing assistance.

REFERENCES  

  1. Abdelrahim D, Faris ME, Hassanein M, et al. Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies. Frontiers in Endocrinology. 2021;12. Accessed March 2, 2022. https://www.frontiersin.org/article/10.3389/fendo.2021.624423
  2. IDF-DAR Practical Guidelines. DAR practical guidelines for healthcare professionals. Published 2021. Accessed March 2, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  3. Jabbar A, Malek R, Hussein Z. Chapter 2. Epidemiology of diabetes and fasting during Ramadan. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  4. Kapoor N, Sahay R, Kalra S, et al. Consensus on Medical Nutrition Therapy for Diabesity (CoMeND) in Adults: A South Asian Perspective. Diabetes Metab Syndr Obes. 2021;14:1703-1728. doi:10.2147/DMSO.S278928
  5. Bennakhi A, Buyukbese MA, Al Saleh Y, Almadani AA, Eliana F. Chapter 1. Introduction to the IDF-DAR ractical Guidelines. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  6. Ahmed SH, Chowdhury TA, Hussain S, et al. Ramadan and Diabetes: A Narrative Review and Practice Update. Diabetes Ther. 2020;11(11):2477-2520. doi:10.1007/s13300-020-00886-y
  7. Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27(10):2306-2311. doi:10.2337/diacare.27.10.2306
  8. Babineaux SM, Toaima D, Boye KS, et al. Multi-country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED). Diabet Med. 2015;32(6):819-828. doi:10.1111/dme.12685
  9. Wan Bebakar WM, Wan Mohamad RM, Hafidh K, et al. Chapter 9. Management of Type 1 diabetes when fasting during Ramadan. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  10. Hanif W, Hassanein M, Elhadd TA, Mohamed NA. Chapter 10. Management of Type 2 diabetes when fasting during Ramadan. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  11. Lessan N, Ali T. Energy Metabolism and Intermittent Fasting: The Ramadan Perspective. Nutrients. 2019;11(5):E1192. doi:10.3390/nu11051192
  12. Lessan N, Ezzat Faris M, Assaad-Khalil SH, Ali T. Chapter 3. What happens to the body? Physiology of fasting during Ramadan. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  13. Lessan N, Hannoun Z, Hasan H, Barakat MT. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: insights from continuous glucose monitoring (CGM). Diabetes Metab. 2015;41(1):28-36. doi:10.1016/j.diabet.2014.11.004
  14. Al-Rawi N, Madkour M, Jahrami H, et al. Effect of diurnal intermittent fasting during Ramadan on ghrelin, leptin, melatonin, and cortisol levels among overweight and obese subjects: A prospective observational study. PLoS One. 2020;15(8):e0237922. doi:10.1371/journal.pone.0237922
  15. Hassanein M, Al Awadi FF, El Hadidy KES, et al. The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM). Diabetes Res Clin Pract. 2019;151:275-284. doi:10.1016/j.diabres.2019.02.020
  16. Basit A, AlOzairi E, Abdelgadir E. Chapter 4. The effects of fasting during Ramadan on physical and mental wellbeing. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  17. Husain R, Duncan MT, Cheah SH, Ch’ng SL. Effects of fasting in Ramadan on tropical Asiatic Moslems. Br J Nutr. 1987;58(1):41-48. doi:10.1079/bjn19870067
  18. Jabbar A, Hassanein M, Beshyah SA, Boye KS, Yu M, Babineaux SM. CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents. Diabetes Res Clin Pract. 2017;132:19-26. doi:10.1016/j.diabres.2017.07.014
  19. Ba-Essa EM, Hassanein M, Abdulrhman S, Alkhalifa M, Alsafar Z. Attitude and safety of patients with diabetes observing the Ramadan fast. Diabetes Res Clin Pract. 2019;152:177-182. doi:10.1016/j.diabres.2019.03.031
  20. Mattoo V, Milicevic Z, Malone JK, et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract. 2003;59(2):137-143. doi:10.1016/s0168-8227(02)00202-4
  21. Cesur M, Corapcioglu D, Gursoy A, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract. 2007;75(2):141-147. doi:10.1016/j.diabres.2006.05.012
  22. Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol. 2009;46(1):63-65. doi:10.1007/s00592-008-0062-7
  23. Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27(7):1367-1374. doi:10.1185/03007995.2011.579951
  24. Bashier A, Bin Hussain A, MK A. Safety and Efficacy of Liraglutide as an Add-On Therapy to Pre-Existing Anti-Diabetic Regimens during Ramadan, A Prospective Observational Trial. Journal of Diabetes & Metabolism. 2015;06. doi:10.4172/2155-6156.1000590
  25. Hassanein M, Echtay A, Hassoun A, et al. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). Int J Clin Pract. 2017;71(10). doi:10.1111/ijcp.12991
  26. Aldawi N, Darwiche G, Abusnana S, Elbagir M, Elgzyri T. Initial increase in glucose variability during Ramadan fasting in non-insulin-treated patients with diabetes type 2 using continuous glucose monitoring. Libyan J Med. 2019;14(1):1535747. doi:10.1080/19932820.2018.1535747
  27. Alawadi F, Mohammed K. Bashier A, Rashid F, Chowdhury TA. Chapter 13. Risks of fasting during Ramadan: Cardiovascular, Cerebrovascular and Renal complications. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  28. Jawad F, Kalra S. Ramadan and diabetes management - The 5 R’s. J Pak Med Assoc. 2015;65(5 Suppl 1):S79-80.
  29. Ahmedani MY, Zainudin SB, AlOzairi E. Chapter 7. Pre-Ramadan Assessment and Education. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  30. El Sayed AA, Hassanein M, Afandi B, Tayeb K, Diop SN. Chapter 6. Diabetes and Ramadan: A Medico-Religious Perspective. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  31. Hassanein M, Al-Arouj M, Hamdy O, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017;126:303-316. doi:10.1016/j.diabres.2017.03.003
  32. Hamdy O, Mohd Yusof BN, Maher S. Chapter 8. The Ramadan Nutrition Plan (RNP) for people with diabetes. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  33. Ahmed WN, Arun CS, Koshy TG, et al. Management of diabetes during fasting and COVID-19 – Challenges and solutions. Journal of Family Medicine and Primary Care. 2020;9(8):3797-3806. doi:10.4103/jfmpc.jfmpc_845_20
  34. Mohd Yusof BN, Wan Zukiman WZHH, Abu Zaid Z, et al. Comparison of Structured Nutrition Therapy for Ramadan with Standard Care in Type 2 Diabetes Patients. Nutrients. 2020;12(3):813. doi:10.3390/nu12030813
  35. Afandi B, Hassanein M, Taha Salih B, Abdo S. Chapter 11. Management of hyperglycaemia in pregnancy when fasting during Ramadan. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  36. Bajaj HS, Abouhassan T, Ahsan MR, et al. Diabetes Canada Position Statement for People With Types 1 and 2 Diabetes Who Fast During Ramadan. Can J Diabetes. 2019;43(1):3-12. doi:10.1016/j.jcjd.2018.04.007
  37. Elhadd T, Dabbous Z, Bashir M, et al. Incidence of hypoglycaemia in patients with type-2 diabetes taking multiple glucose lowering therapies during Ramadan: the PROFAST Ramadan Study. J Diabetes Metab Disord. 2018;17(2):309-314. doi:10.1007/s40200-018-0374-2
  38. Shaltout I, Mohamed M, Iraqi H. Chapter 12. Management of diabetes among the elderly when fasting during Ramadan. In: International Diabetes Federation and DAR International Alliance. Diabetes and Ramadan: Practical Guidelines. International Diabetes Federation and DAR International Alliance; 2021. Accessed March 4, 2022. https://www.idf.org/our-activities/education/diabetes-and-ramadan/healthcare-professionals.html
  39. Hassanein M, Hussein Z, Shaltout I, et al. The DAR 2020 Global survey: Ramadan fasting during COVID 19 pandemic and the impact of older age on fasting among adults with Type 2 diabetes. Diabetes Res Clin Pract. 2021;173:108674. doi:10.1016/j.diabres.2021.108674
  40. IDF. IDF Diabetes Atlas 2021. International Diabetes Federation; 2021. Accessed March 11, 2022. https://diabetesatlas.org/atlas/tenth-edition/

 

Guidelines for the Management of High Blood Cholesterol

ABSTRACT

 

The LDL-C hypothesis holds that high blood LDL-C levels are a major risk factor for atherosclerosis cardiovascular disease (ASCVD) and lowering LDL-C levels will reduce the risk for ASCVD. This hypothesis is based on epidemiological evidence that both within and between populations higher LDL-C levels increase the risk for ASCVD, and conversely, randomized clinical trials (RCTs) demonstrating that lowering LDL-C levels will reduce ASCVD risk. LDL-C levels can be reduced by both lifestyle interventions and cholesterol-lowering drugs. Widely used LDL-C lowering drugs are statins, ezetimibe, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In this chapter we discuss the information provided in the two major guidelines on how to select and treat patients to lower LDL-C levels; the 2018 AHA/ACC/Multi-Society report and the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and representatives from other European organizations guidelines published in 2020. Additionally, we discuss the key principles that clinicians should utilize when deciding who to treat and how aggressively to treat hypercholesterolemia to lower the risk of ASCVD. Specifically, 1) the sooner one initiates LDL-C lowering therapy the greater the benefit, 2) the greater the decrease in LDL-C the greater the benefit, 3) the higher the LDL-C level the greater the benefit, and 4) the higher the absolute risk of ASCVD the greater the benefit. Following these general principles will help clinicians make informed decisions in deciding on their approach to lowering LDL-C levels and will facilitate discussions with patients on the benefits and risks of treatment. These decisions need to balance the benefits of treatment vs. the potential side effects and cost and the preferences of individual patients.

 

INTRODUCTION

 

Atherosclerotic cardiovascular disease (ASCVD) remains the foremost cause of death among chronic diseases. An aging population combined with an atherogenic lifestyle increases the risk of ASCVD. Even so, mortality from ASCVD has been declining in most developed countries. This decline comes from improvements in preventive measures and better clinical interventions. One of the most important advances in the cardiovascular field resulted from identifying risk factors for ASCVD. Risk factors directly or indirectly promote atherosclerosis, or they otherwise predispose to vascular events. The major risk factors are cigarette smoking, dyslipidemia, hypertension, hyperglycemia, and advancing age. Dyslipidemia consists of elevations of atherogenic lipoproteins (LDL, VLDL, Lp(a), and remnants) and low levels of HDL. Advancing age counts as a risk factor because it reflects the impact of all risk factors over the lifespan. Several other factors, called risk enhancing factors, associate with higher risk for ASCVD (1). Lifestyle factors (for example, overnutrition and physical inactivity) contribute importantly to both major and enhancing risk factors. Hereditary factors undoubtedly contribute to the identifiable risk factors; but genetic influences also affect ASCVD risk through other ways not yet understood (2).

 

THE CHOLESTEROL HYPOTHESIS AND CHOLESTEROL LOWERING THERAPY  

 

There is now indisputable evidence that elevated serum cholesterol levels increase the risk of ASCVD. The first evidence for a connection between serum cholesterol levels and atherosclerosis came from studies in laboratory animals (3). Feeding cholesterol to various animal species raises serum cholesterol and causes deposition of cholesterol in the arterial wall (3). The latter recapitulates the early stages of human atherosclerosis. Subsequently, in humans, severe hereditary hypercholesterolemia was observed to cause premature atherosclerosis and ASCVD (3).  Later, population surveys uncovered a positive association between serum cholesterol levels and ASCVD (4,5).  Finally, clinical trials with cholesterol-lowering agents documented that lowering serum cholesterol levels reduces the risk for ASCVD (6). These findings have convincing proven the cholesterol hypothesis. Moreover, the relationship between cholesterol levels and ASCVD risk is bidirectional; raising cholesterol levels increases risk, whereas reducing levels decreases risk (Figure 1).

 

Figure 1. The Cholesterol Hypothesis. Between the years 1955 and 1985, many epidemiologic studies showed a positive relation between cholesterol levels and atherosclerotic cardiovascular disease (ASCVD) events. Over the next 30 years, a host of randomized controlled clinical trials have demonstrated that lowering cholesterol levels will reduce the risk for ASCVD. This bidirectional relationship between cholesterol levels and ASCVD provides ample support for the cholesterol hypothesis.

 

Epidemiological Evidence

 

A relationship between cholesterol levels and ASCVD risk is observed in both developing and developed countries (4,5). Populations with the lowest cholesterol levels and LDL-C levels have the lowest rates of ASCVD. Within populations, individuals with the lowest serum cholesterol or LDL-C levels carry the least risk. In other words, “the lower, the better” for cholesterol levels holds, both between populations and for individuals within specific populations.

 

Pre-Statin Clinical Trial Evidence

 

Several earlier randomized controlled trials (RCTs) tested whether reducing cholesterol levels through diet, bile acid sequestrants, or ileal exclusion operation reduced ASCVD events. A summary of the results of these trials is shown in table 1 (4).

 

Table 1. Summary of Pre-Statin Clinical Trials of Cholesterol-Lowering Therapy

Intervention

No. trials

No. treated

Person-years

Mean cholesterol reduction (%)

CHD incidence

(% change)

CHD Mortality

(%change)

Surgery

1

421

4,084

22

-43

-30

Sequestrants

3

1,992

14,491

9

-21

-32

Diet

6

1,200

6,356

11

-24

-21

This table is derived from National Cholesterol Education Program Adult Treatment Panel III (4)

 

Statins and Clinical Trial Evidence

 

Statins were discovered in the 1970s by Endo of Japan (7). Seven statins have been approved for use in clinical practice by the FDA and they are now generic (for a detailed discussion of statins see the Endotext chapter on Cholesterol Lowering Drugs (8)). Statins inhibit HMG-CoA reductase decreasing cholesterol synthesis and increasing hepatic LDL receptors resulting in a decrease in LDL-C levels. Over the past three decades, a series of RCTs have been carried out that documents the efficacy and safety of statin therapy. In these RCTs, statin therapy has been shown to significantly reduce morbidity and mortality from ASCVD. Although individual RCTs produced significant results, the strongest evidence of benefit comes from meta-analysis. i.e., by combining data from all the trials (6). 

 Meta-analysis has shown that for every mmol/L (39 mg/dL) reduction in LDL-C with statin therapy there is an approximate 22% reduction in ASCVD events (6,9-12). Another report (13) showed that an almost identical relationship holds when several different kinds of LDL-lowering therapy were analyzed together. This response appears to be consistent throughout all levels of LDL-C.  Individual statins vary in their intensity of cholesterol-lowering at a given dose (1,8) (Table 2).  For example, per mg per day, rosuvastatin is twice as efficacious as atorvastatin, which in turn is twice as efficacious as simvastatin. Statins are best classified according to percentage reductions in LDL-C.  As shown in Table 2, moderate- intensity statins reduce LDL-C by 30-49 %, whereas high-intensity statins reduce LDL-C by > 50%.  Absolute reductions vary depending on baseline levels of LDL-C. For example, for a baseline LDL-C of 200 mg/dL, a 50% reduction in LDL-C equates to a 100 mg/dL (2.6 mmol/L) decline; this translates into a 59% reduction in 10-year risk for ASCVD events. In contrast, in a patient with a baseline LDL-C of 100 mg/dL, a 50% reduction in LDL-C equates to a 50 mg/dL (1.3 mmol/L) decline, which will reduce ASCVD risk by about 30%. Thus, at lower and lower levels of LDL-C, progressive reductions of LDL-C produce diminishing benefit from cholesterol-lowering therapy. This modifies the aphorism "lower is better".  Whereas the statement is true, it must be kept in mind that there are diminishing benefits from intensifying cholesterol-lowering therapy when LDL-C levels are already very low. One needs to balance the benefits of further reducing LDL-C levels with the side effects and costs of additional therapy. 

Table 2.  Categories of Intensities of Statins

Drug

Low-Intensity

20-25% LDL-C

Moderate-Intensity

30-49% LDL-C

High Intensity

>50% LDL-C

Lovastatin

10-20 mg

40-80 mg

 

Pravastatin

10-20 mg

40-80 mg

 

Simvastatin

10 mg

20-40 mg

 

Fluvastatin

20-40 mg

80 mg

 

Pitavastatin

 

1-4 mg

 

Atorvastatin

5 mg

10-20 mg

40-80 mg

Rosuvastatin

 

5-10 mg

20-40 mg

 

Non-Statin Cholesterol-Lowering Drugs

 

Other agents are currently available that lower LDL-C levels. Bile acid sequestrants inhibit intestinal absorption of bile acids, which like statins raise hepatic LDL receptors (8). They are moderately efficacious for reducing LDL-C concentrations. A large RCT showed that bile acid sequestrants significantly reduce risk for CHD in patients with baseline elevations in LDL-C (14). Theoretically, bile acid sequestrants could enhance risk reduction in patients with ASCVD who are treated with statins.

 

Ezetimibe blocks cholesterol absorption in the intestine and also raises hepatic LDL receptor activity (8). It moderately lowers LDL-C (15-25%). The combination of statin + ezetimibe is additive for LDL-C lowering (15).  A clinical trial (16)demonstrated that adding ezetimibe to moderate intensity statins in very high-risk patients with ASCVD is beneficial showing that combination therapy reduced risk of cardiovascular events more than a statin alone (16). In this trial, the higher the risk, the greater was risk reduction (17). Ezetimibe is a generic drug and relatively inexpensive.

 

Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of LDL receptors and raises LDL-C levels (8).  Inhibition of PCSK9 increases the number of hepatic LDL receptors and markedly lowers LDL-C concentrations (50-60% decrease) (8,18).  Studies have shown that PCSK9 inhibitors reduce risk in ASCVD patients at very high risk when combined with statins (19,20). PCSK9 inhibitors are relatively expensive drugs.  

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor and thereby inhibits cholesterol synthesis leading to an increase in LDL receptor activity (8,21). Bempedoic acid typically lowers LDL-C by 15-25% (8,21). A RCT has demonstrated that bempedoic acid reduces ASCVD in statin intolerant patients (22). Bempedoic acid is not generic and therefore is relatively expensive.

 

For additional information on cholesterol and triglyceride lowering drugs see the chapters in Endotext that address these topics (8,23).

 

PRIOR U.S. GUIDELINES FOR CHOLESTEROL MANAGEMENT

 

National Cholesterol Education Program (NCEP)

 

The early guidelines for cholesterol management in the United States have been those developed by the NECP. This program was sponsored by the National Heart, Lung and Blood Institute (NHLBI) and included many health-related organizations in the United States (24).  Between 1987 and 2004, three major Adult Treatment Panel (ATP) reports (4,25,26) and one update were published (27) (Table 3). Over time the guidelines recommended more stringent LDL-C goals as the results of RCTs were published and added non-HDL-C levels as a goal.

 

Table 3. National Cholesterol Education Program’s Adult Treatment Panel (ATP) Reports

Guideline

ATP I

ATP II

ATP III

ATP III Update

Year

1987

1994

2001

2004

Thrust

Primary prevention

Secondary prevention

High-risk primary prevention

Very high risk

Drugs

Bile acid resins Nicotinic acid Fibrates

Same as ATPI   +Statins

Same as ATP II

 

Same as ATP III

Major Targets

LDL-C; HDL-C

LDL-C; HDL-C

LDL-C;                Non-HDL-C

LDL-C;         Non-HDL-C

LDL-C goal

     (mg/dL)

Low risk <190 Moderate risk <160              High risk < 130

Low risk   <160 Moderate risk <130             High risk <100

Low risk <160 Moderate risk <130          Moderately high risk <130    

High risk < 100

Low risk <160 Moderate risk <130

Moderately high    risk <130      High risk < 100   Very high risk < 70

 

Transfer of NHLBI Guidelines to American Heart Association (AHA) and the American College of Cardiology (ACC)

 

In 2013, NHLBI made the decision to remove treatment guidelines from its agenda. This was done even though it had almost finished writing prevention guidelines. These included guidelines for high blood cholesterol, high blood pressure, obesity, and nutrition. Late in this process, the guideline process was transferred to the American Heart Association (AHA) and American College of Cardiology (ACC). Then in 2013 the NHLBI guidelines for high blood cholesterol were modified to fit the criteria for guideline development required by AHA/ACC. The 2013 cholesterol guidelines (28) adhered closely to the Institute of Medicine (National Academy of Medicine) recommendations for evidence-based guidelines (29). These recommendations advocated priority to randomized controlled trials (RCTs) as the foundation of evidence-based medicine. The NHLBI cholesterol committee carried out an extensive review of the literature and limited recommendations based largely on RCTs. Most acceptable RCTs had utilized statin therapy in middle-aged people. Therefore, the 2013 report committee did not include detailed recommendations for younger or older adults. Recommendations were largely limited to the age range 40-75 years. High-intensity statin therapy was recommended for patients with established ASCVD. For primary prevention, risk was stratified by use of a pool cohort equation (PCE), which was derived from five large population studies in the United States (30). The PCE was an extension of the Framingham Heart Study risk equations. 10-year risk for ASCVD was based on the following risk factors: age, gender, cigarette smoking, blood pressure, total cholesterol, HDL cholesterol, and presence or absence of diabetes. Although the PCE was validated in another large study (31), it has been criticized by some investigators as being imprecise for many individuals or specific groups (32-36).

 

For primary prevention, an effort was made to determine what level 10-year risk is associated with efficacy of reduction of ASCVD from statin RCTs.  It was determined that statins are effective for risk reduction when 10-year risk for ASCVD is > 7.5%.  Most primary prevention trials employed moderate intensity statins, so these were recommended for most patients; but in one RCT (37), a high-intensity statin appeared to produce greater risk reduction than found with moderate-intensity statins. So high-intensity statins were considered a favorable option in patients at higher 10-year risk. Notably LDL-C goals were not emphasized. It was recognized that these recommendations may not be optimal for all patients; therefore, consideration should be given to any extenuating circumstances that could modify the translation of RCTs directly into clinical care. A clinician patient risk discussion thus was advocated for all patients to consider the pros and cons of statin therapy.

 

There are many guidelines discussing the management of LDL-C, but the 2 major guidelines are the 2018 AHA/ACC/Multi-Society report (1) and the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and representatives from other European organizations guidelines published in 2020 (38). In this chapter these two guidelines will be discussed.

 

2018 AHA/ACC/MULTI-SOCIETY REPORT

 

2013 cholesterol guidelines were revised by AHA/ACC in collaboration with multiple other societies concerned with preventive medicine (1). These guidelines extended those published in 2013. They expanded recommendations to include children, adolescents, young adults (20-39 years), and older patients (> 75 years). Although RCTs may be lacking in these categories, epidemiology and clinical studies indicate that high blood cholesterol is an important risk factor for future ASCVD in these age ranges. From the evidence acquired over many years related to the cholesterol hypothesis, it is reasonable to craft recommendations based on the totality of the evidence. These guidelines proposed a top 10 list of recommendations to highlight the key points. These key points will be examined.

 

Lifestyle Intervention

 

  • In all individuals emphasize a heart healthy lifestyle across the life-course.

 

There is widespread agreement in the cardiovascular field that lifestyle factors contribute to the risk for ASCVD. These factors include cigarette smoking, sedentary life habits, obesity, and an unhealthy eating pattern. The ACC/AHA strongly recommends that a healthy lifestyle be adopted throughout life. These recommendations are strongly supported by 2018 cholesterol guidelines. They are the foundation for cardiovascular prevention and should receive appropriate attention in clinical practice (39). For a detailed discussion of the effect of diet on lipid levels and atherosclerosis see the Endotext chapter The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels (40).

 

Secondary Prevention

 

  • In patients with clinical ASCVD reduce LDL-C with high-intensity statin or maximally tolerated statins to decrease ASCVD risk. The goal of therapy is to reduce LDL-C by 50% or greater. If necessary to achieve this goal consider adding ezetimibe to moderate statin therapy.

 

The strongest evidence for efficacy of statin therapy is a meta-analysis of RTCs carried out in patients with established ASCVD. As previously mentioned, the best fit line comparing percent ASCVD versus LDL-C in secondary prevention studies demonstrates that for every mmol/L (39mg/dL) reduction in LDL-C the risk for ASCVD is decreased by approximately 22% (9). High intensity statins typically reduce LDL-C by 50% or more; this percentage reduction occurs regardless of baseline levels of LDL-C. This explains why the guidelines set a goal for LDL-C secondary prevention to be a > 50% reduction in levels. There are two options to achieve such reductions. RCTs give priority to the use of high-intensity statins. But, if high-intensity statins are not tolerated, similar LDL-C lowering can be attained by combining a moderate-intensity statin with ezetimibe (15,16). The RACING trial, a randomized trial that compared rosuvastatin 10 mg plus ezetimibe 10 mg vs. rosuvastatin 20 mg, demonstrated a similar effect on ASCVD events (41). An approach to lowering LDL-C in patients with ASCVD is shown in Figure 2.

 

Figure 2. Secondary Prevention in Patients with Clinical ASCVD (1).

 

VERY HIGH-RISK PATIENTS WITH ASCVD

 

  • In very high-risk patients with ASCVD first use a maximally tolerated statin +/- ezetimibe to achieve an LDL-C goal of < 70mg/dL (<1.8mMol/L). If this goal is not achieved consider adding a PCSK9 inhibitor.

 

2018 guidelines defined very high risk of future ASCVD events as a history of multiple ASCVD events or one major event plus multiple high-risk conditions (Table 4). This definition is based in large part on subgroup analysis of the IMPROVE-IT trial (16,17).

 

Table 4. Very High Risk of Future ASCVD Events (1)

Major ASCVD Events

Recent ACS (within the past 12 months)

History of MI (other than recent acute coronary syndrome event listed above)

History of ischemic stroke

Symptomatic peripheral arterial disease (history of claudication with ABI <0.85, or previous revascularization or amputation)

High Risk Conditions

Age ≥65 y

Heterozygous familial hypercholesterolemia

History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major ASCVD event(s)

Diabetes mellitus

Hypertension 

CKD (eGFR 15-59 mL/min/1.73 m2)

Current smoking

Persistently elevated LDL-C (LDL-C ≥100 mg/dL [≥2.6 mmol/L]) despite maximally tolerated statin therapy and ezetimibe

History of congestive heart failure

ABI indicates ankle-brachial index; CKD indicates chronic kidney disease.

 

Recent RCTs have demonstrated that the addition of non-statins to statin therapy can enhance risk reduction. These RCTs (and their add-on drugs) were IMPROVE-IT (ezetimibe) (16), FOURIER (evolocumab) (19), and ODYSSEY OUTCOMES (alirocumab) (20).  All RCTs were carried out in patients at very high-risk. For IMPROVE-IT, addition of ezetimibe to statin therapy produced an additional 6% reduction in ASCVD events. In this trial, baseline LDL-C on moderate-intensity statin alone averaged about 70 mg/dL; in spite of this low level, further LDL lowering with addition of ezetimibe enhanced risk reduction. RCTs with the two PCSK9 inhibitors (evolocumab and alirocumab) restricted recruitment to patients having LDL-C > 70 mg/dL on maximally tolerated statin+ ezetimibe. In these RCTs, the duration of therapy was only about 3 years. A marked additional LDL lowering was achieved. In both trials, the risk for ASCVD events was reduced by 15%.

 

2018 guidelines allow consideration of PCSK9 inhibitor as an add-on drug if patients are at very high risk for future ASCVD events and have an LDL-C > 70 mg/dL (or non-HDL-C > 100mg/dL) during treatment with maximally tolerated statin plus ezetimibe (Figure 3). This latter threshold LDL-C was chosen because it was a recruitment criterion for PCSK9 inhibitor therapy in reported RTCs (19,20)

 

An important question about the use of PCSK9 inhibitors is whether they are cost-effective. When they first became available, they were marketed at a very high cost, which was widely considered to be excessive. More recently, the cost of these drugs has declined considerably, and one can anticipate that the price will continue to decrease. An analysis of cost-effectiveness has shown that at current prices in very high-risk patients PCSK9 inhibitors can be cost-effective (42).  Another analysis (43) of approximately 1 million patients with ASCVD in the Veterans Affairs system indicate that approximately 10% of patients will be classified as very high risk and having LDL-C > 70 mg/dL while taking maximal statin therapy plus ezetimibe. These later patients are potential candidates for PCSK9 inhibitors. 

 

Figure 3. Secondary Prevention in Patients with Very High-Risk ASCVD (1).

 Primary Prevention

 

SEVERE PRIMARY HYPERCHOLESTEROLEMIA

 

  • In patients with severe primary hypercholesterolemia (LDL-C greater than 190mg/dL (>4.9mMol/L)) without concomitant ASCVD begin high-intensity statin therapy (or moderate intensity statin + ezetimibe) to achieve an LDL-C goal of < 100mg/dL; if this goal is not achieved consider adding a PCSK9 inhibitor in selected patients at higher risk. Measurement of 10-year risk for ASCVD is not necessary.

 

Patients with severe hypercholesterolemia are known to be at relatively high risk for developing ASCVD (44,45). In view of massive evidence that elevated LDL-C promotes atherosclerosis and predisposes to ASCVD, it stands to reason that such patients deserve intensive treatment with LDL-lowering drugs. RCTs with cholesterol-lowering drugs demonstrate benefit of statin therapy in patients with severe hypercholesterolemia (46,47). It is not necessary to calculate 10-year risk in such patients. Moreover, patients who have extreme elevations of LDL-C (e.g., heterozygous familial hypercholesterolemia) may be candidates for PCSK9 inhibitors if LDL-C cannot be lowered sufficiently with maximal statin therapy plus ezetimibe.

 

PATIENTS WITH DIABETES

 

  • In patients with diabetes mellitus aged 40 to 75 years with an LDL-C ≥70 mg/dL (≥1.8 mmol/L), without concomitant ASCVD, begin moderate-intensity statin therapy. For older patients (> 50 years), consider using high-intensity statin therapy (or moderate intensity statin plus ezetimibe) to achieve a reduction in LDL-C of > 50%. Measurement of 10-year risk for ASCVD is not necessary.

 

Middle-aged patients with diabetes have an elevated lifetime risk for ASCVD (48). The trajectory of risk is steeper in patients with diabetes than in those without. For this reason, estimation of 10-year risk for ASCVD with the pooled cohort equation (PCE) is not a reliable indicator of lifetime risk.  Meta-analysis of RCTs in middle-aged patients with diabetes treated with moderate intensity statins therapy shows significant risk reduction (12). Hence, most middle-aged patients with diabetes deserve statin therapy. With progression of age and accumulation of multiple risk factors, increasing the intensity of statin therapy or adding ezetimibe seems prudent (Tables 5 and 6). It is not necessary to measure 10-year risk before initiation of statin therapy in these patients with diabetes.

 

Table 5. Diabetes Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes (1)

Long duration (≥10 years for type 2 diabetes mellitus or ≥20 years for type 1 diabetes mellitus

Albuminuria ≥30 mcg of albumin/mg creatinine

eGFR <60 mL/min/1.73 m2

Retinopathy

Neuropathy

ABI <0.9

ABI indicates ankle-brachial index.

 

Table 6. ASCVD Risk Enhancers (1)

Family history of premature ASCVD

Persistently elevated LDL > 160mg/dl (>4.1mmol/L

Chronic kidney disease*

Metabolic syndrome**

History of preeclampsia

History of premature menopause

Inflammatory disease (especially rheumatoid arthritis, psoriasis, HIV)

Ethnicity (e.g., South Asian ancestry)

Persistently elevated triglycerides > 175mg/dl (>2.0mmol/L)

Hs-CRP > 2mg/L

Lp(a) > 50mg/dl or >125nmol/L

Apo B > 130mg/dl

Ankle-brachial index (ABI) < 0.9

*Chronic kidney disease definition- eGFR 15–59 mL/min/1.73 m2 with or without albuminuria.

**Metabolic syndrome definition- increased waist circumference, elevated triglycerides [>175 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 in women mg/dL] are factors; tally of 3 makes the diagnosis).

 

Other factors that can increase the risk of ASCVD include social deprivation, physical inactivity,

psychosocial stress, major psychiatric disorders, obstructive sleep apnea syndrome, and metabolic associated fatty liver disease (38).

 

PRIMARY PREVENTION PATIENT WITHOUT OTHER FACTORS

 

  • Initiation of primary prevention should begin with a clinician-patient risk discussion.

 

This discussion is necessary to put a patient’s total risk status in perspective. The risk discussion should always begin with a review of the critical importance of lifestyle intervention. This is true for all age groups. Beyond the issue of lifestyle, the discussion can further consider the potential benefit of a cholesterol-lowering drug, especially statin therapy. When the latter may be beneficial, the provider should next review major risk factors and estimated 10-year risk for ASCVD derived from the pooled cohort equation (PCE) risk calculator (49)  (https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/). Estimation of lifetime risk is also useful, particularly in younger individuals who often have a low 10-year risk but a high lifetime risk. All major risk factors (e.g., cigarette smoking, elevated blood pressure, LDL-C, hemoglobin A1C [if indicated]), should be discussed.

 

In patients 40-75 years, the 10-year risk estimate is most useful. In these patients, four categories of 10-year risk for ASCVD are recognized: low risk (<5%); borderline risk (5-7.4%); intermediate risk (7.5-19.9 %), and high risk (> 20%). Estimates of lifetime risk for patients 20-39 years also are available (https://www.acc.org/guidelines/hubs/blood-cholesterol  or        https://qrisk.org/lifetime/index.php) and should be obtained in younger individuals. Three other components of the risk discussion are: risk enhancing factors (see #8), possible measurement of coronary artery calcium (CAC) (see #9), and a review of extenuating life circumstances (issues of cost and safety considerations, as well as patient motivation and preferences). The decision to initiate statin therapy should be shared between the clinician and patient. All of these factors deserve a full discussion in view of the fact that statin therapy represents a lifetime commitment to taking a cholesterol-lowering drug.

 

Patients should also recognize that atherosclerosis begins early in life and progresses overtime before manifesting as clinical disease. The cumulative LDL-C levels (“LDL-C years”) strongly influence the timing of clinical manifestations (figure 4). In patients with high LDL-C levels (homozygous and heterozygous familial hypercholesterolemia) ASCVD can occur early in life whereas in patients with loss of function mutations in PCSK9 and low LDL-C level have a reduced occurrence of ASCVD.

 

Figure 4. Relationship between cumulative LDL-C exposure, age, and the development of the clinical manifestations of ASCVD. Figure from reference (50).

Additionally, patients should be appraised of comparisons of the reduction in ASCVD events in individuals with genetic variations resulting in life-long reductions in LDL-C levels vs. individuals treated with statins to lower LDL-C later in life. Variants in the HMG-CoA reductase, NPC1L1, PCSK9, ATP citrate lyase, and LDL receptor genes result in a lifelong decrease in LDL-C and a 10mg/dL decrease in LDL-C with any of these genetic variants was associated with a 16-18% decrease in ASCVD events (51). As noted above, a 39mg/dL decrease in LDL-C in the statin trials resulted in a 22% decrease in ASCVD events. Thus, a life-long decrease in LDL-C levels results in a decrease in ASCVD events that is three to four times as great as that seen with short-term LDL-C lowering with drugs later in life suggesting that the sooner the LDL-C level is lowered the better the prevention of cardiovascular events.

 

  • In adults 40 to 75 years of age without diabetes and LDL-C ≥70 mg/dL (≥1.8 mmol/L), RTC's show that moderate intensity statin therapy is efficacious when 10-year risk for developing ASCVD is >5%.Therefore, initiating statin therapy should be considered in the risk discussion.

 

A 10-year risk > 7.5% does not mandate statin therapy but indicates that moderate-intensity statins can reduce risk by 30-40% with a minimum of side effects (52). This fact alone can justify moderate intensity statin therapy, but only if other considerations noted above (#6) are taken into account in the risk discussion. An approach to lipid lowering in primary prevention patients is shown in figure 5.

 

Figure 5. Approach to Primary Prevention in Patients without LDL-C >190mg/dl or Diabetes (1).

 

  • Determine presence of risk-enhancing factors in adults 40 to 75 years of age to inform the decision regarding initiation of statin therapy.

 

If risk assessment based on PCE is equivocal or ambiguous, the presence of risk enhancing factors in patients at intermediate risk (10-year risk 7.5 to 19.9%), can tip the balance in favor of statin therapy. Risk enhancing factors are shown in Table 6.

 

  • IF A DECISION ABOUT STATIN THERAPY IS UNCERTAIN IN ADULTS 40 TO 75 YEARS OF AGE WITHOUT DIABETES MELLITUS, WITH LDL-C LEVELS ≥ 70 MG/DL, AND WITH A 10 YEAR ASCVD RISK OF ≥ 7.5% TO 19.9% (INTERMEDIATE RISK) CONSIDER MEASURING Coronary Artery Calcium (CAC).

 

CAC measurements are a safe and inexpensive method to assess severity of coronary atherosclerosis. CAC scores generally reflect lifetime exposure to coronary risk factors and therefore in young individuals (men < 40 years of age; women < 50 years of age) the long-term predictive value is limited because the CAC score is often 0. Studies show that CAC accumulation is a strong predictor of probability of ASCVD events (53). A CAC core of zero generally is accompanied by few if any ASCVD events over the subsequent decade. Reevaluation in 5-10 years is indicated. A CAC score of 1-100 Agatston units is associated with relatively low rates of ASCVD, both in middle-aged and older patients. In contrast, a CAC >100 Agatston units carries a risk well into the statin-benefit zone. CAC > 300-400 is equivalent to clinical ASCVD. Data such as these led to the following recommendation of 2018 guidelines for patients at intermediate risk by PCE.

 

  1. If CAC is zero, treatment with statin therapy may be withheld or delayed, except in cigarette smokers, those with diabetes mellitus, those with a strong family history of premature ASCVD, and possibly chronic inflammatory conditions such as HIV.
  2. A CAC score of 1 to 99 Agatston units favors statin therapy in intermediate-risk patients ≥55 years of age, whereas benefit in 40-54 years is marginal (note this focuses on 10-year risk and a CAC score in this range in a younger individual is predictive of an increased long-term risk (54)).
  3. A CAC score ≥100 Agatston units (or ≥75th percentile), strongly favors statin therapy, unless otherwise countermanded by clinician–patient risk discussion.

 

Monitoring

 

  • Assess adherence and percentage response to LDL-C lowering medications and/or lifestyle changes with repeat lipid measurement 4 to 12 weeks after statin initiation or dose adjustment and every 3-12 months as needed.

 

Remember that the LDL-C goal for patients with ASCVD or severe hypercholesterolemia is a > 50% reduction in LDL-C. For most such patients, this goal can be achieved by high-intensity statin therapy + ezetimibe. In ASCVD patients at very high risk, the goal is an LDL-C lowering >50% and an LDL-C < 70 mg/dL. To achieve these goals, it may be necessary to combine a PCSK9 inhibitor with maximal statin therapy + ezetimibe.  For statin therapy in primary prevention, the goal is a lowering of > 35%. This goal can be achieved in most patients with a moderate intensity statin + ezetimibe

 

2018 guidelines did not set a precise on-treatment LDL-C target of therapy, but instead, offer percent reductions as goals of therapy. Baseline levels of LDL-C can be obtained either by chart review or withholding statin therapy for about two weeks. In addition, on-treatment LDL-C can provide useful information about efficacy of treatment (Figure 6). This figure shows expected LDL-C levels for 50% or 35% reductions at different baseline levels of LDL-C. For example, in secondary prevention, an on-treatment LDL-C of <70 mg/dL can be considered adequate treatment regardless of baseline LDL-C. On-treatment levels in the range of 70-100 mg/dL are adequate if baseline-LDL C is known to be in the range of 140- 200 mg/dL; if there is uncertainty about baseline levels, reevaluation of statin adherence and reinforcement of treatment regimen is needed. For optimal treatment, on-treatment levels in this range warrant consideration of adding ezetimibe to maximal statin therapy. If on treatment LDL-C is > 100 mg/dL, the treatment regimen is probably inadequate, and intensification of therapy is needed. For primary prevention, the LDL-C goal is a reduction > 35%, and a similar scheme for evaluating efficacy of therapy can be used.

Figure 6. Predicted on-treatment LDL-C compared to baseline LDL-C and suggested actions for each category of on-treatment LDL-C in secondary and primary prevention.

 

Other Issues

 

OTHER AGE GROUPS

 

2018 guidelines offered suggestions for management of high blood cholesterol in children, adolescents, young adults (20-39 years), and elderly patients > 75 years. There is no strong RCT evidence to underline cholesterol management in these populations. Instead, treatment suggestions depend largely on epidemiologic data. Lifestyle intervention is a primary method for cholesterol treatment in these age groups. However, under certain circumstances LDL-lowering drugs may be indicated. This is particularly the case for patients with familial hypercholesterolemia or similar forms of very high LDL-C. In young adults, particularly those with other risk factors, LDL lowering drug therapy (statin or ezetimibe) may be reasonable when LDL-C levels are in the range of 160-189 mg/dL or if the lifetime risk is high. Older adults who have concomitant risk factors are potential candidates for initiation of statins or continuation of existing statin therapy. In all cases, clinical estimation of risk status is critical in a decision to initiate statins.

 

For details on the approach to treating hypercholesterolemia in older adults see the Endotext chapter entitled “Management of Dyslipidemia in the Elderly” (55). For details on the approach to treating hypercholesterolemia children and adolescence see the Endotext section on Pediatric Lipidology.

 

STATIN NON-ADHERENCE     In spite of proven benefit of statin therapy in high-risk patients, there is a relatively high prevalence of nonadherence to the prescribed drug (56). Some studies suggest that up to 50% of patients discontinue use of prescribed statins over the long run (57-60). This finding creates a major challenge to the health care system for prevention of ASCVD. Table 7 lists several factors that may contribute to a high prevalence of nonadherence.  

Table 7. Factors Associated with Statin Nonadherence

Healthcare system factors

Accompanying medical care costs

Lack of medical oversight and follow-up (provider therapeutic inertia)

Provider concern for side effects

Patient factors

Uncertainty of benefit

Lack of health consciousness

Lack of motivation

Lack of perceived benefit

Perceived side effects

Nocebo effects

Myalgias

Myopathy

“Brain fog”

Misattributed symptoms or syndromes (arthritis, spondylosis, neuropathy, insomnia, mental confusion and memory loss, fibromyalgia, gastrointestinal symptoms, liver dysfunction, cataract; cancer).

 When a decision is made to initiate statin therapy, the presumption is that statins are a lifetime treatment. Their use is similar to other medications, such as antihypertensive drugs, which are expected to be taken for the rest of one’s life. Such treatments imply indefinite participation in the healthcare system. This means regular ongoing visits to a prescribing clinic. Even for those with medical insurance there are usually co-pays for the visit, not to mention the cost of transportation to and from the clinic. All of these cost-related issues can be an impediment to long-term statin usage. Provider therapeutic inertia (56) can result from lack of provider education, excessive workload, and concerns about statin side effects. From the patient’s point of view, common issues are lack of understanding of the potential benefits of therapy and lack of health consciousness and motivation. A related problem is the expectation of side effects because of preconditioning by information received from the news media, package inserts, Internet, family, and friends. This expectation can discourage individuals from continuation of statin therapy (nocebo effect) (61). The most common symptoms attributed to statin therapy are muscle pain and tenderness (myalgias) (8).  A complaint of statin intolerance is registered in about 5-15% of patients. If myalgias attributed to statins are due to actual pathological changes, the character of the changes is yet to be determined. In almost all cases, serum creatine kinase (CK) levels are not increased. Still, in rare cases, especially when blood levels of statins are raised, severe myopathy (rhabdomyolysis) can occur. This proves that statins can be myotoxic. Table 8 lists conditions associated with statin-induced severe myopathy (62,63). In most such cases, severe myopathy is reversible. If the cause can be identified and eliminated, a statin can be cautiously reinstituted. Alternatively, a non-statin LDL-lowering drug (e.g., ezetimibe, bempedoic acid, or PCSK9 inhibitor) can be substituted for the offending statin (8,64). For a detailed discussion of statin side effects and the management of patients with statin intolerance see the Endotext chapter on cholesterol lowering drugs (8).

 

Table 8. Factors Associated with Statin - Induced Rhabdomyolysis

Advanced age (>80 y)Small body frame and fragilityFemale sexAsian ethnicityPre-existing neuromuscular conditionKnown history of myopathy or family history of myopathy syndromePre-existing liver disease, kidney disease, hypothyroidismCertain rare genetic polymorphismsHigh-dose statinPostoperative periodsExcessive alcohol intakeDrug interactions (gemfibrozil, antipsychotics, amiodarone, verapamil, cyclosporine, macrolide antibiotics, azole antifungals, protease inhibitors)

 

EUROPEAN GUIDELINES FOR CHOLESTEROL MANAGEMENT

 

The most influential of European guidelines for management of cholesterol and dyslipidemia are those developed by the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and representatives from other European organizations (65). A task force appointed by these organizations have published an update on dyslipidemia management (38). The recommendations of this report resemble in many ways those of the 2018 AHA/ACC guidelines (1). But notable differences can be identified for specific recommendations. A review of these differences may help to identify gaps in knowledge needed to format best recommendations. In the following, recommendations proposed by AHA/ACC and by ESC/EAS will be compared. These comparisons should illuminate areas of uncertainty where more information is needed for definitive recommendations. At the same time, it is important to emphasize that in many critical areas the two sets of guidelines are in strong agreement. These will be noted first.

 

Agreement Between AHA/ACC and ESC/EAS Guidelines

 

There is agreement that elevated LDL-C is the major atherogenic lipoprotein and that LDL-C is the primary target of treatment. Likewise, both guidelines agree that the intensity of LDL-C lowering therapy should depend on absolute risk to patients. In other words, patients who have the highest risk should receive the most intensive cholesterol reduction. Both guidelines emphasize therapeutic lifestyle intervention as the foundation of risk reduction, both for elevated cholesterol and for other risk factors. The highest risk patients are those with ASCVD and are potential candidates for combined drug therapy for LDL-C lowering. For primary prevention, the intensity of treatment depends on absolute risk as determined by population-based algorithms.  For drug therapy, statins are first-line treatment, but in highest risk patients, consideration can be given to adding non-statin drugs (e.g., ezetimibe and PCSK9 inhibitors). Beyond population-based algorithms for primary prevention, measurement of other dyslipidemia markers, or other higher risk conditions can be used as risk- enhancing factors to modify intensity of lipid-lowering therapy.  

 

Differences Between AHA/ACC and ESC/EAS Guidelines

 

DEFINITION OF VERY HIGH RISK    

 

This definition is important because it sets the stage for considering intensive LDL-C lowering and the use of combined drug therapy for LDL-C lowering. AHA/ACC defines very high risk as a history of multiple ASCVD events or of one event + multiple high-risk conditions. This limits the definition of very high risk to the highest risk patients among those with ASCVD. In contrast, ESC/EAS considers all patients with clinical ASCVD or ASCVD on imaging as very high risk. Additionally, ESC/EAS allows extension of the definition to highest risk patients in primary prevention, that is, to patients with multiple risk factors and/or subclinical atherosclerosis (table 9). Overall, more patients will be identified as being at very high risk by ESC/EAS guidelines. This could enlarge the usage of PCSK9 inhibitors. AHA/ACC limits the use of PCSK9 inhibitors to patients at highest risk, because of their high cost. One recent study (43) showed that only about 10% of patients with established ASCVD will be eligible for PCSK9 inhibitors by AHA/ACC recommendations.

 

Table 9. ESC/EAS Cardiovascular Risk Categories

Very High-Risk

Ø  ASCVD, either clinical or unequivocal on imaging

Ø  DM with target organ damage or at least three major risk factors or T1DM of long duration (>20 years)

Ø  Severe CKD (eGFR <30 mL/min/1.73 m2)

Ø  A calculated SCORE >10% for 10-year risk of fatal CVD.

Ø  FH with ASCVD or with another major risk factor

High-Risk

Ø  Markedly elevated single risk factors, in particular Total Cholesterol >8 mmol/L (>310mg/dL), LDL-C >4.9 mmol/L (>190 mg/dL), or BP >180/110 mmHg.

Ø  Patients with FH without other major risk factors.

Ø  Patients with DM without target organ damage, with DM duration > 10 years or another additional risk factor.

Ø  Moderate CKD (eGFR 30-59 mL/min/1.73 m2).

Ø  A calculated SCORE >5% and <10% for 10-year risk of fatal CVD.

Moderate Risk

Ø  Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, without other risk factors.

Ø  Calculated SCORE >1 % and <5% for 10-year risk of fatal CVD*.

Low Risk

Ø  Calculated SCORE <1% for 10-year risk of fatal CVD

SCORE= Systematic Coronary Risk Estimation. * Total CVD event risk is approximately three times higher than the risk of fatal CVD.

  

GOALS FOR LDL-C    

 

In 2013, the AHA/ACC eliminated specific numerical goals for LDL-C in both primary and secondary prevention. Recommendations for LDL-C lowering therapy were based exclusively on RCTs of statin therapy. These recommendations have been criticized for lacking a means to evaluate the efficacy of statin therapy. In 2018, AHA/ACC identified 2 goals for LDL-C lowering, namely, > 50% LDL-C reduction in secondary prevention and > 35% reduction in primary prevention. These values are based on the expected reductions achieved by high-intensity statins for secondary prevention and by moderate-intensity statins for primary prevention.  Again, no numerical targets are identified. The only exception was the recognition of an LDL-C threshold goal of 1.8 mmol/L (70 mg/dL) for consideration of PCSK9 inhibitors in very high-risk patients on maximal statin therapy + ezetimibe.

 

ESC/EAS supports the 50% reduction of LDL-C in high-risk patients but also includes a goal of <1.8 mmol/L (70 mg/dL) (table 10). This goal applies to all high-risk patients, whether in primary or secondary prevention. For very high-risk patients, the goal is an LDL-C of < 1.4 mmol/L (55 mg/dL). For moderate-risk patients in primary prevention, the goal is LDL-C <2.6 mmol/L (100 mg/dL). The guideline task force presumably believed that having defined LDL-C goals facilitates cholesterol-lowering therapy in clinical practice. Additionally, following the ESC/EAS LDL-C goals will most likely result in lower LDL-C levels in many patients.  

 

Table 10. ESC/EAS LDL Cholesterol Goals

Very High Risk

LDL-C reduction of >50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) is recommended

High Risk

LDL-C reduction of >50% from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) is recommended

Moderate Risk

LDL-C goal of <2.6 mmol/L (<100 mg/dL) should be considered

Low Risk

LDL-C goal <3.0 mmol/L (<116 mg/dL) may be considered.

 

In patients with ASCVD who experience a second vascular event within 2 years while on maximally tolerated statin therapy an LDL-C goal of < 1mMol/L (40mg/dL) may be considered.

 

In addition, the ESC/EAS also provided goals for non-HDL-C and apolipoprotein B (table 11).

 

Table 11. ESC/EAS Goals of Therapy

 

Non-HDL-C

Apo B

Very High Risk

<85mg/d;

<65mg/dL

High Risk

<100mg/dL

<80mg/dL

Moderate Risk

<130mg/dL

<100mg/dL

 

Figure 7 provides an overview of the ESC/EAS recommended treatment based on risk and baseline LDL-C levels.

Figure 7. ESC/EAS treatment recommendations based on risk and baseline LDL-C levels.

RISK ESTIMATION FOR PRIMARY PREVENTION  

 

AHA/ACC employed a pooled cohort equation (PCE) developed from five large population groups in the USA to estimate 10-year risk (and lifetime risk) for ASCVD events. ESC/EAS for several years has employed a SCORE algorithm based on risk for ASCVD mortality in European populations. Both PCE and SCORE are used to define “statin eligibility” for primary prevention. A study suggests that more people are “eligible” for statin therapy using PCE compared to SCORE (66). If this finding can be confirmed, it suggests that ESC/EAS guidelines are less aggressive for reducing LDL-C in lower risk individuals (compared to AHA/ACC guidelines). In contrast, ESC/EAS appears to be more aggressive in use of non-statins for LDL lowering in higher risk patients than is AHA/ACC.

 

RISK ENHANCING FACTORS    

 

AHA/ACC proposed that several risk enhancing factors favor the decision to use statin therapy in patients at intermediate risk. The European guidelines provide a similar list of factors that should be considered in determining risk and modifying the SCORE result. Notable among risk enhancing factors were apolipoprotein B (apoB) and lipoprotein (a) (Lp[a]).

 

SUBCLINICAL ATHEROSCLEROSIS    

 

AHA/ACC propose that CAC measurement can assist in deciding whether to use statin therapy in patients at intermediate risk. AHA/ACC in particular noted that the absence of CAC justifies delaying statin therapy. No other modalities of measurement of subclinical atherosclerosis were advocated by AHA/ACC. In contrast, ESC/EAS supported use of both CAC and carotid or femoral plaque burden on ultrasonography to determine risk. These guidelines suggest that the finding of substantial subclinical atherosclerosis in any arterial bed elevates a patient’s risk to the category of established ASCVD and can justify adding non-statin therapy to statins in such patients.

 

GUIDELINE SPECIFICITY  

 

AHA/ACC guidelines place great emphasis on data from RCTs to justify its recommendations.  However, RTC’s related to specific questions typically are limited in number. AHA/ACC recommendations are highly codified and kept to a minimum. ESC/EAS in contrast bases its recommendations both on clinical trials and other types of evidence. It explores available evidence in greater detail, and many of its recommendations are more nuanced. This approach to guideline development has its advantages and disadvantages. For example, it gives the reader a broader base of information to assist in clinical decisions. On the other hand, many of its recommendations are made outside of an RCT-evidence base. Without doubt, cholesterol management in all age and gender groups with various risk factor profiles is complex. The ESC/EAS attempts to provide a rationale for management of this complexity. The AHA/ACC, on the other hand, simplifies management as much as possible; it is written specifically for the general practitioner, and leaves the complexities of management to a lipid specialist. ESC/EAS delves into the complexities in more detail so that its recommendations are applicable to both the general practitioner and specialist.

 

IMPORTANT CHANGES SINCE THESE GUIDELINES WERE PUBLISHED

 

Risk Calculators

 

PREVENT RISK CACULATOR

 

In the US there is a new risk calculator called PREVENT (67). The PREVENT risk calculator is based on a much larger and more contemporary sample than the pooled cohort equation (PCE) risk calculator (68). Prevent is based on data from more than 6 million individuals from 46 datasets, including both population research studies and health system electronic medical records. In contrast, PCE was derived from approximately 25,000 individuals from 5 research datasets.

 

There are several notable differences between the PREVENT and PCE risk calculators.

 

1)         PREVENT calculates risk in patients age 30-79 whereas PCE calculates risk in patients age 40-75.

2)         The PCE calculator uses age, gender, white or African American, total cholesterol, HDL-C, systolic BP, whether on treatment for BP, whether diabetic, and whether smoker as the variables to calculate risk. PREVENT uses age, gender, total cholesterol, HDL-C, systolic BP, BMI, eGFR, whether on BP or lipid lowering medications (i.e., statins), whether diabetic, and whether a current smoker to calculate risk. In addition, PREVENT allows for the use of optional variables, HbA1c, urine albumin/creatinine ratio, and Zip Code (for estimating social deprivation index) for further personalization of risk assessment. Note that PREVENT does not use race or ethnicity but does include variables related to glucose metabolism, renal disease, and obesity and can be used in patients taking statins .

3)         The main result for the PCE calculator is the 10-year risk of cardiovascular disease. The main result of the PREVENT calculator is both the 10-year and 30-year risk (if <60 years of age) of cardiovascular disease, ASCVD only, and heart failure only.

 

It should be noted that fewer patients will be identified as eligible for statin therapy using the PREVENT calculator compared to the PCE calculator. A study found that 18.8% of patients eligible for statin therapy using the PCE calculator would not be identified using the PREVENT calculator (69). Another study found that using the PREVENT calculator would reclassify approximately half of US adults to lower risk categories compared to the PCE calculator (70). Additionally, studies have shown that the mean estimated 10-year ASCVD risk is approximately 50% lower with the PREVENT calculator compared to the PCE calculator (71,72).

 

The current recommendations for treatment were based on the PCE risk estimates and thus, there are concerns that using the PREVENT calculator may result in not treating as many patients. New AHA/ACC guidelines are being developed, and it is possible that the new recommendations will be adjusted to compensate for the differences in the risk calculated using the PCE and PREVENT calculators. Some experts recommend using the PCE calculator when deciding on treatment if one is following the current AHA/ACC guidelines.

 

SCORE2 RISK CALCULATOR

 

The SCORE risk calculator was developed in 2003 to determine the 10-year cardiovascular mortality in healthy individuals (73). In 2021 SCORE was replaced by SCORE2, which updated the risk prediction algorithms and in instead of determining cardiovascular mortality determines cardiovascular disease which includes cardiovascular mortality and non-fatal myocardial function and stroke endpoints (74). The prediction model in SCORE2 was based on 45 cohorts with 677,684 individuals from 13 countries. In addition, SCORE2-OP estimates cardiovascular risk in individuals greater than 70 years of age or older and SCORE2-Diabetes estimates cardiovascular risk in patients with type 2 diabetes (75,76)(https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app)

 

The variables used in SCORE2 to calculate risk are age (40-69), sex, smoking, systolic BP, total cholesterol, HDL-C, and whether they live in a low, moderate, high, or very high-risk region (see below). SCORE2 provides an estimate of the 10-year risk of cardiovascular disease. Low-risk countries: Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, the Netherlands, and the United Kingdom (UK). Moderate-risk countries: Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino, Slovenia, and Sweden. High-risk countries: Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Kazakhstan, Poland, Slovakia, and Turkey. Very high-risk countries: Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Republic of Moldova, Romania, Russian Federation, Serbia, Syria, The Former Yugoslav Republic (Macedonia), Tunisia, Ukraine, and Uzbekistan.

 

In individuals 70 years of age or older one should use the SCORE2-OP calculator and for individuals with type 2 diabetes one should use the SCORE2-Diabetes calculator. SCORE2-OP uses the same variables as SCORE2, but SCORE2-Diabetes includes HbA1c, age at diagnosis of diabetes, and eGFR. Both provide an estimate of the 10-year risk of cardiovascular disease.

 

In conjunction with the development of SCORE2 the European Society of Cardiology developed guidelines for healthy individuals (77). The conversion of 10-year risk to CVD risk categories for healthy individuals is shown in Table 12 and LDL-C goals for these CVD risk categories are shown in table 13. Note that the use of very high risk and high risk is not equivalent to the use of these terms in the  ESC/EAS lipid guidelines discussed above.

 

Table 12. Cardiovascular Disease Risk Categories Based on SCORE2 and SCORE2-OP in Healthy Individuals

 

<50 years

50–69 years

≥70 years

Low-to-moderate CVD risk: risk factor treatment generally not recommended

<2.5%

<5%

<7.5%

High CVD risk: risk factor treatment should be considered

2.5 to <7.5%

5 to <10%

7.5 to <15%

Very high CVD risk: risk factor treatment generally recommended

≥7.5%

≥10%

≥15%

 

Table 13. LDL-C Goal Less Than 100mg/dL

Age

Low-to-moderate CVD risk

High CVD risk

Very high CVD risk

< 50

Usually not indicated

Consider

Recommended

50-69

Usually not indicated

Consider

Recommended

>70

Usually not indicated

Consider

Recommended

In all age groups, consideration of risk modifiers, lifetime CVD risk, treatment benefit, comorbidities, frailty, and patient preferences may further guide treatment decisions.

 

KEY PRINCIPLES 

 

There are certain key principles that clinicians should utilize when deciding who to treat and how aggressively to treat hypercholesterolemia. Understanding these principles will allow clinicians to help their patients decide on the best approach to LDL-C lowering.

 

The Sooner the Better

 

It is widely recognized that atherosclerosis begins early in life and slowly progresses ultimately resulting in clinical manifestations later in life (78). Several studies have demonstrated the presence of atherosclerosis in young individuals (79-83). The extent of the atherosclerotic lesions correlates positively with total cholesterol and LDL-C and negatively with HDL-C levels (79,80,83-90). These studies clearly demonstrate that atherosclerosis begins early in life with the prevalence increasing with age and the extent and onset of lesions is influenced by total cholesterol and LDL-C levels. Moreover, an increased total cholesterol early in life also predicted an increased risk of developing cardiovascular disease later in life (91-93).

 

Genetic studies have further illustrated the key role of exposure to total cholesterol and LDL-C in determining the time when clinical manifestations of ASCVD occur. In patients with homozygous familial hypercholesterolemia (FH), LDL-C are markedly elevated, and cardiovascular events can occur early in life. Greater than 50% of untreated patients with homozygous FH develop clinically significant ASCVD by the age of 30 and cardiovascular events can occur before age 10 in some patients (45). In patients with heterozygous FH LDL-C levels are elevated but not to the levels seen with homozygous FH and cardiovascular events occur later in life but still at a relatively younger age. Untreated males with heterozygous FH have a 50% risk for a fatal or non-fatal myocardial infarction by 50 years of age whereas untreated females have a 30% chance by age 60 (45). Conversely, individuals with genetic variants in PCSK9, HMG-CoA reductase, LDL receptor, NPC1L1, or ATP citrate lyase that lead to a decrease in LDL-C levels have a reduced risk of developing cardiovascular events (50,51). The relationship between genetic disorders that alter LDL-C levels and the time to develop clinical cardiovascular events is illustrated in figure 4. The figure clearly illustrates that the age when one clinically manifests ASCVD depends on the level of LDL-C. With very high LDL-C levels clinical events occur early in life and with low LDL-C levels events will occur at an older age leading to the concept of LDL years.

 

Of major importance is that the reduction in ASCVD events is much greater in individuals with lifelong decreases in LDL-C compared to the reductions in ASCVD events seen with statin treatment (Table 14). A lifelong 10mg/dL decrease in LDL-C due to polymorphisms in genes that affect LDL-C is associated with a 16-18% decrease in ASCVD events (51). In contrast, a decrease in LDL-C of 39mg/dL over 4-5 years with statin therapy results in only a 22% decrease in ASCVD events (6,9). Thus, a life-long decrease in LDL-C levels results in a decrease in cardiovascular events that is three to four times as great as that seen with short-term LDL-C lowering with drugs. Figure 8 illustrates the benefits of early treatment in reducing LDL-C years and delaying the development of ASCVD.

 

Table 14.  Effect of Reduction in LDL-C by Genetic Variants on the Risk of ASCVD

Gene

Odds ratio for ASCVD events per 10mg/dL decrease in LDL-C

(95% CI)

ATP citrate lyase

0.82 (0.78–0.87)

HMG CoA reductase

0.84 (0.82–0.87)

NPC1L1

0.84 (0.79–0.89)

PCSK9

0.83 (0.80–0.87)

LDL receptor

0.83 (0.80–0.87)

Statin treatment decreases ASCVD by approximately 22% per 39mg/dL decrease in LDL-C.

 

Figure 8. The effect of early lowering of LDL-C on the development of ASCVD.

In addition to calculating the 10-year risk of ASCVD events it is important to calculate either the lifetime or 30-year risk. This is particularly important in younger individuals where the 10-year risk of ASCVD events may be relatively low, but the long-term risk may be high. In the discussion of therapy with patients they need to be aware of their long-term risk and the potential advantages of early treatment.

 

Lowering LDL-C levels by lifestyle changes early in life will have long-term benefits.  Additionally, in selected individuals initiating drug therapy sooner rather than latter will reduce ASCVD events later in life.

 

The Lower the Better

 

A variety of different types of studies have clearly demonstrated that more robust lowering of LDL-C results in an increased decrease in ASCVD events.

 

  • Statin trials have demonstrated that ASCVD events are decreased even in patients with low LDL-C levels (10). In patients with an LDL-C less than 70mg/dL, statin treatment resulted in a 37% decrease in ASCVD events despite the patients having a low LDL-C.
  • Intensive statin therapy results in a greater decrease in LDL-C levels compared to moderate statin therapy. Moreover, intensive therapy also results in a greater decrease in ASCVD events (10).
  • Adding ezetimibe to statin therapy resulted in a lower LDL-C than statin therapy alone and furthermore decreased ASCVD events (16).
  • Adding a PCSK9 inhibitor to statin therapy decreases LDL-C levels and results in a greater reduction in ASCVD events than statins alone (19,20).

 

Taken together these studies clearly demonstrate that the lower the LDL-C level the greater the decrease in ASCVD events. However, there may be a threshold where further lowering of LDL-C does not result in further benefits. In the ODYSSEY trial using the PCSK9 inhibitor alirocumab, the decrease in ASCVD events was similar in patients with an LDL-C less than 25mg/dL and those with an LDL-C between 25-50mg/dL (94). Future studies are required to define if there is a threshold where further LDL-C lowering is not beneficial.

 

Clinicians need to balance the benefits of more aggressively lowering LDL-C levels with the risks and costs of high dose or additional drug therapy. Both statins and ezetimibe are generic drugs and very inexpensive. Thus, in many patients the use of the combination of a statin (either high intensity or moderate intensity) and ezetimibe will maximize the decrease in LDL-C and more effectively reduce ASCVD events, with minimal risk and at low cost. In contrast, PCSK9 inhibitors and bempedoic acid are relatively expensive and clinicians will need to balance the benefits and the increased costs.

 

The Higher the LDL-C the Greater the Benefit

 

The percent decrease in LDL-C levels that occurs with statin treatment or the use of other LDL-C lowering drugs is similar regardless of the baseline LDL-C level. However, the absolute decrease in LDL-C will be greater if the starting LDL-C is higher. As discussed earlier, the Cholesterol Treatment Trialists demonstrated that the relative risk reduction in cardiovascular events per 39mg/dL (1mmol/L) decrease in LDL-C is similar in patients with a low or high baseline LDL-C level. Thus, as shown in table 15 the treatment of patients with high baseline LDL-C levels will result in greater decreases in ASCVD events. A meta-analysis of 34 trials with 270,288 individuals found that LDL-C lowering was associated with a progressively greater relative risk reduction in ASCVD events in patients with increased baseline LDL-C levels (95).

 

Table 15. The Higher the Baseline LDL-C the Greater the Reduction in ASCVD

Baseline LDL-C 80mg/dL

Baseline LDL-C 160mg/dL

Atorvastatin 80mg reduces LDL-C by 50% to 40mg/dl (40mg/dL decrease)

Atorvastatin 80mg reduces LDL-C by 50% to 80mg/dl (80mg/dL decrease)

A 40mg/dL decrease in LDL-C will result in an approximate 22% decrease in ASCVD events

An 80mg/dL decrease in LDL-C will result in an approximate 44% decrease in ASCVD events

 

The Greater the Risk of ASCVD the Greater the Benefit

 

Analysis by the Cholesterol Treatment Trialists found that the relative risk reduction was similar regardless of the underlying ASCVD risk (9). However, the absolute risk reduction was much greater in patients with a high risk of ASCVD (table 16) (9). Additionally, studies have shown that in patients with a high polygenic risk score for ASCVD events statin therapy reduces ASCVD events to a greater extent again indicating the higher the risk the greater the benefit of lowering LDL-C (96,97).

 

Table 16. Risk of Cardiovascular Events in High and Low Risk Patients

5-year event risk

Relative Risk (CI) per 39mg/dL reduction in LDL-C

Absolute Decrease in Events per Annum*

<10%

0.68 (0.62-0.74)

0.3%

10-20%

0.79 (0.75-0.84)

0.5%

20-30%

0.81 (0.78-0.85

1.1%

>30%

0.79 (0.75-0.83

2.2%

*Percent of patients on placebo having an event minus percent of patients on statin therapy having an event. Data from Cholesterol Treatment Trialists (9).

 

In the IMPROVE-IT trial lowering LDL-C with ezetimibe and the ODYSSEY and FOURIER trials using PCSK9 inhibitors a greater reduction in ASCVD events was observed in high risk patients (see reference (98) for discussion of these studies). Table 17 provides a list of indicators of high risk.

 

Table 17. High Risk Indicators for ASCVD Events

Diabetes

Atherosclerosis in multiple sites (peripheral arterial disease, cerebral vascular disease, coronary arteries)

History of prior coronary artery bypass graft surgery

Acute coronary syndrome

Multiple MIs

Recent ASCVD events

Genetic lipid disorders

High polygenic risk score

 

Following these general principles will help clinicians make informed decisions in deciding on their approach to lowering LDL-C levels and will facilitate discussions with patients on the benefits and risks of treatment. For an in-depth discussion of these key principles see the following references (98,99).    

 

SUMMARY

 

Advances in the drug therapy of elevated cholesterol levels offer great potential for reducing both new-onset ASCVD and recurrent ASCVD events in those with established disease. This benefit can be enhanced by judicious use of lifestyle intervention. But among drugs, statins are first-line therapy. They are generally safe and inexpensive. They have been shown to reduce ASCVD events in both secondary and primary prevention. Ezetimibe has about half the LDL-lowering efficacy of statins; it too is generally safe and is a relatively inexpensive genetic drug. Ezetimibe can be used as an add-on drug to moderate intensity statins, especially for those who do not tolerate a high-intensity statin or in combination with high intensity statins to markedly decrease LDL-C levels. PCSK9 inhibitors are powerful LDL-lowering drugs, and they appear to be safe. The major drawback is cost. If the cost of these inhibitors can be reduced, they too have the potential for wide usage, especially in patients who are “statin intolerant”. Bempedoic acid has been shown to reduce ASCVD events in statin intolerant patients and in combination with ezetimibe can result in significant decreases in LDL-C levels. A major challenge for use of cholesterol-lowering drugs is the problem of long-term non-adherence.

 

ACKNOWLEDGEMENTS

 

Dr. Scott Grundy, who recently died, was the original author of this chapter and this chapter is an update of his chapter. This chapter is dedicated to Dr. Grundy who has been an inspiration to lipidologists worldwide.

 

This work was supported by grants from the Northern California Institute for Research and Education.

 

REFERENCES

 

  1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e1082-e1143
  2. Aragam KG, Natarajan P. Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications. Circ Res 2020; 126:1159-1177
  3. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015; 161:161-172
  4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106:3143-3421
  5. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-372
  6. Cholesterol Treatment Trialists Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-590
  7. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research 1992; 33:1569-1582
  8. Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  9. Cholesterol Treatment Trialists Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385:1397-1405
  10. Cholesterol Treatment Trialists’ C, Baigent Collaboration, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681
  11. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393:407-415
  12. Cholesterol Treatment Trialists Collaboration, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125
  13. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA2016; 316:1289-1297
  14. The Lipid Research Clinics Coronary Primary Prevention Trial Results. JAMA 1984; 251:351-364
  15. Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, Lam C, Lowe RS, Stepanavage ME, Musliner TA, Cohen JC, Hobbs HH. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab 2010; 95:800-809
  16. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine 2015; 372:2387-2397
  17. Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park J-G, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology 2017; 69:911-921
  18. Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfí A. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep2011; 12:1300-1305
  19. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine 2017; 376:1713-1722
  20. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine 2018; 379:2097-2107
  21. Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 2019; 30:1-9
  22. Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA 2023; 330:131-140
  23. Feingold KR. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  24. Cleeman JI, Lenfant C. New guidelines for the treatment of high blood cholesterol in adults from the National Cholesterol Education Program. From controversy to consensus. Circulation 1987; 76:960-962
  25. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Archives of Internal Medicine 1988; 148:36-69
  26. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1333-1445
  27. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 2004; 44:720-732
  28. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology 2014; 63:2889-2934
  29. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R MM, Miller Wolman D, Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. National Academies Press; 2011.
  30. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014; 63:2935-2959
  31. Muntner P, Colantonio LD, Cushman M, Goff DC, Jr., Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA2014; 311:1406-1415
  32. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. The Lancet2013; 382:1762-1765
  33. Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. JAMA2014; 311:1416-1423
  34. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, Kronmal RA, McClelland RL, Nasir K, Blaha MJ. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 2015; 162:266-275
  35. Damen JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten RJPM, Hooft L, Debray TPA. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med 2019; 17:109-109
  36. Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. Journal of the American College of Cardiology 2016; 67:2118-2130
  37. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 2008; 359:2195-2207
  38. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESCSD Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111-188
  39. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140:e596-e646
  40. Feingold KR. The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  41. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, Heo JH, Rha SW, Cho YH, Lee SJ, Ahn CM, Kim JS, Ko YG, Choi D, Jang Y, Hong MK, Racing investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet 2022; 400:380-390
  42. Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017; 2:1069-1078
  43. Virani SS, Akeroyd JM, Smith SC, Al-Mallah M, Maddox TM, Morris PB, Petersen LA, Ballantyne CM, Grundy SM, Stone NJ. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology 2019; 74:712-714
  44. Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology 2016; 67:2578-2589
  45. Warden BA, Fazio S, Shapiro MD. Familial Hypercholesterolemia: Genes and Beyond. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  46. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 1994; 344:1383-1389
  47. Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract 2016; 2016:e201635-e201635
  48. Feingold KR. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2023.
  49. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Sperling LS, Virani SS, Blumenthal RS. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation 2019; 139:e1162-1177
  50. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 Suppl:S172-177
  51. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med 2019; 380:1033-1042
  52. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal 2019; 210:18-28
  53. Tota-Maharaj R, Blaha MJ, Blankstein R, Silverman MG, Eng J, Shaw LJ, Blumenthal RS, Budoff MJ, Nasir K. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. Mayo Clin Proc 2014; 89:1350-1359
  54. Stone NJ, Smith SC, Jr., Orringer CE, Rigotti NA, Navar AM, Khan SS, Jones DW, Goldberg R, Mora S, Blaha M, Pencina MJ, Grundy SM. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 79:819-836
  55. Streja E, Feingold KR. Evaluation and Treatment of Dyslipidemia in the Elderly. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  56. Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology 2016; 225:184-196
  57. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of Use of Lipid-Lowering Medications. JAMA 1998; 279:1458
  58. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid‐lowering drugs. Medical Journal of Australia 1996; 164:208-211
  59. Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, Woolley JM, Rosenson R, Farkouh M, Muntner P. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci 2014; 348:108-114
  60. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005; 21:485-488
  61. Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. Journal of Clinical Lipidology 2016; 10:739-747
  62. Fitchett DH, Hegele RA, Verma S. Statin Intolerance. Circulation 2015; 131:e389-391
  63. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, American College of Cardiology, American Heart Association, National Heart Lung, Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106:1024-1028
  64. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA2016; 315:1580-1590
  65. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen M-R, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal2016; 37:2999-3058
  66. Lee JC, Zdrojewski T, Pencina MJ, Wyszomirski A, Lachacz M, Opolski G, Bandosz P, Rutkowski M, Gaciong Z, Wyrzykowski B, Navar AM. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. JAMA Cardiol 2016; 1:700-707
  67. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak MG, Palaniappan LP, Sperling L, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele CE, Coresh J, Chronic Kidney Disease Prognosis Consortium, the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and Validation of the American Heart Association's PREVENT Equations. Circulation 2024; 149:430-449
  68. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49-73
  69. Heaton J, Alshami A, Imburgio S, Upadhyaya V, Saybolt M, Apolito R, Hansalia R, Selan J, Almendral J, Sealove B. Comparison of pooled cohort equation and PREVENT risk calculator for statin treatment allocation. Atherosclerosis 2024; 399:118626
  70. Diao JA, Shi I, Murthy VL, Buckley TA, Patel CJ, Pierson E, Yeh RW, Kazi DS, Wadhera RK, Manrai AK. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA 2024; 332:989-1000
  71. Anderson TS, Wilson LM, Sussman JB. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations. JAMA Intern Med 2024; 184:963-970
  72. Carrillo-Larco RM. Cardiovascular predicted risk: A population-based comparison of the pooled cohorts equation and PREVENT. Int J Cardiol 2024; 414:132423
  73. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003
  74. Score working group, E. S. C. Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021; 42:2439-2454
  75. Score Op working group, E. S. C. Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021; 42:2455-2467
  76. S. CORE2-Diabetes Working Group, the E. S. C. Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 2023; 44:2544-2556
  77. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, E. S. C. National Cardiac Societies, E. S. C. Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42:3227-3337
  78. Wilson DP. Is Atherosclerosis a Pediatric Disease? In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2020.
  79. Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650-1656
  80. McGill HC, Jr., McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 1997; 17:95-106
  81. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, Young JB, Nissen SE. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001; 103:2705-2710
  82. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA 1971; 216:1185-1187
  83. Webber BJ, Seguin PG, Burnett DG, Clark LL, Otto JL. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA 2012; 308:2577-2583
  84. Newman WP, 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986; 314:138-144
  85. McGill HC, Jr., McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 1998; 82:30T-36T
  86. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104:2815-2819
  87. Juonala M, Magnussen CG, Venn A, Dwyer T, Burns TL, Davis PH, Chen W, Srinivasan SR, Daniels SR, Kahonen M, Laitinen T, Taittonen L, Berenson GS, Viikari JS, Raitakari OT. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation 2010; 122:2514-2520
  88. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003; 290:2271-2276
  89. Magnussen CG, Venn A, Thomson R, Juonala M, Srinivasan SR, Viikari JS, Berenson GS, Dwyer T, Raitakari OT. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol 2009; 53:860-869
  90. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290:2277-2283
  91. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328:313-318
  92. Pletcher MJ, Vittinghoff E, Thanataveerat A, Bibbins-Domingo K, Moran AE. Young Adult Exposure to Cardiovascular Risk Factors and Risk of Events Later in Life: The Framingham Offspring Study. PLoS One 2016; 11:e0154288
  93. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284:311-318
  94. Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, Odyssey Outcomes Committees Investigators. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation 2021; 143:1109-1122
  95. Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA 2018; 319:1566-1579
  96. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385:2264-2271
  97. Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster V, Reilly DF, Butterworth A, Rader DJ, Ford I, Sattar N, Kathiresan S. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation 2017; 135:2091-2101
  98. Feingold KR, Chait A. Approach to patients with elevated low-density lipoprotein cholesterol levels. Best Pract Res Clin Endocrinol Metab 2022:101658
  99. Feingold KR. Maximizing the benefits of cholesterol-lowering drugs. Curr Opin Lipidol 2019; 30:388-394

Skin Manifestations of Diabetes Mellitus

ABSTRACT

 

Diabetes mellitus is a common and debilitating disease that affects a variety of organs including the skin. Between thirty and seventy percent of patients with diabetes mellitus, both type 1 and type 2, will present with a cutaneous complication of diabetes mellitus at some point during their lifetime. A variety of dermatologic manifestations have been linked with diabetes mellitus; these conditions vary in severity and can be benign, deforming, and even life-threatening. Such skin changes can offer insight into patients’ glycemic control and may be the first sign of metabolic derangement in undiagnosed patients with diabetes. Recognition and management of these conditions is important in maximizing the quality of life and in avoiding serious adverse effects in patients with diabetes mellitus.

 

INTRODUCTION

 

The changes associated with diabetes mellitus can affect multiple organ systems. Between thirty and seventy percent of patients with diabetes mellitus, both type 1 and type 2, will present with a cutaneous complication of diabetes mellitus at some point during their lifetime (1). Dermatologic manifestations of diabetes mellitus have various health implications ranging from those that are aesthetically concerning to those that may be life-threatening. Awareness of cutaneous manifestations of diabetes mellitus can provide insight into the present or prior metabolic status of patients. The recognition of such findings may aid in the diagnosis of diabetes or may be followed as a marker of glycemic control. The text that follows describes the relationship between diabetes mellitus and the skin, more specifically: (1) skin manifestations strongly associated with diabetes, (2) non-specific dermatologic signs and symptoms associated with diabetes, (3) dermatologic diseases associated with diabetes, (4) common skin infections in diabetes, and (5) cutaneous changes associated with diabetes medications.

 

SKIN MANIFESTATIONS STRONGLY ASSOCIATED WITH DIABETES MELLITUS

 

Acanthosis Nigricans

 

EPIDEMIOLOGY

 

Acanthosis nigricans (AN) is a classic dermatologic manifestation of diabetes mellitus that affects men and women of all ages. AN is more common in type 2 diabetes mellitus (2) and is more prevalent in those with darker skin color. AN occurs more frequently in African Americans, Hispanics, and Native Americans (3). AN is observed in a variety of endocrinopathies associated with resistance to insulin such as acromegaly, Cushing syndrome, obesity, polycystic ovarian syndrome, and thyroid dysfunction. Unrelated to insulin resistance, AN can also be associated with malignancies such as gastric adenocarcinomas and genitourinary cancers, as well as with autoimmune disorders, various medications, and familial disorders (4-4F).

 

PRESENTATION

 

AN presents chronically as multiple poorly demarcated plaques with grey to dark brown hyperpigmentation and a thickened velvety to verrucous texture (figure 1). Classically, AN has a symmetrical distribution and is located in intertriginous or flexural surfaces such as the back of the neck, axilla, elbows, palmar hands (also known as “tripe palms”), inframammary creases, umbilicus, or groin. Affected areas are asymptomatic; however, extensive involvement may cause discomfort or fetor. Microscopy shows hyperkeratosis and epidermal papillomatosis with acanthosis. The changes in skin pigmentation are primarily a consequence of hyperkeratosis, not changes in melanin. AN can present prior to the clinical diagnosis of diabetes; the presence of AN should prompt evaluation for diabetes mellitus and for other signs of insulin resistance.

Figure 1. Acanthosis nigricans. From Wikipedia.

 

PATHOGENESIS

 

The pathogenesis of AN in diabetes is multifactorial. It is well-established that a hyperinsulin state directly activates insulin growth factor receptors (IGF), specifically IGF-1, on keratinocytes and fibroblasts, provoking cell proliferation, resulting in the aforementioned cutaneous manifestations of AN (5,6). Hyperinsulinemia also decreases circulating levels of IGF binding protein 1 and 2, increasing IGF-1 blood levels for the same effect (6A).

 

TREATMENT

 

Treatment of AN may improve current lesions and prevent future cutaneous manifestations. AN is best managed with lifestyle changes such as dietary modifications, increased physical activity, and weight reduction. In patients with diabetes, pharmacologic adjuvants, such as metformin, that improve glycemic control and reduce insulin resistance are also beneficial (7). One case report demonstrated the effectiveness of the glucagon peptide receptor 1 (GLP-1) receptor agonist liraglutide in improving the clinical appearance of AN (7A). Primary dermatologic therapies are usually ineffective especially in patients with generalized involvement. However, in those with thickened or macerated areas of skin, topical retinoids, topical vitamin D analogs such as calciprotriol, or topical keratolytics such as ammonium lactate and salicylic acid are the primary treatments used for localized lesions (8-10). Systemic retinoids such as isotretinoin and acitretin have been associated with improvement in patients with extensive involvement but are not often used due to risk of systemic adverse effects and relapse upon discontinuation (10A). Topical urea, trichloroacetic acid, glycolic acid peels, and laser therapy have also been suggested as localized treatment modalities, though addressing the underlying disorder remains the most effective intervention.

 

Diabetic Dermopathy

 

EPIDEMIOLOGY

 

Diabetic dermopathy (DD), also known as pigmented pretibial patches or diabetic shin spots, is the most common dermatologic manifestations of diabetes, occurring in as many as one-half of those with diabetes (11). Although disputed, some consider the presence of DD to be pathognomonic for diabetes. DD has a strong predilection for men and those older than 50 years of age, with the number of lesions increasing with the duration of diabetes, increasing age, and HbA1C levels (12, 12A). Although DD may antecede the onset of diabetes, it occurs more frequently as a late complication of diabetes and in those with microvascular disease. DD often occurs prior to the onset of neuropathy and retinopathy; nephropathy is also regularly present in patients with DD (12A). An association with cardiovascular disease has also been identified, with one study showing 53% of non- insulin-dependent diabetes mellitus with DD had coexisting coronary artery disease (13).

 

PRESENTATION

 

DD initially presents with rounded, dull, red papules that progressively evolve over one-to-two weeks into well-circumscribed, atrophic, brown macules with a fine scale (figure 2). Normally after about eighteen to twenty-four months, lesions dissipate and leave behind an area of concavity and hyperpigmentation. At any time, different lesions can present at different stages of evolution. The lesions are normally distributed bilaterally and localized over bony prominences. The pretibial area is most commonly involved, although other bony prominences such as the forearms, lateral malleoli, or thighs may also be involved. Aside from the aforementioned changes, patients are otherwise asymptomatic. DD is a clinical diagnosis that should not require a skin biopsy, which should be especially avoided in patients with poor wound healing (12A). Histologically, DD is rather nonspecific; it is characterized by lymphocytic infiltrates surrounding vasculature, engorged blood vessels in the papillary dermis, and dispersed hemosiderin deposits. Moreover, the histology varies based on the stage of the lesion. Immature lesions present with epidermal edema as opposed to epidermal atrophy which is representative of older lesions (14).

 

Figure 2. Diabetic Dermopathy.

 

PATHOGENESIS

 

The origin of DD remains unclear, however, mild trauma to affected areas (15), hemosiderin and melanin deposition (16), microangiopathic changes (12A, 17), and destruction of subcutaneous nerves (18) have all been suggested.

 

TREATMENT

 

Treatment is typically avoided given the asymptomatic and self-resolving nature of DD as well as the ineffectiveness of available treatments. However, DD often occurs in the context of microvascular complications and neuropathies (12); hence, patients need to be examined and followed more rigorously for these complications. Although improvement of DD lesions is variable with glycemic control, managing blood glucose can help prevent progression of microvascular complications (18A).

 

Diabetic Foot Syndrome

 

EPIDEMIOLOGY

 

Diabetic Foot Syndrome (DFS) encompasses the neuropathic and vasculopathic complications that develop in the feet of patients with diabetes. Although preventable, DFS is a significant cause of morbidity, mortality, hospitalization, and reduction in quality of life of patients with diabetes. The incidence and prevalence of DFS in patients with diabetes is 1% to 4% and 4% to 10%, respectively (19). Furthermore, DFS is slightly more prevalent in type 1 diabetes compared with type 2 diabetes (20). A more comprehensive review of diabetic foot syndrome can be found in The Diabetic Foot chapter of Endotext (20A).

 

PRESENTATION

 

DFS presents initially with callosities and dry skin related to diabetic neuropathy. In later stages, chronic ulcers and a variety of other malformations of the feet develop. Between 15% and 25% of patients with diabetes will develop ulcers (21). Ulcers may be neuropathic, ischemic, or mixed. The most common type of ulcers are neuropathic ulcers, a painless ulceration resulting from peripheral neuropathy. Ulcers associated with peripheral vascular ischemia are painful but less common. Ulcers tend to occur in areas prone to trauma, classically presenting at the site of calluses or over bony prominences. It is common for ulcers to occur on the toes, forefoot, and ankles. Untreated ulcers usually heal within one year, however, fifty percent of patients with diabetes will have recurrence of the ulcer within three years (22). The skin of affected patients, especially in those with type 2 diabetes, is more prone to fungal infection and the toe webs are a common port of entry for fungi which can then infect and complicate ulcers (23). Secondary infection of ulcers is a serious complication that can result in gangrenous necrosis, osteomyelitis, and may even require lower extremity amputation. Another complication, diabetic neuro-osteoarthropathy (also known as Charcot foot), is an irreversible debilitating and deforming condition involving progressive destruction of weight-bearing bones and joints. Diabetic neuro-osteoarthropathy occurs most frequently in the feet and can result in collapse of the midfoot, referred to as “rocker-bottom foot.” Moreover, a reduction of the intrinsic muscle volume and thickening of the plantar aponeurosis can cause a muscular imbalance that produces a clawing deformation of the toes. An additional complication of diabetes and neuropathy involving the feet is erythromelalgia. Erythromelalgia presents with redness, warmth, and a burning pain involving the lower extremities, most often the feet. Symptoms may worsen in patients with erythromelalgia with exercise or heat exposure and may improve with cooling (24).

 

PATHOGENESIS

 

The pathogenesis of DFS involves a combination of inciting factors that coexist together: neuropathy (25), atherosclerosis (25), and impaired wound healing (26). In the setting of long-standing hyperglycemia, there is an increase in advanced glycosylation end products, proinflammatory factors, and oxidative stress which results in the demyelination of nerves and subsequent neuropathy (27,28). Single-cell RNA sequencing revealed that there is a unique subset of fibroblasts that overexpress factors associated with healing within the wound bed as opposed to the wound edge (28A). Additionally, wound healers demonstrate an increase in M1 macrophages as opposed to non- wound healers which have an increase in M2 macrophages. The effect on sensory and motor nerves can blunt the perception of adverse stimuli and produce an altered gait, increasing the likelihood of developing foot ulcers and malformations. Also, damage to autonomic nerve fibers causes a reduction in sweating which may leave skin in the lower extremity dehydrated and prone to fissures and secondary infection (29). In addition to neuropathy, accelerated arterial atherosclerosis can lead to peripheral ischemia and ulceration (30). It has been reported that there is an association between diabetic patients with Charcot neuroarthropathy and greater impairment of cutaneous microvascular reactivity when compared to non-complicated diabetic groups (30A). Finally, hyperglycemia impairs macrophage functionality as well as increases and prolongs the inflammatory response, slowing the healing of ulcers (31).

 

TREATMENT

 

Treatment should involve an interdisciplinary team-based approach with a focus on prevention and management of current ulcers. Prevention entails daily surveillance, appropriate foot hygiene, and proper footwear, walkers, or other devices to minimize and distribute pressure. An appropriate wound care program should be used to care for ongoing ulcers. Different classes of wound dressing should be considered based on the type of wound. Hydrogels, hyperbaric oxygen therapy, topical growth factors, and biofabricated skin grafts are also available (19). The clinical presentation should indicate whether antibiotic therapy or wound debridement is necessary (19). In patients with chronic treatment resistant ulcers, underlying ischemia should be considered; these patients may require surgical revascularization or bypass.

 

Diabetic Thick Skin

 

Skin thickening is frequently observed in patients with diabetes. Affected areas of skin can appear thickened, waxy, or edematous. These patients are often asymptomatic but can have a reduction in sensation and pain. Although different parts of the body can be involved, the hands and feet are most frequently involved. Ultrasound evaluation of the skin can be diagnostic and exhibit thickened skin. Subclinical generalized skin thickening is the most common type of skin thickening. Diabetic thick skin may represent another manifestation of scleroderma-like skin changes, limited joint mobility, or scleredema diabeticorum, which are each described in more detail below.

 

SCLERODERMA-LIKE SKIN CHANGES

 

Epidemiology

 

Scleroderma-like skin changes are a distinct and easily overlooked group of findings that are commonly observed in patients with diabetes. Ten to fifty percent of patients with diabetes present with the associated skin findings (32). Scleroderma-like skin changes occur more commonly in those with type 1 diabetes and in those with longstanding disease (33). There is no known variation in prevalence between males and females, or between racial groups.

 

Presentation

 

Scleroderma-like skin changes develop slowly and present with painless, indurated, occasionally waxy appearing, thickened skin. These changes occur symmetrically and bilaterally in acral areas. In patients with scleroderma-like skin changes the acral areas are involved, specifically the dorsum of the fingers (sclerodactyly), proximal interphalangeal, and metacarpophalangeal joints. Severe disease may extend centrally from the hands to the arms or back. A small number of patients with diabetes may develop more extensive disease, which presents earlier and with truncal involvement. The risk of developing nephropathy and retinopathy is increased in those with scleroderma-like skin changes who also have type 1 diabetes (33,34). The aforementioned symptoms are also associated with diabetic hand syndrome which may present with limited joint mobility, palmar fibromatosis (Dupuytren's contracture), and stenosing tenosynovitis (“trigger finger”) (35). The physical exam finding known as the “prayer sign” (inability to flushly press palmar surfaces on each hand together) may be present in patients with diabetic hand syndrome and scleroderma-like skin changes (36). On histology, scleroderma-like skin changes reveal thickening of the dermis, minimal-to-absent mucin, and increased interlinking of collagen. Although on physical exam scleroderma may be difficult to distinguish from these skin changes, scleroderma-like skin changes are not associated with atrophy of the dermis, Raynaud’s syndrome, pain, or telangiectasias.

 

Pathogenesis

 

Although not fully understood, the pathogenesis is believed to involve the strengthening of collagen as a result of reactions associated with advanced glycosylation end products or a buildup of sugar alcohols in the upper dermis (37,38).

 

Treatment

 

Scleroderma-like skin changes is a chronic condition that is also associated with joint and microvascular complication. Therapeutic options are extremely limited. One observational report has suggested that very tight blood glucose control may result in the narrowing of thickened skin (39). In addition, aldose reductase inhibitors, which limit increases in sugar alcohols, may be efficacious (38). In patients with restricted ranges of motions, physical therapy can help to maintain and improve joint mobility.

 

LIMITED JOINT MOBILITY

 

Epidemiology

 

Limited Joint Mobility (LJM), also known as diabetic cheiroarthropathy, is a relatively common complication of long-standing diabetes mellitus. The majority of patients with LJM also present with scleroderma-like skin changes (38,40). The prevalence of LJM is 4% to 26% in patients without diabetes and 8% to 58% in patients with diabetes (41).

 

Presentation

 

LJM presents with progressive flexed contractures and hindered joint extension, most commonly involving the metacarpophalangeal and interphalangeal joints of the hand. The earliest changes often begin in the joints of the fifth finger before then spreading to involve the other joints of the hand (38). Patients may present with an inability to flushly press the palmar surfaces of each of their hands together (“prayer sign”) (figure 3) or against the surface of a table when their forearms are perpendicular to the surface of the table (“tabletop sign”) (42).

 

Pathogenesis

 

These changes occur as a result of periarticular enlargement of connective tissue. Pathogenesis likely involves hyperglycemia induced formation of advanced glycation end-products, which accumulate to promote inflammation and the formation of stiffening cross-links between collagen (43). LJM is strongly associated with microvascular and macrovascular changes and diagnosis of LJM should prompt a workup for related sequela (44). Patients with LJM may also be at an increased risk for falls (45).

 

Treatment

 

There are no curative treatments. Symptomatic patients may benefit from non-steroidal anti-inflammatory drugs or targeted injection of corticosteroids (43). LJM is best managed with improved glycemic control (46), as well as regular stretching to maintain and minimize further limitations in joint mobility.

 

Figure 3. Limited Joint Mobility.

 

SCLEREDEMA DIABETOCORUM

 

Epidemiology

 

Scleredema is a chronic and slowly progressive sclerotic skin disorder that is often seen in the context of diabetes, in which case it is classified as scleredema diabeticorum (SD). Whereas 2.5% to 14% of all patients with diabetes have scleredema, over 50% of those with scleredema present with concomitant diabetes (47). SD has a proclivity for men with a long history of diabetes (47A). It remains unclear whether there is a predilection for SD in those with type 1 diabetes (48) compared to those with type 2 diabetes (48).

 

Presentation

 

SD presents with gradually worsening indurated and thickened skin. These skin changes occur symmetrically and diffusely. The most commonly involved areas are the upper back, shoulders, and back of the neck. The face, chest, abdomen, buttocks, and thighs may also be involved; however, the distal extremities are classically spared. The affected areas are normally asymptomatic but there can be reduced sensation. Patients with severe longstanding disease may develop a reduced range of motion, most often affecting the trunk. In extreme cases, this can lead to restrictive respiratory problems. A full-thickness skin biopsy may be useful in supporting a clinical presentation. The histology of SD differentiates it from the autoimmune disease scleroderma, displaying increased collagen and a thickened reticular dermis, with a surrounding mucinous infiltrate, without edema or sclerosis.

 

Pathogenesis

 

Although many theories center on abnormalities in collagen, there is no consensus regarding the pathogenesis of SD. The pathogenesis of SD may involve an interplay between non-enzymatic glycosylation of collagen, increased fibroblast production of collagen and mucin, or decreases in collagen breakdown (50-51A).

 

Treatment

 

SD is normally unresolving and slowly progressive over years. Improved glycemic control may be an important means of prevention but evidence has not shown clinical improvements in those already affected by SD. A variety of therapeutic options have been proposed with variable efficacy. The 2024 European Dermatology Forum Guidelines (51A) recommend medium-to-high dose phototherapy with UVA1 or PUVA as first-line therapy, methotrexate as second-line therapy, and other treatments including immunosuppressants, corticosteroids, intravenous immunoglobulin, and electron-beam therapy as advanced therapies (52). Independent of other treatments, physical therapy is an important therapeutic modality for patients with SD and reduced mobility (51A, 53).

 

Necrobiosis Lipoidica

 

EPIDEMIOLOGY

 

Necrobiosis lipoidica (NL) is a rare chronic granulomatous dermatologic disease that is seen most frequently in patients with diabetes.  Although nearly one in four patients presenting with NL will also have diabetes, only 0.3% to 1.6% of patients with diabetes will develop NL (47A,54). For unknown reasons, NL expresses a strong predilection for women compared to men (55). NL generally occurs in type 1 diabetes during the third decade of life, as opposed to type 2 diabetes in which it commonly presents in the fourth or fifth decades of life (54). The majority of cases of NL presents years after a diagnosis of diabetes mellitus; however, NL may precede diabetes, with 7% to 42% of patients with initial NL going on to develop impaired glucose tolerance or diabetes (47A,56). One study evaluating comorbidities and diabetic complications in patients with NL found high rates of smoking, hypertension, hyperlipidemia, obesity, coronary artery disease, myocardial infarction, thyroid disease, poor kidney function, and poor glucose control (56A). The highest comorbidity rates in patients with NL were patients with type 2 diabetes.

 

PRESENTATION

 

NL begins as a single or group of firm well-demarcated rounded erythematous papules (figure 4). The papules then  expand  and  aggregate into plaques characterized by circumferential red-brown borders and a firm yellow-brown waxen atrophic center containing telangiectasias. NL occurs bilaterally and exhibits Koebnerization. Lesions are almost always found on the pretibial areas of the lower extremities. Additional involvement of the forearm, scalp, distal upper extremities, face, or abdomen may be present on occasion, and the heel of the foot or glans penis even more infrequently. If left untreated, only about 15% of lesions will resolve within twelve years. Despite the pronounced appearance of the lesions, NL is often asymptomatic. However, there may be pruritus and hypoesthesia of affected areas, and pain may be present in the context of ulceration. Ulceration occurs in about one-third of lesions and has been associated with secondary infections and squamous cell carcinoma. The histology of NL primarily involves the dermis and is marked by palisading granulomatous inflammation, necrobiotic collagen, a mixed inflammatory infiltrate, blood vessel wall thickening, and reduced mucin.

 

Figure 4. Necrobiosis Lipoidica.

 

PATHOGENESIS

 

The pathogenesis of NL is not well understood. The relationship between diabetes and NL has led some to theorize that diabetes-related microangiopathy is related to the development of NL (54). Other theories focus on irregularities in collagen, autoimmune disease, neutrophil chemotaxis, or blood vessels (57).

 

TREATMENT

 

NL is a chronic, disfiguring condition that can be debilitating for patients and difficult for clinicians to manage. Differing degrees of success have been reported with a variety of treatments; however, the majority of such reports are limited by inconsistent treatment responses in patients and a lack of large, controlled studies. Corticosteroids are often used in the management of NL and may be administered topically, intralesionally, or orally. Corticosteroids can be used to manage active lesions but is best not used in areas that are atrophic. Success has also been reported with calcineurin inhibitors (e.g., cyclosporine), anti-tumor necrosis factor inhibitors (e.g., infliximab), pentoxifylline, antimalarials (e.g., hydroxychloroquine), PUVA, granulocyte colony stimulating factor, dipyridamole, and low-dose aspirin (54). Appropriate wound care is important for ulcerated lesions; this often includes topical antibiotics, protecting areas vulnerable to injury, emollients, and compression bandaging. Surgical excision of ulcers typically has poor results. Some ulcerated lesion may improve with split-skin grafting. Although still recommended, improved control of diabetes has not been found to lead to an improvement in skin lesions. Patients with newly diagnosed NL should be screened for hypertension, hyperlipidemia, and thyroid disease (56A).

 

Bullosis Diabeticorum

 

EPIDEMIOLOGY

 

Bullosis diabeticorum (BD) is an uncommon eruptive blistering condition that presents in those with diabetes mellitus. Although BD can occasionally present in early-diabetes (58), it often occurs in long-standing diabetes along with other complications such as neuropathy, nephropathy, and retinopathy. In the United States, the prevalence of BD is estimated to be around 0.5% amongst patients with diabetes and is believed to be higher in those with type 1 diabetes (13); however, underreporting of blistering cases in patients with diabetes may indicate a higher prevalence (58A). BD is significantly more common in male patients than in female patients (59). The average age of onset is between 50 and 70 years of age (59).

 

PRESENTATION

 

BD presents at sites of previously healthy-appearing skin with the abrupt onset of one or more non-erythematous, firm, sterile bullae. Shortly after forming, bullae increase in size and become more flaccid, ranging in size from about 0.5 cm to 5 cm. Bullae frequently present bilaterally involving the acral areas of the lower extremities. However, involvement of the upper extremities and even more rarely the trunk can be seen. The bullae and the adjacent areas are nontender. BD often presents acutely, classically overnight, with no history of trauma to the affected area. Generally, the bullae heal within two to six weeks, but then commonly reoccur. Histological findings are often non-specific but are useful in distinguishing BD from other bullous diseases. Histology typically shows an intraepidermal or subepidermal blister, spongiosis, no acantholysis, minimal inflammatory infiltrate, and normal immunofluorescence.

 

PATHOGENESIS

 

There is an incomplete understanding of the underlying pathogenesis of BD and no consensus regarding a leading theory. Various mechanisms have been proposed, some of which focus on autoimmune processes, exposure to ultraviolet light, variations in blood glucose, neuropathy, or changes in microvasculature (60).

 

TREATMENT

 

BD resolve without treatment and are therefore managed by avoiding secondary infection and the corresponding sequelae (e.g., necrosis, osteomyelitis). This involves protection of the affected skin, leaving blisters intact (except for large blisters, which may be aspirated to prevent rupture), and monitoring for infection. Topical antibiotics are not necessary unless specifically indicated, such as with secondary infection or positive culture.

 

NONSPECIFIC DERMATOLOGIC SIGNS AND SYMPTOMS

 

Ichthyosiform Changes of the Shins

 

Ichthyosiform changes of the shins presents with large bilateral areas of dryness and scaling (sometimes described as “fish scale” skin) (figure 5). Although cutaneous changes may occur on the hands or feet, the anterior shin is most classically involved. These cutaneous changes are related to rapid skin aging and adhesion defects in the stratum corneum (61). The prevalence of ichthyosiform changes of the shins in those with type 1 diabetes has been reported to be between 22% to 48% (33,62). These changes present relatively early in the disease course of diabetes. There is no known difference in prevalence between males and females (33). The development of ichthyosiform changes of the shins is related to production of advanced glycosylation end products and microangiopathic changes. Treatment is limited but topical emollients or keratolytic agents may be beneficial (61).

 

Figure 5. Acquired ichthyosiform changes.

 

Xerosis

 

Xerosis is one of the most common skin presentations in patients with diabetes and has been reported to be present in as many as 40% of patients with diabetes (63). Xerosis refers to skin that is abnormally dry. Affected skin may present with scaling, cracks, or a rough texture. These skin changes are most frequently located on the feet of patients with diabetes. It has been reported that diabetic patients that are obese will experience more severe hypohidrosis of the feet (63A). In patients with diabetes, xerosis occurs often in the context of microvascular complications (40). To avoid complications such as fissures and secondary infections, xerosis can be managed with emollients like ammonium lactate (64).

 

Acquired Perforating Dermatosis

 

EPIDEMIOLOGY

 

Perforating dermatoses refers to a broad group of chronic skin disorders characterized by a loss of dermal connective tissue. A subset of perforating dermatoses, known as acquired perforating dermatoses (APD), encompasses those perforating dermatoses that are associated with systemic diseases. Although APD may be seen with any systemic diseases, it is classically observed in patients with chronic renal failure or long-standing diabetes (65). APD occurs most often in adulthood in patients between the ages of 30 and 90 years of age (65,66). The overall prevalence of APD is unknown due to rarity and/or underdiagnosis of the disease. It is estimated that of those diagnosed with APD about 15% also have diabetes mellitus (67). In a review, 4.5% to 10% of patients with chronic renal failure presented with concurrent APD (68,69).

 

PRESENTATION

 

APD presents as groups of hyperkeratotic umbilicated-nodules and papules with centralized keratin plugs. The lesions undergo Koebnerization and hence the extensor surfaces of the arms and more commonly the legs are often involved; eruptions also occur frequently on the trunk. However, lesions can develop anywhere on the body. Lesions are extremely pruritic and are aggravated by excoriation. Eruptions may improve after a few months, but an area of hyperpigmentation typically remains. Histologically, perforating dermatoses are characterized by a lymphocytic infiltrate, an absence or degeneration of dermal connective tissue components (e.g., collagen, elastic fibers), and transepidermal extrusion of keratotic material.

 

PATHOGENESIS

 

The underlying pathogenesis is disputed and not fully understood. It has been suggested that repetitive superficial trauma from chronic scratching may induce epidermal or dermal derangements (70). The glycosylation of microvasculature or dermal components has been suggested as well. Other hypotheses have implicated additional metabolic disturbances, or the accumulation of unknown immunogenic substances that are not eliminated by dialysis (65). APD is also considered a form of prurigo nodularis (70A).

 

TREATMENT

 

APD can be challenging to treat and many of the interventions have variable efficacy. Minimizing scratching and other traumas to involved areas can allow lesions to resolve over a period of months. This is best achieved with symptomatic relief of pruritus. Individual lesions can be managed with topical agents such as keratolytics (e.g., 5% to 7% salicylic acid), retinoids (e.g., 0.01% to 0.1% tretinoin), or high-potency steroids (71). Refractory lesions may respond to intralesional steroid injections or cryotherapy (71). A common initial approach is a topical steroid in combination with emollients and an oral antihistamine. Generalized symptoms may improve with systemic therapy with oral retinoids, psoralen plus UVA light (PUVA), allopurinol (100 mg daily for 2 to 4 months), or oral antibiotics (doxycycline or clindamycin) (72). Additionally, as APD is a form of prurigo nodularis, the use of immunomodulating agents such as dupilumab may be effective in treating the condition. There is evidence of dupilumab monotherapy effectively treating certain forms of APD (72A). Nevertheless, effective management of the underlying systemic disease is fundamental to the treatment of APD. In those with diabetes, APD is unlikely to improve without improved blood glucose control. Moreover, dialysis does not reduce symptoms; however, renal transplantation can result in the improvement and resolution of cutaneous lesions.

 

Eruptive Xanthomas

 

EPIDEMIOLOGY

 

Eruptive xanthomas (EX) are a clinical presentation of hypertriglyceridemia, generally associated with serum triglycerides above 2,000 mg/dL (73). However, in patients with diabetes, lower levels of triglycerides may be associated with EX. The prevalence of EX is around one percent in type 1 diabetes and two percent in type 2 diabetes (74,75). Serum lipid abnormalities are present in about seventy-five percent of patients with diabetes (76). For a detailed discussion of lipid abnormalities in patients with diabetes see the Endotext chapter entitled “Dyslipidemia in Patients with Diabetes” (76A).

 

PRESENTATION

 

EX has been reported as the first presenting sign of diabetes mellitus, granting it can present at any time in the disease course. EX presents as eruptions of clusters of glossy pink-to-yellow papules, ranging in diameter from 1 mm to  4 mm,  overlying an erythematous area (figure 6). The lesions can be found on extensor surfaces of the extremities, the buttocks, and in areas susceptible in Koebnerization. EX is usually asymptomatic but may be pruritic or tender. Histology reveals a mixed inflammatory infiltrate of the dermis which includes triglyceride containing macrophages, also referred to as foam cells.

 

Figure 6. Eruptive Xanthomas

 

PATHOGENESIS

 

Lipoprotein lipase, a key enzyme in the metabolism of triglyceride rich lipoproteins, is stimulated by insulin. In an insulin deficient state, such as poorly controlled diabetes, there is decreased lipoprotein lipase activity resulting in the accumulation of chylomicrons and other triglyceride rich lipoproteins (77). Increased levels of these substances are scavenged by macrophages (78). These lipid-laden macrophages then collect in the dermis of the skin where they can lead to eruptive xanthomas.

 

TREATMENT

 

EX can resolve with improved glycemic control and a reduction in serum triglyceride levels (79). This may be achieved with fibrates or omega-3-fatty acids in addition to an appropriate insulin regimen (80). A more comprehensive review of the treatment of hypertriglyceridemia can be found in the Endotext chapter entitled “Triglyceride Lowering Drugs” (80A).

 

Acrochordons

 

Acrochordons (also known as soft benign fibromas, fibroepithelial polyps, or skin tags) are benign, soft, pedunculated growths that vary in size and can occur singularly or in groups (figure 7). The neck, axilla, and periorbital area are most frequently involved, although other intertriginous areas can also be affected. Skin tags are common in the general population but are more prevalent in those with increased weight or age, and in women. It has been reported that as many as three out of four patients presenting with acrochordons also have diabetes mellitus (81). Patients with acanthosis nigricans may have acrochordons overlying the affected areas of skin. Although disputed, some studies have suggested that the amount of skin tags on an individual may correspond with an individual's risk of diabetes or insulin resistance (82). Excision or cryotherapy is not medically indicated but may be considered in those with symptomatic or cosmetically displeasing lesions.

 

Figure 7. Acrochordons.

 

Diabetes-Associated Pruritus

 

Diabetes can be associated with pruritus, more often localized than generalized. Affected areas can include the scalp, ankles, feet, trunk, or genitalia (83,84). Pruritus is more likely in patients with diabetes who have dry skin or diabetic neuropathy. Other neuropathic conditions may arise in diabetes, such as scalp dysesthesia and meralgia paresthetica; these conditions often present with pruritus, burning, or pain (84A-B). Specifically, for type 2 diabetes, risk factors for pruritus were identified to be age, duration of disease, diabetic peripheral neuropathy, diabetic retinopathy, diabetic chronic kidney disease, peripheral arterial disease, and fasting plasma glucose levels (84C,D,E). Involvement of the genitalia or intertriginous areas may occur in the setting of infection (e.g., candidiasis). Treatments include topical capsaicin, topical ketamine-amitriptyline-lidocaine, oral anticonvulsants (e.g., gabapentin or pregabalin), and, in the case of candida infection, antifungals.

 

Huntley’s Papules (Finger Pebbles)

 

Huntley’s papules, also known as finger pebbles, are a benign cutaneous finding affecting the hands. Patients present with clusters of non-erythematous, asymptomatic, small papules on the dorsal surface of the hand, specifically affecting the metacarpophalangeal joints and periungual areas. The clusters of small papules can develop into coalescent plaques. Other associated cutaneous findings include hypopigmentation and induration of the skin. Huntley’s papules are strongly associated with type 2 diabetes and may be an early sign of diabetic thick skin (85,86). Topical therapies are usually ineffective; however, patients suffering from excessive dryness of the skin may benefit from 12% ammonium lactate cream (87).

 

Keratosis Pilaris

 

Keratosis pilaris is a very common benign keratotic disorder. Patients with keratosis pilaris classically present with areas of keratotic perifollicular papules with surrounding erythema or hyperpigmentation (figure 8). The posterior surfaces of the upper arms are often affected but involvement of the thighs, face, and buttocks can also be seen. Compared to the general population, keratosis pilaris occurs more frequently and with more extensive involvement of the skin in those with diabetes (33,62). Keratosis pilaris can be treated with various topical therapies, including salicylic acid, moisturizers, and emollients.

 

Figure 8. Keratosis Pilaris.

 

Pigmented Purpuric Dermatoses

 

Pigmented purpuric dermatoses (also known as pigmented purpura) are associated with diabetes, more often in the elderly, and frequently coexist with diabetic dermopathy (88,89). Pigmented purpura presents with non-blanching copper-colored patches involving the pretibial areas of the legs or the dorsum of the feet. The lesions are usually asymptomatic but may be pruritic. Pigmented purpuric dermatoses occur more often in late-stage diabetes in patients with nephropathy and retinopathy as a result of microangiopathic damage to capillaries and sequential erythrocyte deposition (90).

 

Palmar Erythema

 

Palmar erythema is a benign finding that presents with symmetric redness and warmth involving the palms (figure 9). The erythema is asymptomatic and often most heavily affects the hypothenar and thenar eminences of the palms. The microvascular complications of diabetes are thought to be involved in the pathogenesis of palmar erythema (91). Although diabetes associated palmar erythema is distinct from physiologic mottled skin, it is similar to other types of palmar erythema such as those related to pregnancy and rheumatoid arthritis.

 

Figure 9. Palmar erythema. From Wikipedia.

 

Periungual Telangiectasias

 

As many as one in every two patients with diabetes are affected by periungual telangiectasias (92). Periungual telangiectasias presents asymptomatically with erythema and telangiectasias surrounding the proximal nail folds (71). Such findings may occur in association with “ragged” cuticles and fingertip tenderness. The cutaneous findings are due to venous capillary dilatation that occurs secondary to diabetic microangiopathy. Capillary abnormalities, such as venous capillary tortuosity, may differ and can represent an early manifestation of diabetes-related microangiopathy (93).

 

Rubeosis Faciei

 

Rubeosis faciei is a benign finding present in about 7% of patients with diabetes; however, in hospitalized patients, the prevalence may exceed 50% (94). Rubeosis faciei presents with chronic erythema of the face or neck. Telangiectasias may also be visible. The flushed appearance is often more prominent in those with lighter colored skin. The flushed appearance is thought to occur secondary to small vessel dilation and microangiopathic changes. Complications of diabetes mellitus, such as retinopathy, neuropathy, and nephropathy are associated with rubeosis faciei (90). Facial erythema may improve with better glycemic control and reduction of caffeine or alcohol intake.

 

Yellow Skin and Nails

 

It is common for patients with diabetes, particularly elderly patients with type 2 diabetes, to present with asymptomatic yellow discolorations of their skin or fingernails. These benign changes commonly involve the palms, soles, face, or the distal nail of the first toe. The accumulation of various substances (e.g., carotene, glycosylated proteins) in patients with diabetes may be responsible for the changes in complexion; however, the pathogenesis remains controversial (95).

 

Onychocryptosis

 

Onychocryptosis, or ingrown toenails, have been reported in patients with diabetes, specifically type 2 diabetes (95A). The great toes are most affected. It is hypothesized that this nail change can occur in diabetic patients because onychocryptosis is correlated with increased body mass index, trauma, weak vascular supply, nail plate dysfunction, and subungual hyperkeratosis.

 

DERMATOLOGIC DISEASES ASSOCIATED WITH DIABETES

 

Generalized Granuloma Annulare

 

EPIDEMIOLOGY

 

Although various forms of granuloma annulare exist, only generalized granuloma annulare (GGA) is thought to be associated with diabetes. It is estimated that between ten and fifteen percent of cases of GGA occur in patients with diabetes (96). Meanwhile, less than one percent of patients with diabetes present with GGA. GGA occurs around the average age of 50 years. It occurs more frequently in women than in men, and in those with type 1 diabetes (97).

 

PRESENTATION

 

GGA initially presents with groups of skin-colored or reddish, firm papules which slowly grow and centrally involute to then form hypo- or hyper-pigmented annular rings with elevated circumferential borders (figure 10). The lesions can range in size from 0.5 cm to 5.0 cm. The trunk and extremities are classically involved in a bilateral distribution. GGA is normally asymptomatic but can present with pruritus. The histology shows dermal granulomatous inflammation surrounding foci of necrotic collagen and mucin. Necrobiosis lipoidica can present similarly to GGA; GGA is distinguished from necrobiosis lipoidica by its red color, the absence of an atrophic epidermis, and on histopathology: the presence of mucin and lack of plasma cells.

 

Figure 10. Generalized granuloma annulare. From Wikipedia.

 

PATHOGENESIS

 

The pathogenesis of GGA is incompletely understood. It is believed to involve an unknown stimulus that leads to the activation of lymphocytes through a delayed- type hypersensitivity reaction, ultimately initiating a proinflammatory cascade and granuloma formation (98). Recent studies have identified Th1, JAK-STAT, and perhaps also Th2 pathway dysregulation in GA lesional skin (97A).

 

TREATMENT

 

GGA has a prolonged often unresolving disease course and multiple treatments have been suggested to better manage GGA. However, much of the information stems from small studies and case reports. Several large retrospective studies suggest the efficacy of intralesional and topical corticosteroids in some patients, with phototherapy being an option for GA refractory to corticosteroids (97A). Antimalarials, retinoids, dapsone, methotrexate, cyclosporine, and calcineurin inhibitors have also been suggested as therapies (97A,98).

 

Psoriasis

 

Psoriasis is a chronic immune-mediated inflammatory disorder that may present with a variety of symptoms, including erythematous, indurated, and scaly areas of skin. Psoriasis has been found to be associated with a variety of risk factors, such as hypertension, obesity, and metabolic syndrome, that increase the likelihood of cardiovascular disease. The development of diabetes mellitus, an additional cardiovascular risk factor, has been strongly associated with psoriasis (99). In particular, younger patients and those with severe psoriasis may be more likely to develop diabetes in the future (99).

 

Lichen Planus

 

Lichen planus is a mucocutaneous inflammatory disorder characterized by firm, erythematous, polygonal, pruritic, papules. These papules classically involve the wrists or ankles, although the trunk, back, and thighs can also be affected. A number of studies have cited an association between lichen planus and abnormalities in glucose tolerance testing. Approximately one in four patients with lichen planus have diabetes mellitus (100). Although the association is contested, it has been reported that patients with diabetes may also be more likely to develop oral lichen planus (101).

 

Vitiligo

 

Vitiligo is an acquired autoimmune disorder involving melanocyte destruction. Patients with vitiligo present with scattered well-demarcated areas of depigmentation that can occur anywhere on the body but frequently involves the acral surfaces and the face (figure 11). Whereas about 1% of the general population is affected by vitiligo, vitiligo is much more prevalent in those with diabetes mellitus. Vitiligo occurs more frequently in women and is also more common in type 1 than in type 2 diabetes mellitus (96,98). Coinciding vitiligo and type 1 diabetes mellitus may be associated with endocrine autoimmune abnormalities of the gastric parietal cells, adrenal, or thyroid (102). A more comprehensive review of polyglandular autoimmune disorders can be found in the Autoimmune Polyglandular Syndromes section of Endotext (102A).

 

Figure 11. Vitiligo. From Wikipedia.

 

Hidradenitis Suppurativa

 

Hidradenitis suppurativa (HS) is a chronic inflammatory condition characterized by inflamed nodules and abscesses located in intertriginous areas such as the axilla or groin (figure 12). These lesions are often painful and malodorous. HS is frequently complicated by sinus formation and the development of disfiguring scars. HS occurs more often in women than men and usually presents in patients beginning in their twenties (103). The prevalence of HS is 0.095% in White populations, increasing more than 3-fold in Black populations (103A). Compared to the general population, diabetes mellitus is three times more common in patients with HS; HS has also been associated with cigarette smoking, diabetes, and low socioeconomic status (103A,104). It is recommended that patients with HS be screened for diabetes mellitus. Although there is no standardized approach to the treatment of HS, a multimodal approach may address underlying follicular occlusion, inflammation, bacterial overgrowth, hormonal and metabolic dysregulation and lifestyle modifications (103A). Some benefits have been reported with the use of antibiotics, retinoids, antiandrogens, or immunomodulators such as tumor necrosis factor (TNF) inhibitors (105).

 

Figure 12. Hidradenitis suppurativa. From Wikipedia.

 

Glucagonoma

 

Glucagonoma is a rare neuroendocrine tumor that most frequently affects patients in their sixth decade of life (106). Patients with glucagonoma may present with a variety of non-specific symptoms. However, necrolytic migratory erythema (NME) is classically associated with glucagonoma and presents in 70% to 83% of patients (106) (107). NME is characterized by erythematous erosive crusted or vesicular eruptions of papules or plaques with irregular borders (figure 13). The lesions may become bullous or blistered and may be painful or pruritic. The abdomen, groin, genitals, or buttocks are frequently involved, although cheilitis or glossitis may also be present. Biopsy at the edge of the lesion may demonstrate epidermal pallor, necrolytic edema, and a perivascular inflammatory infiltrate (108). Patients with glucagonoma may also present with diabetes mellitus. In patients with glucagonoma, diabetes mellitus frequently presents prior to NME (107). Approximately 20% to 40% of patients will present with diabetes mellitus before the diagnosis of glucagonoma (107,109). Of those patients diagnosed with glucagonoma but not diabetes mellitus, 76% to 94% will eventually develop diabetes mellitus (110). A more comprehensive review of glucagonoma can be found in the Glucagonoma section of Endotext (110A).

 

Figure 13. Necrolytic migratory erythema. From Endotext chapter entitled Glucagon & Glucagonoma Syndrome.

 

Melanoma

 

Type 2 diabetes mellitus does not increase the risk of melanoma, but it is associated with more advanced melanoma stages at the time of diagnosis as well as the presence of ulceration (110B). Furthermore, type 2 diabetes mellitus may promote more aggressive melanoma, but further research is needed to better understand the mechanisms involved (110C).

 

Skin Infections

 

The prevalence of cutaneous infections in patients with diabetes is about one in every five patients (111). Compared with the general population, patients with diabetes mellitus are more susceptible to infections and more prone to repeated infections. A variety of factors are believed to be involved in the vulnerability to infection in patients with uncontrolled diabetes, some of these factors include angiopathy, neuropathy, hindrance of the antioxidant system, abnormalities in leukocyte adherence, chemotaxis, and phagocytosis, as well as a glucose-rich environment facilitates the growth of pathogens. Host risk factors associated with skin and soft tissue in patients with DM are uncontrolled hyperglycemia, disruption of skin barrier,  elevated skin pH sensory or autonomic neuropathy, trauma/pressure, venous or arterial insufficiency, and immune system dysfunction (111A).

 

BACTERIAL

 

Erysipelas and Cellulitis

 

Erysipelas and cellulitis are cutaneous infections that occur frequently in patients with diabetes. Erysipelas presents with pain and well-demarcated superficial erythema. Cellulitis is a deeper cutaneous infection that presents with pain and poorly demarcated erythema. Folliculitis is common among patients with diabetes, and is characterized by inflamed, perifollicular, papules and pustules. Treatment for the aforementioned conditions depends on the severity of the infection. Uncomplicated cellulitis and erysipelas are typically treated empirically with oral antibiotics, whereas uncomplicated folliculitis may be managed with topical antibiotics. Colonization with methicillin- resistant Staphylococcus aureus (MRSA) is not uncommon among patients with diabetes (112); however, it is debated as to whether colonized patients are predisposed to increased complications (113) such as bullous erysipelas, carbuncles, or perifollicular abscesses. Regardless, it is important that appropriate precautions are taken in these patients and that antibiotics are selected that account for antimicrobial resistance.

 

Diabetic Foot Infection

 

Infection of the foot is the most common type of soft tissue infection in patients with diabetes. If not managed properly, diabetic foot infections can become severe, possibly leading to osteomyelitis, sepsis, amputation, or even death. Although less severe, the areas between the toes and the toenails are also frequently infected in patients with diabetes. Infections can stem from monomicrobial or polymicrobial etiologies. Staphylococcal infections are the most common (114), although complications with infection by Pseudomonas aeruginosa are also common (115). Pseudomonal infection of the toenail may present with a green discoloration, which may become more pronounced with the use of a Wood’s light. Treatment frequently requires coordination of care from multiple medical providers. Topical or oral antibiotics and surgical debridement may be indicated depending on the severity of the infection.

 

Necrotizing Fasciitis

 

Necrotizing fasciitis is an acute life-threatening infection of the skin and the underlying tissue. Those with poorly controlled diabetes are at an increased risk for necrotizing fasciitis. Necrotizing fasciitis presents early with erythema, induration, and tenderness which may then progress within days to hemorrhagic bullous. Patients will classically present with severe pain out of proportion to their presentation on physical exam. Palpation of the affected area often illicit crepitus. Involvement can occur on any part of the body but normally occurs in a single area, most commonly affecting the lower extremities. Fournier’s gangrene refers to necrotizing fasciitis of the perineum or genitals, often involving the scrotum and spreading rapidly to adjacent tissues. The infection in patients with diabetes is most often polymicrobial. Complications of necrotizing fasciitis include thrombosis, gangrenous necrosis, sepsis, and organ failure. Necrotizing fasciitis has a mortality rate of around twenty percent (116). In addition, those patients with diabetes and necrotizing fasciitis are more likely to require amputation during their treatment (117). Treatment is emergent and includes extensive surgical debridement and broad-spectrum antibiotics.

 

Erythrasma

 

Erythrasma is a chronic asymptomatic cutaneous infection, most often attributed to Corynebacterium minutissimum. Diabetes mellitus, as well as obesity and older age are  associated with erythrasma. Erythrasma presents with non-pruritic non-tender clearly demarcated red brown finely scaled patches or plaques. These lesions are commonly located in intertriginous areas such as the axilla or groin. Given the appearance and location, erythrasma can be easily mistaken for tinea or Candida infection; in such cases, the presence of coral-red fluorescence under a Wood’s light can confirm the diagnosis of erythrasma. Treatment options include topical erythromycin or clindamycin, Whitfield’s ointment, and sodium fusidate ointment. More generalized erythrasma may respond better to oral erythromycin.

 

Malignant Otitis Externa

 

Malignant otitis externa is a rare but serious infection of the external auditory canal that occurs most often in those with a suppressed immune system, diabetes mellitus, or older age. Malignant otitis externa develops as a complication of otitis externa and is associated with infection by Pseudomonas aeruginosa. Patients with malignant otitis externa present with severe otalgia and purulent otorrhea. The infection can spread to nearby structures and cause complications such as chondritis, osteomyelitis, meningitis, or cerebritis. If untreated, malignant otitis externa has a mortality rate of about 50%; however, with aggressive treatment the mortality rate can been reduced to 10% to 20% (118). Treatment involves long-term systemic antibiotics with appropriate pseudomonal coverage, hyperbaric oxygen, and possibly surgical debridement.

 

FUNGAL

 

Candida

 

Candidiasis is a frequent presentation in patients with diabetes. Moreover, asymptomatic patients presenting with recurrent candidiasis should be evaluated for diabetes mellitus. Elevated salivary glucose concentrations (119) and elevated skin surface pH in the intertriginous regions of patients with diabetes (120) may promote an environment in which candida can thrive. Candida infection can involve the mucosa (e.g., thrush, vulvovaginitis), intertriginous areas (e.g., intertrigo, erosion interdigital, balanitis), or nails (e.g., paronychia). Mucosal involvement presents with pruritus, erythema, and white plaques which can be removed when scraped. Intertriginous Candida infections may be pruritic or painful and present with red macerated, fissured plaques with satellite vesciulopustules. Involvement of the nails may present with periungual inflammation or superficial white spots. Onychomycosis may be due to dermatophytes (discussed below) or Candidal infection. Onychomycosis, characterized by subungual hyperkeratosis and onycholysis, is present in nearly one in two patients with type 2 diabetes mellitus. Candidiasis is treated with topical or oral antifungal agents. Patients also benefit from improved glycemic control and by keeping the affected areas dry.

 

Dermatophytes

 

Although it remains controversial, dermatophyte infections appear to be more prevalent among patients with diabetes (121-123). Various regions of the body may be affected but tinea pedis (foot) is the most common dermatophyte infection affecting patients; it presents with pruritus or pain and erythematous keratotic or bullous lesions. Relatively benign dermatophyte infections like tinea pedis can lead to serious sequela, such as secondary bacterial infection, fungemia, or sepsis, in patients with diabetes if not treated hastily. Patients with diabetic neuropathy may be especially vulnerable (124). Treatment may include topical or systemic antifungal medications depending on the severity.

 

Mucormycosis

 

Mucormycosis is a serious infection that is associated with type 1 diabetes mellitus, particularly common in those who develop diabetic ketoacidosis. A variety of factors including hyperglycemia and a lower pH, create an environment in which Rhizopus oryzae, a common pathogen responsible for mucormycosis, can prosper. Mucormycosis may present in different ways. Rhino-orbital-cerebral mucormycosis is the most common  presentation;  it  develops  quickly  and presents with acute sinusitis, headache, facial edema, and tissue necrosis. The infection may worsen and cause extensive necrosis and thrombosis of nearby structures such as the eye. Mucormycosis should be treated urgently with surgical debridement and intravenous amphotericin B. When it is not suitable to administer amphotericin B in patients, the alternative use of new triazoles, posaconazole and isavuconazole, may be beneficial (124A).

 

Toe Web Findings

 

Lastly, abnormal toe web findings (e.g., maceration, scale, or erythema) may be an early marker of irregularities in glucose metabolism and of undiagnosed diabetes mellitus (125). Additionally, such findings may be a sign of epidermal barrier disruption, a precursor of infection (125).

 

CUTANEOUS CHANGES ASSOCIATED WITH DIABETES MEDICATIONS

 

Insulin

 

A number of localized changes are associated with the subcutaneous injection of insulin. The most common local adverse effect is lipohypertrophy, which affects less than thirty percent of patients with diabetes that use insulin (126,127). Lipohypertrophy is characterized by localized adipocyte hypertrophy and presents with soft dermal nodules at injection sites. Continued injection of insulin at sites of lipohypertrophy can result in delayed systemic insulin absorption and capricious glycemic control. With avoidance of subcutaneous insulin at affected sites, lipohypertrophy normally improves over the course of a few months.

 

Furthermore, lipoatrophy is an uncommon cutaneous finding which occurred more frequently prior to the introduction of modern purified forms of insulin. Lipoatrophy presents at insulin injection sites over a period of months with round concave areas of adipose tissue atrophy. Allergic reactions to the injection of insulin may be immediate (within one hour) or delayed (within one day) and can present with localized or systemic symptoms. These reactions may be due to a type one hypersensitivity reaction to insulin or certain additives. However, allergic reactions to subcutaneous insulin are rare, with systemic allergic reactions occurring in only 0.01% of patients (126). Other cutaneous changes at areas of injection include the development of pruritus, induration, erythema, nodular amyloidosis, or calcification.

 

Oral Medications

 

Oral hypoglycemic agents may cause a number of different cutaneous adverse effects such as erythema multiforme or urticaria. DPP-4 inhibitors, such as vildagliptin, can be associated with inflamed blistering skin lesions, including bullous pemphigoid and Stevens-Johnson syndrome, as well as angioedema (128,129). Allergic skin and photosensitivity reactions may occur with sulfonylureas (130). The sulfonylureas, particularly the first-generation drugs chlorpropamide and tolbutamide, are associated with the development of a maculopapular rash during the initial two months of treatment; the rash quickly improves with stoppage of the medication (131,132). In certain patients with genetic predispositions, chlorpropamide may also cause acute facial flushing following alcohol consumption (133). SGLT-2 inhibitors have been associated with an increased risk of genital fungal infections and Fournier’s gangrene (134) (for details see Endotext chapter Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes) (135). Fixed drug eruptions, drug-induced pruritus, and Sweet syndrome/acute febrile neutrophilic dermatosis have also been observed in patients with type 2 diabetes using SGLT2 inhibitors, among other skin lesions (135A). 

 

Glucagon-like Peptide-1 Receptor Agonists

 

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, liraglutide, exenatide, and dulaglutide, are primarily used to manage type 2 diabetes and support weight loss. They can be administered via subcutaneous or oral routes. Dermatologists should be prepared to counsel patients about the possibility of rapid weight loss leading to facial fat loss; this can manifest as the “development of wrinkles, sunken eyes, a hollowed appearance, sagging jowls around the neck and jaw, and alterations in the cheeks, lips, and chin,” with effects also often noticed in the buttocks (135C). This phenomenon is thought to be due to a natural consequence of rapid weight loss combined with slow elastin turnover, rather than a direct effect of these drugs on adipocytes of the face or buttocks and may resolve with weight gain upon drug cessation (135B). While the common drug-related side effects of GLP-1 receptor agonists are gastrointestinal, there have been reports of dermatologic reactions, though these are relatively rare (136,137). Altered skin sensation (including dysesthesia, hyperesthesia, allodynia, and paresthesia) and alopecia were found to be significantly associated with a 50mg weekly dose of oral semaglutide, though the mechanisms and risk factors for these events remain to be characterized (136). Among the few case reports of severe cutaneous adverse events in patients taking GLP-1 agonists, exenatide was the most mentioned drug (136,137). Cases included angioedema, bullous pemphigoid, dermal hypersensitivity, eosinophilic fasciitis, and leukocytoclastic vasculitis, with >90% recovering within days to months of discontinuing the drug (136,137). Despite the side effects, GLP-1 agonists have been used off label in several cases to effectively manage diabetes-associated cutaneous conditions including psoriasis, hidradenitis suppurativa, and acanthosis nigricans (138).

 

Diabetes Devices

 

Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSIIs) are devices used in the treatment of type 1 diabetes. Contact dermatitis is associated with both CGMs and CSIIs, while CSIIs inject insulin subcutaneously and thus carry the risk of insulin-associated skin changes (139).

 

CONCLUSION

 

Diabetes mellitus is associated with a broad array of dermatologic conditions (Table 1). Many of the sources describing dermatologic changes associated with diabetes mellitus are antiquated; larger research studies utilizing modern analytic tools are needed to better understand the underlying pathophysiology and treatment efficacy. Although each condition may respond to a variety of specific treatments, many will improve with improved glycemic control. Hence, patient education and lifestyle changes are key in improving the health and quality of life of patients with diabetes mellitus.

 

Table 1. Frequent Skin Manifestations of Diabetes Mellitus

DISEASE

APPEARANCE

COMMON

LOCATIONS

SYMPTOMS

TREATMENT

Acanthosis Nigricans

Multiple poorly- demarcated plaques with grey to dark-brown hyperpigmentation, and a thickened velvety to verrucoustexture

Back of the neck, axilla, elbows, palmar hands, inframammary creases, umbilicus, groin

Typically, asymptomatic

Improved glycemic control, oral retinoids, ammonium lactate, retinoic acid, salicylic acid

Diabetic Dermopathy

Rounded, dull, red papules that progressively

evolve over one- to-two weeks into well-circumscribed, atrophic, brown macules with a fine scale; lesions present in different stages ofevolution at the sametime

Pretibial area, lateral malleoli, thighs

Typically, asymptomatic

Self-resolving

Diabetic Foot Syndrome

Chronic ulcers, secondary infection,diabetic neuro- osteoarthropathy, clawing deformity

Feet

Typically, asymptomatic but may have abnormal gait

Interdisciplinary team-based approach involving daily surveillance, appropriate foot hygiene, proper footwear/walker, wound care,antibiotics, wound debridement, surgery

Scleroderma- like Skin Changes

Slowly developing painless, indurated, occasionally waxy appearing, thickened skin

Acral areas: dorsum of the fingers, proximal interphalangeal areas, metacarpophalangeal joints

Typically, asymptomatic but may have reduced range of motion

Improved glycemic control, aldose reductase inhibitors, physical therapy

Ichthyosiform Skin Changes

Large bilateral areas of dryness andscaling (may be described as “fishscale” skin)

Anterior shins, hands, feet

Typically, asymptomatic

Emollients, Keratolytics

Xerosis

Abnormally dry skinthat may also present with

scaling or fissures

Most common on thefeet

Typically, asymptomatic

Emollients

Pruritus

Normal or excoriatedskin

Often localized to the scalp, ankles, feet, trunk, or genitalia; however, it may be generalized

Pruritus

Topical capsaicin,topical ketamine-

amitriptyline-lidocaine, oral anticonvulsants, antifungals

 

REFERENCES

 

  1. Meurer M, Stumvoll M, Szeimies R-M. Hautveränderungen bei Diabetes mellitus. Der Hautarzt 2004;55(5):428-35
  2. Stuart CA, Gilkison CR, Smith MM, Bosma AM, Keenan BS, Nagamani M. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clinical Pediatrics 1998;37(2):73-79
  3. Stuart CA, Driscoll MS, Lundquist KF, Gilkison CR, Shaheb S, Smith MM. Acanthosis nigricans. Journal of basic and clinical physiology and pharmacology 1998;9(2-4):407-18
  4. Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. Journal of the American Academy of Dermatology 2000;42(2):357-62

4A.    Kondo Y, Umegaki N, Terao M, Murota H, Kimura T, Katayama I. A case of generalized acanthosis nigricans with positive lupus erythematosus-related autoantibodies and antimicrosomal antibody: autoimmune acanthosis nigricans? Case Rep Dermatol. 2012 Jan;4(1):85-91.

4B.    Yu Q, Li XL, Ji G, Wang Y, Gong Y, Xu H, Shi YL. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. World J Surg Oncol. 2017 Nov 25;15(1):208.

4C.    Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 1994;189(2):203-6

4D.    Mellor-Pita S, Yebra-Bango M, Alfaro-Martínez J, Suárez E. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors. Clin Infect Dis. 2002 Mar 01;34(5):716-7.

4E.    Fleming MG, Simon SI. Cutaneous insulin reaction resembling acanthosis nigricans. Arch Dermatol. 1986 Sep;122(9):1054-6.

4F.    Fukuchi K, Tatsuno K, Matsushita K, Kubo A, Ito T, Tokura Y. Familial acanthosis nigricans with p.K650T FGFR3 mutation. J Dermatol. 2018 Feb;45(2):207-210.

  1. Bhagyanathan M, Dhayanithy D, Parambath VA, Bijayraj R. Acanthosis nigricans: A screening test for insulin resistance–An important risk factor for diabetes mellitus type-2. Journal of family medicine and primary care 2017;6(1):43
  2. Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance. American journal of clinical dermatology 2004;5(3):199-203

6A.    Das A, Datta D, Kassir M, et al. Acanthosis nigricans: A review. J Cosmet Dermatol. 2020;19(8):1857-1865. doi:10.1111/jocd.13544

  1. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatology online journal 2008;14(9)

7A.    Malisiewicz B, Boehncke S, Lang V, Boehncke WH, Buerger C. Epidermal insulin resistance as a therapeutic target in acanthosis nigricans?. Acta Derm Venereol. 2014;94(5):607-608. doi:10.2340/00015555-1778

  1. Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis 2003;71(1):33-34
  2. Ehsani A, Noormohammadpour P, Goodarzi A, et al. Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: A case series of patients in a before-after trial. Caspian journal of internal medicine 2016;7(4):290
  3. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. Journal of the American Academy of Dermatology 2007;57(3):502-08

10A.  Walling HW, Messingham M, Myers LM, Mason CL, Strauss JS. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol. 2003 Dec;2(6):677-81. PMID: 14711151.

  1. Bustan RS, Wasim D, Yderstræde KB, Bygum A. Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state-a systematic review. Danish medical journal 2017;64(1)
  2. Morgan AJ, Schwartz RA. Diabetic dermopathy: A subtle sign with grave implications. Journal of the American Academy of Dermatology 2008;58(3):447-51

12A.  Naik PP, Farrukh SN. Clinical Significance of Diabetic Dermatopathy. Diabetes Metab Syndr Obes. 2020;13:4823-4827. Published 2020 Dec 8. doi:10.2147/DMSO.S286887

  1. Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes research and clinical practice 1998;39(2):101-06
  2. Huntley AC. The cutaneous manifestations of diabetes mellitus. Journal of the American Academy of Dermatology 1982;7(4):427-55
  3. Houck GM, Morgan MB. A reappraisal of the histologic findings of pigmented pretibial patches of diabetes mellitus. Journal of cutaneous pathology 2004;31(2):141-44
  4. McCASH S, Emanuel PO. Defining diabetic dermopathy. The Journal of dermatology 2011;38(10):988-92
  5. Kaňková K, Záhejský J, Márová I, et al. Polymorphisms in the RAGE gene influence susceptibility to diabetes- associated microvascular dermatoses in NIDDM. Journal of Diabetes and its Complications 2001;15(4):185-92
  6. Kiziltan M, Benbir G. Clinical and nerve conduction studies in female patients with diabetic dermopathy. Acta diabetologica 2008;45(2):97-105

18A.  Naik PP, Farrukh SN. Clinical Significance of Diabetic Dermatopathy. Diabetes Metab Syndr Obes. 2020;13:4823-4827. Published 2020 Dec 8. doi:10.2147/DMSO.S286887

  1. Amin N, Doupis J. Diabetic foot disease: from the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World journal of diabetes 2016;7(7):153
  2. Sämann A, Tajiyeva O, Müller N, et al. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross‐sectional study. Diabetic Medicine 2008;25(5):557-63

20A.  Boulton AJM, Whitehouse RW. The Diabetic Foot. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2023

  1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. Jama 2005;293(2):217-28
  2. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. The Lancet 2005;366(9498):1719-24
  3. Mlinarić-Missoni E, Kalenić S, Važić-Babić V. Species distribution and frequency of isolation of yeasts and dermatophytes from toe webs of diabetic patients. Acta dermatovenerologica Croatica 2005;13(2):0-0
  4. Davis MD, O'fallon WM, Rogers III RS, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Archives of Dermatology 2000;136(3):330-36
  5. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. The lancet 2003;361(9368):1545-51
  6. Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes care 2005;28(2):461-71
  7. Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. International journal of molecular sciences 2016;17(6):917
  8. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. International journal of endocrinology 2014;2014

28A.  Theocharidis G, Thomas BE, Sarkar D, Mumme HL, Pilcher WJR, Dwivedi B, Sandoval-Schaefer T, Sîrbulescu RF, Kafanas A, Mezghani I, Wang P, Lobao A, Vlachos IS, Dash B, Hsia HC, Horsley V, Bhasin SS, Veves A, Bhasin M. Single cell transcriptomic landscape of diabetic foot ulcers. Nat Commun. 2022 Jan 10;13(1):181. doi: 10.1038/s41467-021-27801-8. PMID: 35013299; PMCID: PMC8748704.

  1. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001;68(11):928- 30, 32, 34-44
  2. Peripheral Arterial Disease in People With Diabetes. Diabetes Care 2003;26(12):3333-4

30A.  Lanting SM, Chan TL, Casey SL, Peterson BJ, Chuter VH. Cutaneous microvascular reactivity in Charcot neuroarthropathy: a systematic review and meta-analysis. J Foot Ankle Res. 2022 Mar 1;15(1):17. doi: 10.1186/s13047-022-00522-x. PMID: 35232466; PMCID: PMC8886937.

  1. Khanna S, Biswas S, Shang Y, et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PloS one 2010;5(3):e9539
  2. Ahn C, Yosipovitch G, Huang W. Diabetes and the Skin. In: Callen J, Jorizzo J, Zone J, Piette W, Rosenbach M, Vleugels RA, eds. Dermatological Signs of Systemic Disease. Edinburgh: Elsevier, 2017:205-14.
  3. Yosipovitch G, Hodak E, Vardi P, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes care 1998;21(4):506-09
  4. Brik R, Berant M, Vardi P. The scleroderma‐like syndrome of insulin‐dependent diabetes mellitus. Diabetes/Metabolism Research and Reviews 1991;7(2):121-28
  5. Yosipovitch G, Yosipovitch Z, Karp M, Mukamel M. Trigger finger in young patients with insulin dependent diabetes. The Journal of rheumatology 1990;17(7):951-52
  6. Kim RP, Edelman SV, Kim DD. Musculoskeletal complications of diabetes mellitus. Clinical Diabetes 2001;19(3):132-35
  7. Haustein UF. Scleroderma‐like lesions in insulin‐ dependent diabetes mellitus. Journal of the European Academy of Dermatology and Venereology 1999;13(1):50- 53
  8. Yosipovitch G, Loh KC, Hock OB. Medical pearl: Scleroderma-like skin changes in patients with diabetes mellitus. Journal of the American Academy of Dermatology 2003;49(1):109-11
  9. Rho YW, Suhr KB, Lee JH, Park JK. A clinical observation of scleredema adultorum and its relationship to diabetes. The Journal of dermatology 1998;25(2):103-07
  10. Sawatkar G, Kanwar A, Dogra S, Bhadada S, Dayal D. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 south Asian patients. British Journal of Dermatology 2014;171(6):1402-06
  11. Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ. Limited joint mobility syndrome in diabetes mellitus: A minireview. World journal of diabetes 2015;6(9):1108
  12. Fitzgibbons PG, Weiss A-PC. Hand manifestations of diabetes mellitus. The Journal of hand surgery 2008;33(5):771-75
  13. Abate M, Schiavone C, Pelotti P, Salini V. Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy: SAGE Publications Sage UK: London, England, 2010.
  14. Frost D, Beischer W. Limited joint mobility in type 1 diabetic patients. Diabetes care 2001;24(1):95-99
  15. Lopez-Martin I, Benito Ortiz L, Rodriguez-Borlado B, Cano Langreo M, Garcia-Martinez FJ, Martin Rodriguez MF. (Association between limited joint mobility syndrome and risk of accidental falls in diabetic patients). Semergen 2015;41(2):70-5
  16. Lindsay JR, Kennedy L, Atkinson AB, et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a UK clinic population over a 20-year period. Diabetes Care 2005;28(3):658-61
  17. Rongioletti F, Kaiser F, Cinotti E, et al. Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. Journal of the European Academy of Dermatology and Venereology 2015;29(12):2399-404

47A.  Hines A, Alavi A, Davis MDP. Cutaneous Manifestations of Diabetes. Med Clin North Am. 2021;105(4):681-697. doi:10.1016/j.mcna.2021.04.008

  1. Cole GW, Headley J, Skowsky R. Scleredema Diabeticorum: A Common and Distinct Cutaneous Manifestation of Diabetes Mellitus. Diabetes Care 1983;6(2):189-92.
  2. Carrington PR, Sanusi I, Winder PR, Turk LL, Jones C, Millikan LE. Scleredema adultorum. International journal of dermatology 1984;23(8):514-22
  3. Martin C, Requena L, Manrique K, Manzarbeitia F, Rovira A. Scleredema diabeticorum in a patient with type 2 diabetes mellitus. Case reports in endocrinology 2011;2011
  4. Varga J, Gotta S, Li L, Sollberg S, Leonardo M. Scleredema adultorum: case report and demonstration of abnormal expression of extracellular matrix genes in skin fibroblasts in vivo and in vitro. British Journal of Dermatology 1995;132(6):992-99

51A.  Knobler R, Geroldinger-Simić M, Kreuter A, et al. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema. J Eur Acad Dermatol Venereol. 2024;38(7):1281-1299. doi:10.1111/jdv.19937

  1. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clinical Reviews in Allergy & Immunology 2017:1-31
  2. Bray SM, Varghese S, English JC. Ultrasonic massage and physical therapy for scleredema: improving activities of daily living. Archives of dermatology 2010;146(4):453-54
  3. Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. Journal of the American Academy of Dermatology 2013;69(5):783-91
  4. O’toole E, Kennedy U, Nolan J, Young M, Rogers S, Barnes L. Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol 1999;140(2):283-6
  5. Muller SA, Winkelmann R. Necrobiosis lipoidica diabeticorum: a clinical and pathological investigation of 171 cases. Archives of dermatology 1966;93(3):272-81

56A.  Severson KJ, Patel MH, Brumfiel CM, Breen I, Butterfield RJ, Nelson SA, Sekulic A, Pittelkow MR, Mangold AR. Comorbidities and diabetic complications in patients with necrobiosis lipoidica. J Am Acad Dermatol. 2022 Apr;86(4):891-894. doi: 10.1016/j.jaad.2021.03.026. Epub 2021 Mar 17. PMID: 33722550.

  1. Kota SK, Jammula S, Kota SK, Meher LK, Modi KD. Necrobiosis lipoidica diabeticorum: A case-based review of literature. Indian journal of endocrinology and metabolism 2012;16(4):614
  2. Lopez PR, Leicht S, Sigmon JR, Stigall L. Bullosis diabeticorum associated with a prediabetic state. Southern medical journal 2009;102(6):643-44

58A.  Chouk C, Litaiem N. Bullosis Diabeticorum. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 10, 2024.

  1. Larsen K, Jensen T, Karlsmark T, Holstein PE. Incidence of bullosis diabeticorum–a controversial cause of chronic foot ulceration. International wound journal 2008;5(4):591- 96
  2. Lipsky BA, Baker PD, Ahroni JH. Diabetic bullae: 12 cases of a purportedly rare cutaneous disorder. International journal of dermatology 2000;39(3):196-200
  3. Patel N, Spencer LA, English JC, Zirwas MJ. Acquired ichthyosis. Journal of the American Academy of Dermatology 2006;55(4):647-56
  4. Pavlović MD, Milenković T, Dinić M, et al. The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes care 2007;30(8):1964-67
  5. Goyal A, Raina S, Kaushal SS, Mahajan V, Sharma NL. Pattern of cutaneous manifestations in diabetes mellitus. Indian journal of dermatology 2010;55(1):39

63A.  Iacopi E, Riitano N, Dini V, Berta R, Pieruzzi L, Janowska A, Anselmino M, Piaggesi A, Romanelli M. Using Skin Bioengineering to Highlight How Weight and Diabetes Mellitus Modify the Skin in the Lower Limbs of Super- Obese Patients. Diabetes Metab Syndr Obes. 2020 Mar 16;13:729-738.  doi:  10.2147/DMSO.S229042.  PMID: 32214836; PMCID: PMC7083633.

  1. Pavicic T, Korting HC. Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2006;4(11):935-41
  2. Saray Y, Seçkin D, Bilezikçi B. Acquired perforating dermatosis: clinicopathological features in twenty‐two cases. Journal of the European Academy of Dermatology and Venereology 2006;20(6):679-88
  3. Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Acquired reactive perforating collagenosis: current status. The Journal of dermatology 2010;37(7):585-92
  4. Poliak SC, Lebwohl MG, Parris A, Prioleau PG. Reactive perforating collagenosis associated with diabetes mellitus. New England Journal of Medicine 1982;306(2):81-84
  5. Abdelbaqi‐Salhab M, Shalhub S, Morgan MB. A current review of the cutaneous manifestations of renal disease. Journal of cutaneous pathology 2003;30(9):527-38
  6. Robles-Mendez J, Vazquez-Martinez O, Ocampo-Candiani J. Skin manifestations of chronic kidney disease. Actas Dermo-Sifiliográficas 2015;106(8):609-22
  7. Morton C, Henderson I, Jones M, Lowe J. Acquired perforating dermatosis in a British dialysis population. British Journal of Dermatology 1996;135(5):671-77

70A.  Forouzandeh M, Stratman S, Yosipovitch G. The treatment of Kyrle's disease: a systematic review. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1457-1463. doi: 10.1111/jdv.16182. Epub 2020 Feb 5. PMID: 31919924.

  1. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med 2008;75(11):772-74
  2. Wagner G, Sachse MM. Acquired reactive perforating dermatosis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2013;11(8):723-29 doi: 10.1111/ddg.12131(published Online First: Epub Date)|.

72A.  Ying Y, Shuang C, Zhen-Ying Z. Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD. Immun Inflamm Dis. 2022 Mar;10(3):e574. doi: 10.1002/iid3.574. Epub 2021 Dec 24. PMID: 34953055; PMCID: PMC8926492.

  1. Sugandhan S, Khandpur S, Sharma VK. Familial chylomicronemia syndrome. Pediatric dermatology 2007;24(3):323-25
  2. Mahajan S, Koranne R, Sharma S. Cutaneous manifestation of diabetes melitus. Indian Journal of Dermatology, Venereology, and Leprology 2003;69(2):105
  3. Ahmed K, Muhammad Z, Qayum I. Prevalence of cutaneous manifestations of diabetes mellitus. J Ayub Med Coll Abbottabad 2009;21(2):76-9
  4. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015;58(5):886-99

76A.  Feingold KR. Dyslipidemia in Patients with Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2023

  1. Naik NS. Eruptive xanthomas. Dermatology online journal 2001;7(2)
  2. Zaremba J, Zaczkiewicz A, Placek W. Eruptive xanthomas. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii 2013;30(6):399
  3. Parker F. Xanthomas and hyperlipidemias. Journal of the American Academy of Dermatology 1985;13(1):1-30
  4. Ales Z, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomedical Papers 2014;158(2):181-88

80A.  Feingold KR. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2024

  1. Margolis J. Letter: Skin tags in diabetes mellitus. N Engl J Med 1976;295:172-3
  2. Levy L, Zeichner JA. Dermatologic manifestation of diabetes. Journal of diabetes 2012;4(1):68-76
  3. Yamaoka H, Sasaki H, Yamasaki H, et al. Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. Diabetes care 2010;33(1):150-55
  4. Valdes-Rodriguez R, Mollanazar NK, González-Muro J, et al. Itch prevalence and characteristics in a Hispanic geriatric population: a comprehensive study using a standardized itch questionnaire. Acta dermato- venereologica 2015;95(4):417-21

84A. Ju T, Does AV, G. Yosipovitch. Scalp dysesthesia: a neuropathic phenomenon. Journal of the European Academy of Dermatology and Venereology. 2022;36(6):790-796. doi:https://doi.org/10.1111/jdv.17985

84B.  Parisi TJ, Mandrekar J, Dyck PJB, Klein CJ. Meralgia paresthetica: Relation to obesity, advanced age, and diabetes mellitus. Neurology. 2011;77(16):1538-1542. doi:https://doi.org/10.1212/wnl.0b013e318233b356

84C.  Yang QP, Chen YY, Li Z, Xu M. Major Risk Factors Analysis of Pruritus Complicated by Type 2 Diabetes Mellitus and the Effect of Comprehensive Nursing Intervention. Front Surg. 2022 Feb 15;9:842884. doi: 10.3389/fsurg.2022.842884. PMID: 35242808; PMCID: PMC8887712.

84D.  Merdin FA, Aydemir AT, Korkmaz FN, et al. Evaluation of chronic pruritus and associated skin findings in patients with diabetes mellitus. Turkish Journal of Medical Sciences. 2023;53(5):1489-1497. doi:https://doi.org/10.55730/1300-0144.5716

84E.  Yang QP, Chen YY, Li Z, Xu M. Major Risk Factors Analysis of Pruritus Complicated by Type 2 Diabetes Mellitus and the Effect of Comprehensive Nursing Intervention. Front Surg. 2022 Feb 15;9:842884. doi: 10.3389/fsurg.2022.842884. PMID: 35242808; PMCID: PMC8887712.

  1. Guarneri C, Guarneri F, Borgia F, Vaccaro M. Finger pebbles in a diabetic patient: Huntley's papules. International journal of dermatology 2005;44(9):755-56
  2. Tabor CA, Parlette EC. Cutaneous manifestations of diabetes: signs of poor glycemic control or new-onset disease. Postgraduate medicine 2006;119(3):38-44
  3. Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus. Endocrinology and Metabolism Clinics 2013;42(4):869-98
  4. Liau M, Long V, Yang S, Tan K, Aw D. Pigmented purpuric dermatosis  in  Singapore:  a  clinic-epidemiological characterisation. Hong Kong Journal of Dermatology & Venereology 2016;24(2):65-69
  5. Lithner F. Purpura, pigmentation and yellow nails of the lower extremities in diabetics. Journal of Internal Medicine 1976;199(1‐6):203-08
  6. Demirseren DD, Emre S, Akoglu G, et al. Relationship between skin diseases and extracutaneous complications of diabetes mellitus: clinical analysis of 750 patients. American journal of clinical dermatology 2014;15(1):65-70
  7. Serrao R, Zirwas M, English JC. Palmar erythema. American journal of clinical dermatology 2007;8(6):347-56
  8. Landau J, Davis E. The small blood-vessels of the conjunctiva and nailbed in diabetes mellitus. The Lancet 1960;276(7153):731-34
  9. Oumeish OY. Skin disorders in patients with diabetes. Clinics in dermatology 2008;26(3):235-42
  10. Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. Clinical Diabetes 2015;33(1):40-48
  11. Bristow I. Non‐ulcerative skin pathologies of the diabetic foot. Diabetes/metabolism research and reviews 2008;24(S1)

95A.  Yesudian PD, Nwabudike LC, de Berker D. Nail changes in diabetes. Clin Exp Dermatol. 2022 Jan;47(1):9-15. doi: 10.1111/ced.14859. Epub 2021 Sep 21. PMID: 34293827.

  1. Mendes AL, Miot HA, Haddad Junior V. Diabetes mellitus and the skin. Anais brasileiros de dermatologia 2017;92(1):8-20
  2. Yun JH, Lee JY, Kim MK, et al. Clinical and pathological features of generalized granuloma annulare with their correlation: a retrospective multicenter study in Korea. Annals of dermatology 2009;21(2):113-19

97A.  Joshi TP, Duvic M. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol. 2022;23(1):37-50. doi:10.1007/s40257-021-00636-1

  1. Cyr PR. Diagnosis and management of granuloma annulare. American family physician 2006;74(10)
  2. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatology 2013;149(1):84-91
  3. Seyhan M, Özcan H, Sahin I, Bayram N, Karincaoğlu Y. High prevalence of glucose metabolism disturbance in patients with lichen planus. Diabetes research and clinical practice 2007;77(2):198-202
  4. Guggenheimer J, Moore PA, Rossie K, et al. Insulin- dependent diabetes mellitus and oral soft tissue pathologies: I. Prevalence and characteristics of non- candidal lesions. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2000;89(5):563-69
  5. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009;67(11):376- 87

102A. Sperling MA, Angelousi A, Yau M. Autoimmune Polyglandular Syndromes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2024

  1. Von der Werth J, Williams H. The natural history of hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology 2000;14(5):389-92

103A. Jenkins T, Isaac J, Edwards A, Okoye GA. Hidradenitis Suppurativa. Dermatol Clin. 2023;41(3):471-479. doi:10.1016/j.det.2023.02.001

  1. Bui T-L, Silva-Hirschberg C, Torres J, Armstrong AW. Hidradenitissuppurativa  and  diabetes  mellitus: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 2017
  2. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. Journal of the American Academy of Dermatology 2009;60(4):539-61
  3. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome–cumulative experience with an elusive endocrine tumour. Clinical endocrinology 2011;74(5):593-98
  4. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The Glucagonoma Syndrome Clinical and Pathologic Features in 21 Patients. Medicine 1996;75(2):53-63
  5. Kovács RK, Korom I, Dobozy A, Farkas G, Ormos J, Kemény L. Necrolytic migratory erythema. Journal of cutaneous pathology 2006;33(3):242-45
  6. Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatictumors  with  glucagon  hypersecretion:  a retrospective study of 23 cases during 20 years. Medical Oncology 2007;24(3):330-37
  7. Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. Journal of general internal medicine 2013;28(11):1525-29

110A de Herder WW, Hofland J. Glucagon & Glucagonoma Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2023

110B. Tønder JE, Bønnelykke-Behrndtz ML, Laurberg T, Røssell EL, Sollie M. Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes: a systematic review and meta-analysis. BMC Cancer. 2024;24(1). doi:https://doi.org/10.1186/s12885-024-12598-8

110C. Kaneko A, Hisashi Kanemaru, Satoru Mizuhashi, et al. Relationship between Type 2 diabetes mellitus and aggressiveness of melanoma. Journal of Dermatological Science. 2022;106(1):65-67. doi:https://doi.org/10.1016/j.jdermsci.2022.03.006

  1. Macedo GMC, Nunes S, Barreto T. Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. Diabetology & metabolic syndrome 2016;8(1):63

111A. Polk C, Sampson MM, Roshdy D, Davidson LE. Skin and Soft Tissue Infections in Patients with Diabetes Mellitus. Infect Dis Clin North Am. 2021 Mar;35(1):183-197. doi: 10.1016/j.idc.2020.10.007. Epub 2020 Dec 7. PMID: 33303332.

  1. Kutlu SS, Cevahir N, Akalin S, et al. Prevalence and risk factors for methicillin-resistant Staphylococcus aureus colonizationin  a  diabetic  outpatient  population:  a prospective cohort study. American journal of infection control 2012;40(4):365-68
  2. Hartemann‐Heurtier A, Robert J, Jacqueminet S, et al. Diabetic foot ulcer and multidrug‐resistant organisms: risk factors and impact. Diabetic Medicine 2004;21(7):710-15
  3. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian journal of endocrinology and metabolism 2012;16(Suppl1):S27
  4. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67(3):351-68
  5. Bonne SL, Kadri SS. Evaluation and management of necrotizing soft tissue infections. Infectious Disease Clinics 2017;31(3):497-511
  6. Dworkin M, Westercamp M, Park L, McIntyre A. The epidemiology of necrotizing fasciitis including factors associated with death and amputation. Epidemiology & Infection 2009;137(11):1609-14
  7. Bhandary S, Karki P, Sinha B. Malignant otitis externa: a review. Pacific health dialog 2002;9(1):64-67
  8. Sashikumar R, Kannan R. Salivary glucose levels and oral candidal carriage in type II diabetics. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2010;109(5):706-11
  9. Yosipovitch G, Tur E, Cohen O, Rusecki Y. Skin surface pH in intertriginous areas in NIDDM patients: possible correlation to candidal intertrigo. Diabetes Care 1993;16(4):560-63
  10. SaunteDML, Holgersen  JB, Hædersdal M, et al. Prevalence of toe nail onychomycosis in diabetic patients. Acta dermato-venereologica 2006;86(5):425-28
  11. Alteras I, Saryt E. Prevalence of pathogenic fungi in the toe-webs and toe-nails of diabetic patients. Mycopathologia 1979;67(3):157-59
  12. Romano C, Massai L, Asta F, Signorini A. Prevalence of dermatophytic skin and nail infections in diabetic patients. Mycoses 2001;44(3‐4):83-86
  13. Rich P. Onychomycosis and tinea pedis in patients with diabetes. Journal of the American Academy of Dermatology 2000;43(5):S130-S34

124A. Sharma A, Goel A. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha). 2022 Feb 26:1–25. doi: 10.1007/s12223-021-00934-5. Epub ahead of print. PMID: 35220559; PMCID: PMC8881997.

  1. Sinikumpu S-P, Auvinen J, Jokelainen J, et al. Abnormal skin in toe webs is a marker for abnormal glucose metabolism. A cross-sectional survey among 1,849 adults in Finland. Scientific reports 2017;7:9125
  2. Richardson T, Kerr D. Skin-related complications of insulin therapy.American  journal of  clinical   dermatology 2003;4(10):661-67
  3. Lima AL, Illing T, Schliemann S, Elsner P. Cutaneous Manifestations of Diabetes Mellitus: A Review. American Journal of Clinical Dermatology 2017:1-13
  4. Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoidassociated  with  dipeptidyl  peptidase  IV inhibitors. A case report and review of literature. Journal of dermatological case reports 2014;8(1):24
  5. Byrd JS, Minor DS, Elsayed R, Marshall GD. DPP-4 inhibitors and angioedema: a cause for concern? Annals of Allergy, Asthma & Immunology 2011;106(5):436-38
  6. Hitselberger JF, Fosnaugh RP. Photosensitivity due to chlorpropamide. JAMA 1962;180(1):62-63
  7. Walker G, Kinsell LW. Clinical experience with chlorpropamide. California medicine 1961;94(6):344
  8. Walker G, Slater J, Westlake E, Nabarro J. Clinical experience with tolbutamide. British medical journal 1957;2(5040):323
  9. Leslie R, Pyke D. Chlorpropamide-alcohol flushing: a dominantly inherited trait associated with diabetes. Br med J 1978;2(6151):1519-21
  10. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current medical research and opinion 2014;30(6):1109-19
  11. Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. In: Feingold KR, Anawalt B, Boyce A, et al editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2024

135A. Mederle AL, Dumitrescu P, Borza C, Nilima Rajpal Kundnani. Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors. Journal of Clinical Medicine. 2024;14(1):188-188. doi:https://doi.org/10.3390/jcm14010188

135B. Carboni A, Woessner S, Martini O, Marroquin NA, Waller J. Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon. J Drugs Dermatol. 2024;23(1):1367-1368. doi:10.36849/JDD.7613

135C. Mansour MR, Hannawa OM, Yaldo MM, Nageeb EM, Chaiyasate K. The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. J Plast Reconstr Aesthet Surg. 2024;96:225-227. doi:10.1016/j.bjps.2024.07.051‌

  1. Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: A scoping review. Journal of the American Academy of Dermatology. 2024;91(1):166-168. doi:https://doi.org/10.1016/j.jaad.2024.03.021
  2. Salazar CE, Patil MK, Osaigbokan Aihie, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Archives of Dermatological Research. 2024;316(6). doi:https://doi.org/10.1007/s00403-024-02969-3
  3. Lal K, Herringshaw E. The Use of GLP-1 Agonists in the Management of Cutaneous Disease. J Clin Aesthet Dermatol. 2024;17(9):34-37.
  4. Podwojniak A, Flemming J, Tan IJ, Ghani H, Neubauer Z, Jones A. Cutaneous adverse effects from diabetes devices in pediatric patients with type 1 diabetes mellitus: Systematic review. JMIR Dermatology. 2024;7. doi:10.2196/59824

 

Atypical Forms of Diabetes

ABSTRACT

 

While most patients with diabetes have Type 1 diabetes (T1D) or Type 2 diabetes (T2D) there are other etiologies of diabetes that occur less frequently. In this chapter we will discuss a number of these less common causes of diabetes. It is clinically very important to recognize these uncommon causes of diabetes as treatment directed towards the underlying etiology can at times result in the remission of diabetes (for example Cushing’s Syndrome) or be required to avoid other complications of the underlying disorder (for example hemochromatosis, which in addition to causing diabetes can lead to severe liver disease and congestive heart failure). In this chapter the following disorders that are associated with diabetes are discussed: 1) genetic disorders of insulin action (Type A insulin resistance, Donohue Syndrome/Leprechaunism, Rabson-Mendenhall syndrome); 2) maternally inherited diabetes mellitus and deafness syndrome; 3) disorders of the exocrine pancreas (pancreatitis, trauma/pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis); 4) endocrinopathies (acromegaly, Cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, primary hyperaldosteronism); 5) drug induced; 6) infections; 7) immune mediated (stiff-man syndrome, anti-insulin receptor antibodies); 8) ketosis prone diabetes (Flatbush diabetes); and 9) genetic disorders sometimes associated with diabetes (Down syndrome, Klinefelter syndrome, Turner syndrome, Wilsons syndrome, Wolfram syndrome, Friedreich ataxia, Bardet-Biedl syndrome [Laurence-Moon-Biedl syndrome], myotonic dystrophy, Prader-Willi syndrome, Alström syndrome, and Werner syndrome). Gestational diabetes, monogenic diabetes (maturity onset diabetes of the young (MODY) and neonatal diabetes), lipodystrophy, fibrocalculous pancreatic disease, diabetes associated with HIV infection, diabetes due to the autoimmune polyglandular syndromes, and post-transplant diabetes are not discussed in this chapter as they are discussed in other Endotext chapters.

 

INTRODUCTION

 

While most patients with diabetes have Type 1 diabetes (T1D) or Type 2 diabetes (T2D) there are other etiologies of diabetes that occur less frequently. In this chapter we will discuss a number of these less common causes of diabetes (see table 1). Note that gestational diabetes, monogenic diabetes (maturity onset diabetes of the young (MODY) and neonatal diabetes), lipodystrophy, fibrocalculous pancreatic disease, malnutrition related diabetes (being written), diabetes associated with HIV infection, diabetes due to the autoimmune polyglandular syndromes, and post-transplant diabetes are discussed in separate Endotext chapters (1-7). It is clinically very important to recognize these uncommon causes of diabetes as treatment directed towards the underlying etiology can at times result in the remission of diabetes (for example Cushing’s Syndrome) or be required to avoid other complications of the underlying disorder (for example hemochromatosis, which in addition to causing diabetes can lead to severe liver disease and congestive heart failure). Additionally, recognizing the type of diabetes can allow for the appropriate treatment. For example, recognizing ketosis prone diabetes facilitates discontinuing insulin therapy.

 

Table 1. Non-Type 1 Non-T2D Classification       

Genetic defects of beta-cell development and function

MODY (common causes- GCK, HNF1A, HNF4A, HNF1B) 

Neonatal Diabetes (common causes- KCNJ11, ABCC8, INS, 6q24)

1.     Mitochondrial DNA

Genetic defects in insulin action

1.     Type A insulin resistance

2.     Donohue Syndrome (Leprechaunism)

3.     Rabson-Mendenhall syndrome

4.     Lipoatrophic diabetes

Diseases of the exocrine pancreas

1.     Pancreatitis

2.     Fibrocalculous pancreatic disease

3.     Trauma/pancreatectomy

4.     Neoplasia

5.     Cystic fibrosis

6.     Hemochromatosis (iron overload)

Thalassemia (iron overload)

Endocrinopathies

1.     Acromegaly

2.     Cushing’s syndrome

3.     Glucagonoma

4.     Pheochromocytoma

5.     Hyperthyroidism

6.     Somatostatinoma

7.     Primary hyperaldosteronism

Drug- or chemical-induced hyperglycemia

1.     Vacor

2.     Pentamidine

3.     Nicotinic acid

4.     Glucocorticoids

5.     Diazoxide

6.     Check point inhibitors

7.     Phenytoin (Dilantin)

8.     Interferon alpha

9.     Immune suppressants

10.  Others (statins, psychotropic drugs, b-Adrenergic agonists, thiazides, fluoroquinolones, beta-adrenergic drugs, teprotumumab, etc.)

Infections

1.     Congenital rubella

2.     Hepatitis C virus

3.     HIV

COVID-19

Immune-mediated diabetes

1.     Stiff-man syndrome

2.     Anti-insulin receptor antibodies

3.     Autoimmune polyglandular syndromes

Diabetes of unknown cause

1.     Ketosis-prone diabetes (Flatbush diabetes)

Other genetic syndromes sometimes associated with diabetes

1.     Down syndrome

2.     Klinefelter syndrome

3.     Turner syndrome

4.     Wilsons syndrome

5.     Wolfram syndrome

6.     Friedreich ataxia

7.     Bardet-Biedl syndrome (Laurence-Moon-Biedl syndrome)

8.     Myotonic dystrophy

9.     Prader-Willi syndrome

10.  Alström syndrome

 

MATERNALLY INHERITED DIABETES MELLITUS AND DEAFNESS (MIDD)

 

Maternally inherited diabetes mellitus and deafness (MIDD) is a mitochondrial disorder characterized by diabetes and progressive sensorineural hearing loss (8-10). Mitochondrial DNA is only transmitted from the mother as the sperm lacks mitochondrial DNA (8). Therefore, over 50% of affected individuals with MIDD have a mother with diabetes. A mother with this disorder transmits the mutation to almost all of her offspring (11). However, the proportion of somatic cells with the mutation can vary considerably, a condition called heteroplasmy (9). The higher the number of somatic cells with a mutation the greater is the penetrance of symptoms and disease severity. Additionally, the proportion of somatic cells with a mutation can vary from tissue to tissue and may explain the variability in the manifestations of this disorder (9). The prevalence of mitochondrial diabetes in the diabetes population depends on ethnic background and ranges between 0.2% and 2%, with the highest prevalence in Japan (11).

 

MIDD is associated with a point mutation in a transfer ribonucleic acid (tRNA) gene at position 3243 with an A to G transition (8-10). In addition to diabetes and auditory impairment, the m.3243A>G mutation can cause other clinical manifestations including central neurological and psychiatric disorders, eye disease, myopathy, cardiac disorders, renal disease, endocrine disease, and gastrointestinal disease (8,9). Other point mutations in mitochondrial DNA can also result in diabetes and deafness but these mutations are rare in comparison to m.3243A>G (8,9,11).

 

It is thought that defects in mitochondrial function result in the decreased production of ATP following glucose uptake by beta cells resulting in decreased insulin secretion in response to elevated glucose levels (8,9). Additionally, mitochondrial dysfunction in the highly metabolically active pancreatic islets ultimately results in the loss of B‐cell mass further compromising insulin secretion (9). Insulin sensitivity is usually normal (11). Other tissues that are metabolically active may also be adversely effected by the inability of the mitochondria to produce ATP including the cells in the cochlea (9).

 

The clinical syndrome of MIDD can phenotypically resemble either T1D or T2D (9,11). The age of onset varies between childhood and mid-adulthood. Approximately 20% of patients present acutely with high glucose levels and even ketoacidosis (9). Most patients do not have islet cell antibodies but they are present in a small number of patients (9). This could be due to concomitant T1D or to the development of antibodies secondary to beta cell destruction due to mitochondria dysfunction. Patients tend to be thin rather than obese (9). This disorder can be distinguished from MODY by the presence of multi-organ involvement, particularly sensorineural hearing loss, and maternal rather than autosomal dominant transmission. Initially patients may be treated with diet and/or oral agents but overtime most patients with MIDD progress to requiring insulin therapy (8,9,11).

 

As the name implies, this disorder is recognized by the presence of diabetes and deafness and a family history of these conditions in maternal relatives (9,11). Hearing loss is present in approximately 75% of patients and typically precedes the development of diabetes (9). Hearing loss is more common and severe in males (9). Approximately 10-15% of patients, in addition to having diabetes and deafness, also have the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes (9). The m.3243A>G mutation can cause a wide spectrum of abnormalities that include neurological abnormalities (strokes, dementia, seizures), psychiatric disorders including recurrent major depression, schizophrenia and a variety of phobias, macular retinal dystrophy with pigmentation, proximal myopathy, cardiomyopathy, renal failure, short stature, endocrine dysfunction, and gastrointestinal complaints (9). The finding of classical retinal dystrophy and hyperpigmentation on routine eye exam should suggest the diagnosis of maternally inherited diabetes mellitus and deafness. Once suspected the diagnosis of MIDD should be confirmed by genetic testing for the mitochondrial DNA point mutation at position 3243 (A>G). This is usually initially carried out on blood cells but if negative, urinary cells or skeletal muscle can be tested and if necessary one can test for other mutations that cause similar phenotypes (12). Once a diagnosis is confirmed first-degree family members at risk should be screened for the mutation and provided with genetic counseling. For those carrying the mutation without clinical manifestations, screening for diabetes and monitoring of kidney function, hearing, and cardiac function should be carried out.

 

GENETIC DEFECTS IN INSULIN ACTION

 

Overview of Insulin Receptor Defects

 

Mutations in the insulin receptor can cause different degrees of insulin resistance but do not need to be associated with diabetes per se (13). A large number of different mutations have been described and they can be classified as mutations that prevent synthesis of the receptor, inhibit transport of the receptor to the plasma membrane, decrease insulin binding to the receptor, impair transmembrane signaling, or increase receptor degradation (14). Pancreatic beta cell hyperplasia and hyperinsulinemia can compensate for the insulin resistance preventing hyperglycemia. Fasting hypoglycemia and postprandial hyperglycemia may be observed. Over time the beta cells’ ability to secrete insulin diminishes and frank diabetes usually develops. Treatment of the diabetes may require very high doses of insulin (15). Unfortunately, insulin sensitizers have not been very effective in patients with insulin receptor defects. In contrast to the typical patients with insulin resistance, obesity, dyslipidemia, hypertension, and fatty liver are not usually present (15,16). Acanthosis nigricans, pigmentation in the neck or axillae, is a visible sign of severe insulin resistance (13,15). In females, severe insulin resistance is usually associated with hyperandrogenism, oligomenorrhea or amenorrhea, anovulation, hirsutism, acne, and masculinization (13,15). It is hypothesized that ovarian dysfunction and acanthosis nigricans are due to high levels of insulin acting via the IGF1 receptors (16). The amount of residual insulin receptor function determines the specific syndrome in patients with insulin receptor mutations (Figure 1).

 

 

Type A Insulin Resistance

 

This autosomal dominant disorder includes patients with severe insulin resistance and acanthosis nigricans (13,15). Patients have normal growth and females show ovarian hyperandrogenism that typically presents in the peripubertal period (15). In females, hyperglycemia develops after ovarian hyperandrogenism and acanthosis nigricans. Males display only acanthosis nigricans and they often remain undiagnosed even after the development of symptomatic diabetes, which may not occur until the patients are adults. These patients have mutations in the insulin receptor gene that decreases the activity of the insulin receptor (14,15). In addition, mutations in transcription factors that stimulate the expression of insulin receptors can lead to a similar phenotype as mutations in the insulin receptor (13,16). Inherited defects in pathways downstream of the insulin receptor can also lead to clinical abnormalities similar to mutations in the insulin receptor (13,16).

 

Donohue Syndrome (Leprechaunism)

 

Donohue syndrome is a rare congenital (1:1,000,000), autosomal recessive syndrome characterized by very severe insulin resistance due to mutations in the insulin receptor gene, dysmorphic features such as protuberant and low-set ears, flaring nostrils and thick lips, growth retardation, failure to thrive, and early death (14). The name leprechaunism relates to the elfin features of those affected. Clinical features include in addition to acanthosis nigricans, hypertrichosis, hirsutism, dysmorphic facies, breast enlargement, abdominal distension, and lipoatrophy. Patients have extremely high levels of insulin and can develop impaired glucose tolerance or overt diabetes. The prognosis for infants with this condition is very poor and most will die in the first year of life. When parents, who are heterozygous for mutations in the insulin receptor are studied, many of these individuals are insulin resistant (14).

 

Rabson-Mendenhall Syndrome

 

The Rabson-Mendenhall syndrome represents another disorder of extreme insulin resistance (15). This autosomal recessive syndrome is associated with mutations in the insulin receptor gene (13). Initially fasting hypoglycemia, postprandial hyperglycemia, and marked hyperinsulinemia may be observed (13). When beta-cells decompensate, hyperglycemia may become very difficult to treat. Clinical features include in addition to acanthosis nigricans, phallic enlargement, precocious pseudopuberty, short stature, and abnormal teeth, hair, and nails (14,15). Hyperplasia of the pineal gland is an unusual feature (14). Prognosis is poor as diabetes is difficult to control even with high insulin doses (14). Hyperglycemia leads to microvascular disease and/or diabetic ketoacidosis resulting in death in the second and third decades of life (13). Leptin administration has resulted in an improvement in this syndrome (17,18).

 

DISEASES OF THE EXOCRINE PANCREAS

 

Diseases that destroy the pancreas can cause diabetes even in individuals who do not have risk factors for diabetes (19). In the medical literature this is often referred to as Type 3C diabetes. Acquired causes of damage to the pancreas include pancreatitis, trauma, infection, pancreatic carcinoma, and pancreatectomy. Inherited disorders that affect the endocrine pancreas, such as hemochromatosis, thalassemia, and cystic fibrosis, can also cause insulin deficiency and diabetes. The distribution of causes for diabetes secondary to pancreatic disorders in one study was chronic pancreatitis (79%), pancreatic ductal adenocarcinoma (8%), hemochromatosis (7%), cystic fibrosis (4%), and previous pancreatic surgery (2%) (20). The prevalence of diabetes secondary to pancreatic disease is estimated to range from 1% to 9% and likely will depend on the patient population studied (21). In a population study carried out in New Zealand the prevalence of diabetes secondary to pancreatic disorders was close to that of T1D (22).

 

Pancreatitis

 

Pancreatitis may lead to the destruction of the beta cells due to inflammation and irreversible fibrotic damage (23). In addition to destroying the beta cells, pancreatitis also leads to the destruction of glucagon secreting alpha-cells and pancreatic polypeptide secreting cells (23). The decrease in insulin secretion is the primary mechanism leading to hyperglycemia. In addition, the decrease in secretion of pancreatic polypeptide leads to a decrease in hepatic insulin sensitivity resulting in increased hepatic glucose production (21,23,24). Nutrient malabsorption that occurs secondary to pancreatitis leads to impaired incretin secretion that can result in diminished insulin release by the remaining beta-cells (25). Acute pancreatitis can induce transient hyperglycemia (stress hyperglycemia) that can last for several weeks or permanent hyperglycemia (21,26,27). The risk of developing diabetes after acute pancreatitis is increased after severe pancreatitis, hypertriglyceridemia or alcohol as the etiology of pancreatitis, and the occurrence of pancreatic necrosis (28). Other predictors of the development of diabetes include obesity, a family history of diabetes, exocrine pancreatic insufficiency, history of pancreatic surgery, pancreatic calcifications, and long duration of pancreatitis (29).

 

The prevalence of diabetes secondary to pancreatitis varies greatly with studies in North America estimating a prevalence of 0.5%-1.15% whereas in Southeast Asia, where tropical or fibrocalcific pancreatitis is endemic, a prevalence of approximately 15%-20% has been reported (23) (see chapter in Tropical Endocrinology Section of Endotext entitled “Fibrocalculous Pancreatic Diabetes” for an in depth discussion of this entity (7). Recently, data from the UK Royal College of General Practitioners Research and Surveillance Centre found 559 cases of diabetes following pancreatic disease in 31,789 cases of adults newly diagnosed with diabetes (1.8%) (30). Most cases of diabetes following pancreatic disease were classified as T2D (30). In another study approximately 50% of the patients with diabetes secondary to pancreatitis were not recognized and were incorrectly thought to have T2D. It is very likely that many cases of diabetes secondary to pancreatitis are not recognized to be due to pancreatic disease.

 

The prevalence of diabetes in patients with diagnosed pancreatitis has ranged between 26-80%, depending on the cohort and duration of follow up (21,23,31). The prevalence of diabetes increases with the duration of pancreatitis and early onset of calcific disease (23). Because of the high risk of diabetes in patients with pancreatitis these patients should be periodically screened for the presence of diabetes with measurement of fasting glucose and/or A1c levels.

 

At times it can be difficult to distinguish diabetes secondary to pancreatitis from T1D or T2D. The following diagnostic criteria have been proposed (Table 2) (23).

 

Table 2. Proposed Diagnostic Criteria for Diabetes Secondary to Pancreatitis

Major Criteria (must be present)

Presence of exocrine pancreatic insufficiency (monoclonal fecal elastase-1 test or direct function tests)    

Pathological pancreatic imaging (endoscopic ultrasound, MRI, CT)    

Absence of T1D associated autoimmune markers

Minor Criteria

Absent pancreatic polypeptide secretion    

Impaired incretin secretion (e.g., GLP-1)    

No excessive insulin resistance (e.g., HOMA-IR)    

Impaired beta cell function (e.g., HOMA-B, C-Peptide/glucose-ratio)    

Low serum levels of lipid soluble vitamins (A, D, E and K)

 

It should be recognized that these proposed criteria have not been rigorously tested nor are all criteria available in routine clinical practice. In addition, there are a number of key considerations. First, long-standing T1D and T2D are associated with exocrine pancreatic failure (32). It has been estimated that 26% to 74% of patients with T1D and 28% to 36% of patients with T2D have evidence of exocrine pancreatic insufficiency (19). Second, patients with diabetes are at a higher risk for developing acute and/or chronic pancreatitis (33). Lastly, patients with previous episodes of pancreatitis may also develop T1D or T2D independently of their exocrine pancreatic disease. When diabetes occurs in patients with a pre-existing diagnosis of chronic pancreatitis it is likely that pancreatitis is an important contributor to the development of diabetes.

 

Testing for T1D associated autoimmune markers can be helpful in separating T1D from diabetes secondary to pancreatic disease. The presence of islet cell antibodies supports the diagnosis of T1D. The pancreatic polypeptide response to insulin-induced hypoglycemia, secretin-infusion, or a mixed nutrient ingestion can be helpful in separating T2D from diabetes secondary to pancreatic disease. Patients with diabetes secondary to pancreatitis have an absent or reduced pancreatic polypeptide response while patients with T2D have an elevated pancreatic polypeptide response (23,31). Studies have shown that pancreatic polypeptide regulates hepatic insulin sensitivity and the absence of pancreatic polypeptide leads to hepatic insulin resistance and enhances hepatic glucose production, which could contribute to the abnormal glucose metabolism that occurs with pancreatic disease (21).

 

In patients with diabetes secondary to pancreatitis hyperglycemia can be mild to very severe depending upon the degree of pancreatic destruction leading to impaired insulin production and secretion (19,21,23). Glycemic control may be unstable due to the loss of glucagon secretion in response to hypoglycemia, carbohydrate malabsorption, and inconsistent food intake due to pain and/or nausea secondary to pancreatitis (i.e., “brittle diabetes”) (19,21,23). Whether glycemic control is worse in patients with diabetes secondary to pancreatitis is uncertain as older studies reported worse glycemic control and more recent studies have reported that glycemic control was similar to other patients with diabetes (19). The ability to obtain good glycemic control is likely to be related to the degree of pancreatic insufficiency with patients with a total absence of pancreatic function being more difficult to control.

 

In patients with relatively mild diabetes treatment with metformin is indicated. A nationwide cohort study in New Zealand and Denmark reported that metformin increased survival in patients with post pancreatitis diabetes (34,35). The GI side effects (nausea, abdominal complaints, diarrhea) of metformin may not be tolerable in some patients with pancreatitis. In observational studies metformin therapy has been associated with a reduction in the development of pancreatic cancer in patients with diabetes (36). Given the increased risk of pancreatic cancer in patients with diabetes and/or pancreatitis, a reduction in the development of pancreatic cancer would be a potential added benefit of metformin therapy (37-39). There are conflicting data on whether treatment with DPP4-inhibitors or GLP1-analogues can cause pancreatitis, but until this issue has been unequivocally settled, it is wise to refrain from using these drugs in patients who have had pancreatitis without a clear reversible etiology (for example, gallstone pancreatitis status post cholecystectomy). Note that two meta-analyses have demonstrated an 80% increased risk of acute pancreatitis in patients using DPP-4 inhibitors compared with those receiving standard care (40,41). In contrast, meta-analyses of large cardiovascular outcome studies have not demonstrated an increase in pancreatitis in patients treated with GLP-1 receptor agonists, but these studies typically excluded patients with a history of pancreatitis (42,43). Thiazolidinediones should probably be avoided as patients with pancreatitis and malabsorption are at increased risk for osteoporosis and thiazolidinediones may potentiate this problem.

 

Chronic pancreatitis is a progressive disease and therefore it is likely that glycemic control will worsen overtime and most patients will eventually require insulin therapy (23). Many patients will have severe insulin deficiency and will need to be treated with insulin therapy using regimens employed in patients with T1D. Because of the absence of glucagon secretion patients with diabetes secondary to pancreatitis are more susceptible to severe hypoglycemia with insulin therapy but diabetic ketoacidosis is not commonly observed due to the absence of glucagon.

 

Patients with diabetes secondary to pancreatitis are at risk for microvascular complications and lower extremity arterial disease and therefore routine testing for eye disease, kidney disease, foot ulcers, and neuropathy should be instituted (44-47).

 

Finally, it should be recognized that patients with diabetes secondary to pancreatitis will almost always have exocrine pancreatic insufficiency (31). Many patients with chronic pancreatitis manifest fat malabsorption without symptoms and therefore a thorough evaluation is required. Oral pancreatic enzyme replacement is beneficial for these patients. Of note, pancreatic enzyme supplementation can improve incretin secretion and thereby may benefit glycemic control (21,25,48). Fat soluble vitamin deficiency commonly occurs (Vitamin A, D, and K) and many patients require supplementation with fat-soluble vitamins.

 

Pancreatectomy

 

The metabolic abnormalities that occur after pancreatic surgery depend on the amount and area of the pancreas removed and whether the remaining pancreas is normal or diseased (24). The basis for this variability is due to the distribution of β and non-β islet cell types in the pancreas. Islet density is relatively low in the head of the pancreas and gradually increases through the body toward the tail region by greater than 2-fold and thus α- and β-cells predominate in the tail. In contrast, the cells that secrete pancreatic polypeptide are mainly localized in the head of the pancreas. Distal pancreatectomy usually causes little change in the metabolic status unless more than 50% of parenchyma is excised in patients with diffuse disease or more than 80% in patients with normal pancreatic function (24). The risk of a patient developing diabetes after a distal pancreatectomy varies greatly (24,49). The risk of new diabetes is reduced with central pancreatectomy compared to distal pancreatectomy (50). Resection of the head of the pancreas results in a decrease in pancreatic polypeptide, hepatic insulin resistance, and fasting hyperglycemia. Approximately 20% of patients develop diabetes after resection of the head of the pancreas (24). It should also be recognized that removal of pancreatic tissue can accelerate the development of T2D by decreasing insulin secretion in patients with impaired glucose metabolism (51).

 

Patients who have undergone total surgical pancreatectomy have a deficiency of insulin, glucagon, and pancreatic polypeptide and require insulin treatment. In general, there are several differences from typical T1D, including exocrine deficiency, low insulin requirements, and a higher risk of hypoglycemia due to the decrease in glucagon, which stimulates hepatic glucose production (glycogenolysis and gluconeogenesis). Pancreatectomized patients are prone to hypoglycemia and a delayed recovery from hypoglycemia. In an evaluation of 180 patients post total pancreatectomy 42% experienced one or more hypoglycemic events on a monthly basis (52). In addition to treatment with insulin, pancreatic enzyme supplements are always needed. SGLT2 inhibitors and GLP-1 receptor agonists have been shown to improve glycemic control in patients with diabetes post pancreatectomy (53,54). GLP-1 receptor agonists improve postprandial glycemia by decreasing gastric emptying and reducing postprandial responses of gut-derived glucagon (54). Intraportal islet auto transplantation has been used to prevent the development of diabetes with total pancreatectomy and/or reduce the risk of developing difficult to control diabetes (55-57).

 

Pancreatic Cancer

 

A high percentage of patients with pancreatic carcinoma have diabetes (21,58). In one study 68% of patients with pancreatic cancer also had diabetes (59). The prevalence of diabetes in patients with pancreatic cancer is much higher than in other common malignancies (58,59). In patients with pancreatic cancer who also have diabetes, the diagnosis of diabetes occurred less than 2 years prior to the diagnosis of pancreatic cancer in 74% of patients (60). In a population-based study less than 1% of patients over the age of 50 with newly diagnosed diabetes were diagnosed with pancreatic cancer within 3 years (61). In a study of 115 patients over 50 years of age who were hospitalized for new-onset diabetes 5.6% were found to have a pancreatic cancer (62). Many patients with pancreatic cancer lose weight and therefore deteriorating glycemic control in conjunction with weight loss and anorexia should raise the possibility of an occult pancreatic cancer (58,63). Other clues to the presence of pancreatic cancer in a patient with new onset diabetes are the lack of a family history of diabetes, a BMI < 25, recent thromboembolism, history of pancreatitis, GI symptoms, and the absence of features of the metabolic syndrome such as dyslipidemia and hypertension. Given the high incidence of diabetes relative to the incidence of pancreatic cancer the routine screening of all patients who develop diabetes is not cost effective. However, in selected patients with the features described above screening is appropriate.

 

Conversely, long standing T2D increases the risk of developing pancreatic cancer by approximately 1.5 to 2-fold indicating a bidirectional relationship (24,58,64). This risk may persist even after adjustment for obesity and smoking, risk factors for pancreatic cancer. Diabetes is both a risk factor for the development of pancreatic cancer and a complication of pancreatic cancer.

 

As discussed above diabetes may develop secondary to chronic pancreatitis. Chronic pancreatitis increases the risk of pancreatic cancer. Thus, patients with diabetes secondary to chronic pancreatitis are at a higher risk of developing pancreatic cancer (65).  

 

The strongest evidence linking pancreatic cancer with incident diabetes is the beneficial effects of cancer resection on glycemic control (58). In a small study in 7 patients, Permert and colleagues reported an improvement in diabetes status and glucose metabolism after subtotal pancreatectomy (66). Similarly, Pannala and colleagues in a larger study reported that after pancreaticoduodenectomy, diabetes resolved in 17 of 30 patients (57%) with new-onset diabetes but was unaffected in patients with longstanding diabetes (60). Litwin and colleagues noted similar improvements in glucose metabolism after surgery in patients with pancreatic cancer but a deterioration in patients with chronic pancreatitis (67). Finally, studies have also shown that a good response to chemotherapy in patients with pancreatic cancer can also improve glucose levels (68). Taken together these results demonstrate a benefit from tumor removal and suggest that new-onset diabetes associated with pancreatic cancer may be a paraneoplastic phenomenon.

 

The mechanism accounting for the development of new onset diabetes by pancreatic cancers is unknown (58). In contrast to other pancreatic disorders the etiology of diabetes is not due to destruction of the pancreas as patients with new onset diabetes and pancreatic cancer have hyperinsulinemia rather than low insulin levels and as noted above the diabetes improves after resection (21). Additionally, pancreatic cancers may be very small and thus unlikely to cause pancreatic insufficiency. Pancreatic cancer is associated with insulin resistance but the factors leading to insulin resistance are unknown (21).

 

In patients with pancreatic cancer the main goal of the treatment of diabetes is to prevent the short- term metabolic complications and facilitate the ability of the patient to tolerate treatment of the pancreatic cancer (surgery and chemotherapy). Given the poor survival of patients with pancreatic cancer, prevention of the long-term sequelae of diabetes is not a major focus. Metformin is a preferred hypoglycemic agent because there are observational studies suggesting that metformin may improve survival in patients with pancreatic cancer (69-71). However, randomized trials have failed to demonstrate the benefit of metformin therapy in patients with pancreatic cancer (72,73).

 

Hemochromatosis

 

Hemochromatosis is an autosomal recessive disorder characterized by increased iron absorption by the GI tract and increased total body iron stores (74). The excess iron is sequestered in many different tissues including the liver, skin, heart, and pancreas. The classic triad of hemochromatosis is diabetes mellitus, hepatomegaly, and increased skin pigmentation (“bronze diabetes”), but clinical features also include gonadal failure, arthropathy, and cardiomyopathy (74).

 

In early studies diabetes was present in over 50% of patients with hemochromatosis (75,76). More recently the prevalence of diabetes in patients with hemochromatosis has decreased to approximately 20% of patients, presumably due to the early diagnosis and treatment of hemochromatosis due to genetic testing (75-78). In patients with hemochromatosis screening for the presence of diabetes should be periodically carried out.

 

Diabetes was typically observed in persons who also had severe iron overload and cirrhosis (76). It should be noted that iron overload from any cause can result in diabetes (79). For example, patients with thalassemia develop iron overload due to the need for frequent transfusions (80,81). The prevalence of diabetes in patients with thalassemia has been declining since the more aggressive and widespread use of iron chelation therapy (81).

 

There are two abnormalities that lead to abnormal glucose metabolism in patients with hemochromatosis and iron overload (75). First, iron overload leads to beta cell damage with decreased insulin production and secretion. Pathologic examination revealed hemosiderin deposition and iron-induced fibrosis of the islets (76). The decrease in insulin secretion is the primary defect leading to the development of diabetes (75,76,78). Of note glucagon secretion does not appear to be deficient in patients with diabetes and hemochromatosis suggesting that the iron overload has a preferential toxicity for beta cells compared to alpha cells (76,82,83). Similarly, basal and stimulated pancreatic polypeptide levels are also not decreased in diabetic patients with hemochromatosis (84). Thus, the hormonal abnormalities differ in patients with iron overload induced diabetes compared to patients with pancreatitis induced diabetes. The second abnormality is insulin resistance that occurs due to iron overload hepatic damage and/or secondary to obesity (75,76). In addition, a genetic predisposition to diabetes potentiates the development of metabolic dysfunction. Many patients with hemochromatosis and diabetes have a relative with diabetes (85).

 

The typical micro and macrovascular complications of diabetes occur in patients with hemochromatosis (76,85). In a study by Griffiths and colleagues, 11 of 49 patients with hemochromatosis and diabetes had diabetic retinopathy (86). Sixty percent of the patients with hemochromatosis who had diabetes for greater than 10 years had retinopathy. The incidence of retinopathy is similar to that observed in the general diabetes population (85,86). Similarly, Becker and Miller observed that 7 of 22 patients with diabetes and hemochromatosis had pathologic evidence of diabetic glomerulopathy (87).

 

The treatment of hemochromatosis by phlebotomy has a variable impact on glucose metabolism (75). In patients who do not yet have complications or organ damage an improvement of insulin secretory capacity and normalization of glucose tolerance has been observed (75,76). Glucose metabolism often improves in patients with impaired glucose tolerance (75,88). In patients with diabetes improvement in glucose metabolism by phlebotomy may occur but is not as common as in “pre-diabetics” (75,88,89). In one study 28% of patients with diabetes and hemochromatosis on insulin or oral agents showed improved glucose control following phlebotomy therapy (90).

 

Cystic Fibrosis

 

Cystic Fibrosis is an autosomal recessive disorder due to a defect in the chloride transport channel (91). Cystic fibrosis related diabetes is rare in children but is present in approximately 20% of adolescents and 40-50% of adults with cystic fibrosis (92,93). As patients with cystic fibrosis live longer it is likely that the number of patients with cystic fibrosis and diabetes will increase. The development of diabetes is associated with more severe cystic fibrosis gene mutations, increasing age, worse pulmonary function, undernutrition, liver dysfunction, pancreatic insufficiency, a family history of diabetes, female gender, and corticosteroid use (92,93).

 

The primary defect in patients with cystic fibrosis related diabetes is decreased insulin production and secretion due to fibrosis and atrophy of the pancreas with a reduction of islet mass (92). In addition, mutations in the cystic fibrosis transmembrane conductance regulator gene may have direct effects on the ability of beta cells to secrete insulin (93,94). Beta cell dysfunction is not complete with residual insulin secretion and thus patients with cystic fibrosis related diabetes do not typically develop ketosis (92). Reduced alpha cell mass also occurs so while fasting glucagon levels are normal, glucagon secretion in response to hypoglycemia is impaired (92). Peripheral and hepatic insulin resistance may also occur secondary to infections, inflammation, and cirrhosis (93).

 

Some of the clinical features of cystic fibrosis related diabetes are similar to T1D as patients are young, not obese, insulin deficiency is the primary defect, and features of the metabolic syndrome (hyperlipidemia, hypertension, visceral adiposity) are not usually present (92). However, cystic fibrosis related diabetes is not an autoimmune disease (islet cell antibodies are not present) and ketosis is rare because endogenous insulin is still produced (92). Fasting glucose levels are often normal initially with elevated postprandial glucose levels due to a reduced and delayed insulin response to carbohydrates while basal insulin is often adequate to maintain normal fasting glucose levels (95). Patients with cystic fibrosis related diabetes are not at high risk of developing atherosclerosis and heart disease is not a major issue (92-94). This is likely due to malabsorption leading to low life-long plasma cholesterol levels and the shortened length of life (92,93). As life expectancy increases and medical therapy with Cystic Fibrosis Transmembrane Regulator (CFTR) modulators improves, the risk of macrovascular disease may increase. Microvascular complications do occur in cystic fibrosis related diabetes and are related to the duration of diabetes and glycemic control (92,93,95). The American Diabetes Association recommends screening for complications of diabetes beginning 5 years after the diagnosis of cystic fibrosis related diabetes (96)

 

Lung disease is a major cause of morbidity and mortality in patients with cystic fibrosis and both insulin insufficiency and hyperglycemia negatively affect cystic fibrosis lung disease (97). Numerous studies have shown that the occurrence of diabetes in patients with cystic fibrosis is associated with more severe lung disease and increased mortality and this adverse effect disproportionately affects women (92,95,97). In patients with cystic fibrosis lung function is critically dependent on maintaining normal weight and lean body mass. Insulin deficiency leads to a catabolic state with the loss of protein and fat (92). Multiple studies have shown that insulin replacement therapy improves nutritional status and pulmonary function in patients with cystic fibrosis related diabetes (92). In addition, elevated blood glucose levels result in elevated blood glucose levels in the airways, which promotes the growth of pathogenic microorganisms and increases pulmonary infections (92,95). Of note recent studies have shown that the marked increase in mortality in patients with cystic fibrosis related diabetes compared to patients with cystic fibrosis only has decreased (98). It is likely that early diagnosis and aggressive treatment have improved survival in patients with cystic fibrosis related diabetes.

 

Because of the adverse effects of diabetes on lung function in patients with cystic fibrosis routine screening for diabetes is recommended (97). It is recommended that annual screening begin at age 10 (97). While fasting glucose and A1c levels are routine screening tests for diabetes, in patients with cystic fibrosis these tests are not sensitive enough (97). Fasting glucose and A1c testing will fail to diagnose approximately 50% of patients with cystic fibrosis related diabetes (94,97). However, recent studies have suggested that a screening A1c >5.5% would detect more than 90% of patients with diabetes and therefore with further confirming studies measuring A1c levels could become an initial screening approach (96).  As noted above, abnormalities in postprandial glucose characterizes cystic fibrosis related diabetes and it is therefore recommended that an oral glucose tolerance test (OGTT) be utilized for the diagnosis of diabetes in patients with cystic fibrosis (97). Studies have shown that the diagnosis of diabetes by OGTT correlates with clinically important cystic fibrosis outcomes including the rate of lung function decline, the risk of microvascular complications, and the risk of early death (97). Moreover, the OGTT identified patients who benefited from insulin therapy (97). Additional screening recommendations are shown in Table 3 and the interpretation of these tests are shown in Table 4.

 

Table 3. ADA and Cystic Fibrosis Foundation Recommendations for Screening for Cystic Fibrosis Related Diabetes (CFRD) (97)

1) The use of A1C as a screening test for CFRD is not recommended.

2) Screening for CFRD should be performed using a 2-h 75-g OGTT. 

3) Annual screening for CFRD should begin by age 10 years in all CF patients who do not have CFRD.

4) CF patients with acute pulmonary exacerbation requiring intravenous antibiotics and/or systemic glucocorticoids should be screened for CFRD by monitoring fasting and 2-h postprandial plasma glucose levels for the first 48 h. If elevated blood glucose levels are found by SMBG, the results must be confirmed by a certified laboratory.

5) Screening for CFRD by measuring mid- and immediate post-feeding plasma glucose levels is recommended for CF patients on continuous enteral feedings, at the time of gastrostomy feeding initiation, and then monthly by SMBG. Elevated glucose levels detected by SMBG must be confirmed by a certified laboratory.

6) Women with CF who are planning a pregnancy or confirmed pregnant should be screened for preexisting CFRD with a 2-h 75-g fasting OGTT if they have not had a normal CFRD screen in the last 6 months. 

7) Screening for gestational diabetes mellitus is recommended at both 12–16 weeks’ and 24–28 weeks’ gestation in pregnant women with CF not known to have CFRD, using a 2-h 75-g OGTT with blood glucose measures at 0, 1, and 2 h. 

8) Screening for CFRD using a 2-h 75-g fasting OGTT is recommended 6–12 weeks after the end of the pregnancy in women with gestational diabetes mellitus (diabetes first diagnosed during pregnancy). 

9) CF patients not known to have diabetes who are undergoing any transplantation procedure should be screened preoperatively by OGTT if they have not had CFRD screening in the last 6 months. Plasma glucose levels should be monitored closely in the perioperative critical care period and until hospital discharge. Screening guidelines for patients who do not meet diagnostic criteria for CFRD at the time of hospital discharge are the same as for other CF patients.

CF= cystic fibrosis; CRFD= cystic fibrosis related diabetes; OGTT= oral glucose tolerance test, SMBG= self-monitored blood glucose

 

Table 4. Criteria for the Diagnosis of Cystic Fibrosis Related Diabetes (97)

1) During a period of stable baseline health the diagnosis of CFRD can be made in CF patients according to standard ADA criteria. Testing should be done on 2 separate days to rule out laboratory error unless there are unequivocal symptoms of hyperglycemia (polyuria and polydipsia); a positive FPG or A1C can be used as a confirmatory test, but if it is normal the OGTT should be performed or repeated. If the diagnosis of diabetes is not confirmed, the patient resumes routine annual testing.

·       2-h OGTT plasma glucose >200 mg/dl (11.1 mmol/l)

·       FPG >126 mg/dl (7.0 mmol/l)

·       A1C > 6.5% (A1C <6.5% does not rule out CFRD because this value is often spuriously low in CF.)

·       Classical symptoms of diabetes (polyuria and polydipsia) in the presence of a casual glucose level >200 mg/dl (11.1 mmol/l)

2) The diagnosis of CFRD can be made in CF patients with acute illness (intravenous antibiotics in the hospital or at home, systemic glucocorticoid therapy) when FPG levels >126 mg/dl (7.0 mmol/l) or 2-h postprandial plasma glucose levels >200 mg/dl (11.1 mmol/ l) persist for more than 48 h.

3) The diagnosis of CFRD can be made in CF patients on enteral continuous drip feedings when mid- or post-feeding plasma glucose levels exceed 200 mg/dl (11.1 mmol/l) on 2 separate days.

4) Diagnosis of gestational diabetes mellitus is diagnosed based on 0-, 1-, and 2-h glucose levels with a 75-g OGTT if any one of the following is present:

·       FPG >92 mg/dl (5.1 mmol/l)

·       1-h plasma glucose >180 mg/dl (10.0 mmol/l)

·       2-h plasma glucose >153 mg/dl (8.5 mmol/l)

CF patients with gestational diabetes mellitus are not considered to have CFRD, but require CFRD screening 6–12 weeks after the end of the pregnancy.

5) The onset of CFRD should be defined as the date a person with CF first meets diagnostic criteria, even if hyperglycemia subsequently abates.

CF= cystic fibrosis; CRFD= cystic fibrosis related diabetes; OGTT= oral glucose tolerance test

 

There is evidence that elevations in glucose below the levels typically used to diagnose diabetes result in adverse effects on the lungs (95). Thus, some experts recommend that treatment should be considered for individuals with abnormal glucose levels which do not meet the criteria for diabetes if there is evidence of declining lung function or weight loss (95).

 

A unique feature in the treatment of patients with cystic fibrosis related diabetes is that insulin is the treatment of choice in all patients (97). Studies have shown that cystic fibrosis patients on insulin therapy who achieve good glycemic control demonstrate improvement in weight, protein anabolism, pulmonary function, and survival (97). No specific insulin treatment regimen is recommended, and the regimen should be individualized for the patient. For example, a patient with elevated postprandial glucose levels will benefit from mealtime rapid acting insulin. It should be noted that patients with cystic fibrosis induced diabetes still have endogenous insulin production, which allows for the achievement of good glycemic control. Oral diabetes agents are not as effective as insulin in improving nutritional and metabolic outcomes and therefore are not recommended (97). However, in patients who do not tolerate insulin (for example frequent hypoglycemia), oral agents, such as DPP4 inhibitors, may be beneficial (99). For most patients with cystic fibrosis related diabetes an A1c < 7% is recommended but the A1c goal can be higher or lower for certain patients based on clinical judgement. Also of note is that cystic fibrosis patients require a high-calorie, high-salt, high-fat diet.

 

Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator modulator, is a relatively new agent to treat cystic fibrosis and has been shown to partially reverse the disease. Interestingly in case reports ivacaftor has been shown to markedly improve glycemic control (93,100). In a recent retrospective observation study approximately 1/3 of patients with CFRD had either a resolution of their diabetes or marked improvement with ivacaftor therapy (101). Additionally, the risk of developing CFRD is decreased in patients treated with ivacaftor (102). Studies using three Cystic Fibrosis Transmembrane Regulator (CFTR) modulators (elexacaftor /tezacaftor/ ivacaftor) improved glycemic control and reduced insulin requirements (103-105). These beneficial effects are likely to be due to an improvement in insulin secretion and/or insulin sensitivity (93,106,107). Note the response to these Cystic Fibrosis Transmembrane Regulator (CFTR) modulators depends on the specific mutation causing cystic fibrosis (107).

 

INFECTIONS

 

Viral Infections

 

Viral infections, particularly enterovirus and herpes virus infections, have been postulated to play a role in triggering the autoimmune reaction that leads to the development of T1D (108-111). This phenomenon is discussed in detail in the Endotext chapter on changing the course of the disease in T1D (112). A phase 2 study with the anti-viral agents, pleconaril and ribavirin, demonstrated preservation of residual insulin production in children and adolescents with new-onset T1D (113). In rare instances a viral infection has been associated with the fulminant development of diabetes due to the destruction of beta cells (114). For a review of the link of viral infections with the development of diabetes see a review by Jeremiah and colleagues (111).

 

Congenital Rubella

 

Congenital rubella infection has been shown to predispose to the development of T1D that usually presents before five years of age (115). It has been estimated that approximately 1-6% of individuals with the rubella syndrome will develop diabetes in childhood or adolescence (115,116). The mechanism for this association is unknown. In addition, studies have also shown that patients with congenital rubella also develop T2D (116). In one series 22% of individuals with congenital rubella developed diabetes later in life (116). Fortunately, with increased vaccinations, congenital rubella has become a disease of the past in developed countries.

 

Hepatitis C Virus (HCV)

 

Meta-analyses and large database studies have demonstrated that hepatitis V virus (HCV) infection is associated with an increased risk of T2D (117-122). In a meta-analysis of 34 studies the risk of diabetes in patients with HCV infection was increased by approximately 70% (117). Moreover, HCV infection is associated with an increased risk of T2D independent of the severity of the associated liver disease (i.e. occurs in patients without liver disease) but the risk of T2D was higher in HCV patients with cirrhosis (118). As expected, the risk of diabetes is increased in HCV patients if the BMI is increased, there is a family history of diabetes, older age, more severe liver disease, and male sex. Conversely, the prevalence of HCV infection in patients with T2D is higher than in non-diabetic controls (118,122,123). In a meta-analysis of 22 studies with 78,051 individuals it was found that patients with T2D were at a higher risk of HCV infection than non-diabetic patients (OR = 3.50; CI = 2.54-4.82) (123). Finally, diabetes is a significant risk factor for the development of liver cirrhosis and hepatocellular carcinoma in HCV infected patients (122,124-127).

 

Given the increased risk of diabetes in HCV infected patients it seems prudent to routinely screen HCV positive patients for diabetes. Conversely, screening patients with diabetes for HCV infection seems reasonable given the availability of drugs that can effectively treat HCV infections.

 

Patients with diabetes and HCV infection are insulin resistant in the liver and peripheral tissues (122,127,128). Insulin resistance is present in HCV infection in the absence of significant liver dysfunction and prior to the development of diabetes (128). Treatment that reduces viral load decreases insulin resistance and the risk of developing diabetes in HCV (122,128,129). The insulin resistance in individuals with HCV infections may be due to inflammation induced by cytokines such as TNF-alpha or monocyte chemoattractant protein-1, released from HCV-induced liver inflammation (122,127). Additionally, HCV may directly activate the mTOR/S6K1 signaling pathway, inhibiting IRS-1 protein function and thereby down-regulating GLUT-4 and up-regulating the gluconeogenic enzyme phosphoenolpyruvate carboxykinase-2 (122,127). Beta cell dysfunction may also contribute to the development of diabetes during HCV infection (111,130).

 

Studies have shown that direct-acting antiviral agents that eradicate HCV infection are associated with improved glycemic control in patients with diabetes indicated by decreased A1c levels and decreased insulin use (127,131). Additionally, in a database study of anti-viral treatment for HCV infection, a decrease in end-stage renal disease, ischemic stroke, and acute coronary syndrome was reported in  patients with diabetes (132). These beneficial results on key outcomes need to be confirmed in randomized trials (this may be impossible as withholding treatment of HCV is not appropriate). Treatment of diabetes with metformin or thiazolidinediones is preferred as studies have suggested that these drugs may lower the risk of hepatocellular carcinoma, liver-related death, or liver transplantation in patients infected with HCV (133,134).

 

COVID-19

 

There is a bidirectional relationship between diabetes and COVID-19. Both T1D and T2D are important risk factors for morbidity and mortality with COVID-19 infections, which is discussed in the Endotext chapter entitled “Diabetes Mellitus and Infections” (135). Studies have also shown that COVID-19 infections are associated with hyperglycemia and new onset diabetes (136,137). In a large meta-analysis of 20 studies the risk of new incident type 1 diabetes was increased (HR1.44; 95% CI: 1.13-1.82) and the risk of new incident type 2 diabetes was also increased (HR 1.47; 95% CI: 1.36-1.59) (138). Other meta-analyses have reported similar results (139-142). A meta-analysis observed that the risk of diabetes increased 1.17-fold (1.02-1.34) after COVID-19 infection compared to patients with general upper respiratory tract infections (140). The risk of new diabetes in patients with COVID-19 was highest for patients in intensive care (HR 2.88) and hospitalized patients (HR 2.15) (138). For non-hospitalized patients the risk of developing new diabetes was much lower (HR=1.16; 95% CI: 1.07-1.26; p = 0.002) (138).

 

A very large data-based study with millions of patients found that the risk of developing T2D prior to the availability of COVID-19 vaccination was increased and that this increased risk was still elevated by approximately 30% 1 year after the COVID-19 infection (143). The risk of developing T2D is highest soon after COVID-19 infection (four times higher during the first 4 weeks) and 60% of those diagnosed with T2D after COVID-19 still had evidence of diabetes 4 months after infection (i.e. persistent T2D) (143). The risk of developing T1D was elevated but this increase was no longer seen one year after the COVID-19 infection (143). The increased risk of developing both T1D and T2D was greater in people who were hospitalized with COVID-19 and therefore the risk of developing diabetes was reduced, but not entirely ameliorated, in vaccinated individuals compared with unvaccinated people (143). The absolute risk of developing diabetes was greatest in patients at increased risk for diabetes (obesity, certain ethnic groups, individuals with “prediabetes”, etc. (143).

 

The mechanisms that account for an increased risk of diabetes following COVID-19 infections are unresolved. There are a number of suggested mechanisms.

 

  • Diabetes could be secondary to acute illness and stress induced hyperglycemia. Stress induced hyperglycemia has been observed after other acute conditions including other infections (137,144).
  • Pre-existing diabetes could first be recognized during a COVID-19 infection or during follow-up. This could account for some of the patients that appear to develop new T2D as many patients with T2D are unaware that they have diabetes (145).
  • COVID-19 infection could trigger beta cell autoimmunity. This is particularly relevant to the development of T1D as viral infections have been hypothesized to initiate beta cell autoimmunity (112,137).
  • The SARS-CoV-2 virus could directly damage the beta cells leading to decreased insulin secretion and hyperglycemia (137).
  • SARS-CoV-2 virus could lead to pancreatitis indirectly affecting beta cell function.
  • The strong immune response that is seen in COVID-19 infections (cytokine storm) could indirectly lead to beta cell dysfunction and insulin resistance. Additionally, elevated cytokines could persist for an extended period leading to insulin resistance and abnormal glucose metabolism (146)
  • SARS-CoV-2 virus infects adipose tissue and may cause adipose dysfunction (decreased adiponectin and increased insulin resistance) (147,148). Persistent adipose tissue infection could result in inflammation and alteration of adipokines and cytokines leading to diabetes.
  • The use of high dose glucocorticoids in patients with severe COVID-19 could lead to hyperglycemia and diabetes.
  • Changes in environment that occurred during the COVID-19 pandemic, such as decreased exercise, increased food intake, increased weight gain, etc., could enhance the risk of developing diabetes (149).

 

Hopefully, future studies will better characterize the mechanisms leading to new onset diabetes in patients with COVID-19 infections and determine whether there are unique mechanisms for this association.

 

ENDOCRINOPATHIES

 

A number of endocrine disorders are associated with an increased occurrence of diabetes (Table 1). Increased levels of growth hormone, glucocorticoids, catecholamines, and glucagon cause insulin resistance while increased levels of catecholamines, somatostatin, and aldosterone (by producing hypokalemia) decrease insulin secretion and hence can adversely affect glucose homeostasis. The disturbance in glucose metabolism occurring secondary to endocrine disorders may vary from a moderate degree of glucose intolerance to overt diabetes with symptomatic hyperglycemia. Additionally, endocrine disorders can worsen glycemic control in patients with pre-existing diabetes.

 

Acromegaly

 

This condition is caused by excessive production of growth hormone (GH) from the pituitary (150). The prevalence of DM in patients with acromegaly is between 10-40%; the prevalence of diabetes and glucose intolerance effects more than 50% of patients (150-153). As expected, there is an increased prevalence of diabetes with age, elevated BMI, a family history of diabetes, and longer duration of acromegaly (151). Diabetes may be present at the time of the diagnosis of acromegaly (154). Higher plasma IGF-1 concentrations correlate with an increased risk of diabetes, suggesting that the biochemical severity of acromegaly influences the risk of developing abnormalities of glucose metabolism (155). Patients with acromegaly should be screened for abnormalities in glucose metabolism (152). The prevalence of acromegaly in patients with diabetes is unknown but is likely to be very low given that acromegaly is an uncommon disorder (60 per million) and diabetes is very common (150).

 

GH is a counter regulatory hormone to insulin and is secreted during hypoglycemia (156,157). In patients with acromegaly insulin resistance is the major abnormality leading to disturbances in glucose metabolism (151,153,154,158). The insulin resistance is driven primarily through GH induced lipolysis, which results in glucose-fatty acid substrate competition leading to decreased glucose utilization in muscle (151,154,158). Additionally, inhibition of post receptor signaling pathway of the insulin receptor also likely plays a role in the insulin resistance (158). Increased hepatic gluconeogenesis also contributes to the hyperglycemia (151,158). Lipolysis increases the delivery of glycerol and fatty acids to the liver, which serves as a substrate and energy source for gluconeogenesis. In some patients with acromegaly increased insulin secretion compensates for the insulin resistance and glucose metabolism remains normal (151). If insulin secretion cannot increase sufficiently to compensate for the insulin resistance glucose intolerance or diabetes develops (151).

 

Treatment is directed at the cause of the acromegaly (150). Successful surgical removal of the pituitary adenoma improves hyperglycemia and glucose metabolism has been reported to normalize in 23–58% of people with pre-operative diabetes after surgical cure of acromegaly (151,152,154). Lower IGF-1 and growth hormone levels post operatively correlate with remission of diabetes (159). A meta-analysis of 31 studies with 619 patients treated with somatostatin analogues for acromegaly reported a decrease in insulin levels and glucose levels during a glucose tolerance test but no change in fasting glucose or A1c levels (160). Another meta-analysis of 47 studies with 1297 participants reported that somatostatin analogues also did not affect fasting plasma glucose but worsened 2 hour oral glucose tolerance test and resulted in a mild but significant increase in HbA1c (161) The absence of greater benefit in glucose homeostasis with somatostatin analogues could be secondary to somatostatin analogues inhibiting insulin secretion (150). Of note, while first generation somatostatin analogues appear to have mild or neutral effects on glucose metabolism in patients with acromegaly, treatment with pasireotide, a second-generation somatostatin analogue, aggravated glucose metabolism leading to the development of diabetes in some instances (162-164). The adverse effect of pasireotide is due to inhibiting insulin secretion and decreasing the incretin effect. There is little data on the impact of cabergoline on glucose homeostasis in patients with acromegaly, but the available studies suggest that it modestly improves glucose metabolism or has no effect (152,165). Studies have shown that bromocriptine can improve glucose homeostasis (151,152,166).  Finally, treatment with the growth hormone receptor antagonist, pegvisomant, has beneficial effects on glucose homeostasis (164,167,168).

 

The treatment of diabetes in patients with acromegaly is similar to the treatment in other patients with diabetes (151,153). Patients with acromegaly are often lean with low body fat and therefore dietary recommendations may need to be modified. Additionally, since insulin resistance is the primary defect in patients with acromegaly the use of insulin sensitizers may be especially effective but there are no studies comparing the efficacy of various hypoglycemic agents in patients with acromegaly (151). Data suggests that active acromegaly with elevated GH levels enhances the development of microvascular disease (154). The effect of acromegaly on the development of macrovascular disease is unclear (154). Ketoacidosis is uncommon in patients with diabetes and acromegaly.   

 

Cushing’s Syndrome

 

Cushing’s syndrome is due to elevated glucocorticoids that can be caused by the overproduction of ACTH by pituitary adenomas or ectopic ACTH producing tumors, overproduction of glucocorticoids by the adrenal glands due to adenomas or hyperplasia, or the exogenous administration of glucocorticoids (169). In patients with Cushing’s syndrome diabetes is present in 20-47% of the patients, while impaired glucose tolerance (IGT) is present in 21-64% of cases (170). Risk factors for the development of diabetes in patients with Cushing syndrome include age, obesity, and a family history of diabetes (170). The prevalence of diabetes varies depending on the etiology of Cushing’s syndrome (pituitary 33%, ectopic 74%, adrenal 34%) (171). In patients with endogenous Cushing’s syndrome the relationship of the degree of hypercortisolism and abnormalities in glucose metabolism has been inconsistent with some studies showing a correlation and other studies no relationship (172). For example, in one study, in patients with endogenous Cushing’s syndrome the prevalence of abnormalities in glucose metabolism and diabetes did not differ in patients with slightly elevated (not greater than 2x the upper limit of normal), moderately elevated (2-5X the ULN), and severely elevated (>5x the ULN) levels of urinary free cortisol (173). In patients with exogenous Cushing’s syndrome high doses of glucocorticoids and longer duration of treatment are more likely to cause diabetes (152,172). Elevated glucocorticoids are more likely to cause high glucose levels in the afternoon or evening and in the postprandial state (152). Hyperglycemia resulting from exogenous steroids occurs in concert with the time-action profile of the steroid regimen employed, such that once daily morning administration of an intermediate acting steroid (prednisone or methylprednisone) causes peak hyperglycemia within 12 hours (post-prandial) while long-acting or frequently administered steroids cause both fasting and postprandial hyperglycemia.

 

Patients with Cushing’s syndrome should be screened for the presence of abnormalities in glucose metabolism (172). It should be noted that fasting glucose levels are often normal with abnormalities present during an oral glucose tolerance test (170,172). Screening with A1c levels or with an oral glucose tolerance test are therefore preferred. The abnormalities in glucose metabolism may contribute to the increased risk of atherosclerosis in patients with Cushing’s syndrome.

 

The prevalence of Cushing’s syndrome in patients with diabetes is uncertain with studies reporting very different results ranging from 0 to 9% (172). The selection process used, and the criteria used to determine the presence of Cushing’s syndrome likely greatly influences the results with studies that select patients with marked obesity, poor glycemic control, and poorly controlled hypertension finding a higher percentage of patients with diabetes having Cushing’s syndrome. A recent meta-analysis of 14 studies with a total of 2827 patients with T2D reported that 1.4% had Cushing’s syndrome based on biochemical analysis (174). In a multicenter study carried out in Italy between 2006 and 2008, 813 patients with known T2D without clinically overt hypercortisolism were evaluated for Cushing’s syndrome (175). After extensive evaluation 6 patients (0.7%) were diagnosed with Cushing’s syndrome. Four patients had an adrenal adenoma and their diabetes was markedly improved with the disappearance of diabetes in three patients and discontinuation of insulin therapy in the remaining patient. One patient had bilateral macronodular adrenal hyperplasia and one patient had ACTH dependent Cushing’s syndrome with a normal pituitary MRI.

 

In approximately 15-35% of patients with an incidental adrenal nodule mild autonomous cortisol secretion with T2D is present (176,177). After surgical removal of the adenoma in patients with autonomous cortisol secretion diabetes normalized or improved in 62.5% of patients (5 of 8) (178). However, not all studies have seen such dramatic improvements in diabetes after adenoma removal (179). Clearly additional studies (preferably large, randomized trials) are required to better define the prevalence of mild subclinical Cushing’s syndrome in patients with diabetes and whether treating the subclinical Cushing’s syndrome in these patients will improve their glycemic control. For a detailed discussion of autonomous cortisol secretion see the chapter on Adrenal Incidentalomas in the Adrenal section of Endotext (180).

 

Currently, routinely screening patients with T2D for Cushing’s syndrome is not recommended (172). Nevertheless, clinicians should be aware of the possibility of Cushing’s syndrome and screen appropriate patients with T2D (young patients, negative family history of diabetes, patients with physical findings suggestive of Cushing’s syndrome, patients with difficult to control diabetes or hypertension) (172).    

 

Glucocorticoids function as a counter regulatory hormone to insulin and increase in response to hypoglycemia (181). Glucocorticoids disrupt glucose metabolism primarily by inducing insulin resistance in liver and muscle and by stimulating hepatic gluconeogenesis (170,172). The increase in hepatic gluconeogenesis is mediated by several mechanisms including a) directly stimulating the expression of gluconeogenic enzymes b) stimulating proteolysis and lipolysis leading to an increase delivery of amino acids, glycerol, and fatty acids to the liver that provides substrates and energy sources for gluconeogenesis c) inducing insulin resistance and d) enhancing the action of glucagon (170,172). The glucocorticoid induced increase in insulin resistance is due to inhibition of the post-receptor signaling pathway of the insulin receptor, which will result in a decrease in the uptake of glucose by skeletal muscle and adipose tissue (170). In addition to the above glucocorticoids can accelerate the degradation of Glut4 in beta cells, which impairs the ability of beta cells to secrete insulin in response to glucose (182).

 

Treatment of Cushing’s syndrome by removal of a pituitary tumor, an ectopic ACTH producing tumor, or an adrenal lesion result in a marked improvement in glucose metabolism and in many patients a remission of the diabetes (170,172). In patients with persistent Cushing’s syndrome drug therapy may be needed to normalize cortisol levels. Studies have shown that ketoconazole (200–1200 mg/day), levoketoconazole (150-600 mg twice daily), metyrapone (250–4500 mg/day), mifepristone (300–2000 mg/day) (approved to treat diabetes in patients with Cushing’s syndrome),osilodrostat (1-30 mg twice daily), or cabergoline (1-7mg/day) improves glucose metabolism in patients with Cushing’s syndrome (152,172,183).  In contrast, pasireotide has been shown to significantly worsen glucose tolerance, despite control of hypercortisolism, in patients with Cushing’s syndrome (152,172,183). In patients with exogenous Cushing’s syndrome it is important to use as low a dose as possible of glucocorticoids for the shortest period of time to avoid complications of therapy including disrupting glucose homeostasis (184).

 

The management of diabetes in patients with Cushing’s syndrome is similar to the treatment of other patients with diabetes (152,183). Since insulin resistance is a key defect in patients with Cushing’s syndrome the use of insulin sensitizers may be especially effective but there are no studies comparing the efficacy of various hypoglycemic agents in patients with Cushing’s syndrome (152). Pioglitazone and rosiglitazone can increase the risk of osteoporosis, and it should be noted that patients with Cushing’s syndrome also have a high risk of osteoporosis. As noted above, postprandial glucose levels are preferentially increased in Cushing’s syndrome and therefore drugs that lower postprandial glucose levels, such as DPP4 inhibitors, GLP1 receptor agonists, alpha glucosidase inhibitors, and rapid acting insulin may be very useful (152). In glucocorticoid-treated patients requiring a basal-bolus insulin regimen, a higher requirement of short-acting insulin than basal insulin is frequently required (usually approximately 70% of total insulin dose as prandial and 30% as basal) (152). Because of the insulin resistance in patients with Cushing’s syndrome higher doses of insulin are often required to achieve glycemic control. Patients with Cushing’s syndrome are at higher risk for developing macrovascular disease and therefore aggressive treatment of dyslipidemia and hypertension is required (185,186).  

 

Pheochromocytoma

 

Pheochromocytomas are rare neuroendocrine tumors that secrete norepinephrine, epinephrine, and dopamine (187). In pheochromocytomas the prevalence of diabetes has been estimated to be between 15-40% and impaired glucose tolerance as high as 50% (188-191). Patients with diabetes were older, had a longer known duration of hypertension, higher plasma epinephrine and norepinephrine levels, increased urinary metanephrine excretion, and larger tumors (189-191). Surprisingly the BMI did not differ between patients with and without diabetes perhaps because more active tumors with higher catecholamine levels lead to weight loss (189,190). In most instances the diabetes is relatively mild but in rare instances can be severe with ketoacidosis (192). The association of hypertension with diabetes in a young patient who is not overweight is a clue to the presence of a pheochromocytoma (189).

 

Catecholamines, acting primarily by the beta-adrenergic receptors, stimulate glucose production in the liver by increasing glycogenolysis and increase insulin resistance leading to a decrease in tissue disposal of glucose, which together result in elevations in glucose levels (193,194). In addition, catecholamines acting via the alpha-adrenergic receptors, inhibit insulin secretion by the beta cells and acting via the beta-adrenergic receptors, increase glucagon secretion by the alpha cells (195). A decrease in insulin secretion and an increase in glucagon secretion would facilitate the development of hyperglycemia.

 

With tumor resection diabetes resolves or markedly improves in the majority of patients (>50-90%) with a pheochromocytoma (189,190,196). A duration of diabetes of less than 3 years is associated with a remission of diabetes (197). It should be noted that post-surgical removal of a pheochromocytoma, hypoglycemia can occur in approximately 5% of patients (198). Most of these hypoglycemic episodes occur in the first 24 hours and are more likely to occur in patients with large tumors and high urinary metanephrine levels (198). If surgery is unsuccessful the use of alpha and beta blockers may improve insulin resistance and glucose homeostasis (199).

 

Hyperthyroidism 

 

Hyperthyroidism induces insulin resistance and hyperglycemia, by increasing intestinal glucose absorption and hepatic glucose production (200,201).  Thyroid hormones increase hepatic glucose production by stimulating endogenous glucose production by increasing gluconeogenesis and glycogenolysis (201). Hyperthyroidism in patients without diabetes may increase glucose intolerance (202). Whether hyperthyroidism causes frank diabetes is unclear because much of the older literature that purports that hyperthyroidism causes diabetes used criteria for diabetes that differs greatly from current guidelines. For example, the study of Kreines and colleagues reported that 57% of patients with hyperthyroidism had diabetes but the criteria for diabetes was a 1 hour glucose >160mg/dL plus a 2 hour value >120 mg/dL during an oral glucose tolerance test (203). A study from China using oral glucose tolerance tests did not find a major difference in the prevalence of diabetes in patients with Grave’s disease (11.3%) vs controls (10.0%) (204). In a careful review of the literature Roa Dueñas et al found that hyperthyroidism was not related to type 2 diabetes except for one study in which hyperthyroidism had a positive association with the risk of T2D (5 studies, with a total of 148,684 participants and 11,154 incident cases of type 2 diabetes) (200). In a meta-analysis of these studies the results showed a non-significant association with the risk of T2D (HR 1.16; 95% CI 0.90-1.49). A meta-analysis of 12 cohorts with 32,747 participants also failed to demonstrate that subclinical hyperthyroidism was associated with the development of T2D (205). In contrast, a large retrospective cohort study found that after 10 years of follow-up T2D was increased (HR 1.30; 95% CI 1.21-1.39) (206). Thus, the effect of hyperthyroidism on the development of T2D if present is likely to be modest with most studies demonstrating no relationship. The duration of hyperthyroidism may be a key variable and health care systems where hyperthyroidism is promptly treated may fail to demonstrate that hyperthyroidism leads to incident T2D.

 

It should be noted that hyperthyroidism may worsen glycemic control in patients with diabetes by increasing intestinal glucose absorption, decreasing insulin sensitivity, and increasing glucose production (207). Teprotumumab, which is used to treat thyroid eye disease, may worsen glycemic control in patients with diabetes and induce hyperglycemia in patients without diabetes (208,209) (discussed in drug induced diabetes section below).

 

Additionally, T1D and Grave’s disease can occur together as part of the autoimmune polyglandular syndrome (210).

 

Glucagonoma

 

Glucagonomas are extremely rare and are associated with a characteristic rash termed necrolytic migratory erythema (82% of patients), painful glossitis, cheilitis, angular stomatitis, normochromic normocytic anemia (50-60%), weight loss (60-90%), mild diabetes mellitus (68-80%), hypoaminoacidemia, low zinc levels, deep vein thrombosis (50%), and depression (50%) (211,212). Glucagon stimulates hepatic glucose production by increasing gluconeogenesis and glycogenolysis leading to an increase in plasma glucose levels (213). Removal of the tumor results in the remission of diabetes.

 

Somatostatinoma

 

Somatostatinomas are extremely rare tumors that may present with a triad of diabetes mellitus, diarrhea/steatorrhea, and gallstones, but weight loss and hypochlorhydria also occur (214). Approximately seventy-five percent of patients with pancreatic somatostatinomas have diabetes  while diabetes occurs in only approximately 10% of patients with intestinal tumors. Typically, the diabetes is relatively mild and can be controlled with diet, oral hypoglycemic agents, or small doses of insulin (214). Somatostatin inhibits insulin secretion which can result in elevations in plasma glucose levels (214). Increased secretion of somatostatin by cells in the pancreas may be in closer proximity to beta cells and more effective in inhibiting insulin secretion than somatostatin secreted by intestinal cells. Somatostatin also inhibits glucagon secretion and therefore diabetic ketoacidosis is very unusual but has been reported (214,215). Additionally, replacement of functional islet cell tissue by the pancreatic tumor may also contribute to the development of diabetes in patients with a pancreatic somatostatinoma (214). Removal of the tumor results in remission of diabetes.

 

Primary Hyperaldosteronism  

 

Hypokalemia secondary to hyperaldosteronism can impair insulin secretion and result in diabetes. Potassium replacement will improve glucose homeostasis. Additionally, aldosterone induces insulin resistance in adipocytes, skeletal muscle, and liver and decreases insulin secretion independent of potassium levels (216).

 

In a large meta-analysis the risk of diabetes (OR 1.33, 95% CI 1.01–1.74) and the metabolic syndrome (OR 1.53, 95% CI 1.22–1.91) was modestly increased in patients with primary hyperaldosteronism (217). Hyperaldosteronism increases the risk of cardiovascular disease and renal disease (216,218,219).

 

DRUG-INDUCED DIABETES

 

A large number of different drugs have been shown to adversely affect glucose homeostasis (Table 1). Most of these drug’s act in conjunction with other risk factors for T2D and are usually not the sole cause of diabetes. Drug-induced hyperglycemia is often mild and may be clinically asymptomatic, but in some instances can result in the development of severe hyperglycemia manifesting as diabetic ketoacidosis. There are a number of mechanisms by which drugs induce alterations in glucose metabolism including inducing insulin resistance or inhibiting insulin secretion. In most cases diabetes remits when the drug is stopped but in some instances diabetes can be permanent. Use of a rodenticide (N-3 pyridylmethyl-N’4 nitrophenylurea, VacorÒ), structurally related to streptozotocin, was removed from the market in the 1980s because the ingestion of this compound resulted in insulin-dependent diabetes due to beta cell destruction (220). In this section we will focus on drugs that cause major changes in glucose homeostasis or drugs that are commonly used in clinical practice.

 

Antihypertensive Drugs

 

In a meta-analysis the risk of developing diabetes varied between different classes of antihypertensive drugs (221).  The odds ratios were: angiotensin receptor blocker (ARB) 0.57; angiotensin converting enzyme (ACE) inhibitor 0.67; calcium channel blocker (CCB); 0.75; placebo; 0.77; beta blocker; 0.90 with the thiazide group set at 1.00. Similarly, in the ALLHAT study the risk of developing diabetes was greater in the thiazide group than in patients treated with an ACE inhibitor or a CCB (222). In a meta-analysis of 10 studies of beta-blockers and 12 studies of diuretics in patients without diabetes it was found that beta-blockers increased fasting blood glucose concentrations by 11.5 mg/dL and diuretics by 13.9 mg/dl (223). As one would expect, lower doses of thiazides (hydrochlorothiazide or chlorthalidone ≤25 mg daily) had less effect on glucose levels (224). In a meta-analysis of twelve studies with 94,492 patients beta-blocker therapy resulted in a 22% increased risk for new-onset diabetes compared with nondiuretic antihypertensive agents (225). Thus, both thiazide diuretics and beta blockers increase the risk of developing diabetes while ARBs and ACE inhibitors reduce the risk (226). CCB, alpha receptor blockers (prazosin and doxazosin), and clonidine do not increase the risk of developing of diabetes (227).

 

The hyperglycemia secondary to thiazide diuretics may in some instances be due to decreased insulin secretion secondary to potassium loss, which can be improved with potassium replacement (228). Studies have suggested that combining thiazides with potassium-sparing diuretics reduces the development of hyperglycemia (229). In addition, thiazides may directly affect insulin secretion similar to diazoxide (see below). Finally, thiazides also increase insulin resistance and enhance hepatic glucose production (228).

 

The effect on glucose metabolism differs between different beta-blockers and carvedilol, a third-generation beta-blocker, has beneficial effects on glucose metabolism (226,228). A greater inhibition of insulin secretion occurs with non-selective beta-blocking agents (228). Beta blockers decrease insulin secretion and increase insulin resistance (226,228). In addition, beta-blockers increase weight, which also could adversely affect glucose homeostasis (230). Finally, beta-blockers increase the risk of severe hypoglycemia by decreasing the recovery from hypoglycemia and masking the symptoms of hypoglycemia (231).

 

Diazoxide

 

Diazoxide is a non-diuretic benzothiadiazine derivative, which increases plasma glucose levels by inhibiting insulin secretion through opening the potassium/ATP channels in beta cells (232). Diazoxide is used to control hypoglycemia in patients with insulinomas (233).

 

Statins

 

In a meta-analysis of 13 trials with over 90,000 subjects, there was a 9% increase in the incidence of diabetes during follow-up among subjects receiving statin therapy (234). All statins appear to increase the risk of developing diabetes. A more recent meta-analysis comparing low or moderate intensity statin therapy vs. placebo found that there was a 10% increase in the incidence of new diabetes whereas with high intensity statin therapy there was a 36% increase (235). In patients on intensive vs. moderate statin therapy, Preiss et al observed that patients treated with intensive statin therapy had a 12% greater risk of developing diabetes compared to subjects treated with moderate dose statin therapy (236). Older subjects, obese subjects, and subjects with high glucose levels were at a higher risk of developing diabetes while on statin therapy (235,237). Thus, statins may be unmasking and accelerating the development of diabetes that would have occurred naturally in these subjects at some point in time. In patients without risk factors for developing diabetes, treatment with statins does not appear to increase the risk of developing diabetes.

 

The mechanism by which statins increase the risk of developing diabetes is unknown (237). Studies suggest that the inhibition of HMG-CoA reductase per se may be leading to the statin induced increased risk of diabetes via weight gain (237). However, a large number of studies have now shown that polymorphisms in a variety of different genes that lead to a decrease in LDL cholesterol levels are also associated with an increase in diabetes suggesting that decreases in LDL cholesterol levels per se alter glucose metabolism and increase the risk of diabetes (237). How decreased LDL cholesterol levels effect glucose metabolism is unknown.

 

In some studies statins have been shown to increase insulin resistance (238) and in some studies to decrease insulin secretion (239,240). Clearly further studies are required to understand the mechanisms by which statins increase the risk of developing diabetes.

 

Niacin

 

A meta-analysis examined the effect of niacin therapy on the development of new onset diabetes (241). In 11 trials with 26,340 non-diabetic participants, niacin therapy was associated with a 34% increased risk of developing diabetes. This increased risk results in one additional case of diabetes per 43 initially non-diabetic individuals who are treated with niacin for 5 years. Results were similar in patients who were receiving niacin therapy in combination with statin therapy. It has been recognized for many years that niacin induces insulin resistance (242). The mechanisms by which niacin induces insulin resistance are unknown but possible mechanisms include a rebound increase in free fatty acids with niacin therapy or the accumulation of diacylglycerol (242).

 

Pentamidine

 

Pentamidine is an antiprotozoal agent known to cause hypoglycemia and hyperglycemia (228). Pentamidine induces a direct cytolytic effect on pancreatic beta cells leading to insulin release and hypoglycemia, which is then followed by beta cell destruction and insulin deficiency resulting in diabetes (243,244).

 

Phenytoin (Dilantin)

 

Phenytoin can cause hyperglycemia and there have been cases of diabetic ketoacidosis (245,246). The adverse effect of phenytoin on glucose metabolism is mediated primarily by an inhibition of insulin secretion (228).

 

Alpha Interferon

 

Treatment with alpha interferon in rare instances can cause T1D. Of 987 patients treated with alpha interferon for chronic hepatitis C, 5 patients developed T1D (247). The clinical course is characterized by the abrupt development of severe hyperglycemia at times with ketoacidosis (248). High titers of anti-islet autoantibodies are present and almost all patients require permanent insulin therapy (248). Treatment with interferon alpha facilitates the development of autoimmune disorders including T1D (249). Other autoimmune disorders frequently occur, particularly thyroid dysfunction.

 

Checkpoint Inhibitors

 

There are several checkpoint inhibitors; ipilimumab a cytotoxic T-lymphocyte-associated protein 4 inhibitor (CTLA-4 inhibitor); nivolumab and pembrolizumab, programmed cell death protein 1 inhibitors (PD-1 inhibitors); atezolizumab, avelumab, and durvalumab. programmed cell death 1 ligand inhibitors (PD-L1 inhibitors) (250). Both CTLA-4 and PD-1 play a key role in the maintenance of immunological tolerance to self-antigens thereby preventing autoimmune disorders (250). Immune mediated hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency, hypoparathyroidism, and insulin-deficient diabetes have been reported as a complication of the use of these drugs (250,251). In a meta-analysis of 38 randomized clinical trials with 7551 patients, autoimmune diabetes occurred in only 0.2% of the patients and was primarily seen with the use of PD-1 inhibitors (250). In another meta-analysis of 101 studies with 19,922 patients the incidence of autoimmune diabetes was 2.0% (95% CI, 0.7–5.8) for nivolumab and 0.4% (95% CI, 0.2–1.3) for pembrolizumab (251). The occurrence of autoimmune diabetes with other checkpoint inhibitors was rare (251).

 

The onset of diabetes ranges from a few weeks up to one year after initiating therapy and typically presents with polyuria, polydipsia, weight loss, and dehydration (251,252). Severe hyperglycemia and ketoacidosis are commonly observed (252). Because of the acute occurrence, A1c levels may not be elevated. C-peptide levels are very low and approximately 50% of patients have islet cell antibodies (GAD, ICA, IAA or IA-2; GAD antibodies are the most commonly observed) (251,252). Insulin treatment is required, and it is likely that the diabetes will be irreversible (251,252).

 

For additional information on the checkpoint inhibitor associated diabetes see the Endotext chapter “Immune Checkpoint Inhibitors Related Endocrine Adverse Events” in the Disorders that Affect Multiple Organs section (253).

 

Antipsychotic Drugs

 

Many studies have linked second generation antipsychotic medications with the development of T2D (Table 5) (254,255). In a meta-analysis of a large number of studies it was reported that olanzapine and clozapine treatment resulted in a greater increase in glucose abnormalities than aripiprazole, quetiapine, risperidone and ziprasidone (256). Another meta-analysis has further shown that aripiprazole has a reduced risk of T2D compared to other antipsychotic agents (257). With regards to first generation antipsychotic drugs, chlorpromazine has a high risk of disrupting glucose metabolism while haloperidol, fluphenazine, and perphenazine have a low risk (254). It is thought that antipsychotic drugs induce diabetes by multiple mechanisms: (1) they inhibit insulin signalling in muscle cells, hepatocytes, and adipocytes thereby causing insulin resistance; (2) they induce obesity, which can also cause insulin resistance; and (3) they can cause direct damage to β-cells, leading to dysfunction and apoptosis of β-cells (255,258).

 

Table 5. Risk of Diabetes of Selected First- and Second-Generation Antipsychotics

 

Risk of diabetes*

First-generation antipsychotic

  Chlorpromazine

  Fluphenazine

  Perphenazine          

  Haloperidol  

 

+++

+

+

+

Second-generation antipsychotic

  Clozapine     

  Olanzapine  

  Quetiapine   

  Risperidone 

  Ziprasidone  

  Aripiprazole  

  Paliperidone 

  Lurasidone   

 

+++

+++

++

++

+

+

+

+

*Relative to other antipsychotics. Not all the risk of diabetes or weight gain are related to the antipsychotics. Table modified from (255)

 

Androgen Deprivation Therapy

 

A number of studies have shown that androgen deprivation therapy increases the risk of developing diabetes (259). For example, a study by Tsai reported that androgen deprivation therapy was associated with a 1.61-fold increased diabetes risk and the number needed to harm was 29 (260). The androgen deprivation induced diabetes typically develops after a year of treatment (259). Androgen deprivation therapy induces insulin resistance (259). The increase in insulin resistance may be due to an increase in visceral fat mass and/or an increase in pro-inflammatory adipokines such as TNF-a, IL-6, and resistin (259).

 

Immunosuppressive Drugs

 

Immunosuppressive drugs used after organ transplantations increase the risk of diabetes (261). In general, tacrolimus has been associated with a greater risk of developing diabetes compared to cyclosporine (261,262). The calcineurin inhibitors, tacrolimus and cyclosporine, decrease insulin secretion and synthesis (261,262). Additionally, tacrolimus and cyclosporine inhibit glucose uptake in human subcutaneous and omental adipocytes (262).

 

Mechanistic Target of Rapamycin Inhibitors (mTOR inhibitors)

 

mTOR inhibitors, sirolimus and everolimus, can induce diabetes (263). The adverse effect of mTOR inhibitors on glucose metabolism is due to insulin resistance secondary to a reduction of the post receptor insulin signalling pathway and a reduction of insulin secretion via a direct effect on the pancreatic beta cells (261,263).

 

Asparaginase

 

Hyperglycemia is common with the use of asparaginase treatment ranging from 2.5% to 23% in the pediatric population and as high as 76% in adults with PEG-asparaginase use (264,265). Hyperglycemia usually resolves within 12 days after the last dose (264). Risk factors predisposing to hyperglycemia with asparaginase treatment include a history of impaired glucose tolerance, age >10 years, obesity, family history of diabetes mellitus, and history of Down syndrome (264,265). Diabetic ketoacidosis has been described with asparaginase treatment but is not a common occurrence (264). Decreased insulin secretion, increased insulin resistance, and increased glucagon secretion may contribute to the hyperglycemia observed with asparaginase. Additionally, asparaginase can induce pancreatitis, which can also lead to hyperglycemia (264).

 

Antibiotics

 

Fluoroquinolones have been associated with an increased risk of hyperglycemia, particularly in the elderly (228). The risk of developing hyperglycemia is greatest with gatifloxacin (228).

 

Beta-Adrenergic Drugs

 

High doses of beta-adrenergic drugs can lead to hyperglycemia likely due to the stimulation of hepatic gluconeogenesis (228).

 

Teprotumumab

 

Teprotumumab blocks the activation of the insulin-like growth factor-1 receptor (IGF-1 receptor). Initial studies in patients with thyroid eye disease found that approximately 10% of patients had hyperglycemia and one-third of these individuals with hyperglycemia did not have pre-existing diabetes or impaired glucose tolerance but the study by Amarikwa et al found a higher risk of hyperglycemia (209,266,267). Older age, prediabetes/diabetes, and Asian and Hispanic ethnicity may increase the risk of hyperglycemia. Case reports of diabetic ketoacidosis and hyperglycemic hyperosmolar state have been reported (268,269). In some but not all patients glycemia returns towards normal when teprotumumab treatment is completed. Blocking the activation of the IGF-1 receptor may lead to an increase in growth hormone secretion leading to hyperglycemia (270). Additionally, adverse effects on insulin receptors that interact with the IGF-1 receptor may lead to insulin resistance (270).

 

Glucocorticoids, Somatostatin, Growth Hormone, and Glucagon

 

The effects of these hormones on glucose metabolism were discussed in the section on Endocrinopathies.

 

HIV Antiretroviral Therapy

 

The effect of the drugs used to treat patients living with HIV on the development of diabetes is discussed in the Endotext chapter “Diabetes in People Living with HIV” in the Diabetes section (6).

 

IMMUNE-MEDIATED

 

Latent Autoimmune Diabetes in Adults (LADA)

 

LADA is an autoimmune disorder that resembles T1D but shows a later onset and slower progression towards requiring insulin therapy (271-273). The ADA includes LADA as T1D whereas WHO classifies LADA as a hybrid form of diabetes (T1D and T2D) (96) (https://www.who.int/publications/i/item/classification-of-diabetes-mellitus). Epidemiological studies suggest that LADA may account for 2–12% of all cases of diabetes in the adult population (271,272,274). To differentiate LADA from T1D and T2D, the Immunology of Diabetes Society has proposed three criteria: (a) adult age of onset (> 30 years of age); (b) presence of at least one circulating autoantibody (GAD, ICA, IAA or IA-2) and; (c) insulin independence for the first 6 months after the time of diagnosis (271,272). Of the various antibodies associated with autoimmune diabetes, GAD antibodies are present in most patients with LADA (271,272,274). Patients with high titers of GAD antibodies progress to requiring insulin more rapidly (273). LADA subjects appear to have a faster decline in C-peptide levels compared to autoantibody negative patients with T2D (274). It should be noted that classic T1D can occur in adults and this is defined as those adult patients with antibodies (GAD, ICA, IAA or IA-2) that require insulin therapy at diagnosis or soon after diagnosis (272,274). In contrast, patients with LADA can often go many years before requiring insulin therapy (272). Whether LADA is just a slowly progressing form of T1D or a hybrid T1D and T2D is unclear (Table 6).

 

Table 6. Comparison of T1D, LADA, and T2D

 

T1D

LADA

T2D

Age of onset

Tend to be young

>age 25

Tend to be adult

Family history

Occasional

Occasional

Usually

C-peptide

Low, often undetectable

Varies

Normal or high

Auto-ab

+

+

-

Weight

Tend to be lean

Tend to be lean

Usually overweight

Metabolic syndrome

No

Varies

Usually

Insulin requirement

Yes

Varies

Varies

Genetic risk

HLA

PTPN22

INS

SH283

PFKFB3

Intermediate between T1D & T2D

TCF7L2

FTO

SLC30A8

 

In a retrospective study, Fourlanos and colleagues pointed out several features that increase the likelihood of a patient with “T2D” having LADA (275). These features include age of onset <50 years of age,  acute symptoms (polyuria, polydipsia, weight loss), BMI <25 kg/m2, personal history of autoimmune disease, and family history of autoimmune disease (275). The presence of at least two of these clinical features indicated a 90% sensitivity and 71% specificity for identifying a patient with LADA (275). As compared to patients with T2D, LADA patients have a lower rate of hypertension, lower total cholesterol levels, higher HDL cholesterol levels, and a decreased frequency of the metabolic syndrome (272,274). HLA-DQB1 risk genotypes have been consistently positively associated and protective genotypes have been negatively associated with LADA (273). However, in addition to genotypes that are associated with T1D, patients with LADA also have an increased frequency of genotypes that are associated with T2D (TCF7L2, FTO, and SLC30A8) (273). Having a healthy lifestyle and a BMI<25 is associated with a reduced risk of LADA including in individuals with a genetic susceptibility (276). Individuals with other autoimmune diseases are more likely to develop LADA (277).

 

Some have proposed GAD antibody testing all patients with T2D (278) to diagnose LADA but given the given the increased costs and the relatively frequent occurrence of false positive tests compared to true positives in a low-risk population this strategy is not widely accepted (279). The ADA suggests selective testing in adults without traditional risk factors for T2D and/or younger age (96). 

 

In LADA patients glycemic control can initially be achieved with hypoglycemic agents other than insulin but overtime patients progress to requiring insulin therapy. Sulfonylureas seem to accelerate the progress to requiring insulin therapy and therefore should be avoided (280). Because of the progressive loss of beta cell function there is an increased risk of diabetic ketoacidosis with SGLT2 inhibitors and therefore these drugs should be used with caution. Monitoring ketone levels in patients with LADA treated with SGLT2 inhibitors would be prudent. Novel therapies to preserve beta cell function would be ideal for patients with LADA but at this time there are no proven strategies to preserve beta cell function. However, there are several studies from China that suggest that vitamin D may slow the loss of beta cell function (281-283)

 

In a long- term follow-up (median 17.3 years) comparing microvascular outcomes in patients with LADA or T2D it was observed that the risk of renal failure/death, blindness, vitreous hemorrhage, or retinal photocoagulation was decreased in the patients with LADA during the first 9 years (adjusted HR 0.45; p<0.0001), whereas in subsequent years their risk was higher (HR 1·25; p=0.047) (284). This difference was attributed to higher A1c levels in the LADA patients. The prevalence of coronary heart disease and cardiovascular mortality is similar in patients with LADA and T2D (285,286). Mortality is increased in patients with LADA (HR 1.44), compared to controls (287).

 

Autoimmune Polyglandular Syndromes

 

T1D can occur as part of the autoimmune polyglandular syndromes. These disorders are discussed in the Endotext chapter “Autoimmune Polyglandular Syndromes” in the Disorders that Affect Multiple Organs section (4).

 

Stiff-Person syndrome

 

Stiff-person syndrome is a rare autoimmune disorder of the nervous system with fluctuating stiffness and spasm of the skeletal muscles that occurs more frequently in females than males (approximately 2/3 women) (288). Rigidity is caused by simultaneous contracture of agonist and antagonist muscles. Muscle involvement is symmetrical, and the lower extremities are affected more commonly than the upper extremities and proximal limb and axial muscles are affected more severely than distal muscles (288). Most patients have very high levels of anti-glutamic acid decarboxylase (GAD) antibodies (288). 30-65% of these individuals also develop beta cell destruction and T1D (289). Diabetes may occur several years prior to the development of the stiff-person syndrome (60%) or after the development of the stiff-person syndrome (288,289). The stiff person syndrome without GAD antibodies is not associated with diabetes (289). The GAD antibodies in patients with T1D and stiff-person syndrome recognize a different set of epitopes and have distinct biological effects (290). Other autoimmune manifestations are also common, particularly thyroid disorders and pernicious anemia (288,289). It should be noted that a variety of neurological disorders (cerebellar ataxia, limbic and extra-limbic encephalitis, nystagmus/oculomotor dysfunction, drug-resistant epilepsy, etc.) are associated with GAD antibodies (290).

 

Autoimmune Insulin Resistance Type B Syndrome

 

Insulin resistance can result from autoantibodies directed against the insulin receptor, which either inhibit insulin from binding to the receptor or stimulate the receptor (291). Thus, they can cause either hyperglycemia or hypoglycemia, even alternating in the same patient. Low titers of insulin receptor antibodies typically lead to hypoglycemia while high titers result in hyperglycemia but the possibility of epitope switching may also determine if hyperglycemia or hypoglycemia is manifest (292,293). The patients usually present with very high glucose levels with high fasting insulin levels  and significant weight loss (291,293). Serum triglyceride levels are typically low and HDL cholesterol levels normal, which contrasts with typical patients with insulin resistance who usually have high triglyceride levels and low HDL cholesterol levels. This difference is explained by post receptor insulin resistance stimulating lipogenesis whereas insulin resistance localized to the receptor does not (294). The diagnosis can be confirmed by demonstrating the presence of autoantibodies to the insulin receptor. The prevalence of type B insulin resistance syndrome is unknown but is quite rare (291). Middle-aged women are most often affected and often have other manifestations of autoimmune disease such as SLE or Sjogren’s. However, this disorder can also affect males and younger patients. In some instances, the type B insulin resistance syndrome occurs as a paraneoplastic manifestation of lymphoma or multiple myeloma. Patients may have signs of insulin resistance including acanthosis nigricans and ovarian hyperandrogenism. Of note the acanthosis nigricans may involve the lips and the periocular region resulted in a typical facial appearance (291). Serum testosterone levels are often elevated in females (291). Patients often need excessive amounts of insulin (1,000 U or more per day). One can add insulin sensitizers such as metformin and/or thiazolidinediones to try to reduce the insulin dose, which can in some patients be greater than 10,000U per day (291). Treatment includes immunosuppression and/or plasmapheresis to halt the autoantibody production and decrease antibody levels (295). Treatment with rituximab, high-dose steroids, and cyclophosphamide until remission, followed by maintenance therapy with azathioprine is very effective in inducing and maintaining remissions. Approximately 1/3 of patients will undergo a spontaneous remission with reversal of the hyperglycemia/hypoglycemia and the clinical manifestations (291).

 

DIABETES OF UNKNOWN CAUSE

 

Ketosis-Prone Diabetes in Adults (Flatbush Diabetes)

 

This syndrome is characterized by the acute onset of severe hyperglycemia with or without ketoacidosis, which after several weeks to months no longer requires insulin therapy and can be treated with diet or oral hypoglycemic agents (296,297). These patients typically have a history of polyuria, polydipsia, and weight loss for less than 4 to 6 weeks indicating an abrupt onset of the disorder in glucose metabolism and no history of an event that could have precipitated the hyperglycemia (297). The initial presentation is suggestive of T1D. While in most patients insulin therapy can be stopped there are some patients who continue to require insulin treatment (296). This syndrome occurs in black populations (African American, African-Caribbean, sub-Saharan African), Hispanic populations, and Asian (Chinese, Indian, and Japanese) populations but is not typically seen in Caucasians (296,297).  The typical patient is male, middle-aged, overweight or modestly obese with a strong family history of diabetes (296,297). Patients are negative when tested for islet cell antibodies (GAD, ICA, IAA or IA-2) (296). Recurrent episodes of ketoacidosis can occur, but the clinical course is typical of patients with T2D (296,297). Treatment with hypoglycemic agents reduces the risk of recurrence (297,298). SGLT2 inhibitors should be used with caution given the risk of recurrent ketoacidosis. With long-term follow-up many patients eventually require insulin therapy similar to what is observed in patients with T2D (298).

 

During the episode of severe hyperglycemia patients with ketosis-prone diabetes have lost the ability of glucose to stimulate beta cell insulin secretion but nonglycemic pharmacologic agents (glucagon and arginine) can stimulate insulin secretion (296). After restoration of normal glycemia the ability of glucose to stimulate insulin secretion returns towards normal and by 8-12 weeks has maximally improved (296). Usually patients with this syndrome have a modest reduction in stimulated insulin secretion (296). Why these patients temporarily lose the ability for glucose to stimulate insulin secretion is unknown. Additionally, during the acute episode of hyperglycemia the patients are severely insulin resistant, which improves during a period of euglycemia (297,298).

 

Clinically, it is important to recognize this syndrome as some patients presenting with diabetic ketoacidosis, particularly if they are non-Caucasians, may not have T1D but rather have ketosis-prone diabetes. It is estimated that between 20% and 50% of African-American and Hispanic patients with a new diagnosis of diabetic ketoacidosis have ketosis-prone diabetes (297). After restoration of euglycemia the management of these patients is similar to the management of patients with T2D, and they frequently do not require permanent insulin treatment.

 

OTHER GENETIC SYNDROMES SOMETIMES ASSOCIATED WITH DIABETES

 

There are a number of inherited monogenic disorders that secondarily can be associated with diabetes. The mechanisms linking these disorders with diabetes are often not clear.

 

Chromosomal Abnormalities

 

DOWN SYNDROME

 

Down syndrome is due to trisomy of chromosome 21 and occurs in 1 in every 787 liveborn babies (299). Down syndrome is often associated with autoimmune disorders like T1D and thyroiditis (299,300). The prevalence rate of T1D in patients with Down syndrome has been estimated to be between 1.4 and 10.6%, which is higher than in the general population (301). In another study there was a 4-fold increased prevalence of diabetes in patients with Down syndrome (302). Diabetes in patients with Down syndrome often presents earlier in life with 22% of participants developing diabetes by 2 years of age (303). The presence of diabetes is often associated with other autoimmune disorders, particularly hypothyroidism and celiac disease (300). Anti-glutamic acid decarboxylase antibodies (GAD antibodies) are very frequently present in Down syndrome subjects who develop diabetes (300). Downs syndrome patients with diabetes have similar HLA genotypes as non-Down syndrome patients with T1D (300). Interestingly, while patients with Down syndrome and diabetes are typically treated with simpler regimens their glycemic control tends to be as good or better than the usual patient with T1D, perhaps related to a simpler lifestyle and acceptance of routine (300). The cause of the increased autoimmunity in patients with Down syndrome may be due to the abnormal expression of the AIRE gene, which regulates T-cell function and self-recognition and is located on chromosome 21 (21q22.3 region) (299,300).

 

While the incidence of T2D is similar between patients with Down syndrome and controls, the onset of T2D occurs at a much earlier age (304). The incidence for T2D is >10 times higher in patients aged 5–14 years with Down syndrome compared to controls. In individuals under the age of 45, Down syndrome is associated with an increased incidence of diabetes while over the age of 45, the incidence of diabetes is increased in controls.  Notable the BMI in increased in younger patients with Down syndrome compared to controls and could contribute to the increase in T2D.

 

KLINEFELTER SYNDROME

 

Klinefelter syndrome is due to an extra X chromosome in men (XXY) resulting in hypergonadotropic hypogonadism, low testosterone levels, gynecomastia, and reduced intelligence (305,306). The prevalence of Klinefelter syndrome is approximately 1 in 500 to 1 in 1000 males (305,306). Patients with Klinefelter syndrome are frequently obese, insulin resistant, and at increased risk to develop T2D (50% have the metabolic syndrome) (307,308). The decreased muscle mass and increased fat mass that often occur in patients with Klinefelter syndrome contribute to the high prevalence of insulin resistance and metabolic syndrome. The prevalence of overt diabetes in Klinefelter syndrome is estimated to be between 10-39% (307,309). Additionally, the prevalence of diabetes is even higher (up to 57%) in patients with more severe karyotypes (48, or 49 chromosomes) (307). Klinefelter syndrome patients develop diabetes earlier in life (onset around 30 years) and their BMI is lower than what is usually observed in patients with T2D (307). Hypogonadism is associated with insulin resistance and an increased risk of diabetes and whether testosterone therapy will be of benefit in preventing or treating diabetes in patients with Klinefelter syndrome is uncertain (309). Given the increased risk of developing T2D, patients with Klinefelter syndrome should be periodically screened for diabetes.

 

Interestingly, one study reported an increased prevalence of T1D in patients with Klinefelter syndrome (310). Furthermore, a study reported that 8.2% of patients with Klinefelter syndrome had autoantibodies specific to T1D (Insulin Abs, GAD Abs, IA-2 Abs, Znt8 Abs) (311). Additional studies are required to better elucidate whether Klinefelter syndrome increases the risk of developing T1D.

 

TURNER SYNDROME

 

Turner syndrome is the most common chromosomal abnormality in girls, affecting approximately 1:2,500 female live births (312). The condition is caused by complete or partial deletion of an X chromosome (312). The incidence of both T1D and T2D has been reported to be increased in patients with Turner syndrome (313). However, the link between T1D and Turner syndrome is not well characterized while the link with T2D is clearly established (314,315). For example, in a study of 224 patients with Turner syndrome 56 (25%) had T2D whereas only 1 patient (<0.5%) had T1D (316). Patients with Turner syndrome have an increased risk of autoimmune disorders, particularly hypothyroidism and celiac disease, but the prevalence of autoimmune T1D is much less (315,317). Four percent of patients with Turner syndrome have been shown to have GAD antibodies, which is greater than the 1% prevalence seen in the general population (317).

 

The prevalence of glucose intolerance is estimated to be from 15-50% while the prevalence of T2D is estimated to be approximately 10-25% (315,316). T2D occurs at a relatively young age in patients with Turner syndrome. A 25%-70% lifetime risk for diabetes has been described (318). Decreased beta cell function and decreased insulin sensitivity was observed in teenagers with Turner syndrome and was accompanied by an increased prevalence of impaired fasting glucose and impaired glucose tolerance compared to controls (319). Increased obesity is common in patients with Turner syndrome, which likely contributes to the abnormalities in glucose metabolism (314). Both insulin resistance and decreased insulin secretion are present in patients with Turner syndrome but the development of hyperglycemia in patients with T2D appears to be driven by decreased insulin secretion (314,315). Because of the high prevalence of diabetes, it is recommended to screen A1c with or without fasting glucose levels annually beginning at 10-12 years of age or sooner with symptoms of diabetes and then every 1-2 years (315,318). When diabetes is diagnosed,measuring diabetes auto-antibodies is helpful in differentiating T1D vs, T2D in patients with Turner syndrome (318). Growth hormone therapy does not appear to increase the risk or worsen diabetes (314,315). Growth hormone therapy may lead to a decrease in adiposity and impaired glucose tolerance, which suggests it may actually improve glucose homeostasis (315). Similarly, sex steroid hormone replacement therapy also does not appear to have major adverse effects on glucose metabolism in patients with Turner syndrome (314).

 

WILLIAMS SYNDROME

 

Williams syndrome (Williams-Beuren syndrome) is a multisystem disorder characterized by transient infantile hypercalcemia, distinctive facial dysmorphism, and supravalvular aortic stenosis (320,321). In addition, gastrointestinal problems, dental anomalies, developmental delay/intellectual disability, anxiety disorders, and attention deficit disorder may occur as well as a variety of endocrine abnormalities including reduced statural growth, obesity, dyslipidemia, early pubertal development, hypothyroidism, and decreased bone density (320,322). Williams syndrome is due to a deletion on chromosome 7q, leading to the loss of 25–27 contiguous genes and thus individuals with Williams syndrome have only a single copy of these genes (321). This deletion almost always arises de novo in the affected individual. The estimated prevalence of Williams syndrome is ~1/7,500 and effects both males and females (321).

 

Numerous studies have shown a high prevalence of T2D and impaired glucose tolerance in patients with Williams syndrome (320). The abnormalities in glucose metabolism occur during adolescence and are not necessarily associated with obesity (320). Of note insulin resistance is observed initially followed by a loss of insulin secretion (320). Markers of islet autoimmunity are not observed (320). In a review of 7 studies with 154 participants with Williams syndrome and an average age ranging from 13 to 35 years of age it was observed that 18% had diabetes and 42% impaired glucose tolerance (320). Because of this high risk for diabetes, it is recommended that patients with Williams syndrome be screened for diabetes beginning in adolescence (320). Note-worthy is that A1c was frequently not abnormal and therefore screening should be with fasting glucose levels or an oral glucose tolerance test (320).

 

Diseases of the Endoplasmic Reticulum

 

The endoplasmic reticulum folds and modifies newly formed proteins to make them function properly. Therefore, diseases affecting the endoplasmic reticulum usually affect many organs. Wolfram syndrome is the best known but there are other genetic syndromes that affect the endoplasmic reticulum and cause diabetes (323).

 

WOLFRAM SYNDROME 

 

Wolfram syndrome is a rare autosomal recessive genetic disorder characterized by T1D, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration (324,325). There are also rare autosomal dominant forms of this disorder (325). This syndrome is sometimes called DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). The prevalence is approximately one per 770,000 but varies depending upon the specific population (324,325). The onset of the clinical picture is highly variable in both severity and clinical manifestations (325). This disorder typically has a very poor prognosis with the median age at death being 30 years (324). Diabetes mellitus is usually the first manifestation, typically diagnosed around age 6 (324). The diabetes is not immune mediated but is characterized by insulin deficiency (325). Almost all patients require insulin therapy (325). Residual beta cell function persists and therefore good glycemic control tends to be easier to achieve in Wolfram syndrome than immune mediated T1D (325). However, over time C-peptide levels decrease (326). The development of optic atrophy and hearing loss in children with diabetes are clues to the presence of this syndrome. Until the onset of optic atrophy and hearing loss these patients are usually thought to have typical T1D with an absence of antibodies (325). Confirmation of the diagnosis can be made by identifying mutations in the WFS1 gene (Wolfram syndrome type 1) (324). The WFS1 gene encodes a transmembrane protein (wolframin) localized to the ER (endoplasmic reticulum) and mutations result in ER stress leading to beta cell dysfunction and death (324).

 

Mutations in CISD2 gene cause a similar recessive type of Wolfram syndrome (Wolfram syndrome type 2) with patients exhibiting bleeding from upper intestinal ulcers and defective platelet aggregation without diabetes insipidus and psychiatric disorders (325). CISD2 encodes for a protein that moves between the ER and mitochondrial outer membrane (325).  

 

Unfortunately, there are currently no specific treatments to restore ER function and prevent the complications of this disorder.

 

Base Pair Repeat Syndromes     

 

FRIEDRICHS ATAXIA

 

Friedreich ataxia is a rare recessive disorder caused by triplet repeats (GAA) in the mitochondrial frataxin gene characterized by slowly progressive ataxia associated with dysarthria, muscle weakness, spasticity particularly in the lower limbs, scoliosis, bladder dysfunction, absent lower limb reflexes, and loss of position and vibration sense (327). The onset usually occurs before 25 years of age (327). Cardiomyopathy occurs in 2/3 of patients and up to 30% of patients have diabetes (327). The disorder affects approximately 1 in 30,000 Caucasians.

 

Diabetes occurs in 8-32% of patients with Friedrichs ataxia, and an even higher percentage have impaired glucose tolerance (328,329). Hyperglycemia commonly develops approximately 15 years after the manifestation of neurological symptoms often presenting acutely with patients requiring insulin therapy (328,329). In a number of instances patients present with ketoacidosis (329). Both insulin deficiency and insulin resistance have been reported in patients with Friedreich ataxia (329). It is hypothesized that mutations in frataxin result in alterations in mitochondria function that impair the ability of beta cells to secrete insulin in response to glucose and increase the risk of beta cell death (329). Diabetes is an independent predictor of reduced survival in Friedrichs ataxia (330).

 

There are no controlled studies comparing different diabetes therapies in patients with Friedreich ataxia. Metformin and thiazolidinediones inhibit the mitochondrial respiratory chain and therefore they should probably be used with caution in patients with mitochondrial disease (329). Additionally, thiazolidinediones increase the risk of congestive heart failure and patients with Friedreich ataxia have a high risk of cardiomyopathies and therefore should be avoided. Insulin is often required to achieve glycemic control.

 

HUNTINGTON’S DISEASE

 

Huntington’s disease is an autosomal dominant disorder that begins in adulthood (usually 30-50 years of age) and has distinctive motor defects (chorea, dystonia, and dyskinesia), psychiatric symptoms (depression and anxiety), and cognitive decline (331). This disorder is due to an unstable expansion of CAG repeats in the first exon of the gene that encodes the protein huntingtin (331). The prevalence of this disorder is approximately 5-12 per 100,000 (331,332). While an early study reported that approximately 10% of patients with Huntington’s disease have diabetes a careful review of recent studies reached the conclusion that the prevalence of diabetes in patients with Huntington’s disease is not increased and might actually be decreased (332,333).

 

MYOTONIC DYSTROPHY

 

Myotonic dystrophy type 1 is an autosomal-dominantly inherited disease characterized by myotonia, distal muscular dystrophy, cataracts, hypogonadism, and frontal hair loss that occurs in middle age (334). The disease is due to a CTG triplet repeat expansion in the myotonic dystrophy protein kinase gene (334). In genetic new-born screening the estimated prevalence is  approximately 1:2100 individuals (335). Diabetes is not a characteristic finding in myotonic dystrophy type 1, but the prevalence is increased 2-4-fold in patients with this disorder compared to the general population (334,336,337). A large study in Korea with 387 patients with myotonic dystrophy type 1 found that 27% had diabetes (338). Patients with myotonic dystrophy type 1 and diabetes have elevated insulin levels suggesting insulin resistance (334,336). Pioglitazone alone and in combination with metformin has been reported to improve glycemic control in patients with myotonic dystrophy and diabetes (339,340).

 

Obesity Syndromes

 

BARDET-BIEDLE SYNDROME (BBS)

 

Bardet-Biedl syndrome (BBS), also earlier referred to as Laurence Moon Biedl syndrome, is a rare autosomal recessive disease with a prevalence of about 1/125,000 (341,342). BBS belongs to the group of ciliopathies characterized by obesity, retinal degeneration, finger anomalies, hypogonadism, renal abnormalities, and intellectual impairment (341,342). It can result from autosomal recessive mutations in at least 26 genes (BBS), which play a key role in the structure and function of cilia (341-343). In a study of 152 patients with BBS it was reported that approximately 75% were obese and the average BMI was 35.7kg/m2 (342). Twenty-five of these patients with BBS had diabetes (16.4%) with 24 having T2D and 1 having T1D (342). Of the 24 patients with T2D six patients were diet controlled, eight were taking metformin, and 10 were on insulin therapy. The mean A1c of subjects with T2D was 7.8 (342). The risk of developing diabetes increases with age. In the BBS patients without diabetes fasting glucose, insulin levels, and HOMA-IR were significantly increased in the BBS group compared with an age and BMI matched control group (342). The metabolic syndrome was present in 54% of the patients with BBS (342). There is evidence that BBS genes affect cilia that alter leptin trafficking and signaling thereby impacting the melanocortin 4 receptor (MC4R) pathway (344). In a small trial setmelanotide reduced body weight (16.3% decrease at 12 months) and hunger in individuals with BBS (345). Other trials also observed a decrease in body weight and hunger in individuals with BBS treated with setmelanotide (346,347). One would anticipate that weight loss will reduce the risk of diabetes on patients with BBS. Setmelanotide is approved by the FDA for the treatment of BBS.

 

PRADER WILLI SYNDROME (PWS)

 

PWS is a rare autosomal dominant disorder, affecting 1 in 15,000 newborns, due to a mutation or deletion of several genes in an imprinting region on chromosome 15 (344,348). PWS in children is associated with excessive eating and morbid obesity, hypogonadism, low muscle tone, growth hormone deficiency, and short stature (344,348). The hyperphagia that occurs in PWS is believed to be due to a hypothalamic abnormality resulting in lack of satiety. This leads to excessive obesity in children, which is often associated with T2D due to severe insulin resistance (348). Approximately 20- 25% of adults with PWS have T2D with a mean age of onset of 20 years (348,349). Individuals with PWS who develop early diabetes have severe obesity, a high prevalence of psychiatric and metabolic disorders, and a family history of overweight and T2D (349). Screening for diabetes is recommended annually if obese or beginning in adolescence or with rapid significant weight gain or other symptoms. In recent years the earlier diagnosis and education of parents, use of growth hormone therapy, and the frequency of group homes specific for PWS have led to a reduction in the development of morbid obesity resulting in a decrease in the development of T2D among individuals with PWS (348). Metformin has been shown to be effective in the treatment of PWS patients with diabetes (350). Studies of GLP1 receptor agonists demonstrated lowering of A1c levels and weight loss is some patients (351,352).

 

ALSTROM SYNDROME

 

Alstrom syndrome is a rare autosomal recessive disorder with a prevalence of less than one per million characterized by retinal dystrophy, hearing loss, childhood truncal obesity, insulin resistance and hyperinsulinemia, T2D, hypertriglyceridemia, short stature in adulthood, cardiomyopathy, and progressive pulmonary, hepatic, and renal dysfunction (353-355). Symptoms appear in infancy and multi-organ pathology lead to a decreased life expectancy (353,354). The syndrome is caused by mutations in ALMS1, which is a ciliary protein and hence many of the features of Alstrom syndrome resemble those seen in the Bardet-Biedl syndrome (353-355). Diagnosis is confirmed by finding biallelic pathogenic variants in ALMS1 gene.

 

Severe insulin resistance secondary to abnormalities in GLUT4 trafficking, hyperinsulinemia, and impaired glucose tolerance frequently present in early childhood and are often accompanied by acanthosis nigricans (353,355). T2D develops early in life with a mean age of onset at 16 years (353). In one study 82% of patients with Alstrom syndrome older than 16 years of age had T2D (356). Weight loss with diet, exercise, and medications is indicated (357). Therapy with oral agents, particularly insulin sensitizing agents, may be effective but insulin therapy may be required (353,357). GLP-1 receptor agonists induced weight loss and improved glycemic control (358).

 

Miscellaneous

 

WERNER SYNDROME (WS)

 

Werner syndrome (WS) is an autosomal recessive progeroid syndrome due to biallelic WRN pathogenic variants (359). Clinical features include accelerated aging, short stature, skin atrophy, decreased skeletal muscle mass, hair graying and baldness, partial loss of subcutaneous fat, and cataracts (359). Clinical problems include hypogonadism, osteoporosis, dyslipidemia, atherosclerosis, and cancer (359). Diabetes occurs in 50-75% of patients with WS (360). It is recommended that patients with WS be screened yearly for diabetes (359). The mean age of onset of diabetes is 30-40 years (360). The BMI of most patients with WS is low to normal but patients with diabetes have a higher BMI that is still in the normal range and increased visceral fat (360). It is thought that a decrease in subcutaneous fat leads to visceral fat and insulin resistance ultimately resulting in diabetes. Treatment with thiazolidines (TZDs) or metformin is felt to be beneficial but one needs to balance the beneficial effects of TZDs on glucose metabolism with the risk of osteoporosis associated with TZDs in WS patients who are increased risk for osteoporosis (360). In a case report metreleptin improved glycemia and reduced triglyceride and cholesterol levels (361).

 

PORPHYRIA

 

Porphyria cutanea tarda has been associated with diabetes (362), but given that many patients with this disorder also have iron overload, genes for hemochromatosis, and HCV and HIV infection it is very difficult to tell if porphyria cutanea tarda per se is responsible for the association with diabetes (363,364).

 

ACKNOWLEDGEMENTS

 

This work was supported by grants from the Northern California Institute for Research and Education.

 

REFERENCES

 

  1. Akinci B, Sahinoz M, Oral E. Lipodystrophy Syndromes: Presentation and Treatment. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  2. Naylor RN, Philipson LH. Diagnosis and Clinical Management of Monogenic Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2020.
  3. Pham PT, Sidhu HS, Pham PM, Pham PC. Diabetes Mellitus After Solid Organ Transplantation. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  4. Sperling MA, Angelousi A, Yau M. Autoimmune Polyglandular Syndromes. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  5. Wang XY, Cleary EM, Thung SF, KK V, Buschur EO. Gestational Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  6. Sarkar S, Brown TT. Lipid Disorders in People with HIV. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  7. Unnikrishnan AG, R.C. B, Kumaran S, Kalra S. Fibrocalculous Pancreatic Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  8. Li HZ, Li RY, Li M. A review of maternally inherited diabetes and deafness. Front Biosci (Landmark Ed) 2014; 19:777-782
  9. Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med2008; 25:383-399
  10. Chanoine JP, Thompson DM, Lehman A. Diabetes Mellitus Associated with Maternally Inherited Diabetes and Deafness (MIDD): From Pathogenic Variant to Phenotype. Diabetes 2025; 74:153-163
  11. Maassen JA, Jahangir Tafrechi RS, Janssen GM, Raap AK, Lemkes HH, t Hart LM. New insights in the molecular pathogenesis of the maternally inherited diabetes and deafness syndrome. Endocrinol Metab Clin North Am2006; 35:385-396, x-xi
  12. Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, Anselm I, Cohen BH, Falk MJ, Greene C, Gropman AL, Haas R, Hirano M, Morgan P, Sims K, Tarnopolsky M, Van Hove JL, Wolfe L, DiMauro S. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015; 17:689-701
  13. Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev 2011; 32:498-514
  14. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41:1473-1490
  15. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore)2004; 83:209-222
  16. Stears A, O'Rahilly S, Semple RK, Savage DB. Metabolic insights from extreme human insulin resistance phenotypes. Best Pract Res Clin Endocrinol Metab 2012; 26:145-157
  17. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 2004; 89:1548-1554
  18. Okawa MC, Cochran E, Lightbourne M, Brown RJ. Long-term effects of metreleptin in Rabson-Mendenhall Syndrome on glycemia, growth, and kidney function. J Clin Endocrinol Metab 2021;
  19. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease? Eur J Intern Med 2013; 24:203-206
  20. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev 2012; 28:338-342
  21. Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, Goodarzi MO, Habtezion A, Korc M, Kudva YC, Pandol SJ, Yadav D, Chari ST, Consortium for the Study of Chronic Pancreatitis D, Pancreatic C. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 2016; 1:226-237
  22. Pendharkar SA, Mathew J, Petrov MS. Age- and sex-specific prevalence of diabetes associated with diseases of the exocrine pancreas: A population-based study. Dig Liver Dis 2017; 49:540-544
  23. Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol2013; 19:7276-7281
  24. Salvatore T, Marfella R, Rizzo MR, Sasso FC. Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist. Int J Surg 2015; 21 Suppl 1:S72-77
  25. Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 1980; 19:198-204
  26. Petrov MS. DIAGNOSIS OF ENDOCRINE DISEASE: Post-pancreatitis diabetes mellitus: prime time for secondary disease. Eur J Endocrinol 2021; 184:R137-R149
  27. Hart PA, Bradley D, Conwell DL, Dungan K, Krishna SG, Wyne K, Bellin MD, Yadav D, Andersen DK, Serrano J, Papachristou GI. Diabetes following acute pancreatitis. Lancet Gastroenterol Hepatol 2021; 6:668-675
  28. Zahariev OJ, Bunduc S, Kovacs A, Demeter D, Havelda L, Budai BC, Veres DS, Hosszufalusi N, Eross BM, Teutsch B, Juhasz MF, Hegyi P. Risk factors for diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10:1257222
  29. Goodarzi MO, Petrov MS, Andersen DK, Hart PA. Diabetes in chronic pancreatitis: risk factors and natural history. Curr Opin Gastroenterol 2021; 37:526-531
  30. Woodmansey C, McGovern AP, McCullough KA, Whyte MB, Munro NM, Correa AC, Gatenby PAC, Jones SA, de Lusignan S. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care 2017; 40:1486-1493
  31. Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, Brand R, Frulloni L, Anderson MA, Whitcomb DC. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology 2013; 13:336-342
  32. Hardt PD, Krauss A, Bretz L, Porsch-Ozcurumez M, Schnell-Kretschmer H, Maser E, Bretzel RG, Zekhorn T, Klor HU. Pancreatic exocrine function in patients with type 1 and type 2 diabetes mellitus. Acta Diabetol 2000; 37:105-110
  33. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32:834-838
  34. Cho J, Scragg R, Pandol SJ, Goodarzi MO, Petrov MS. Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. Diabetes Care 2019; 42:1675-1683
  35. Davidsen L, Jensen MH, Cook ME, Vestergaard P, Knop FK, Drewes AM, Olesen SS. Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study. Eur J Endocrinol 2024; 190:44-53
  36. Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, Ren ZG, Jiang GL. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014; 106:19-26
  37. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433-1437
  38. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011; 40:339-351
  39. Cho J, Scragg R, Petrov MS. Postpancreatitis Diabetes Confers Higher Risk for Pancreatic Cancer Than Type 2 Diabetes: Results From a Nationwide Cancer Registry. Diabetes Care 2020; 43:2106-2112
  40. Roshanov PS, Dennis BB. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Diabetes Res Clin Pract 2015; 110:e13-17
  41. Tkac I, Raz I. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Diabetes Care 2017; 40:284-286
  42. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Ohman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018; 6:105-113
  43. Liu Y, Tian Q, Yang J, Wang H, Hong T. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. Diabetes Metab Res Rev 2018; 34:e3061
  44. Couet C, Genton P, Pointel JP, Louis J, Gross P, Saudax E, Debry G, Drouin P. The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus. Diabetes Care 1985; 8:323-328
  45. Tiengo A, Segato T, Briani G, Setti A, Del Prato S, Devide A, Padovan D, Virgili F, Crepaldi G. The presence of retinopathy in patients with secondary diabetes following pancreatectomy or chronic pancreatitis. Diabetes Care1983; 6:570-574
  46. Briani G, Riva F, Midena E, Trevisan R, Sgnaolin E, Jori E, Munari R, Bruttomesso D, Segato T, Tiengo A. Prevalence of microangiopathic complications in hyperglycemia secondary to pancreatic disease. J Diabet Complications 1988; 2:50-52
  47. Ziegler O, Candiloros H, Guerci B, Got I, Crea T, Drouin P. Lower-extremity arterial disease in diabetes mellitus due to chronic pancreatitis. Diabete Metab 1994; 20:540-545
  48. Kuo P, Stevens JE, Russo A, Maddox A, Wishart JM, Jones KL, Greville H, Hetzel D, Chapman I, Horowitz M, Rayner CK. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011; 96:E851-855
  49. Imamura S, Niwano F, Babaya N, Hiromine Y, Matsumoto I, Kamei K, Yoshida Y, Taketomo Y, Yoshida S, Takeyama Y, Noso S, Maeda N, Ikegami H. High Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study. J Clin Endocrinol Metab 2024; 109:619-630
  50. Klotz R, Schilling C, Kuner C, Hinz U, Klaiber U, Holze M, Tjaden C, Loos M, Buchler MW, Hackert T. Central pancreatectomy prevents postoperative diabetes. J Hepatobiliary Pancreat Sci 2023; 30:951-961
  51. Mezza T, Cefalo CMA, Cinti F, Quero G, Pontecorvi A, Alfieri S, Holst JJ, Giaccari A. Endocrine and Metabolic Insights from Pancreatic Surgery. Trends Endocrinol Metab 2020; 31:760-772
  52. Suto H, Kamei K, Kato H, Misawa T, Unno M, Nitta H, Satoi S, Kawabata Y, Ohtsuka M, Rikiyama T, Sudo T, Matsumoto I, Hirao T, Okano K, Suzuki Y, Sata N, Isaji S, Sugiyama M, Takeyama Y. Diabetic control and nutritional status up to 1 year after total pancreatectomy: a nationwide multicentre prospective study. Br J Surg2021; 108:e237-e238
  53. Baekdal M, Nielsen SW, Hansen CP, Storkholm JH, van Hall G, Hartmann B, Holst JJ, Vilsboll T, Lund A, Knop FK. Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care2024; 47:71-80
  54. Juel CTB, Lund A, Andersen MM, Hansen CP, Storkholm JH, Rehfeld JF, van Hall G, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsboll T, Knop FK. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Diabetologia 2020; 63:1285-1298
  55. Chaouch MA, Leon P, Cassese G, Aguilhon C, Khayat S, Panaro F. Total pancreatectomy with intraportal islet autotransplantation for pancreatic malignancies: a literature overview. Expert Opin Biol Ther 2021:1-7
  56. Robertson GS, Dennison AR, Johnson PR, London NJ. A review of pancreatic islet autotransplantation. Hepatogastroenterology 1998; 45:226-235
  57. Jablonska B, Mrowiec S. Total Pancreatectomy with Autologous Islet Cell Transplantation-The Current Indications. J Clin Med 2021; 10
  58. Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese JL. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes 2017; 66:1103-1110
  59. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2013; 42:198-201
  60. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134:981-987
  61. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129:504-511
  62. Damiano J, Bordier L, Le Berre JP, Margery J, Dupuy O, Mayaudon H, Bauduceau B. Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab 2004; 30:203-207
  63. Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, Chari ST. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 2011; 40:768-772
  64. Song S, Wang B, Zhang X, Hao L, Hu X, Li Z, Sun S. Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer: A Meta-Analysis. PLoS One 2015; 10:e0134321
  65. Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Kalayarasan R. Diabetes and pancreatic cancer: Exploring the two-way traffic. World J Gastroenterol 2021; 27:4939-4962
  66. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80:1047-1050
  67. Litwin J, Dobrowolski S, Orlowska-Kunikowska E, Sledzinski Z. Changes in glucose metabolism after Kausch-Whipple pancreatectomy in pancreatic cancer and chronic pancreatitis patients. Pancreas 2008; 36:26-30
  68. Gardner TB, Hessami N, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Zaki B, Tsapakos MJ, Suriawinata AA, Putra J, Tsongalis GJ, Mody K, Gordon SR, Pipas JM. The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus. Pancreas 2014; 43:1018-1021
  69. Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget2017; 8:25242-25250
  70. Jian-Yu E, Graber JM, Lu SE, Lin Y, Lu-Yao G, Tan XL. Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 2018; 25:2595-2607
  71. Wan G, Sun X, Li F, Wang X, Li C, Li H, Yu X, Cao F. Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis. Cell Physiol Biochem 2018; 49:837-847
  72. Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiora P, Sordi V, Lampasona V, Ceraulo D, Di Terlizzi G, Doglioni C, Falconi M, Piemonti L. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Clin Cancer Res 2016; 22:1076-1085
  73. Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2015; 16:839-847
  74. Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Int J Hematol 2018; 107:31-43
  75. Pelusi C, Gasparini DI, Bianchi N, Pasquali R. Endocrine dysfunction in hereditary hemochromatosis. J Endocrinol Invest 2016; 39:837-847
  76. Barton JC, Acton RT. Diabetes in HFE Hemochromatosis. J Diabetes Res 2017; 2017:9826930
  77. O'Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH. Declining prevalence of diabetes mellitus in hereditary haemochromatosis--the result of earlier diagnosis. Diabetes Res Clin Pract 2008; 81:316-320
  78. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, Kushner JP. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006; 49:1661-1669
  79. Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab 2013; 17:329-341
  80. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev 2007; 5:642-648
  81. Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 2008; 6 Suppl 1:158-169
  82. Nelson RL, Baldus WP, Rubenstein AH, Go VL, Service FJ. Pancreatic alpha-cell function in diabetic hemochromatotic subjects. J Clin Endocrinol Metab 1979; 49:412-416
  83. Passa P, Luyckx AS, Carpentier JL, Lefebvre PJ, Canivet J. Glucagon secretion in diabetic patients with idiopathic haemochromatosis. Diabetologia 1977; 13:509-513
  84. Lassmann V, Passa P, Vague P, Vialettes B. Pancreatic polypeptide secretion in diabetic patients with idiopathic haemochromatosis. Diabete Metab 1987; 13:106-109
  85. Dymock IW, Cassar J, Pyke DA, Oakley WG, Williams R. Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 1972; 52:203-210
  86. Griffiths JD, Dymock IW, Davies EW, Hill DW, Williams R. Occurrence and prevalence of diabetic retinopathy in hemochromatosis. Diabetes 1971; 20:766-770
  87. Becker D, Miller M. Presence of diabetic glomerulosclerosis in patients with hemochromatosis. N Engl J Med1960; 263:367-373
  88. Hatunic M, Finucane FM, Norris S, Pacini G, Nolan JJ. Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism 2010; 59:1811-1815
  89. Buysschaert M, Paris I, Selvais P, Hermans MP. Clinical aspects of diabetes secondary to idiopathic haemochromatosis in French-speaking Belgium. Diabetes Metab 1997; 23:308-313
  90. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976; 45:611-623
  91. Sferra TJ, Collins FS. The molecular biology of cystic fibrosis. Annu Rev Med 1993; 44:133-144
  92. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B, Committee CCC. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care2010; 33:2677-2683
  93. Yoon JC. Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes. J Endocr Soc 2017; 1:1386-1400
  94. Kayani K, Mohammed R, Mohiaddin H. Cystic Fibrosis-Related Diabetes. Front Endocrinol (Lausanne) 2018; 9:20
  95. Bridges N, Rowe R, Holt RIG. Unique challenges of cystic fibrosis-related diabetes. Diabet Med 2018;
  96. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S17-S38
  97. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33:2697-2708
  98. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32:1626-1631
  99. Santhakumar A, Lewis F, Pickles J, Winterbottom H, Punt S, Beynon J, Tofeec K, Barry P, Brennan A. Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience. J Cyst Fibros 2024; 23:853-856
  100. Hayes D, Jr., McCoy KS, Sheikh SI. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med 2014; 190:590-591
  101. Gaines H, Jones KR, Lim J, Medhi NF, Chen S, Scofield RH. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complications 2021; 35:107845
  102. Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros 2020; 19:68-79
  103. Aguilera Garcia I, Garcia Moreno RM, Lopez Plaza B, Barquiel Alcala B, Vazquez Perez P, Barreda Bonis AC, Zamarron de Lucas E, Palma Milla S, Prados Sanchez MC, Gonzalez Perez de Villar N. Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice. Diabetes Res Clin Pract 2024; 216:111839
  104. Taelman V, Declercq D, Van Biervliet S, Weygaerde YV, Lapauw B, Van Braeckel E. Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis. Clin Nutr ESPEN 2023; 58:73-78
  105. Nielsen BU, Olsen MF, Mabuza Mathiesen IH, Pressler T, Ritz C, Katzenstein TL, Olesen HV, Skov M, Jensen-Fangel S, Almdal TP, Faurholt-Jepsen D. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment. J Cyst Fibros 2024; 23:103-108
  106. Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, Moran A. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013; 14:417-421
  107. Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis-related diabetes: Current status and future directions. Diabetes Metab Syndr 2023; 17:102899
  108. Richardson SJ, Morgan NG. Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. Curr Opin Pharmacol 2018; 43:11-19
  109. Principi N, Berioli MG, Bianchini S, Esposito S. Type 1 diabetes and viral infections: What is the relationship? J Clin Virol 2017; 96:26-31
  110. Rodriguez-Calvo T, Sabouri S, Anquetil F, von Herrath MG. The viral paradigm in type 1 diabetes: Who are the main suspects? Autoimmun Rev 2016; 15:964-969
  111. Jeremiah SS, Moin ASM, Butler AE. Virus-induced diabetes mellitus: revisiting infection etiology in light of SARS-CoV-2. Metabolism 2024; 156:155917
  112. VanBuecken D, Lord S, Greenbaum CJ. Changing the Course of Disease in Type 1 Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  113. Krogvold L, Mynarek IM, Ponzi E, Mork FB, Hessel TW, Roald T, Lindblom N, Westman J, Barker P, Hyoty H, Ludvigsson J, Hanssen KF, Johannesen J, Dahl-Jorgensen K. Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nat Med 2023; 29:2902-2908
  114. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979; 300:1173-1179
  115. Gale EA. Congenital rubella: citation virus or viral cause of type 1 diabetes? Diabetologia 2008; 51:1559-1566
  116. Burgess MA, Forrest JM. Congenital rubella and diabetes mellitus. Diabetologia 2009; 52:369-370; author reply 373
  117. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49:831-844
  118. Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. Rev Endocr Metab Disord 2018; 19:405-420
  119. Choi HY, Kim Y, Cho H, Kim BH, Ki M. Risk of diabetes in viral hepatitis B or C patients compared to that in noninfected individuals in Korea, 2002-2013: A population-based cohort study. J Viral Hepat 2018; 25:272-280
  120. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012; 18:1642-1651
  121. Lin YJ, Shaw TG, Yang HI, Lu SN, Jen CL, Wang LY, Wong KH, Chan SY, Yuan Y, L'Italien G, Chen CJ, Lee MH, Group REVEALHS. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. Liver Int 2017; 37:179-186
  122. Gastaldi G, Goossens N, Clement S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res 2017; 8:149-159
  123. Guo X, Jin M, Yang M, Liu K, Li JW. Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review. Sci Rep 2013; 3:2981
  124. Li X, Gao Y, Xu H, Hou J, Gao P. Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients. Sci Rep 2017; 7:9087
  125. Li X, Xu H, Gao Y, Pan M, Wang L, Gao P. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naive chronic hepatitis C patients in China. Medicine (Baltimore) 2017; 96:e6508
  126. Cao LH, Lu FM, Lu XJ, Zhu LY. Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus. J Cell Biochem 2018; 119:9513-9518
  127. Colaci M, Malatino L, Antonelli A, Fallahi P, Giuggioli D, Ferri C. Endocrine disorders associated with hepatitis C virus chronic infection. Rev Endocr Metab Disord 2018; 19:397-403
  128. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Dig Liver Dis 2016; 48:105-111
  129. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS, Chung RT. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8:458-462
  130. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004; 41:132-138
  131. Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, Chang M, Ioannou GN. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care 2017; 40:1173-1180
  132. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology2014; 59:1293-1302
  133. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107:46-52
  134. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96:2601-2608
  135. Zhou K, Lansang MC. Diabetes Mellitus and Infection. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  136. Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA, Buse JB. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021; 44:2645-2655
  137. Hirani D, Salem V, Khunti K, Misra S. Newly detected diabetes during the COVID-19 pandemic: What have we learnt? Best Pract Res Clin Endocrinol Metab 2023; 37:101793
  138. Zhou J, Wang Y, Xu R. Association of COVID-19 infection and the risk of new incident diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2024; 15:1429848
  139. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab 2021; 23:870-874
  140. Zhang T, Mei Q, Zhang Z, Walline JH, Liu Y, Zhu H, Zhang S. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med 2022; 20:444
  141. Lai H, Yang M, Sun M, Pan B, Wang Q, Wang J, Tian J, Ding G, Yang K, Song X, Ge L. Risk of incident diabetes after COVID-19 infection: A systematic review and meta-analysis. Metabolism 2022; 137:155330
  142. Wong R, Lam E, Bramante CT, Johnson SG, Reusch J, Wilkins KJ, Yeh HC. Does COVID-19 Infection Increase the Risk of Diabetes? Current Evidence. Curr Diab Rep 2023; 23:207-216
  143. Taylor K, Eastwood S, Walker V, Cezard G, Knight R, Al Arab M, Wei Y, Horne EMF, Teece L, Forbes H, Walker A, Fisher L, Massey J, Hopcroft LEM, Palmer T, Cuitun Coronado J, Ip S, Davy S, Dillingham I, Morton C, Greaves F, Macleod J, Goldacre B, Wood A, Chaturvedi N, Sterne JAC, Denholm R. Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people. Lancet Diabetes Endocrinol 2024; 12:558-568
  144. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009; 373:1798-1807
  145. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16:642-652
  146. Montefusco L, Ben Nasr M, D'Addio F, Loretelli C, Rossi A, Pastore I, Daniele G, Abdelsalam A, Maestroni A, Dell'Acqua M, Ippolito E, Assi E, Usuelli V, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Finzi G, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Nebuloni M, Folli F, Zuccotti GV, Galli M, Fiorina P. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab 2021; 3:774-785
  147. Martinez-Colon GJ, Ratnasiri K, Chen H, Jiang S, Zanley E, Rustagi A, Verma R, Chen H, Andrews JR, Mertz KD, Tzankov A, Azagury D, Boyd J, Nolan GP, Schurch CM, Matter MS, Blish CA, McLaughlin TL. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Sci Transl Med 2022; 14:eabm9151
  148. Reiterer M, Rajan M, Gomez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V, Bram Y, Hoffman K, Bhardwaj P, Piloco P, Rubio-Navarro A, Uhl S, Carrau L, Houhgton S, Redmond D, Shukla AP, Goyal P, Brown KA, tenOever BR, Alonso LC, Schwartz RE, Schenck EJ, Safford MM, Lo JC. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab 2021; 33:2174-2188 e2175
  149. Valabhji J, Barron E, Bradley D, Bakhai C, Khunti K, Jebb S. Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme. Lancet Diabetes Endocrinol 2021; 9:649-651
  150. Carroll PV, MN J. Acromegaly. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  151. Hannon AM, Thompson CJ, Sherlock M. Diabetes in Patients With Acromegaly. Curr Diab Rep 2017; 17:8
  152. Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. J Endocrinol Invest 2016; 39:235-255
  153. Esposito D, Boguszewski CL, Colao A, Fleseriu M, Gatto F, Jorgensen JOL, Ragnarsson O, Ferone D, Johannsson G. Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol 2024; 20:541-552
  154. Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends Endocrinol Metab 2016; 27:470-483
  155. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014; 17:81-89
  156. Lim CT, Khoo B. Normal Physiology of ACTH and GH Release in the Hypothalamus and Anterior Pituitary in Man. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2025.
  157. Yuen KCJ. Growth hormone Stimulation Tests in Assessing Adult Growth Hormone Deficiency. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2019.
  158. Olarescu N, Gunawardane K, Hansen T, Møller N, Jørgensen J. Normal Physiology of Growth Hormone in Adults. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2019.
  159. Dutta P, Hajela A, Gupta P, Rai A, Sachdeva N, Mukherjee KK, Pathak A, Dhandapani S. The predictors of recovery from diabetes mellitus following neurosurgical treatment of acromegaly: A prospective study over a decade. Neurol India 2019; 67:757-762
  160. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009; 94:1500-1508
  161. Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM. Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies. J Clin Endocrinol Metab 2018;
  162. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2:875-884
  163. Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K, Pedroncelli AM, Fleseriu M. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 2016; 53:210-219
  164. Gatto F, Arecco A, Amaru J, Arvigo M, Campana C, Milioto A, Esposito D, Johannsson G, Cocchiara F, Maggi DC, Ferone D, Puddu A. Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. Int J Mol Sci 2025; 26
  165. Varaldo E, Prencipe N, Bona C, Cuboni D, Aversa LS, Sibilla M, Bioletto F, Berton AM, Gramaglia C, Gasco V, Ghigo E, Grottoli S. Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly. J Endocrinol Invest 2024; 47:3019-3028
  166. Wass JA, Cudworth AG, Bottazzo GF, Woodrow JC, Besser GM. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980; 12:53-59
  167. Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol 2013; 169:99-108
  168. Brue T, Lindberg A, Jan van der Lely A, Akerblad AC, Koltowska-Haggstrom M, Gomez R, Droste M, Hey-Hadavi J, Strasburger CJ, Camacho-Hubner C. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 2019; 63:563-572
  169. Juszczak A, Morris D, Grossman A. Cushing's Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  170. Ferrau F, Korbonits M. Metabolic Syndrome in Cushing's Syndrome Patients. Front Horm Res 2018; 49:85-103
  171. Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011; 165:383-392
  172. Scaroni C, Zilio M, Foti M, Boscaro M. Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. Endocr Rev 2017; 38:189-219
  173. Guarnotta V, Amato MC, Pivonello R, Arnaldi G, Ciresi A, Trementino L, Citarrella R, Iacuaniello D, Michetti G, Simeoli C, Colao A, Giordano C. The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome. Endocrine 2017; 55:564-572
  174. Steffensen C, Pereira AM, Dekkers OM, Jorgensen JO. DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol 2016; 175:R247-R253
  175. Terzolo M, Reimondo G, Chiodini I, Castello R, Giordano R, Ciccarelli E, Limone P, Crivellaro C, Martinelli I, Montini M, Disoteo O, Ambrosi B, Lanzi R, Arosio M, Senni S, Balestrieri A, Solaroli E, Madeo B, De Giovanni R, Strollo F, Battista R, Scorsone A, Giagulli VA, Collura D, Scillitani A, Cozzi R, Faustini-Fustini M, Pia A, Rinaldi R, Allasino B, Peraga G, Tassone F, Garofalo P, Papini E, Borretta G. Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J Clin Endocrinol Metab 2012; 97:3467-3475
  176. Aresta C, Favero V, Morelli V, Giovanelli L, Parazzoli C, Falchetti A, Pugliese F, Gennari L, Vescini F, Salcuni A, Scillitani A, Persani L, Chiodini I. Cardiovascular complications of mild autonomous cortisol secretion. Best Pract Res Clin Endocrinol Metab 2021; 35:101494
  177. Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, Murad MH, O'Reilly MW, Arlt W, Bancos I. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med 2019; 171:107-116
  178. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009; 249:388-391
  179. Sereg M, Szappanos A, Toke J, Karlinger K, Feldman K, Kaszper E, Varga I, Glaz E, Racz K, Toth M. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol 2009; 160:647-655
  180. Chatzellis E, Kaltsas G. Adrenal Incidentalomas. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  181. Babic N, Yeo K, Hannoush Z, Weiss R. Endocrine Testing Protocols: Hypothalamic Pituitary Adrenal Axis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  182. Gremlich S, Roduit R, Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 1997; 272:3216-3222
  183. Mehlich A, Bolanowski M, Mehlich D, Witek P. Medical treatment of Cushing's disease with concurrent diabetes mellitus. Front Endocrinol (Lausanne) 2023; 14:1174119
  184. Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid Therapy and Adrenal Suppression. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2018.
  185. Juszczak A, Sulentic P, Grossman A. Cushing's Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2004.
  186. Feingold K. The Effect of Endocrine Disorders on Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  187. Pacak K, Tella SH. Pheochromocytoma and Paraganglioma. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2018.
  188. Adlan MA, Bondugulapati LN, Premawardhana LD. Glucose intolerance and diabetes mellitus in endocrine disorders - two case reports and a review. Curr Diabetes Rev 2010; 6:266-273
  189. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003; 21:1703-1707
  190. Beninato T, Kluijfhout WP, Drake FT, Lim J, Kwon JS, Xiong M, Shen WT, Gosnell JE, Liu C, Suh I, Duh QY. Resection of Pheochromocytoma Improves Diabetes Mellitus in the Majority of Patients. Ann Surg Oncol 2017; 24:1208-1213
  191. Zhang W, Yu J, Chen Y, Zhou Y, Cui Y, Li T, Wang Y, Ren W, Tong A, Li Y. Glucose Disorders in Patients With Pheochromocytoma/Paraganglioma: Profile and Influence Effects in a Large Cohort With 705 Patients. Endocr Pract 2024;
  192. Douma S, Petidis K, Kartali N, Mahera K, Sabanis C, Zamboulis C. Pheochromocytoma presenting as diabetic ketoacidosis. J Diabetes Complications 2008; 22:295-296
  193. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65:717-721
  194. Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest 1980; 65:682-689
  195. Halter JB, Beard JC, Porte D, Jr. Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. Am J Physiol 1984; 247:E47-52
  196. Araujo-Castro M, Minguez Ojeda C, Garcia Centeno R, Lopez-Garcia MC, Lamas C, Hanzu FA, Mora M, Del Castillo Tous M, Rodriguez de Vera Gomez P, Parra Ramirez P, Alvarez-Escola C, Blanco Carrera C, Barahona San Millan R, Recasens M, Valdes N, Gracia Gimeno P, de Miguel Novoa P, Vicente A, Manjon L, Garcia Sanz I, Michalopoulou T, Calatayud M. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas. Endocr Relat Cancer 2022; 29:645-655
  197. Khatiwada S, Agarwal S, Kandasamy D, Jyotsna VP, Kumar R, Kumar Bansal V, Pandey RM, Gupta N, Tandon N. Diabetes mellitus in pheochromocytoma and paraganglioma: Prevalence, dynamics of insulin secretion / sensitivity and predictors of remission. Diabetes Metab Syndr 2020; 14:2169-2175
  198. Chen Y, Hodin RA, Pandolfi C, Ruan DT, McKenzie TJ. Hypoglycemia after resection of pheochromocytoma. Surgery 2014; 156:1404-1408; discussion 1408-1409
  199. Diamanti-Kandarakis E, Zapanti E, Peridis MH, Ntavos P, Mastorakos G. Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. Hormones (Athens) 2003; 2:61-66
  200. Roa Duenas OH, Van der Burgh AC, Ittermann T, Ligthart S, Ikram MA, Peeters R, Chaker L. Thyroid Function and the Risk of Prediabetes and Type 2 Diabetes. J Clin Endocrinol Metab 2022; 107:1789-1798
  201. Nishi M. Diabetes mellitus and thyroid diseases. Diabetol Int 2018; 9:108-112
  202. Andersen OO, Friis T, Ottesen B. Glucose tolerance and insulin secretion in hyperthyroidism. Acta Endocrinol (Copenh) 1977; 84:576-587
  203. Kreines K, Jett M, Knowles HC, Jr. Observations in hyperthyroidism of abnormal glucose tolerance and other traits related to diabetes mellitus. Diabetes 1965; 14:740-744
  204. Yang L, Shen X, Yan S, Yuan X, Lu J, Wei W. HbA1c in the diagnosis of diabetes and abnormal glucose tolerance in patients with Graves' hyperthyroidism. Diabetes Res Clin Pract 2013; 101:28-34
  205. Alwan H, Villoz F, Feller M, Dullaart RPF, Bakker SJL, Peeters RP, Kavousi M, Bauer DC, Cappola AR, Yeap BB, Walsh JP, Brown SJ, Ceresini G, Ferrucci L, Gussekloo J, Trompet S, Iacoviello M, Moon JH, Razvi S, Bensenor IM, Azizi F, Amouzegar A, Valdes S, Colomo N, Wareham NJ, Jukema JW, Westendorp RGJ, Kim KW, Rodondi N, Del Giovane C. Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies. Eur J Endocrinol 2022; 187:S35-S46
  206. Sarabhai T, Kostev K. Thyroid disorders and the incidence of type 2 diabetes: insights from a 10-year cohort study in Germany. Endocr Connect 2025; 14
  207. Mouradian M, Abourizk N. Diabetes mellitus and thyroid disease. Diabetes Care 1983; 6:512-520
  208. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med 2017; 376:1748-1761
  209. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marino M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med 2020; 382:341-352
  210. Sperling M, A. A, Yau M. Autoimmune Polyglandular Syndromes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  211. de Herder WW, Hofland J. Glucagon & Glucagonoma Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  212. Song X, Zheng S, Yang G, Xiong G, Cao Z, Feng M, Zhang T, Zhao Y. Glucagonoma and the glucagonoma syndrome. Oncol Lett 2018; 15:2749-2755
  213. Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med 2016; 10:1141-1151
  214. de Herder WW, Hofland J. Somatostatinoma. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  215. Theodoraki A, Khoo B, Hamda A, Grillo F, Meyer T, Bouloux PM. Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations. Endocr Pract 2010; 16:835-837
  216. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150:776-783
  217. Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6:41-50
  218. Katsuragawa S, Tsurutani Y, Takiguchi T, Saito J, Nishikawa T. Impact of primary aldosteronism on renal function in patients with type 2 diabetes. J Diabetes Investig 2021; 12:217-225
  219. Papadopoulou-Marketou N, Vaidya A, Dluhy R, Chrousos GP. Hyperaldosteronism. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2020.
  220. Feingold KR, Lee TH, Chung MY, Siperstein MD. Muscle capillary basement membrane width in patients with vacor-induced diabetes mellitus. J Clin Invest 1986; 78:102-107
  221. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207
  222. Allhat Officers Coordinators for the Allhat Collaborative Research Group The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997
  223. Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and beta-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. Br J Clin Pharmacol 2015; 79:733-743
  224. Zhang X, Zhao Q. Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. J Clin Hypertens (Greenwich)2016; 18:342-351
  225. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100:1254-1262
  226. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014; 6:517-530
  227. Li Z, Wei H, Li R, Wu B, Xu M, Yang X, Zhang Y, Liu Y. The effects of antihypertensive drugs on glucose metabolism. Diabetes Obes Metab 2024; 26:4820-4829
  228. Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf2015; 38:1153-1168
  229. Martins VM, Ziegelmann PK, Ferrari F, Bottino LG, Lucca MB, Correa HLR, Blum GB, Helal L, Fuchs SC, Fuchs FD. Thiazide diuretics alone or combined with potassium-sparing diuretics to treat hypertension: a systematic review and network meta-analysis of randomized controlled trials. J Hypertens 2023; 41:1108-1116
  230. Verhaegen AA, Van Gaal LF. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2019.
  231. Davis H, Spanakis E, Cryer P, Siamashvili M, Davis S. Hypoglycemia During Therapy of Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  232. Koch-Weser J. Diazoxide. N Engl J Med 1976; 294:1271-1273
  233. de Herder WW, Hofland J. Insulinomas. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  234. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735-742
  235. Cholesterol Treatment Trialists Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol 2024; 12:306-319
  236. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305:2556-2564
  237. Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  238. Abbasi F, Lamendola C, Harris CS, Harris V, Tsai MS, Tripathi P, Abbas F, Reaven GM, Reaven PD, Snyder MP, Kim SH, Knowles JW. Statins Are Associated With Increased Insulin Resistance and Secretion. Arterioscler Thromb Vasc Biol 2021; 41:2786-2797
  239. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015; 58:1109-1117
  240. Carmena R, Betteridge DJ. Diabetogenic Action of Statins: Mechanisms. Curr Atheroscler Rep 2019; 21:23
  241. Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart 2016; 102:198-203
  242. Feingold KR, Grunfeld C. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  243. Shen M, Orwoll ES, Conte JE, Jr., Prince MJ. Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med1989; 86:726-728
  244. Bouchard P, Sai P, Reach G, Caubarrere I, Ganeval D, Assan R. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes 1982; 31:40-45
  245. Carter BL, Small RE, Mandel MD, Starkman MT. Phenytoin-induced hyperglycemia. Am J Hosp Pharm 1981; 38:1508-1512
  246. Gharib H, Munoz JM. Endocrine manifestations of diphenylhydantoin therapy. Metabolism 1974; 23:515-524
  247. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283-291
  248. Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21:233-239
  249. Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun 2018; 94:7-15
  250. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:173-182
  251. de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res 2019; 51:145-156
  252. Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr Oncol 2019; 26:e111-e114
  253. Elshimy G, Raj R, Akturk HK, Schriber A, Sisterna N, Ahmad I, Jacob A, Michels AW, Correa R. Immune Checkpoint Inhibitors Related Endocrine Adverse Events. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  254. Whicher CA, Price HC, Holt RIG. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. Eur J Endocrinol 2018; 178:R245-R258
  255. Holt RIG. Association Between Antipsychotic Medication Use and Diabetes. Curr Diab Rep 2019; 19:96
  256. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123:225-233
  257. Citrome L, Kalsekar I, Baker RA, Hebden T. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin 2014; 30:1629-1641
  258. Chen J, Huang XF, Shao R, Chen C, Deng C. Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes. Front Neurosci 2017; 11:643
  259. Tzortzis V, Samarinas M, Zachos I, Oeconomou A, Pisters LL, Bargiota A. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens) 2017; 16:115-123
  260. Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol 2015; 193:1956-1962
  261. Pham P, Sarkar M, Pham P, Pham P. Diabetes Mellitus After Solid Organ Transplantation. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  262. Chakkera HA, Kudva Y, Kaplan B. Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus. Clin Pharmacol Ther2017; 101:114-120
  263. Verges B. mTOR and Cardiovascular Diseases: Diabetes Mellitus. Transplantation 2018; 102:S47-S49
  264. Ahmad MH, Shafiq I. Diabetic ketoacidosis following PEG-asparaginase therapy. Endocrinol Diabetes Metab Case Rep 2018; 2018:18-0064
  265. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981; 99:46-50
  266. Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 2021; 9:360-372
  267. Amarikwa L, Mohamed A, Kim SH, Kossler AL, Dosiou C. Teprotumumab-Related Hyperglycemia. J Clin Endocrinol Metab 2023; 108:858-864
  268. Carter C, Marks M, Bundeff AW, Adewodu T, Alderman L. A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease. Endocrine 2024; 83:65-68
  269. Shah K, Charitou M. A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease. AACE Clin Case Rep 2022; 8:148-149
  270. Stan MN, Krieger CC. The Adverse Effects Profile of Teprotumumab. J Clin Endocrinol Metab 2023; 108:e654-e662
  271. Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev 2012; 28 Suppl 2:40-46
  272. Kumar A, de Leiva A. Latent autoimmune diabetes in adults (LADA) in Asian and European populations. Diabetes Metab Res Rev 2017; 33
  273. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014; 383:1084-1094
  274. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94:4635-4644
  275. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29:970-975
  276. Herzog K, Ahlqvist E, Alfredsson L, Groop L, Hjort R, Lofvenborg JE, Tuomi T, Carlsson S. Combined lifestyle factors and the risk of LADA and type 2 diabetes - Results from a Swedish population-based case-control study. Diabetes Res Clin Pract 2021; 174:108760
  277. Santoso C, Wei Y, Ahlqvist E, Tuomi T, Carlsson S. Autoimmune diseases and the risk and prognosis of latent autoimmune diabetes in adults. Diabetologia 2025; 68:331-341
  278. Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, Leslie RD. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Diabetes 2020; 69:2037-2047
  279. Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT. Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care 2021; 44:1243-1251
  280. Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011:CD006165
  281. Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009; 25:411-416
  282. Zhang Z, Yan X, Wu C, Pei X, Li X, Wang X, Niu X, Jiang H, Zeng X, Zhou Z. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect beta-cell function in LADA patients: A 1-year pilot study. Diabetes Metab Res Rev 2020; 36:e3298
  283. Yan X, Li X, Liu B, Huang J, Xiang Y, Hu Y, Tang X, Zhang Z, Huang G, Xie Z, Zhou H, Liu Z, Wang X, Leslie RD, Zhou Z. Combination therapy with saxagliptin and vitamin D for the preservation of beta-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial. Signal Transduct Target Ther 2023; 8:158
  284. Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol 2020; 8:206-215
  285. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L, Sarelin L. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999; 22:1347-1353
  286. Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes Metab 2019; 21:2115-2122
  287. Wei Y, Herzog K, Ahlqvist E, Andersson T, Nystrom T, Zhan Y, Tuomi T, Carlsson S. All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults. Diabetes Care 2023; 46:1857-1865
  288. McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69:230-238
  289. Rathbun JT, Imber J. Stiff Person Syndrome and Type 1 Diabetes Mellitus: a Case of the Chicken or the Egg? J Gen Intern Med 2019;
  290. Baizabal-Carvallo JF. The neurological syndromes associated with glutamic acid decarboxylase antibodies. J Autoimmun 2019; 101:35-47
  291. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002; 81:87-100
  292. Taylor SI, Shahidzadeh Yazdi Z, Oral EA. Letter to the Editor From Taylor et al "Type B Insulin Resistance Syndrome: A Rare Cause of Hypoglycemia". JCEM Case Rep 2024; 2:luae001
  293. Brown N, Elston MS. Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin. J Clin Endocrinol Metab 2024; 109:936-943
  294. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119:315-322
  295. Klubo-Gwiezdzinska J, Lange M, Cochran E, Semple RK, Gewert C, Brown RJ, Gorden P. Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study. Diabetes Care 2018; 41:2353-2360
  296. Lebovitz HE, Banerji MA. Ketosis-Prone Diabetes (Flatbush Diabetes): an Emerging Worldwide Clinically Important Entity. Curr Diab Rep 2018; 18:120
  297. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med2006; 144:350-357
  298. Smiley D, Chandra P, Umpierrez GE. Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus. Diabetes Manag (Lond) 2011; 1:589-600
  299. Whooten R, Schmitt J, Schwartz A. Endocrine manifestations of Down syndrome. Curr Opin Endocrinol Diabetes Obes 2018; 25:61-66
  300. Guaraldi F, Rossetto Giaccherino R, Lanfranco F, Motta G, Gori D, Arvat E, Ghigo E, Giordano R. Endocrine Autoimmunity in Down's Syndrome. Front Horm Res 2017; 48:133-146
  301. Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 1998; 15:160-163
  302. Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: A nationwide population-based study. Diabetologia 2006; 49:1179-1182
  303. Aitken RJ, Mehers KL, Williams AJ, Brown J, Bingley PJ, Holl RW, Rohrer TR, Schober E, Abdul-Rasoul MM, Shield JP, Gillespie KM. Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care 2013; 36:1181-1185
  304. Aslam AA, Baksh RA, Pape SE, Strydom A, Gulliford MC, Chan LF, Consortium G-D. Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records. Diabetes Care 2022; 45:2892-2899
  305. Behre HM, Bergmann M, Simoni M, Tuttelmann F. Primary Testicular Failure. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2015.
  306. Blackburn J, Ramakrishnan A, Graham C, Bambang K, Sriranglingam U, Senniappan S. Klinefelter Syndrome: A Review. Clin Endocrinol (Oxf) 2025;
  307. Salzano A, D'Assante R, Heaney LM, Monaco F, Rengo G, Valente P, Pasquali D, Bossone E, Gianfrilli D, Lenzi A, Cittadini A, Marra AM, Napoli R. Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives. Endocrine 2018; 61:194-203
  308. Groth KA, Skakkebaek A, Host C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome--a clinical update. J Clin Endocrinol Metab 2013; 98:20-30
  309. Gravholt CH, Chang S, Wallentin M, Fedder J, Moore P, Skakkebaek A. Klinefelter Syndrome: Integrating Genetics, Neuropsychology, and Endocrinology. Endocr Rev 2018; 39:389-423
  310. Bojesen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab 2006; 91:1254-1260
  311. Panimolle F, Tiberti C, Granato S, Semeraro A, Gianfrilli D, Anzuini A, Lenzi A, Radicioni A. Screening of endocrine organ-specific humoral autoimmunity in 47,XXY Klinefelter's syndrome reveals a significant increase in diabetes-specific immunoreactivity in comparison with healthy control men. Endocrine 2016; 52:157-164
  312. Sybert VP, McCauley E. Turner's syndrome. N Engl J Med 2004; 351:1227-1238
  313. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51:147-158
  314. Sun L, Wang Y, Zhou T, Zhao X, Wang Y, Wang G, Gang X. Glucose Metabolism in Turner Syndrome. Front Endocrinol (Lausanne) 2019; 10:49
  315. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Soderstrom-Anttila V, Stochholm K, van Alfen-van derVelden JA, Woelfle J, Backeljauw PF, International Turner Syndrome Consensus G. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017; 177:G1-G70
  316. Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab 2009; 94:3289-3296
  317. Mortensen KH, Cleemann L, Hjerrild BE, Nexo E, Locht H, Jeppesen EM, Gravholt CH. Increased prevalence of autoimmunity in Turner syndrome--influence of age. Clin Exp Immunol 2009; 156:205-210
  318. Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A, Maciel-Guerra AT, Gutmark-Little I, Fleischer K, Hong D, Klein KO, Prakash SK, Shankar RK, Sandberg DE, Sas TCJ, Skakkebaek A, Stochholm K, van der Velden JA, International Turner Syndrome Consensus G, Backeljauw PF. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol 2024; 190:G53-G151
  319. Sheanon N, Elder D, Khoury J, Casnellie L, Gutmark-Little I, Cernich J, Backeljauw PF. Increased Prevalence of Beta-Cell Dysfunction despite Normal HbA1c in Youth and Young Adults with Turner Syndrome. Horm Res Paediatr 2021; 94:297-306
  320. Stanley TL, Leong A, Pober BR. Growth, body composition, and endocrine issues in Williams syndrome. Curr Opin Endocrinol Diabetes Obes 2021; 28:64-74
  321. Kozel BA, Barak B, Kim CA, Mervis CB, Osborne LR, Porter M, Pober BR. Williams syndrome. Nat Rev Dis Primers 2021; 7:42
  322. Morris CA. Williams Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, eds. GeneReviews((R)). Seattle (WA)2017.
  323. Stone SI, Abreu D, McGill JB, Urano F. Monogenic and syndromic diabetes due to endoplasmic reticulum stress. J Diabetes Complications 2021; 35:107618
  324. Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep 2016; 16:6
  325. Rigoli L, Bramanti P, Di Bella C, De Luca F. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res 2018; 83:921-929
  326. Ray MK, Chen L, White NH, Ni R, Hershey T, Marshall BA. Longitudinal progression of diabetes mellitus in Wolfram syndrome: The Washington University Wolfram Research Clinic experience. Pediatr Diabetes 2022; 23:212-218
  327. Bidichandani SI, Delatycki MB. Friedreich Ataxia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  328. Pappa A, Hausler MG, Veigel A, Tzamouranis K, Pfeifer MW, Schmidt A, Bokamp M, Haberland H, Wagner S, Bruckel J, de Sousa G, Hackl L, Bollow E, Holl RW. Diabetes mellitus in Friedreich Ataxia: A case series of 19 patients from the German-Austrian diabetes mellitus registry. Diabetes Res Clin Pract 2018; 141:229-236
  329. Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem 2013; 126 Suppl 1:94-102
  330. Bidichandani SI, Delatycki MB, Napierala M, Duquette A. Friedreich Ataxia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  331. Pandey M, Rajamma U. Huntington's disease: the coming of age. J Genet 2018; 97:649-664
  332. Montojo MT, Aganzo M, Gonzalez N. Huntington's Disease and Diabetes: Chronological Sequence of its Association. J Huntingtons Dis 2017; 6:179-188
  333. Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet 1985; 27:62-67
  334. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl) 2004; 82:510-529
  335. Hartman J, Patki T, Johnson NE. Diagnosis and Management of Myotonic Dystrophy Type 1. JAMA 2024; 331:1227-1228
  336. Winters SJ. Endocrine Dysfunction in Patients With Myotonic Dystrophy. J Clin Endocrinol Metab 2021; 106:2819-2827
  337. Alsaggaf R, Pfeiffer RM, Wang Y, St George DMM, Zhan M, Wagner KR, Amr S, Greene MH, Gadalla SM. Diabetes, metformin and cancer risk in myotonic dystrophy type I. Int J Cancer 2020; 147:785-792
  338. Lee JY, Jeong HN. Nationwide incidence of myotonic dystrophy type 1 and the status of multi-organ involvement. J Neurol 2021;
  339. Abe H, Mita T, Kudo K, Funayama T, Tokoro M, Kaga H, Ikeda F, Kanazawa A, Hirose T, Kawamori R, Watada H. Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. Endocr J 2009; 56:911-913
  340. Takeshima K, Ariyasu H, Ishibashi T, Kawai S, Uraki S, Koh J, Ito H, Akamizu T. Myotonic dystrophy type 1 with diabetes mellitus, mixed hypogonadism and adrenal insufficiency. Endocrinol Diabetes Metab Case Rep 2018; 2018
  341. Tsang SH, Aycinena ARP, Sharma T. Ciliopathy: Bardet-Biedl Syndrome. Adv Exp Med Biol 2018; 1085:171-174
  342. Mujahid S, Hunt KF, Cheah YS, Forsythe E, Hazlehurst JM, Sparks K, Mohammed S, Tomlinson JW, Amiel SA, Carroll PV, Beales PL, Huda MSB, McGowan BM. The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic Population. J Clin Endocrinol Metab 2018; 103:1834-1841
  343. Dollfus H, Lilien MR, Maffei P, Verloes A, Muller J, Bacci GM, Cetiner M, van den Akker ELT, Grudzinska Pechhacker M, Testa F, Lacombe D, Stokman MF, Simonelli F, Gouronc A, Gavard A, van Haelst MM, Koenig J, Rossignol S, Bergmann C, Zacchia M, Leroy BP, Mosbah H, Van Eerde AM, Mekahli D, Servais A, Poitou C, Valverde D. Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations. Eur J Hum Genet 2024; 32:1347-1360
  344. Esbati R, Yazdani O, Simonetti J. Management of Obesity-Related Genetic Disorders. Endocrinol Metab Clin North Am 2025; 54:17-38
  345. Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, Stewart M, Yanovski J. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab 2020; 22:2133-2140
  346. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GA, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clement K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol 2022; 10:859-868
  347. Argente J, Verge CF, Okorie U, Fennoy I, Kelsey MM, Cokkinias C, Scimia C, Lee HM, Farooqi IS. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol 2025; 13:29-37
  348. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  349. Clerc A, Coupaye M, Mosbah H, Pinto G, Laurier V, Mourre F, Merrien C, Diene G, Poitou C, Tauber M. Diabetes Mellitus in Prader-Willi Syndrome: Natural History during the Transition from Childhood to Adulthood in a Cohort of 39 Patients. J Clin Med 2021; 10
  350. Chan NN, Feher MD, Bridges NA. Metformin therapy for diabetes in Prader-Willi syndrome. J R Soc Med 1998; 91:598
  351. Ng NBH, Low YW, Rajgor DD, Low JM, Lim YY, Loke KY, Lee YS. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. Clin Endocrinol (Oxf) 2022; 96:144-154
  352. Gimenez-Palop O, Romero A, Casamitjana L, Pareja R, Rigla M, Caixas A. Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes. Endocrinol Diabetes Nutr (Engl Ed) 2024; 71:83-87
  353. Marshall JD, Maffei P, Collin GB, Naggert JK. Alstrom syndrome: genetics and clinical overview. Curr Genomics2011; 12:225-235
  354. Hearn T. ALMS1 and Alstrom syndrome: a recessive form of metabolic, neurosensory and cardiac deficits. J Mol Med (Berl) 2019; 97:1-17
  355. Dassie F, Favaretto F, Bettini S, Parolin M, Valenti M, Reschke F, Danne T, Vettor R, Milan G, Maffei P. Alstrom syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity. Endocrine 2021; 71:618-625
  356. Marshall JD, Bronson RT, Collin GB, Nordstrom AD, Maffei P, Paisey RB, Carey C, Macdermott S, Russell-Eggitt I, Shea SE, Davis J, Beck S, Shatirishvili G, Mihai CM, Hoeltzenbein M, Pozzan GB, Hopkinson I, Sicolo N, Naggert JK, Nishina PM. New Alstrom syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med 2005; 165:675-683
  357. Tahani N, Maffei P, Dollfus H, Paisey R, Valverde D, Milan G, Han JC, Favaretto F, Madathil SC, Dawson C, Armstrong MJ, Warfield AT, Duzenli S, Francomano CA, Gunay-Aygun M, Dassie F, Marion V, Valenti M, Leeson-Beevers K, Chivers A, Steeds R, Barrett T, Geberhiwot T. Consensus clinical management guidelines for Alstrom syndrome. Orphanet J Rare Dis 2020; 15:253
  358. Ali S, Baig S, Wanninayake S, da Silva Xavier G, Dawson C, Paisey R, Geberhiwot T. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alstrom syndrome patients. Diabetes Obes Metab 2024; 26:989-996
  359. Oshima J, Martin GM, Hisama FM. Werner Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  360. Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Mori S, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:142-145
  361. Atallah I, McCormick D, Good JM, Barigou M, Fraga M, Sempoux C, Superti-Furga A, Semple RK, Tran C. Partial lipodystrophy, severe dyslipidaemia and insulin resistant diabetes as early signs of Werner syndrome. J Clin Lipidol 2022; 16:583-590
  362. Christiansen AL, Bygum A, Hother-Nielsen O, Rasmussen LM. Diagnosing diabetes mellitus in patients with porphyria cutanea tarda. Int J Dermatol 2018; 57:763-769
  363. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med 2017; 377:862-872
  364. Singal AK. Porphyria cutanea tarda: Recent update. Mol Genet Metab 2019;